92A
POSTER SESSIONS HEPATOLOGY, October, 2014
Poster Sessions
Poster Session 1
Saturday, November 8
POSTER VIEWING: 2:00 - 7:30 PM
Hall C
Presenters in attendance:
5:30 - 7:00 PM
Those posters identified as AASLD Presidential Poster of Distinction
by a ribbon icon have received review scores that place them
within the top 10 percent of all posters. We encourage you to
make them a priority as you visit the poster sessions.
Ascites, Renal Dysfunction and
Hepatorenal Syndrome
241: Reversal of Hepatorenal Syndrome Type 1
(HRS-1) with Terlipressin plus Albumin versus Placebo
plus Albumin - Not All Responses Are Created Equal -
An Analysis of the REVERSE and OT-0401 Trials
Arun J. Sanyal, Thomas D. Boyer, R Todd Frederick, Fredric
Regenstein, Lorenzo Rossaro, Victor Araya, Hugo E. Vargas, K.
Rajender Reddy, Khurram Jamil, Stephen Chris Pappas
242: New Multivariate Models to Predict Glomerular
Filtration Rate in Patients with Cirrhosis
Ayse L. Mindikoglu, Thomas C. Dowling, Laurence S. Magder,
Robert H. Christenson, Matthew R. Weir, Stephen L. Seliger,
William R. Hutson, Charles Howell
243: No evidence of reduced mortality due to albumin
NOVEMBER 8
substitution in HCC-free cirrhotic patients undergoing
SATURDAY
large volume paracentesis: a systematic review and
meta-analysis
Fabian Kütting, Jens Schubert, Jeremy Franklin, Agnes Pelc,
Andrea Bowe, Vera Hoffmann, Münevver Demir, Dirk Nierhoff,
Ulrich Toex, Hans-Michael Steffen
244: Serum creatinine within 48 hours after
hospitalization is a strong predictor of mortality in
patients with cirrhosis with complications provided the
peak creatinine is above 1.2 mg/dl
Anantha Nuthalapati, Nicholas Schluterman, Deborah Greenberg,
Anuj Khanna, Paul J. Thuluvath
245: Unprecipitated acute kidney injury can occur
amongst stable patients with cirrhosis and ascites but
no other complications
Florence Wong, Peter Jepsen, Hugh R. Watson, Hendrik V. Vilstrup
246: Evaluation of serum cystatin C as a marker of
early renal impairment in patients with liver cirrhosis
Mahmoud S. Omar, Wael Abdel-Razek, Gamal Abo-Raia, Medhat
Assem, Gasser El-Azab
Denotes AASLD Presidential Poster of Distinction
247: Chronic Kidney Disease Epidemiology
Collaboration Equation combining Creatinine and
Cystatin C is superior to other Creatine- and Cystatin
C-based Equations in Assessing Renal Function in
Patients with Cirrhosis
Elisabeth Krones, Sabine Zitta, Stefan Neunherz, Katharina
Artinger, Tatjana Stojakovic, Gilbert Reibnegger, Franziska
Durchschein, Juliana Buchgrabner, Vanessa Stadlbauer, Peter
Fickert, Alexander R. Rosenkranz
248: Bile pigment nephropathy and acute tubular
necrosis in decompensated cirrhotics and acute on
chronic liver failure
Suman Nayak, Rajendra P. Mathur, Sivaramakrishnan
Ramanarayanan, Gyan Prakash, Shiv K. Sarin, Chitranshu
Vashishtha, Manoj Kumar, Rakhi Maiwall, Ajeet S. Bhadoria
249: Plasma Renin concentration is associated with
portal hypertension, liver dysfunction, ascites and
hyponatremia and may predict mortality in cirrhosis
Rafael Paternostro, Simona Bota, Philipp Schwabl, Remy
Schwarzer, Thomas Reiberger, Mattias Mandorfer, Monika
Ferlitsch, Michael Trauner, Markus Peck-Radosavljevic, Arnulf
Ferlitsch
250: Alpha-2a Adrenoceptor Subtype Stimulation by
Guanfacine Restores Diuretic Efficiency in Experimental
Cirrhosis and Refractory Ascites: Comparison with
Clonidine Effects
Giovanni Sansoe, Manuela Aragno, Raffaella Mastrocola,
Maurizio Parola
251: Albumin Infusions in Patients with Cirrhosis who
Present with Acute Kidney Injury and its Effect on Renal
Function
Derek J. Feussner, Amy P. Myers, James C. Slaughter, Andrew
Scanga
252: Nosocomial spontaneous bacterial peritonitis
is associated with increased mortality compared to
community-acquired spontaneous bacterial peritonitis
Nicolas M. Intagliata, Zachary Henry, Nitin K. Ahuja, Neeral L.
Shah, Curtis K. Argo, Stephen H. Caldwell, Patrick G. Northup
253: Microscopic Urinanalysis May Represent a
Sensitive Test for Kidney Injury in Cirrhotic and
Cholestatic Patients with Preserved Kidney Function
Elisabeth Krones, Julia Fritz, Christoph Schwarz, Franziska
Durchschein, Kathrin Eller, Gernot Zollner, Werner Ribitsch,
Tatjana Stojakovic, Sabine Zitta, Juliana Buchgrabner, Alexander
R. Rosenkranz, Peter Fickert
254: Relative Adrenal Insufficiency in Cirrhotic Patients
with Ascites
Virendra Singh, Rajiv R. Singh, Rama Walia, Naresh Sachdeva,
Ashish Bhalla, Navneet Sharma, Yogesh K. Chawla
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
255: Urinary NGAL Levels Reflect the Therapeutic Effects
of norUDCA in Mice with Cholemic Nephropathy
Elisabeth Krones, Dietmar Glaenzer, Franziska Durchschein,
Alexander Kirsch, Kathrin Eller, Michael Trauner, Alexander R.
Rosenkranz, Peter Fickert
256: Prevalence of hyperdynamic circulation in
cirrhosis: lack of association to presence and severity of
ascites
Cristina Ripoll, Phillip Hohaus, Marcus Hollenbach, Robin A.
Greinert, Alexander Zipprich
257: Outcomes in Patients Receiving Rifaximin along
with Systemic Antibiotics for the Inpatient Treatment of
Spontaneous Bacterial Peritonitis
Jennifer D. Twilla, Anuj Sharma, Satheesh Nair, Emily H. Wong,
Sanjaya K. Satapathy
258: Clinical Predictors of Morbidity and Mortality in
Hospitalized Children with Ascites
Grace Felix, Thammasin Ingviya, Ann O. Scheimann, Pavis
Laengvejkal, Alexandra Vasilescu, Hejab Imteyaz, Eric C.
Seaberg, Wikrom Karnsakul
259: Beyond Dr. Google: Early results of a personalized
weight-tracking smartphone application and alert
system for patients with ascites
Chanda Ho, Neil Shah, Nabil Alshurafa, Behnam Shahbazi,
Hassan Ghasemzadeh, Norah Terrault
260: Determination of renal function through creatinine
and cystatin C-dependent formulas in comparison to
DTPA-Tc-99 clearance in Mexican cirrhotic patients
Jonathan Aguirre-Valadez, Haydee Verduzco-Aguirre, Ariadna
K. Flores-Balbuena, Octavio R. García-Flores, Ricardo Macías-
Rodríguez, Cristino Cruz-Rivera, Jose A. Niño-Cruz, Ignacio
Garcia, Aldo Torre
261: Predictors for the Development of Cardiac Ascites
in Patients Referred for Cardiac Transplantation
Brian Kim, Amy Tan, Berkeley N. Limketkai, Sean Pinney, Thomas
D. Schiano
262: Computer-assisted image analysis of fibrosis on
liver biopsy : relationship with portal pressure, histology
and clinical data
Nicolas Goossens, Sophie Restellini, Sophie Clément, Laura
Rubbia-Brandt, Laurent Spahr
263: Non-invasive measurement of acute hemodynamic
changes using inert gas rebreathing during routine
therapeutic paracentesis in tense ascites
Christoph Antoni, Joachim Saur, Thomas Zimmerer, Nenad
Suvajac, Julia D. Michels, Matthias Ebert, Frederik Trinkmann
264: PTFE-covered TIPS position relative to the
hepatocaval junction and impact on shunt patency
Charles N. Weber, Gregory J. Nadolski, Michael C. Soulen
265: WITHDRAWN
Poster Viewing: 2:00 – 7:30 PM
93A
266: Response guided ascitic tap in spontaneous
bacterial peritonitis predicts outcome
Ashok K. Choudhury, Ankur Jindal, Chandan K. Kedarisetty,
Tanmay S. Vyas, Ajeet S. Bhadoria, Shiv K. Sarin
267: Does transjugular intrahepatic portosystemic shunt
(TIPS) with covered stents modify the natural course of
decompensed cirrhosis?
Xavier Adhoute, Paul Castellani, Guillaume Penaranda, Olivier
Monnet, Herve Perrier, Bernard L. Pol, Cyril Muller, Arthur Laquiere,
Valerie Oules, Patrick Beaurain, Christian Boustiere, Olivier Bayle,
Marc Bourlière
Behavioral, Quality of Life, and Practice
Issues
268: Factors associated with medication adherence
in patients living with cirrhosis
Suzanne Polis, Ling Zhang, Amany Zekry, Ritin Fernandez
269: Children with HCV: The impact of disease and
treatment on patients, caregivers and families
Rachel A. Annunziato, Samantha G. Lee, Elizabeth Galici,
Alexander Newcorn, Ronen Arnon
270: A single-center report of hepatitis A and
hepatitis B vaccination performance in patients with
chronic hepatitis C (CHC): A quality improvement project
Bobbi Jo Quigley, Matthew Kowgier, Colina Yim
271: Two Types of Fatigue in Subjects with Chronic
Liver Disease Can Be Distinguished Through Correlations
NOVEMBER 8
SATURDAY
with Physical Activity and Mental Symptoms
Ali A. Weinstein, Heibatollah Baghi, Carey Escheik, Lynn Gerber,
Zobair Younossi
272: Characteristics of Nutritional Intake in End-Stage
Liver Disease Secondary to Viral Hepatitis, NASH, and
Alcoholic Liver Disease
Anna Marie Hefner, Cynthia D. Connelly, Kathy S. James,
Catherine Hill, Preeti Reshamwala, Tarek Hassanein
Cholangiocyte Biology
273: Absence of the intestinal microbiota
exacerbates hepatobiliary disease in a murine model of
primary sclerosing cholangitis
James H. Tabibian, Steven P. O’Hara, Christy E. Trussoni, Pamela
S. Tietz, Patrick L. Splinter, Taofic Mounajjed, Lee R. Hagey,
Nicholas F. LaRusso
274: Lipopolysaccharide (LPS)-induced cholangiocyte
N-Ras activation requires epidermal growth factor
receptor (EGFR) activation
Christy E. Trussoni, Patrick L. Splinter, James H. Tabibian, Steven
P. O’Hara
Presenters in Attendance 5:30 – 7:00 PM
 94A POSTER SESSIONS
Poster Sessions
275: Ezrin, a membrane cytoskeletal cross-linker is
essential for the regulation of biliary flow in mice
Ryo Hatano, Kaori Akiyama, Shinji Asano
276: Regulation of cholangiocyte IL-6 release by
extracellular adenosine
Elise G. Lavoie, Jessica R. Goree, Michel Fausther, Jonathan A.
Dranoff
277: Role of the miR-125b- regulated HDC/histamine/
VEGF axis during the progression of biliary proliferation
in the PSC/MDR2-/- mouse model
Yuyan Han, Laura Hargrove, Lindsey Kennedy, Allyson B. Graf,
Sharon DeMorrow, Fanyin Meng, Quy P. Nguyen, Victoria Huynh,
Heather L. Francis
278: Characterization of cultured cholangiocytes
isolated from livers of patients with primary sclerosing
cholangitis
Christy Trussoni, James H. Tabibian, Steven P. O’Hara, Patrick L.
Splinter, Julie Heimbach, Nicholas F. LaRusso
Cholestasis and Autoimmune Liver
Disease
279: The Fraction of Bile Ducts Lost in Portal Areas
Correlates with Degree of Fibrosis and Alkaline
Phosphatase Levels in Patients with Primary Biliary
Cirrhosis
Mazen Noureddin, David E. Kleiner, Xiongce Zhao, Jason L.
Eccleston, Daniel Woolridge, Nabil Noureddin, T. Jake Liang, Jay
NOVEMBER 8
H. Hoofnagle, Theo Heller
SATURDAY
280: Altered Functional Connections in the Brain of
Patients With Primary Biliary Cirrhosis are Associated
with Fatigue
Victoria Mosher, Mark G. Swain, Robert P. Myers, Glenda M.
MacQueen, Bradley G. Goodyear
281: Sub-stratification of hepatocellular carcinoma
risk in men with primary biliary cirrhosis: results of an
international multicenter study
Palak J. Trivedi, Willem J. Lammers, Henk R. van Buuren, Annarosa
Floreani, Albert Pares, Angela C. Cheung, Cyriel Y. Ponsioen,
Christophe Corpechot, Marlyn J. Mayo, Pietro Invernizzi, Pier
Maria Battezzati, Frederik Nevens, Andrew Mason, Kris V.
Kowdley, Ka-Kit Li, Tony Bruns, Mohamad Imam, Teru Kumagi,
Nora Cazzagon, Irene Franceschet, Llorenc Caballeria, Kirsten
Boonstra, Raoul Poupon, Ana Lleo, Keith D. Lindor, Harry L.
Janssen, Bettina E. Hansen, Gideon Hirschfield
282: A Mouse Model of Fibrous Cholangiopathy
Sumera Rizvi, Anuradha Krishnan, Maria Eugenia Guicciardi,
Steven F. Bronk, Gregory J. Gores
283: Increased BMI is associated rapid progression
of fibrosis in Primary Sclerosing Cholangitis (PSC)
Aliya Gulamhusein, Danielle Reid, Bertus Eksteen
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
284: Activation of mDCs and CD8+ T cells is
associated with PSC-like cholangiopathy induced by
small bowel bacterial overgrowth in a mouse model of
autoimmune biliary disease
Qingqing Wang, Vijay Saxena, Bin Wang, Lili Miles, Marnie A.
Ryan, Jorge A. Bezerra, William M. Ridgway, Jaimie D. Nathan
285: Changes of the hepatic transcriptome in human
extrahepatic cholestasis
Frank G. Schaap, Marlon J. Jetten, Marcel H. Herwijnen, Maarten
L. Coonen, Jos C. Kleinjans, Peter L. Jansen, Steven Olde Damink
286: High serum levels and liver expression of
sclerostin in patients with primary biliary cirrhosis.
Association with markers of bone remodeling and
severity of cholangitis
Silvia Ruiz-Gaspa, Laia Gifre, Nuria Guañabens, Rosa Miquel,
Pilar Peris, Ana Monegal, Albert Pares
287: Contribution of polymorphic LINE-1
retrotransposon insertion in SLCO1B3 gene to
susceptibility to drug-induced cholestasis
Tatehiro Kagawa, Kazuya Anzai, Kota Tsuruya, Yoshitaka Arase,
Shunji Hirose, Koichi Shiraishi, Tetsuya Mine
288: The role of repeated brush cytology in detecting
dysplasia or cholangiocarcinoma in primary sclerosing
cholangitis before liver transplantation
Ammar Majeed, Annika Bergquist, Gunnar Söderdahl, Maria
Castedal, Karouk Said
289: Contribution of Next Generation Sequencing to
the genotyping of patients with hereditary cholestasis
and cholelithiasis
Véronique D. Barbu, Isabelle Jéru, Christophe Corpechot, Eric
Fernandez, Laure Muller, Fabienne Dufernez, Olivier Chazouillères,
Yannick Marie, Zhenyu Xu, Chantal Housset
290: Fenofibrate is Effective adjunctive Therapy in
the Treatment of Primary Biliary Cirrhosis: A Meta-
Analysis
Alla Grigorian, Houssam E. Mardini, Christophe Corpechot, Raoul
Poupon, Cynthia Levy
291: Fenofibrates do not improve transplant-free
survival despite biochemical response in patients with
primary biliary cirrhosis
Angela C. Cheung, Javier M. Meza-Cardona, Matthew Kowgier,
E. Jenny Heathcote, Harry L. Janssen, Jordan J. Feld
292: Assessment of Environmental Exposures among
1000 North American Primary Sclerosing Cholangitis
Patients with and without Inflammatory Bowel Disease
John E. Eaton, Brian D. Juran, Elizabeth J. Atkinson, Erik M.
Schlicht, Xiao Xie, Mariza de Andrade, Craig Lammert, Velimir
A. Luketic, Joseph A. Odin, Ayman A. Koteish, Kris V. Kowdley,
Kapil B. Chopra, Gideon M. Hirschfield, Naga P. Chalasani,
Konstantinos Lazaridis
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
293: Efficacy Trial of All-trans Retinoic Acid (ATRA)
in combination with Ursodeoxycholic Acid (UDCA) in
Primary Sclerosing Cholangitis (PSC)
David N. Assis, Osama Abdelghany, Shi-Ying Cai, Andrea A.
Gossard, John E. Eaton, Jill C. Keach, Yanhong Deng, Stephenson
W. Nkinin, Kenneth D R. Setchell, Maria Ciarleglio, Keith D.
Lindor, James L. Boyer
294: Galectin-3 Plays a Role in Primary Biliary
Cirrhosis by Mediating Inflammasome Signaling
Jijing Tian, Tzu-I Chao, Yu Sasaki, Fu-Tong Liu, M. Eric Gershwin,
Natalie Torok, Joy Jiang
295: An International Phase 3 Study of the FXR Agonist
Obeticholic Acid in PBC Patients: Effects on Markers
of Cholestasis Associated with Clinical Outcomes and
Hepatocellular Damage
Frederik Nevens, Pietro Andreone, Giuseppe Mazzella, Simone I.
Strasser, Christopher L. Bowlus, Pietro Invernizzi, Joost Drenth, Paul
J. Pockros, Jaroslaw Regula, Michael Trauner, Annarosa Floreani,
Simon Hohenester, Velimir A. Luketic, Mitchell L. Shiffman, Karel J.
van Erpecum, Victor Vargas, Catherine Vincent, Bettina E. Hansen,
Roya Hooshmand-Rad, Shawn Sheeron, David Shapiro
296: Noninvasive testing are poor surrogate markers
for fibrosis staging and liver-related outcomes in
patients with primary biliary cirrhosis who do not
respond to ursodeoxycholic acid
Angela C. Cheung, Javier M. Meza-Cardona, Matthew Kowgier,
Harry L. Janssen, Jordan J. Feld
297: Applicability and Prognostic Value of Histologic
Scoring Systems in Primary Sclerosing Cholangitis
Elisabeth M. de Vries, Joanne Verheij, Stefan G. Hubscher,
Mariska M. Leeflang, Kirsten Boonstra, Ulrich Beuers, Cyriel Y.
Ponsioen
298: Relation of gallbladder enlargement with bile
acid homeostasis and colorectal malignancy in primary
sclerosing cholangitis
Mourad Aissou, Lionel Arrivé, Dominique Rainteau, Sara Lemoinne,
Astrid Donald D. Kemgang Fankem, Delphine Firrincieli, Nicolas
Chignard, Christophe Corpechot, Olivier Chazouillères, Chantal
Housset
299: Do patients with “early” PBC benefit from UDCA
treatment? -results from the nationwide cohort study in
Japan-
Atsushi Tanaka, Junko Hirohara, Yasuni Nakanuma, Hirohito
Tsubouchi, Hajime Takikawa
300: A possible involvement of endoplasmic reticulum
stress in the process of biliary epithelial autophagy and
senescence in primary biliary cirrhosis
Motoko Sasaki, Masami Miyakoshi, Yasunori Sato, Yasuni
Nakanuma
301: Younger patients presenting with Primary Biliary
Cirrhosis are more likely to have cognitive impairment
Laura Griffiths, David Jones, Jessica K. Dyson, George F. Mells,
Richard N. Sandford
Poster Viewing: 2:00 – 7:30 PM
95A
302: Ongoing Activation of Autoantigen-Specific B cells
in Primary Biliary Cirrhosis
Jun Zhang, Weici Zhang, Patrick S. Leung, Christopher L. Bowlus,
Sandeep S. Dhaliwal, Ross L. Coppel, Aftab A. Ansari, Guo-Xiang
Yang, Jinjun Wang, Thomas P. Kenny, Xiao-Song He, M. Eric
Gershwin
303: Risk stratification in primary biliary cirrhosis using
the UK-PBC Research Cohort
Marco Carbone, Stephen Sharp, Michael A. Heneghan, James
Neuberger, Gideon M. Hirschfield, Andrew K. Burroughs, Andrew
Bathgate, Mervyn H. Davies, Carolyn Adgey, Paul Trembling, Kate
D. Williamson, Laura Griffiths, Teegan R. Lim, Nick Wareham,
David E. Jones, Graeme J. Alexander, Richard N. Sandford,
Heather J. Cordell, George F. Mells
304: NGM282 is a Potent Modulator of Bile Acid
Synthesis in Humans via Suppression of CYP7A1
Activity
Stephen Rossi, Michael Elliott, Kenneth D. Setchell, Stephenson W.
Nkinin, Jian Luo, Lei Ling, Krishna P. Allamneni, Hui Tian, Alex M.
DePaoli
305: Obeticholic Acid in PBC Patients: The Utility
of Titration Based on Therapeutic Response and
Tolerability
Christopher L. Bowlus, Paul J. Pockros, Joost Drenth, Annarosa
Floreani, Catherine Vincent, Velimir A. Luketic, Karel J. van
Erpecum, Victor Vargas, Mitchell L. Shiffman, Frederik Nevens,
Richard Pencek, Roya Hooshmand-Rad, David Shapiro
306: Clinical Course And Outcome Of Patients With
Sclerosing Cholangitis In Critically Ill Patients (Sc-Cip):
NOVEMBER 8
High Mortality Without Liver Transplantation
SATURDAY
Harald Hofer, Gernot Zollner, Peter Fickert, Ivo Graziadei, Michael
Trauner
307: Successful Immunotherapy of Autoimmune
Cholangitis by Adoptive Transfer of Foxp3+ Regulatory
T Cells
Hajime Tanaka, Weici Zhang, Guo-Xiang Yang, Koichi
Tsuneyama, Patrick S. Leung, Ross L. Coppel, Aftab A. Ansari,
Zhe-Xiong Lian, William M. Ridgway, M. Eric Gershwin
308: Protein Profiles of Apoptotic Bodies from Biliary
Epithelial Cells
Ana Lleo, Weici Zhang, W. Hayes McDonald, Patrick S. Leung,
Ross L. Coppel, Aftab A. Ansari, David H. Adams, Simon C.
Afford, Pietro Invernizzi, M. Eric Gershwin
309: Efficacy of Obeticholic Acid In Primary Biliary
Cirrhosis as Assessed by Response Criteria Associated
With Clinical Outcome: A Poise Analysis
Velimir A. Luketic, Pietro Invernizzi, Michael Trauner, Jaroslaw
Regula, Giuseppe Mazzella, Simone I. Strasser, Annarosa
Floreani, Simon Hohenester, Karel J. van Erpecum, Paul J. Pockros,
Bettina E. Hansen, Henk R. van Buuren, Frederik Nevens, Richard
Pencek, Roya Hooshmand-Rad, David Shapiro
Presenters in Attendance 5:30 – 7:00 PM
 96A POSTER SESSIONS
Poster Sessions
310: FXR Agonist Obeticholic Acid: Pruritus, A Common
Side Effect Ameliorated by Dose Titration
Ulrich Beuers, David E. Jones, Marlyn J. Mayo, Pietro Andreone,
Giuseppe Mazzella, Simon Hohenester, Annarosa Floreani,
Simone I. Strasser, Christopher L. Bowlus, Pietro Invernizzi, Joost
Drenth, Paul J. Pockros, Jaroslaw Regula, Velimir A. Luketic, Karel J.
van Erpecum, Victor Vargas, Catherine Vincent, Roya Hooshmand-
Rad, Shawn Sheeron, David Shapiro
311: Incidence of and Risk Factors for Primary Biliary
Cirrhosis-associated Hepatocellular Carcinoma: Large-
Scale Data from China
Xue-Xiu Zhang, Li-Feng Wang, Zheng Zhang, Fu-Sheng Wang
312: Possible impairment of mucosal-associated
invariant T cells in the liver of patients with primary
biliary cirrhosis
Toru Setsu, Satoshi Yamagiwa, Kentaro Tominaga, Naruhiro
Kimura, Hiroki Honda, Hiroteru Kamimura, Masaaki Takamura,
Minoru Nomoto
313: Circulating bile acids and sterol levels in patients
with cholestatic pruritus. Effects of albumin dialysis
using MARS
Albert Pares, Miriam Perez-Cormenzana, Alvaro Diaz-Gonzalez,
Rebeca Mayo, Azucena Castro, Antoni Mas
314: The neogenesis of high endothelial venules and the
formation of tertiary lymphoid organs in primary biliary
cirrhosis
Hayato Baba, Koichi Tsuneyama
315: Geoepidemiology of primary biliary cirrhosis in
NOVEMBER 8
Central Greece
SATURDAY
Nikolaos Gatselis, Kalliopi Zachou, Asterios I. Saitis, Elias Spyrou,
George K. Koukoulis, George N. Dalekos
316: Hepatic sarcoidosis: To treat or not to treat?
Nicole M. Welch, Andrew Aronsohn, K. Gautham Reddy, Nancy
Reau, Donald M. Jensen, Helen S. Te
317: Age at Presentation and Gender are Predictors
of Increased Mortality Over Long-Term Follow-Up in
Primary Biliary Cirrhosis (PBC)
Jessica K. Dyson, Laura Griffiths, Samantha J. Ducker, David E.
Jones
318: The FXR Agonist Obeticholic Acid (OCA) Improves
Liver Biochemistry Parameters Correlated With Clinical
Benefit Across a Range of Patient Characteristics
Pietro Andreone, Giuseppe Mazzella, Simone I. Strasser,
Christopher L. Bowlus, Pietro Invernizzi, Joost Drenth, Paul J.
Pockros, Jaroslaw Regula, Michael Trauner, Annarosa Floreani,
Simon Hohenester, Velimir A. Luketic, Mitchell L. Shiffman, Karel J.
van Erpecum, Victor Vargas, Catherine Vincent, Bettina E. Hansen,
Frederik Nevens, Richard Pencek, Roya Hooshmand-Rad, Shawn
Sheeron, David Shapiro
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
319: FXR Agonist Obeticholic Acid: Sustained
Improvement in Markers of Cholestasis and Long-Term
Safety in Patients with Primary Biliary Cirrhosis through
4 Years
Kris V. Kowdley, Richard Pencek, Tonya Marmon, David Shapiro,
Roya Hooshmand-Rad
320: Secondary Sclerosing Cholangitis Following Major
Burn Injury
Ella Veitsman, Yael Haviv-Yadid, Oranit Cohen-Ezra, Orit Pappo,
Yael Inbar, Josef Haik, Galia Rahav, Ziv Ben Ari
321: Discrepant Expression of miR-139-5p Between
Serum and Liver in Patients with Primary Biliary
Cirrhosis, and its Possible Cellular Origin
Tomohiro Katsumi, Masashi Ninomiya, Kyoko Tomita, Chikako
Sato, Kazuo Okumoto, Yuko Nishise, Hisayoshi Watanabe,
Takafumi Saito, Yoshiyuki Ueno
322: Patient Experience and Characteristics of
Cholestatic Pruritus in the UK-PBC Research Cohort
Vinod S. Hegade, George F. Mells, Ulrich Beuers, Andreas E.
Kremer, Pietro Invernizzi, Tom H. Karlsen, Gideon Hirschfield,
Richard N. Sandford, Stuart Kendrick, David E. Jones
323: HLA-DR3 transgenic NOD mice, a novel model for
autoantigen induced autoimmune hepatitis
Yipeng Wang, Muhammed Yuksel, Junhua Guo, Ningwen Tai,
Xiaoyan Xiao, Pascal Lapierre, David Chella, Huiping Yan, Isabelle
Colle, Giorgina Mieli Vergani, Diego Vergani, Yun Ma, Li Wen
324: Long term follow-up and 10-year outcomes of
second-line therapy in Autoimmune Hepatitis
Daniel Klintman, Naina Shah, Javier Bustamante, Michael A.
Heneghan
325: Circulating macrophage activation markers,
CD163 and CD206, are associated with disease severity
and treatment response in patients with autoimmune
hepatitis
Henning Gronbaek, Martin Kreutzfeldt, Niels Jessen, Sidsel
Rødgaard-Hansen, Konstantin Kazankov, Thomas D. Sandahl,
Hendrik V. Vilstrup, Holger J. Møller
326: Can a dietary supplement induce autoimmune
hepatitis?
Marina Roytman, Peter Poerzgen, Christine L. Lee, Leslie
Huddleston, Peter K. Bryant-Greenwood, Timothy Kuo, Linda L.
Wong, Naoky Tsai
327: Analysis of Liver Stiffness Measured by Transient
Elastography in Autoimmune Hepatitis
Ja Kyung Kim, Hae Won Kim, Jung Il Lee, Kwan Sik Lee
328: The IL-7/CD127 axis negatively modulates the
function of regulatory T-cells in autoimmune hepatitis
Rodrigo Liberal, Charlotte R. Grant, Yun Ma, Michael A.
Heneghan, Giorgina Mieli-Vergani, Diego Vergani, Maria Serena
Longhi
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
329: Down-regulation of hepcidin production in patients
with autoimmune liver diseases
Nikolaos Gatselis, Aggeliki Lyberopoulou, Kalliopi Zachou,
Georgia Chachami, Petros Eliades, Stella Gabeta, Efrosyni
Paraskeva, Avgi Mamalaki, George K. Koukoulis, George Simos,
George N. Dalekos
330: Prevalence, Natural History And Outcome Of
Overlap Syndrome Versus Autoimmune Hepatitis In The
Indian Continent
Lovkesh Anand, Cyriac A. Philips, Varsha Bhat, Chhagan Bihari,
Ajeet S. Bhadoria, Shiv K. Sarin
331: Prednisolone Changes mRNA and lincRNA
Expression Profiles to Suppress Autoimmunity in CD4+ T
Cells of Autoimmune Hepatitis Type 1
Ryo Nakagawa, Ryosuke Muroyama, Sayaka Ito, Keiko Takano,
Wenwen Li, Kaku Goto, Masanori Nakano, Chisato Saeki, Yasuo
Matsubara, Naoya Kato, Mikio Zeniya
332: Fast corticosteroid tapering and early fibrosis
stages: important risk factors for type 1 autoimmune
hepatitis relapse in Japan
Atsushi Takahashi, Kazumichi Abe, Hiromasa Ohira, Yasuhiro
Miyake, Masanori Abe, Kazuhide Yamamoto, Yoshiyuki Suzuki,
Morikazu Onji, Hirohito Tsubouchi
333: Serum sterol levels indicate distorted cholesterol
homeostasis in cirrhotic patients with primary biliary
cirrhosis
Marcin Krawczyk, Ewa Wunsch, Dieter Luetjohann, Frank Lammert,
Piotr Milkiewicz
334: Metabolic syndrome induces a more rapid
progression of fibrosis evaluated with transient
elastography in early primary biliary cirrhosis
Nora Cazzagon, Laura Costa, Irene Franceschet, Alessandra Buja,
Liliana Chemello, Luisa Cavalletto, Francesco P. Russo, Annarosa
Floreani
335: Fibrates improve liver tests in primary sclerosing
cholangitis with incomplete biochemical response to
ursodeoxycholic acid: update of a pilote study
Sara Lemoinne, Christophe Corpechot, Astrid Donald D. Kemgang
Fankem, Farid Gaouar, Raoul Poupon, Olivier Chazouillères
336: Related Factors for Treatment-Dependent
Autoimmune Hepatitis
Berna Gürsel, Fulya Gunsar, Funda Yilmaz, Zeki Karasu, Galip
ERsoz, Ulus S. Akarca
Donor Factors and Allocation
337: Successful ex-vivo normothermic oxygenated
machine perfusion of human donor livers
Janske Reiling, David S. Lockwood, Andrew H. Simpson, Catherine
M. Campbell, Kim Bridle, Nishreen Santrampurwala, Laurence J.
Britton, Darrell H. Crawford, Cornelis H. Dejong, Jonathan Fawcett
Poster Viewing: 2:00 – 7:30 PM
97A
338: Serum zinc levels are associated with
decompensated liver function and reduced survival in
patients awaiting liver transplantation
Kilian Friedrich, Christian Rupp, Andreas Wannhoff, Wolfgang
Stremmel, Daniel Gotthardt
339: The impact of Model for End Stage Liver
Disease Sodium (MELD-Na) prioritization for liver
transplantation on wait list and post-transplant survival
Sheeva Johnson, Barry Schlansky, Willscott E. Naugler
340: Impact of Donation after cardiac death (DCD)
allografts on incidence and severity of recurrent
hepatitis C (HCV) and graft survival post liver
transplantation (LT) for HCV
Shiva Kumar, Rachel Pedersen
341: Improving the Quality of MELD Upgrade Petitions
for Hepatocellular Carcinoma Beyond the Milan Criteria
in UNOS Region 8
Joel P. Wedd, Jane Gralla, Betsy Gans, Sue Dunn, Harvey
Solomon, Michael D. Voigt, Scott W. Biggins
342: Utilization of Simultaneous Liver-Kidney
Transplants Continues to Vary Dramatically by UNOS
Region
Paul J. Gaglio, Wendy Rabbenou, Sander S. Florman, Tomoaki
Kato, Milan Kinkhabwala, Glyn Morgan, Mark S. Orloff, Lewis
Teperman, Samantha DeLair
343: Palliative Care Utilization in ESLD Patients Denied
Transplant Candidacy
Sean G. Kelly, Parul D. Agarwal
NOVEMBER 8
SATURDAY
344: Waiting for liver transplant (LT): Outcomes for
LT candidates listed with low MELD without exception
points
Allison J. Kwong, Jennifer C. Lai, Jennifer L. Dodge, John P. Roberts
345: Predicting Recurrent Hepatocellular Carcinoma
and Survival after Liver Transplantation: The importance
of time to transplant
Marypat Pauly, Bradley Winston, Jean-Luc Szpakowski, Lisa M.
Nyberg, David H. Smith, Jin Sun, Alice Ducey, Celia D. Clarke,
Barbara Piasecki, Ruth Brentari
346: Value Of Preoperative Evaluation Of Cadavaric
Liver Donors With Transient Elastography In Marginal
Liver Donors
Remy Schwarzer, Simona Bota, Rafael Paternostro, Jagdeep
Singh, Tamara Braunschmid, Ferdinand Mühlbacher, Clemens
Kietaibl, Thomas Reiberger, Mattias Mandorfer, Michael Trauner,
Markus Peck-Radosavljevic, Gabriela Berlakovich, Arnulf Ferlitsch
347: Significance of Initial Poor Function after Liver
Transplantation
Gilles Uijtterhaegen, Thamara Perera, Jan R. Colpaert, Hans Van
Vlierberghe, Roberto Troisi, Xavier Rogiers, Darius Mirza
348: WITHDRAWN
Presenters in Attendance 5:30 – 7:00 PM
 98A POSTER SESSIONS HEPATOLOGY, October, 2014

Poster Sessions
349: Clinician Assessments of Health Status Predict
Need for Liver Transplant (LT) Independent of MELD,
Especially in Women
Jennifer C. Lai, Kenneth E. Covinsky, Hilary Hayssen, Blanca C.
Lizaola, John P. Roberts, Norah Terrault, Sandy Feng
350: Transplant-needed alcoholic cirrhosis: which
patients can reach the transplant waiting list? A
preliminary case-control study
Benjamin Rolland, Anne Clerget, Alexandre Louvet, Sébastien
Dharancy, Philippe Mathurin, Olivier COTTENCIN
351: The Impact of an Institutional Change in
Prothrombin Time Methodology on INR and MELD
Scores in Liver Transplant Evaluations
Dennis Kumral, Nicolas M. Intagliata, Neeral L. Shah, Stephen H.
Caldwell, Patrick G. Northup, Curtis K. Argo
Encephalopathy and Other
Complications
352: iPod Video Games Training Improves Overall
Cognitive Performance in Patients with Covert Hepatic
Encephalopathy
Jasmohan S. Bajaj, Leroy Thacker, Douglas M. Heuman, James
Hovermale, Edith A. Gavis, HoChong Gilles, Melanie White,
James Wade
353: The role of probiotics in the treatment of
minimal hepatic encephalopathy. A prospective,
randomized, placebo-controlled, double-blind study
NOVEMBER 8
358: Hepatic and Renal expression of the ammonia
transporter Rhesus protein (Rhcg) plays a critical
role in modulating hyperammonemia and hepatic
encephalopathy in liver failure
Yalda Sharifi, Gavin Wright, Nathan Davies, Abeba Habtesion,
Fausto Andreola, Rajiv Jalan
359: Pentoxifylline therapy for hepatopulmonary
syndrome: Longer duration is superior to combination
with rifaximin, a RCT
Naveen Kumar, Chandan K. Kedarisetty, Sachin Kumar, Ankur
Jindal, Ajeet S. Bhadoria, Shiv K. Sarin
360: Prevalence of Bone Disease in Cirrhosis
Mohamed A. Chinnaratha, Rosemary J. McCormick, Rachel
Wundke, Richard J. Woodman, Alan J. Wigg
361: Branched-chain amino acids improve intestinal
malabsorption of dietary long-chain fatty acids and
preserve intestinal fatty acid transporters in liver
cirrhosis
Yasunori Yamamoto, Hiroki Utsunomiya, Teruki Miyake, Keitaro
Kawasaki, Hiroaki Nunoi, Kenichirou Mori, Yoshio Ikeda, Yoichi
Hiasa
362: Association between Malnutrition in Patients
with Liver Cirrhosis and the Presence of Hepatic
Encephalopathy
Astrid Ruiz-Margáin, Ricardo Macías-Rodríguez, Andres Duarte-
Rojo, Angeles Espinosa-Cuevas, Aldo Torre
363: Bumetanide normalizes brain edema in rats
with bile duct ligation: evidence for increased BBB

Jiannis Vlachogiannakos, Panayota Vasianopoulou, Nikos Viazis,

permeability via NKCC1
SATURDAY

Matilda Chroni, Theodoros Voulgaris, Spiros D. Ladas, Dimitrios

Jimmy Huynh, Cristina R. Bosoi, Christian Parent-Robitaille,
G. Karamanolis
Mélanie Tremblay, Christopher F. Rose
354: Differential expression of neurodegeneration
364: Incidence and outcome of newly diagnosed portal
related genes in a new model of episodic hepatic
vein thrombosis in patients with cirrhosis awaiting liver
encephalopathy
transplantation
Teresa García-Lezana, Jordi Romero-Giménez, Laia Chavarria,
Cindy S. Law, Manjil Chatterji, Kristina Chacko, Thomas D.
Marc Oria, Joan Genescà, Juan Cordoba
Schiano, Charissa Y. Chang
355: Ammonia acts as a damage associated
365: The determination of prognosis and disease
molecular pattern (DAMP) producing multi organ injury
progression in patients with established cirrhosis
and inflammation through a Toll-Like-Receptor-4 (TLR4)
Zita Galvin, Audrey Dillon, Jennifer Russell, Damien Lowry,
dependent pathway
Stephen Stewart
Yalda Sharifi, Gavin Wright, Francesco De Chiara, Nathan
Davies, Laia Chavarria, Marc Oria, Francesco Scaravilli, Rajiv
366: Effect of lactulose administration on gut microbiota
Jalan
in patients with liver cirrhosis
Rakesh Aggarwal, Amit Goel, Aditya N. Sarangi, Ankur Singh,
356: Portal hypertension due to outflow block in non-
S. Avani
cirrhotic patients with nonalcoholic fatty liver disease
Yohei Koizumi, Masashi Hirooka, Hironori Ochi, Fujimasa Tada,
367: Relation of CT determined Sarcopenia to
Teruki Miyake, Yoshio Tokumoto, Atsushi Hiraoka, Masanori Abe,
Anthropometry, Dietary Calorific and Protein Intake and
Bunzo Matsuura, Yoichi Hiasa
Survival in Patients with Chronic Liver Disease
Sarah E. Brown, Ziva Mrevlje, Frances Dorman, Natasha Vidas,
357: Adrenal insufficiency is associated with the
Pauline A. Kane, Michael A. Heneghan, Julia Wendon, William
clinical outcome in patients with decompensated
Bernal
cirrhosis
Evangelos Cholongitas, Ioannis Goulis, George Kokkonis,
Parthenis Chalevas, Spyros Gerou, Evangelos Akriviadis
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
368: Comparison of Psychometric Hepatic
Encephalopathy Score (PHES) and Inhibitory Control Test
(ICT) in diagnosis of minimal hepatic encephalopathy
Jerzy Jaroszewicz, Justyna Zbrzezniak, Natalia Kilisinska,
Agnieszka Stawicka, Aleksandra Swiderska, Mateusz Panasiuk,
Tadeusz W. Lapinski, Robert Flisiak
369: Comorbid Conditions and Demographic Factors
Associated With Poor Outcome in Cirrhotic Patients
Undergoing Orthopedic Surgery in a Large Health
Maintenance Organization
Eric M. Nyberg, Michael Batech, T Craig Cheetham, Anshuman
Singh
370: The Challenging Diagnosis of Minimal Hepatic
Encephalopathy: Does Critical Flicker Frequency
Correlate to the Psychometric Hepatic Encephalopathy
Score?
Audrey Dillon, Zita Galvin, Stephen Stewart
371: Sarcopenia and Myosteatosis Increase the Risk of
Hepatic Encephalopathy in Cirrhotic Patients
Aldo J. Montano-Loza, Andres Duarte-Rojo, Christopher F. Rose
372: Bacterial antigen translocation in patients with
cirrhosis and minimal hepatic encephalopathy is
associated with increased serum ammonia and nitric
oxide levels
Pablo Bellot, Rocío Gallego-Durán, Alba Moratalla, Javier
Ampuero, Pedro Zapater, Manuela Roger, Blanca Figueruela,
Belén Martínez, José M. González-Navajas, Jose Such, Manuel
Romero-Gómez, Ruben Frances
373: Diabetes causes hepatic encephalopathy through
bacterial translocation—analysis of data from three
randomized controlled trials
Peter Jepsen, Hendrik V. Vilstrup, Hugh R. Watson
374: The combination of MELD-Score and Critical Flicker
Frequency could filter patients needing no further testing
for covert hepatic encephalopathy
Robin A. Greinert, Cristina Ripoll, Marcus Hollenbach, Alexander
Zipprich
375: High Prevalence of Nodular Regenerative
Hyperplasia in Patients with End-Stage Heart Failure
and Outcomes after Cardiac Transplantation
Ken D. Nguyen, Aung Kaung, Anish V. Patel, Michelle Kittleson,
Marc L. Friedman, Maha Guindi, Vinay Sundaram, Tram T. Tran
376: Algorithm for Correcting Vitamin D Deficiency
in Patients Awaiting or Being Evaluated for Liver
Transplantation
Shai Posner, Emily Schonfeld, Alexis Pappas, Dana R. Berg, Kian
Bichoupan, Thomas D. Schiano, Andrea D. Branch, Jonathan
Barsa
Poster Viewing: 2:00 – 7:30 PM
99A
377: Hepatopulmonary syndrome screening in a large
transplant center: Prevalence and impact on survival
Manuel Mendizabal, David S. Goldberg, Federico Piñero, Diego
T. Arufe, Pablo A. Testa, Juan M. Coronel, Maria Pia Raffa, Sergio
Baratta, Luis G. Podesta, Michael B. Fallon, Marcelo O. Silva
378: Disturbed sleep is highly prevalent in patients with
cirrhosis and is independently associated with poor
quality of life
Mollie Jackson, Raghavender Gotur, Edra Nordstrom, Eric S.
Orman, Raj Vuppalanchi, Naga P. Chalasani, Marwan Ghabril
379: Apraxia in Patients with Liver Cirrhosis. Influence
of Hepatic Encephalopathy
Montserrat O. Flavia, Victor Vargas, Carlos Jacas, M. Ventura,
Irene Conejo, Rafael Esteban, Joan Cordoba
380: Trends of Serial MELD Scores has an Incremental
Prognostic Value in Predicting In-Hospital Mortality of
ICU Cirrhotic Patients
Thoetchai Peeraphatdit, Charat Thongprayoon, Niyada Naksuk,
Roongruedee Chaiteerakij, Lewis R. Roberts
381: Metformin reduces hyperammonemia in
portacaval shunted rats inhibiting intestinal glutaminase
activity
Antonio Gil-Gómez, Isidora Ranchal, Ana Isabel Gomez-Sotelo,
Marta García-Valdecasas, Angela Rojas, Jose A. Del Campo,
Manuel Romero-Gómez
382: Cost-effectiveness of rifaximin treatment in patients
with hepatic encephalopathy
Duygu Bozkaya, Andrew C. Barrett, Kristen Migliaccio-Walle
NOVEMBER 8
SATURDAY
383: Fragmented QRS is an independent predictor of
mortality in patients with decompensated cirrhosis
Mehmet Demir
384: Pancreatic congestion in liver cirrhosis correlates
with impaired insulin secretion
Taira Kuroda, Masashi Hirooka, Mitsuhito Koizumi, Hironori Ochi,
Yoshiko Hisano, Kenji Bando, Bunzo Matsuura, Teru Kumagi,
Yoichi Hiasa
385: Correlations of portal hypertensive gastropathy
with clinical/hemodynamic complications and survival
in patients with liver cirrhosis
Hyo Sun Kim, Ki Tae Suk, Eun Jin Kim, Sang Hyun Park, Chang
Seok Bang, Dong Joon Kim
386: Portal vein thrombosis is not associated with
increased mortality in cirrhotic patients
Kristin Berry, Justin Taylor, Iris W. Liou, George N. Ioannou
387: Pre-Transplant Hepatic Encephalopathy is
Associated with Significantly Lower Survival Following
Liver Transplantation
Robert J. Wong, Robert G. Gish, Ramsey Cheung, Aijaz Ahmed
Presenters in Attendance 5:30 – 7:00 PM
 100A POSTER SESSIONS
Poster Sessions
388: Increased risk of Portal Vein Thrombosis in Non-
Alcoholic Steatohepatitis (NASH) and Cryptogenic
Cirrhosis: Evidence for a Thrombophilic State
Jonathan G. Stine, Neeral L. Shah, Curtis K. Argo, Shawn Pelletier,
Stephen H. Caldwell, Patrick G. Northup
389: Hypercalcemia: A complication and predictor of
mortality among patients with severe liver dysfunction
Suman Nayak, Rajendra P. Mathur, Sivaramakrishnan
Ramanarayanan, Gyan Prakash, Shiv K. Sarin, Manoj Kumar,
Chitranshu Vashishtha, Rakhi Maiwall, Ajeet S. Bhadoria
390: Platelet-derived microparticles in decompensated
cirrhosis: relation to blood platelet level and indices of
coagulation
Nicolas M. Intagliata, Stephen H. Caldwell, Christine K. Rudy, Tae
Hee Lee, Patrick G. Northup, Patcharin Pramoonjago, Josephine
Lannigan, Uta Erdbrugger
391: Splenomegaly : splenic volume measurement by
ultrasound, validity and reliability, clinical implications
in liver cirrhosis
Sang Gyune Kim, Young Seok Kim, Hee Jae Jung, Sae Hwan Lee,
Soung Won Jeong, Jae Young Jang, Young Don Kim, Gab Jin
Cheon, Hong Soo Kim, Boo Sung Kim
392: Hepatic encephalopathy may be associated with
enzymatic impairment of ammonia metabolism: Is there
a case for studying urea cycle function in cirrhosis?
Raghavender Gotur, Bryan E. Hainline, Qin Sun, Eric S. Orman,
Naga P. Chalasani, Marwan Ghabril
393: Nutritional assessment in cirrhotic outpatients and
NOVEMBER 8
its impact on quality of life
SATURDAY
Claudia I. Blanco, Ma Guadalupe Martinez Galindo, Alejandro
Ramon R. Angeles Labra, Jose Armando Carmona Castañeda,
Griselda Martínez Ramírez, Adriana López Luría, María D. Avila
Langarica, María A. Barragán Valarezo, Elizabeth Perez Cruz,
Dolores Enciso González, Felipe Zamarripa Dorsey
394: Splenic artery embolization is associated with
increased morbidity and mortality in patients with
cirrhosis or liver transplantation
Indira Donepudi, Narayan Dharel, Angelo H. Paredes, Richard K.
Sterling, R. Todd Stravitz, Brian J. Strife, Mohammad S. Siddiqui,
Scott Matherly, Puneet Puri, Velimir A. Luketic, Carolyn Driscoll,
Arun J. Sanyal
395: Clinical significance of minimal hepatic
encephalopathy
Zita Galvin, Audrey Dillon, Damien Lowry, Jennifer Russell,
Stephen Stewart
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
396: Hyperammonemia (HA) as a Predictor of Episodic
Neurocognitive Dysfunction: Lessons From Clinical
Studies of Patients with Urea Cycle Disorders (UCDs)
and Hepatic Encephalopathy (HE)
Bruce F. Scharschmidt, Richard Rowell, Marzena Jurek, Dion F.
Coakley, Masoud Mokhtarani, Uta Lichter-Konecki, Susan A.
Berry, George Diaz, Brendan Lee, William Rhead, Don C. Rockey,
Marwan Ghabril, Parvez S. Mantry, Robert S. Brown, John M.
Vierling
397: Hepatic Encephalopathy, A Preventable
Readmission: Implementation of Quality Indicators at a
Tertiary Care Center
Abdul Haseeb, Juan F. Gallegos-Orozco
398: Sarcopenia in patients with liver cirrhosis – a
gender specific complication?
Thomas Zimmerer, Thomas Hoertig, Christoph Antoni, Matthias
Ebert, Johanna C. Nissen
399: VIATORR endoprosthesis do not self-expand
to their nominal diameters in cirrhotic livers: new
evidence toward the risk reduction of post-TIPS hepatic
encephalopathy
Filippo Schepis, Francesco Vizzutti, Guido Marzocchi, Pietro
Quaretti, Antonio G. Rampoldi, Roberto Agazzi, Rita Golfieri,
Angelo Luca, Fabrizio Fanelli, Cristian Caporali, Stefano Colopi,
Luigi Rega, Umberto Arena, Ilaria Fiorina, Lorenzo Moramarco,
Aldo Airoldi, Roberto Nani, Matteo Renzulli, Cristina Mosconi,
Raffaele Bruno, Stefano Fagiuoli, Alessandro Cannavale, Tommaso
Di Maira, Stefano Gitto, Erica Villa
400: Portal vein thrombosis significantly increases
mortality in advanced cirrhosis with improved prognosis
being associated with portal vein recanalization
Carlos Noronha Ferreira, Teresa Rodrigues, Patrícia Sousa,
Fernando Ramalho, Paula Alexandrino, José F. Velosa
401: The Performance of Objective Nutrition Assessment
Tools and the Evaluation of Nutritional Intake in the Pre-
Liver Transplant Populatio
Kaleb J. Marr, Abdel Aziz M. Shaheen, Louisa Lam, Lauren
Schock, Melanie Stapleton, Kelly W. Burak, Maitreyi Raman
402: A multicenter survey of the efficacy and safety of
danaparoid sodium treatment for portal vein thrombosis
Takaaki Ohtake, Kunihiko Tsuji, Teruaki Kawanishi, Takuro
Machida, Hideyasu Takagi, Shinichi Mezawa, Yasuyuki Yazaki,
Yasuhisa Shinomura, Yutaka Kohgo
403: Change in epidemiology of chronic liver disease,
2004-2013
Sumeet K. Asrani, Maria A. Kouznetsova, Andrew Masica, Brett
Stauffer, Michael Hagan, Patrick Kamath, James F. Trotter, Fasiha
Kanwal
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
404: Blood Group Non-O is a Risk Factor for Portal
Vein Thrombosis
Elisabeth P. Plompen, Sarwa Darwish Murad, Massimo Primignani,
Elwyn Elias, Jonel Trebicka, Luc Lasser, Bettina E. Hansen, Juan
Carlos Garcia-Pagan, Dominique Valla, Frank W. Leebeek, Harry
L. Janssen
Experimental Cholestasis
405: Role of the microRNA-FoxA2 axis in biliary-
committed progenitor cells during cholestatic liver injury
Kelly McDaniel, Fanyin Meng, Heather L. Francis, Yuyan Han,
Julie Venter, Nan Wu, Morgan Quezada, Ying Wan, Shannon S.
Glaser, Gianfranco Alpini
406: Modulation of β-catenin in experimental
cholestasis: A therapeutic opportunity
Kari Nejak-Bowen, Satdarshan (Paul) S. Monga
407: Post-translational regulation of Polycystin 2 (PC2)
protein expression by ubiquitination and autophagy as
a novel mechanism of cholangiocyte repair and reaction
to biliary damage
Carlo Spirli, Carola M. Morell, Ambra Villani, Luca Fabris, Romina
Fiorotto, Mario Strazzabosco
408: ENDTP1/CD39 deficiency aggravates liver injury
and fibrosis in sclerosing cholangitis model in Mdr2-/-
mice
Zhen-Wei Peng, Naoki Ikenaga, Susan B. Liu, Simon C. Robson,
Yury Popov
409: High Systemic Autotaxin Induces Itch in Mice
Ruth Bolier, Dagmar Tolenaars, Andreas E. Kremer, Joanne
Verheij, Ulrich Beuers, Piter J. Bosma, Ronald Oude Elferink
410: Knockdown of the melatonin receptor, MT2,
enhances biliary hyperplasia and liver fibrosis in
cholestatic bile duct ligated (BDL) mice: novel evidence
for a hepatoprotective role of MT2
Nan Wu, Yuyan Han, Debolina Ray, Julie Venter, Kelly McDaniel,
Allyson Martinez, Shanika Avila, Eugenio Gaudio, Paolo Onori,
Antonio Franchitto, Fanyin Meng, Micheleine Guerrier, Holly A.
Standeford, Gianfranco Alpini, Shannon S. Glaser
411: Attenuated liver fibrosis modulated by miR-141
in secretin knockout mice during cholestatic liver injury
induced by bile duct ligation (BDL)
Yuyan Han, Allyson Martinez, Ying Wan, Kelly McDaniel, Julie
Venter, Heather L. Francis, Holly A. Standeford, Shanika Avila,
Debolina Ray, Haibo Bai, Nan Wu, Yoshiyuki Ueno, Shannon S.
Glaser, Gianfranco Alpini, Fanyin Meng
412: Activation of Sirtuin1 pathway reverses liver injury
in a cholic acid fed mouse model of cholestasis
Supriya Kulkarni, Carol J. Soroka, James L. Boyer
Poster Viewing: 2:00 – 7:30 PM
101A
413: Inhibition of mast cell histamine secretion by
cromolyn sodium treatment decreases BDL-induced liver
inflammation and fibrosis
Laura Hargrove, Fanyin Meng, Lindsey Kennedy, Allyson B. Graf,
Quy P. Nguyen, Yuyan Han, Victoria Huynh, Heather L. Francis
414: Disruption of the normal circadian cycle by
prolonged exposure to darkness attenuates biliary
hyperplasia and liver fibrosis in MDR2 KO mice by
modulation of core clock gene expression
Allyson Martinez, Debolina Ray, Yuyan Han, Fanyin Meng, Julie
Venter, Heather L. Francis, Sharon DeMorrow, Shanika Avila,
Micheleine Guerrier, Kelly McDaniel, Lindsey Kennedy, Haibo Bai,
Holly A. Standeford, Gianfranco Alpini, Shannon S. Glaser
415: Absence of BSEP/ABCB11 protects from cholestatic
liver injury in mice
Claudia D. Fuchs, Gustav Paumgartner, Annika Wahlström,
Peter Chiba, Tatjana Stojakovic, Thierry Claudel, Hanns-Ulrich
Marschall, Michael Trauner
416: Endoplasmic reticulum stress suppresses
hepatic Abcb11 expression but does not induce overt
cholestasis in mice
Anne S. Henkel, Brian E. LeCuyer, Shantel Olivares, Richard Green
417: Central expression of the hypothalamic
neuropeptide galanin is upregulated in rodent models
of primary sclerosing cholangitis
Matthew McMillin, Gabriel A. Frampton, Cheryl Galindo, Heather
L. Francis, Sharon DeMorrow
418: Ezetimibe prevents diosgenin-induced cholestatic
NOVEMBER 8
liver injury in mice
SATURDAY
Yuji Tanaka, Toshinori Kamisako
419: Necroptosis in human primary biliary cirrhosis and
in murine models of bile acid toxicity
Marta B. Afonso, Marta Caridade, Pedro M. Rodrigues, Helena
Cortez-Pinto, Rui E. Castro, Cecília M. Rodrigues
Fibrosis: Clinical and Translational
420: Paracrine Signaling From Transplanted
Hepatocytes But not From Liver Sinusoidal Endothelial
Cells (LSEC) Rescues Mice From Acetaminophen (APAP)-
Induced Acute Liver Failure (ALF)
Preeti Viswanathan, Yogeshwar Sharma, Sriram Bandi, Sanjeev
Gupta
421: Pleiotrophin Regulates the Ductular Reaction
by Controlling the Migration of Cells in Liver Progenitor
Niches
Gregory A. Michelotti, Anikia Tucker, Mariana V. Machado,
Marzena Swiderska-Syn, Steve S. Choi, Leandi Kruger, Katherine
S. Garman, Cynthia A. Moylan, Cynthia D. Guy, Heather
Himburg, John P. Chute, Anna Mae Diehl
Presenters in Attendance 5:30 – 7:00 PM
 102A POSTER SESSIONS
Poster Sessions
422: Vivo Morpholino local inhibition of hepatic
gonadotropin-releasing hormone (GnRH) expression
reduces liver fibrosis in cholestatic rats through
increased miR-125a expression
Debolina Ray, Yuyan Han, Fanyin Meng, Julie Venter, Heather L.
Francis, Sharon DeMorrow, Yoshiyuki Ueno, Matthew McMillin,
Paolo Onori, Haibo Bai, Allyson Martinez, Eugenio Gaudio,
Shannon S. Glaser, Gianfranco Alpini
423: Alternatively activated M2 macrophages promotes
hepatocyte differentiation in hepatic progenitor cell
mediated liver regeneration in acute on chronic liver
failure patients
Dhananjay Kumar, Sheetalnath Rooge, Smriti Shubham, Adil
Bhat, Charvi Syal, Archana Rastogi, Chhagan Bihari, Viniyendra
Pamecha, Anupam Kumar, Shiv K. Sarin
424: The pro-inflammatory and pro-fibrogenic actions
of the HIV-envelope protein gp120 are mediated by
inflammasome activation and miR-29b
Andrea Cappon, Raffaele Bruno, Sandra Gessani, Andrea
Masotti, Fabio Marra
425: Activation of Toll-Like-Receptors (TLR) on isolated
Kupffer cells (KC) and sinusoidal endothelial cells (SEC)
of the liver: Opposing effects on the production of the
vasoconstrictor Thromboxane B2
Julia Schewe, Lisa Selzner, Ingrid Liss, Burkhard Göke, Alexander
L. Gerbes, Christian J. Steib
426: Cannabinoid Receptor 1 is Involved in Hepatic
Inflammation and Fibrosis in Mice by Regulating Bone
Marrow-Derived Monocyte/Macrophage
NOVEMBER 8
SATURDAY
Ping Mai, Le Yang, Lin Wang, Lei Tian, Shuangshuang Jia,
Yuanyuan Zhang, Xin Liu, Lin Yang, Liying Li
427: Hepatic progenitor cells contribute to the
progression of liver fibrosis induced by 2-AAF/CCl4 in
rats through the non-canonical wnt pathway
Jiamei Chen, Yongping Mu, Yuyou Duan, Ping Liu
428: Downregulation of pro-fibrotic and pro-
inflammatory genes in liver sinusoidal endothelial cells
following activation of the bile acid receptors FXR and
TGR5
Rachel McMahan, Cara Porsche, Michael Edwards, Luciano
Adorini, Moshe Levi, Hugo R. Rosen
429: Repair-related Activation of Hedgehog
Signaling in Stromal Cells Promotes Intrahepatic
Hypothyroidism
Brittany Bohinc, Gregory A. Michelotti, Guanhua Xie, Herbert
Pang, Ayako Suzuki, Cynthia D. Guy, Dawn L. Piercy, Leandi
Kruger, Marzena Swiderska-Syn, Mariana V. Machado, Thiago
A. Pereira, Ann Marie Zavacki, Manal F. Abdelmalek, Anna Mae
Diehl
430: MicroRNA profiling of circulating exosomes
during experimental liver fibrosis
Li Chen, Ruju Chen, David Brigstock
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
431: Soluble CD146, a novel endothelial marker, is
related to the severity of liver disease
Efrossini Nomikou, Alexandra Alexopoulou, Larisa E. Vasilieva,
Danai Agiasotelli, Spyros P. Dourakis
432: Species differences in the antifibrotic effect of
imatinib
Inge M. Westra, Dorenda Oosterhuis, Rick Mutsaers, Geny M.
Groothuis, Peter Olinga
433: Precise liver fibrosis staging by automated
morphometry of liver biopsies: E-Metavir
Paul Cales, Julien Chaigneau, Jerome Boursier, Gilles Hunault,
Sophie Michalak, Frederic Oberti, Isabelle Fouchard-Hubert,
Sandrine Bertrais, Marie Christine Rousselet
434: Genome Wide Association Study (GWAS) identifies
a SNP near the MRC2 (mannose receptor C, type 2)
gene associated with increased liver collagen content in
Caucasian HBV patients
Nezam H. Afdhal, Thomas J. Urban, Zachary D. Goodman, Keyur
Patel, Dongliang Ge, Xin Guo, Zhaoshi Jiang, Xi Zhao, Matthew
Paulson, Anuj Gaggar, Jeffrey Bornstein, Mani Subramanian,
John G. McHutchison, Sarah E. Kleinstein, Nanye Long, David B.
Goldstein, Rohit Loomba, Alexander J. Thompson
435: Factors influencing liver stiffness in chronic liver
disease
Chikage Nakano, Hiroko Iijima, Tomoko Aoki, Kenji Hashimoto,
Masahiro Yoshida, Akio Ishii, Tomoyuki Takashima, Nobuhiro
Aizawa, Naoto Ikeda, Hironori Tanaka, Hirayuki Enomoto,
Masaki Saito, Seiichi Hirota, Shuhei Nishiguchi
436: Cartilage oligomeric matrix protein (COMP) serum
levels: a new non-invasive biomarker of liver fibrosis in
patients with chronic viral hepatitis
Stella Gabeta, Kalliopi Zachou, Zakera Shums, Nikolaos Gatselis,
George K. Koukoulis, Gary L. Norman, George N. Dalekos
437: New canine liver cirrhotic model to develop a less
invasive regeneration therapy using cultured autologous
bone marrow-derived cells
Takashi Matsuda, Taro Takami, Tsuyoshi Ishikawa, Naoki
Yamamoto, Shuji Terai, Isao Sakaida
438: Spleen prevents the development of liver fibrosis
by Kupffer cell deactivation through lipocalin-2
production in mice
Tomonori Aoyama, Akira Uchiyama, Kazuyoshi Kon, Hironao
Okubo, Shunhei Yamashina, Kenichi Ikejima, Shigehiro Kokubu,
Akihisa Miyazaki, Sumio Watanabe
439: Serum Lysyl Oxidase Like 2 (sLOXL2) Levels
Correlate with Ishak Fibrosis Score and Decrease with
Treatment with Tenofovir Disoproxil Fumarate (TDF) in
Patients with Chronic Hepatitis B (CHB)
W. Ray Kim, Rohit Loomba, Preeti Lal, Raul E. Aguilar Schall,
Ann D. Johnson, Jeffrey D. Bornstein, Mani Subramanian, John G.
McHutchison, Stephen A. Harrison, Arun J. Sanyal
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
440: How long a prognosis by liver fibrosis tests is
accurate?
Sandrine Bertrais, Jerome Boursier, Frédéric Oberti, Isabelle
Fouchard-Hubert, Valerie Moal, Paul Cales
441: Exhaled Breath Analysis Reveals New Biomarkers
to Diagnose Advanced Fibrosis in Patients with Chronic
Liver Disease
Mohammed Eyad Yaseen Alsabbagh, Ahmad Tarek Chami, Singh
Gurshawn, Mina Shaker, Ibrahim A. Hanouneh, David Grove,
Rocio Lopez, Nizar N. Zein, Raed Dweik, Naim Alkhouri
442: Oral Treatment with PBI-4050 Reduces Fibrosis in
Carbon Tetrachloride (CCl4)-Induced Hepatic Fibrosis
Brigitte Grouix, Kathy Hince, François Sarra-Bournet, Alexandra
Felton, Mikaël Tremblay, Shaun Abbott, Jean-Simon Duceppe,
Boulos Zacharie, Pierre Laurin, Lyne Gagnon
443: Wisteria floribunda agglutinin-positive Mac-2
binding protein as a predictor of liver fibrosis in patients
with non-alcoholic fatty liver disease
Masanori Abe, Teruki Miyake, Atsushi Kuno, Yasuharu Imai,
Yoshiyuki Sawai, Keisuke Hino, Yuichi Hara, Shuhei Hige, Michiie
Sakamoto, Masaaki Korenaga, Yoichi Hiasa, Masashi Mizokami,
Hisashi Narimatsu
444: Less invasive liver regeneration therapy for liver
cirrhosis using cultured autologous bone marrow-
derived mesenchymal stem cells with redox-regulatory
capacity
Taro Takami, Shuji Terai, Luiz Fernando Quintanilha, Bruno D.
Paredes, Koichi Fujisawa, Naoki Yamamoto, Isao Sakaida
445: A novel glycobiomarker: Wisteria floribunda
agglutinin Macrophage Colony-Stimulating Factor
Receptor for predicting carcinogenesis and survival of
liver cirrhosis patients
Etsuko Iio, Makoto Ocho, Akira Togayachi, Noboru Shinkai,
Masanori Nojima, Atsushi Kuno, Yuzuru Ikehara, Izumi Hasegawa,
Kei Fujiwara, Shunsuke Nojiri, Takashi Joh, Masashi Mizokami,
Hisashi Narimatsu, Yasuhito Tanaka
446: Cholecystectomy Is Associated with an Increased
Rate of Hepatic Fibrosis Development Compared to
Patients with Chronic Hepatitis C Infection who are Non-
responders to Interferon/Ribavirin
Donald J. Martin, Rick A. Weideman, Terri Crook, Geri Brown
447: Pro-C3-levels in patients with HIV/HCV coinfection
reflect fibrosis stage and degree of portal hypertension
Christian Jansen, Diana J. Leeming, Mattias Mandorfer, Inger
Byrjalsen, Robert Schierwagen, Philipp Schwabl, Morten A.
Karsdal, Evrim Anadol, Christian P. Strassburg, Jürgen K.
Rockstroh, Markus Peck-Radosavljevic, Søren Møller, Flemming
Bendtsen, Aleksander Krag, Thomas Reiberger, Jonel Trebicka
Poster Viewing: 2:00 – 7:30 PM
103A
448: Longitudinal hepatic and PBMC gene expression
profiling of HIV and/or HCV-infected patients with
advanced liver disease treated with simtuzumab, an
anti-LOXL2 antibody
Eric G. Meissner, Mary McLaughlin, Lindsay A. Matthews, Bittoo
Kanwar, Jeffrey D. Bornstein, Joseph A. Kovacs, Shyam Kottilil,
Caryn G. Morse
449: Aspirin Use is Associated with Lower Liver Fibrosis
Indices among Adults in the United States
Zhenghui G. Jiang, Linda Feldbrügge, Elliot B. Tapper, Yury Popov,
Tahereh Ghaziani, Simon C. Robson, Kenneth Mukamal
450: Fibrosis regression in hepatitis C patients with
cirrhosis: Ishak fibrosis score and CPA pre treatment
predict regression post sustained virological response
Paolo Nieddu, Ameet Dhar, Robert D. Goldin, Nimzing Ladep,
Sarosh Khan, Mark R. Thursz, Ashley S. Brown
451: Assessment of regression of fibrosis using
Fibroscan® in patients with chronic hepatitis B receiving
antiviral treatment beyond 5 years
Young Eun Chon, Myung Sung Min, Kyu Sik Jung, Kwang-Hyub
Han, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Jun Yong
Park
452: Development of Novel Lipidnanoparticle siRNA
Delivery System Targeting Collagen Chaperone Protein
HSP47 for Clinical Treatment of Liver Fibrosis
Wenbin Ying, Jun Zhang, Yun Liu, Li Wang, Jihua Liu, Jian Liu,
Jingyuan Yu, Jean-Pierre Clamme, Jiping Yao, Lishuang Xu, Donald
A. Kaiser, Yasunobu Tanaka, Miyono Miyazaki, Keiko Kajiwara,
Kenjiro Minomi, Yoshiro Niitsu
NOVEMBER 8
SATURDAY
453: Subclinical cirrhosis diagnosed by transient
elastography demonstrates increased risk of severe
clinical outcomes and HCC
Tianyan Chen, Remy E. Wong, Kathleen C. Rollet-Kurhajec, Rasha
Alshaalan, Philip Wong, Marc Deschenes, Peter Ghali, Giada
Sebastiani
454: Irbesartan for severe fibrosis in chronic hepatitis C:
a double-blind randomized trial (ANRS HC19 Fibrosar)
Paul Cales, Yannick Bacq, Jean-Pierre Vinel, Corinne Bonny,
Jean-Louis Payen, Dominique Guyader, Albert Tran, Dominique
G. Larrey, Christine Silvain, Marie Christine Rousselet, Frederic
Oberti, Mélanie Simony, Fabrice Carrat
455: Improvements in APRI and FIB-4 fibrosis scores
correlate with decreases in sCD14 in HIV-1 infected
adults receiving cenicriviroc over 48 weeks
Melanie Thompson, Will Chang, Helen Jenkins, Amy Flynt, Millie
Gottwald, Eric Lefebvre
456: A 6-Gene Score Associated With Advanced Stages
of Presymptomatic HBV Related Fibrosis
Mingyi Xu, Ying Qu, Qingqing Zhang, Lungen Lu
Presenters in Attendance 5:30 – 7:00 PM
 104A POSTER SESSIONS
Poster Sessions
457: Localizations and functional roles of MMP-1 in
the early and advanced stages of human non-alcoholic
steatohepatitis
Hiroaki Yokomori, Isao Okazaki, Masaya Oda, Wataru Ando,
Yutaka Suzuki, Tsutsui Nobuhiro, Eigoro Yamanouchi, Hajime
Kuroda, Soichi Kojima, Mitsuko Hara, Yutaka Inagaki
458: Increased autophagy is associated with ductular
reaction in human cirrhotic livers
Tzu-Min Hung, Po-Huang Lee
459: The hitch with non-invasive tests of liver fibrosis:
evaluated by binary AUROC but used with stage
classifications
Paul Cales, Jerome Boursier, Isabelle Fouchard-Hubert, Frederic
Oberti, Victor de Ledinghen, Vincent Leroy
Hemochromatosis, Wilson Disease, a-1
Antitrypsin Deficiency
460: Hfe and hemojuvelin regulate hepcidin
expression and iron metabolism via the same pathway:
Genetic evidence from single and double knockout mice
Patricia Kent, Nicole Wilkinson, Marco Constante, Konstantinos
Gkouvatsos, John Wagner, Manuela M. Santos, Kostas
Pantopoulos
461: Acute Intermittent Porphyria: High incidence of
Pathogenic HMB-Synthase (HMBS) Non-Synonymous
SNPs (nsSNPs) in Genomic Databases Suggests Other
Genetic/Environmental Factors Cause the Acute Attacks
NOVEMBER 8
Brenden Chen, Jörg Hakenberg, Ramakrishnan R. Srinivasan,
SATURDAY
Dana O. Doheny, Inga Peter, Constanza Solis-Villa, Rong Chen,
David F. Bishop, Makiko Yasuda, Robert J. Desnick
462: Lorcaserin Improves the NASH Clinical Score in the
Majority of High-Risk Patients: a Retrospective Analysis
of Three Phase 3 Studies
Wajahat Z. Mehal, Randi Fain, Alan Glicklich, Yuhan Li, William
Shanahan, William Soliman
463: No increased risk of hepatocellular carcinoma
in cirrhosis due to Wilson’s disease during long term
follow up
Suzanne van Meer, Robert A. de Man, Aad P. van den Berg,
Roderick Houwen, Francisca Linn, Peter D. Siersema, Karel J. van
Erpecum
464: Patients with Wilson disease without detectable
ATP7B mutations
Albert Stättermayer, Heinz M. Zoller, Karl Heinz Weiss, Ferenc
Szalay, Radan Bruha, Roderick Houwen, Rudolf E. Stauber, Petra
E. Steindl-Munda, Harald Hofer, Wolfgang Stremmel, Peter Ferenci
465: Sex differences in liver SAM:SAH ratios and
gene transcript levels after pre-and post-natal choline
supplementation and copper chelation treatment in an
animal model of Wilson disease
Valentina Medici, Noreene Shibata, Kusum K. Kharbanda,
Charles H. Halsted
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
466: Using hIPSCs to model liver disease associated
with classic mutations of alpha-1 antitrypsin
Tamara Taketani, Maria P. Ordonez, Lawrence S. Goldstein
467: A propensity score-matched cohort study of the
effect of vitamin E in NAFLD patients
Gi Hyun Kim, Jin Wook Kim, Jung Wha Chung, Eun Sun Jang,
Sook-Hyang Jeong
468: Variability in erythrocyte and plasma porphyrin
levels in erythropoietic protoporphyria and X-linked
protoporphyria
Eric Gou, John D. Phillips, Manisha Balwani, Montgomery Bissell,
Joseph R. Bloomer, Herbert L. Bonkovsky, Robert J. Desnick,
Hetanshi Naik, Karl E. Anderson
469: Osteoporosis and bone fractures in alcoholic liver
disease: A systematic review and meta-analysis
Chang Seok Bang, Hyo Sun Kim, Sang Hyun Park, Eun Jin Kim, Ki
Tae Suk, Dong Joon Kim
470: Elevated alkaline phosphatase predicts response
in polycystic liver disease during somatostatin analogue
therapy: a multi-center pooled analysis on individual
patient data
Tom J. Gevers, Frederik Nevens, Vicente E. Torres, Marie C.
Hogan, Joost Drenth
471: A Phase I Pharmacokinetic Profiling Study in
Patients Receiving Trientine Dihydrochloride for the
Treatment of Wilson Disease
Karl Heinz Weiss, Ulrike Teufel, Jan Pfeiffenberger, Christian
Rupp, Andreas Wannhoff, Wolfgang Stremmel, Daniel Gotthardt
Imaging in Cancer
472: Hemodynamic differences in the very early phase
of hepatocellular carcinoma (HCC) using contrast-
enhanced ultrasonography (CEUS)
Akiko Saito, Satoshi Katagiri, Masakazu Yamamoto, Keiko
Shiratori, Masayuki Nakano, Toshio Morizane
473: Correlation of Enhancement Pattern of CEUS with
Histopathologic Feature in Small Nodular Lesions in
Chronic Liver Disease
Seung Kak Shin, Yun Soo Kim, Oh Sang Kwon, Duck Joo Choi,
Ju Hyun Kim
474: Preoperative predictive value of
18F-fluorodeoxyglucose positron emission tomography/
computed tomography for microvascular invasion of
small hepatocellular carcinoma
Tomoki Kobayashi, Hiroshi Aikata, Hiromi Kan, Takayuki
Fukuhara, Noriaki Naeshiro, Tomokazu Kawaoka, Masataka
Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami,
Hideyuki Hyogo, Kazuaki Chayama
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
475: Indication of super-delayed phase image
acquisition of Gd-EOB-DTPA enhanced MRI to improve
poor contrast images on routine hepatobiliary phase
images for detection of liver lesion
Satoshi Kobayashi, Kazuto Kozaka, Azusa Kitao, Norihide
Yoneda, Hiroshi Ikeno, Osamu Matsui, Toshifumi Gabata
476: Single-center experience with stereotactic liver
surgery: A review over 5 years
Vanessa M. Banz, Pascale Tinguely, Mathias Worni, Philip
Mueller, Daniel Inderbitzin, Delphine Ribes, Matthias Peterhans,
Stefan Weber, Daniel Candinas
477: Complications related to percutaneous biopsies
of the liver, pancreas, lymph nodes and tumors in the
retroperitoneal space performed under ultrasound
control
Stoyan S. Handzhiev
478: Increased Rate of Pre-transplant Magnetic
Resonance Imaging Under-staging of Hepatocellular
Carcinoma in Patients With Transjugular Intrahepatic
Portosystemic Shunts
She-Yan Wong, Dina Halegoua-De Marzio, Colette Shaw, Jesse
M. Civan
479: Hepatic Angiomyolipoma Mimicking
Hepatocellular Carcinoma: Clinical, Magnetic Resonance
Imaging and Pathological Characteristics in 9 Cases
Chunping Wang, Hongyan Li, Hong Wang, Xiaodong Guo,
Changchun Liu, Xudong Gao, Jianhui Qu, Ze Liu, Xiu juan Chang,
Yin Ying Lu, Zhen Zeng, Min Lou, Ke-Qin Hu, Yongping Yang
480: Metabolic tumor volume by Fluorine-18
fluorodeoxyglucose positron emission tomography as
useful predictor for early recurrence after recurrence in
intrahepatic cholangiocarcinoma
Satoru Seo, Etsuro Hatano, Yuji Nakamoto, Kenji Takemoto, Kojiro
Taura, Tadahiro Uemura, Kentaro Yasuchika, Akira Mori, Toshimi
Kaido, Hideaki Okajima, Shinji Uemoto
481: A safety, feasibility and accuracy study of
laparoscopic computer-assisted navigated microwave
ablation of liver tumors
Pascale Tinguely, Delphine Ribes, Jacob Freedman, Silja Karlgren,
Fusagila Matteo, Matthias Peterhans, Stefan Weber, Daniel
Candinas, Henrik Nilsson
Imaging in Fibrosis
482: Diagnostic Accuracy and Reliability of Supersonic
Shear Imaging in Comparison with Transient
Elastography for Assessment of Liver Fibrosis in Patients
with Chronic Liver Disease
Masato Yoneda, Emmanuel Thomas, Seth N. Sclair, Eugene R.
Schiff
Poster Viewing: 2:00 – 7:30 PM
105A
483: Recombinant Human Acid Sphingomyelinase
Clears Hepatic Sphingomyelin in Adults with Niemann-
Pick Disease Type B
Beth Thurberg, Melissa Wasserstein, Simon Jones, Thomas D.
Schiano, Gerald F. Cox
484: Comparison of 2-dimensional and 3-dimensional
magnetic resonance elastography (MRE) for diagnosis
of advanced fibrosis in patients with biopsy-proven
NAFLD: A prospective study
Rohit Loomba, Tanya Wolfson, William Haufe, Jonathan Hooker,
Nikolaus M. Szeverenyi, Brandon Ang, Archana Bhatt, Cynthia A.
Behling, Mark A. Valasek, Grace Y. Lin, Anthony C. Gamst, David
A. Brenner, Meng Yin, Richard Ehman, Claude B. Sirlin
485: The feasability of Transient Elastography using M
and XL probes for assesing liver stiffness – a practice
audit of 3235 examinations on a multi-etiology cohort
Ioan Sporea, Flavia Motiu, Alina Popescu, Roxana Sirli, Ruxandra
G. Mare, Oana Gradinaru Tascau, Alexandra Deleanu, Isabel
Dan
486: Quantitative Assessment of Liver Fibrosis by Digital
Image Analysis: Relationship to Ishak Staging and
Elasticity by Shear-wave Elastography
Ender G. Yegin, Korkut Yegin, Faruk Erdem Kombak, Emrah
Karatay, Davut Tüney, Cigdem Ataizi Celikel, Osman C. Ozdogan
487: Accuracy of Real-Time Shear Wave Elastography
for Assessing Liver Fibrosis in Chronic Liver Disease: A
Pilot Study
Oranit Cohen-Ezra, Yeroham Kleinbaum, Orit Pappo, Muriel
Webb, Ella Veitsman, Tania Bradichevsky, Yael Inbar, Sima
NOVEMBER 8
Katsherginsky, Peretz Weiss, Keren Tsaraf, Ziv Ben-Ari
SATURDAY
488: The Usefulness of Non-invasive Liver Stiffness
Measurement by Fibroscan® for Risk Management
of HCC in Chronic Hepatitis C Patients Who Achieved
Sustained Virological Response (SVR)
Nobuhito Taniki, Hirotoshi Ebinuma, Nobuhiro Nakamoto, Akihiro
Yamaguchi, Takeru Amiya, Yuko Wakayama, Hiroko Murata,
Po-sung Chu, Shingo Usui, Hidetsugu Saito, Takanori Kanai
489: Magnetic resonance elastography is useful as non-
invasive diagnostic method for predicting liver fibrosis
in nonalcoholic fatty liver disease
Kento Imajo, Takaomi Kessoku, Yasushi Honda, Yuji Ogawa,
Hironori Mawatari, Masato Yoneda, Satoru Saito, Atsushi
Nakajima
490: Spleen stiffness correlates with spleen size but not
liver fibrosis in patients with alcoholic liver disease
Maja Thiele, Bjørn S. Madsen, Aleksander Krag
491: Muscle fat infiltration using total psoas density in
computed tomography predicts mortality in cirrhosis
Christos K. Triantos, Andreas Karatzas, Maria Kalafateli, Paraskevi
Tselekouni, Georgios Tsiaoussis, Nikolaos Koukias, Efstratios
Koutroumpakis, Konstatinos Thomopoulos, Vasiliki Nikolopoulou,
Christina Kalogeropoulou, Chrisoula Labropoulou-Karatza C
Presenters in Attendance 5:30 – 7:00 PM
 106A POSTER SESSIONS
Poster Sessions
492: Supersonic shear imaging predicts cirrhosis and
advanced fibrosis in chronic hepatitis C patients
Shih-Jer Hsu, Yu L. Tan, Ding-Shinn Chen, Jia-Horng Kao
493: The usefulness of spleen stiffness evaluated by
Acoustic Radiation Force Impulse (ARFI) elastography
for assessing liver fibrosis
Simona Bota, Ioan Sporea, Oana Gradinaru Tascau, Alina
Popescu, Roxana Sirli, Mirela Danila
494: Comparison between 2D-real time Shear Wave
Elastography (2D-SWE) and simple serological scores
for liver fibrosis assessment for clinical routine,
considering Transient Elastography (TE) as reference
method
Simona Bota, Rafael Paternostro, Alexandra Etschmaier, Remy
Schwarzer, Petra Salzl, Mattias Mandorfer, Tuul Purevsambuu,
Monika Ferlitsch, Christian Kienbacher, Thomas Reiberger,
Michael Trauner, Markus Peck-Radosavljevic, Arnulf Ferlitsch
495: The two faces of non-invasive assessment of liver
disease severity: correlation between liver stiffness and
hepatic vein arrival times
Francesco Ridolfi, Teresa Abbattista, Annamaria Schimizzi,
Eugenio Brunelli
496: Alkaline phosphatase, but not ongoing alcohol
abuse, influence liver stiffness measurements in
alcoholic liver disease
Maja Thiele, Bjørn S. Madsen, Christian Jansen, Christian P.
Strassburg, Jonel Trebicka, Aleksander Krag
497: Noninvasive evaluation of portal hypertension by
NOVEMBER 8
spleen elastography
SATURDAY
Karel Dvorak, Vaclav Smid, Renata Sroubkova, Jaromir Petrtyl,
Radan Bruha
498: Extracorporeal Shock Wave Lithotripsy for
Difficult-to-Retrieve Common Bile Duct Stones: A Seven
Year Single Center Experience
Syed M. Hassan, Kapeel Raja, Asad A. Khan, Nasir Hassan Luck,
Munnawar Khaliq, Muhammad Manzoor, Zaigham Abbas
499: The correlation between histology and the three
elastographic techniques available in our department
Ioan Sporea, Oana Gradinaru Tascau, Alina Popescu, Madalina
Popescu, Roxana Sirli, Flavia Motiu
500: Usefulness of Acoustic Noninvasive Assessment
of Liver Stiffness: Radiation Force Impulse (ARFI)
Elastography for staging of liver fibrosis and differential
diagnosis of hepatic tumor
Shunsuke Nakajima, Takaaki Ohtake, Takumu Hasebe, Koji
Sawada, Masami Abe, Yasuaki Suzuki, Mikihiro Fujiya, Yutaka
Kohgo
501: Assessment of hepatic fibrosis with Superb Micro-
vascular Imaging: a preliminary report
Nobuko Koyama, Jiro Hata, Takeshi Sato, Noriaki Manabe,
Hiroshi Imamura, Ken Haruma, Keisuke Hino
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
502: Shear Wave Elastography and Hepatorenal Index
for the Assessment of Liver Fibrosis and Steatosis:
a Novel technique and its Predictive Accuracy and
Optimal Measurement Location
George Therapondos, Michael T. Perry, Neal Savjani, Adriana
Dornelles, Edward I. Bluth
503: Liver stiffness measurement in psoriatic patients:
metabolic factor, disease factor or methotrexate play
important role?
Jamrus Pongpit, Saneerat Porntharukchareon, Wasana
Stitchantrakul, Ammarin Thakkinstian, Piyaporn Kaewdoung,
Kwannapa Promson, Supanna Petraksa, Natta Rajatanavin,
Chomsri Kositchaiwat, Abhasnee Sobhonslidsuk
Immunosuppression
504: Short Waiting Time Predicts Early Recurrence of
Hepatocellular Carcinoma after Liver Transplantation:
A Multicenter Study Supporting the “Ablate and Wait”
Principle
Neil Mehta, Julie Heimbach, Denise M. Harnois, Jennifer L. Dodge,
Justin M. Burns, David Lee, William Sanchez, John P. Roberts,
Francis Y. Yao
505: Biomarkers significantly improve the
performance of the Milan criteria in predicting
Hepatocellular carcinoma (HCC) recurrence post liver
transplantation (LT)
Roongruedee Chaiteerakij, Xiaodan Zhang, Benyam D. Addissie,
Essa A. Mohamed, William S. Harmsen, J Paul Theobald, Brian
E. Peters, Joseph Balsanek, Melissa M. Ward, Nasra H. Giama,
Catherine D. Moser, Abdul M. Oseini, Naoki Umeda, Denise M.
Harnois, Michael Charlton, Hiroyuki Yamada, Shinji Satomura,
Alicia Algeciras-Schimnich, Melissa R. Snyder, Terry M. Therneau,
Lewis R. Roberts
506: Injury of Peribiliary Glands of Donor Liver Bile
Ducts Plays a Pivotal Role in the Development of Non-
anastomotic Biliary Strictures after Liver Transplantation
Negin Karimian, Sanna op den Dries, Pepijn D. Weeder, Andrie
Westerkamp, Fernanda Bomfati, Janneke Wiersema-Buist, Bote
G. Bruinsma, Annette S. Gouw, James F. Markmann, Ton Lisman,
Heidi Yeh, Korkut Uygun, Paulo N. Martins, Robert J. Porte
507: Early Post-Operative Neutrophil Gelatinase
Associated Lipocalin (NGAL)-Associated Acute Kidney
Injury Predicts the Development of Chronic Kidney
Disease and Mortality Following Liver Transplantation
Elizabeth C. Verna, Giuseppe Cullaro, Joseph F. Pisa, Robert S.
Brown, Gebhard Wagener
508: The Impact of Deconditioning In Advanced
Cirrhosis
Michael A. Dunn, Deborah A. Josbeno, Mark Sturdevant, Amy
R. Schmotzer, Elizabeth A. Kallenborn, Jaideep Behari, Doug
Landsittel, Andrea DiMartini, Anthony Delitto
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
509: Narcotics Increase Rate of Rejection and Mortality
After Liver Transplantation Regardless of Underlying
Disease Etiology
Mina Pirzadeh, Amir Prushani, Syed-Mohammed R. Jafri, Maria
C. Segovia
510: Positive impact of everolimus on regulatory T cells
after liver transplantation
Clement Barjon, Kaldoun Ghazal, Geraldine Dahlqvist, Faouzi
Saliba, Francois Durand, Christophe Duvoux, Lynda Aoudjehane,
Yvon Calmus, Filomena Conti
511: Predictors of excessive alcohol use following liver
transplantation for alcoholic liver disease: A nationwide
competing risks analysis of psychiatric comorbidity and
occupational status (1990-2013)
Gro Askgaard, Janne S. Tolstrup, Thomas A. Gerds, Ole Hamberg,
Mette Kjær
512: Prevalence and prediction of major adverse
cardiovascular events after liver transplantation using a
novel database
Lisa B. VanWagner, Marina Serper, Raymond Kang, Anton I.
Skaro, Josh Levitsky, Samuel Hohmann, Donald M. Lloyd-Jones
513: Calcineurin inhibitor withdrawal following by
mycophenolate mofetil monotherapy using therapeutic
drug monitoring in maintenance liver transplant
recipients
Guillaume Lassailly, Franck Saint-Marcoux, Juliette Boulanger,
Valerie Canva, Philippe Mathurin, Alexandre Louvet, Odile Goria,
Stephanie Truant, Gilles Lebuffe, Emmanuel Boleslawski, François
René Pruvot, Sebastien Dharancy
514: Alpha-fetoprotein Slope >7.5 ng/mL/month
Predicts Post-transplant Tumor Recurrence and Micro-
vascular Invasion for Hepatocellular Carcinoma within
Milan Criteria
Jeanne-Marie Giard, Neil Mehta, Jennifer L. Dodge, John P.
Roberts, Francis Y. Yao
515: WITHDRAWN
516: Treatment of acute cellular rejection episodes does
not influence fibrosis progression rate in patients with
recurrence HCV after liver transplantation
Pinelopi Manousou, Emmanuel Tsochatzis, Ioanna Parisi,
Francesca Saffioti, Alexandra Mansell, Silvia Aspite, David W.
Patch, James O’Beirne, Douglas Thorburn, Tu Vinh Luong, Amar P.
Dhillon, Massimo Pinzani, Andrew K. Burroughs
517: Pre-transplant Type 2 Hepatorenal Syndrome is
Associated with Persistently Impaired Renal Function
after Liver Transplantation
Hiang K. Tan, Max Marquez, Florence Wong, Eberhard L. Renner
Poster Viewing: 2:00 – 7:30 PM
107A
518: A Single-Center Experience with Preoperative
Selective Internal Radiation Therapy (SIRT) with Y-90
with or without Transarterial Chemoembolization
(TACE), as a Bridging Procedure, in Liver Transplant
Recipients (OLT) with Unresectable Hepatocellular
Carcinoma (uHCC): Efficacy of Combination Therapy
(Rx)
Carlos G. Fasola, Parvez S. Mantry, Bahar Madani, Jeffrey S.
Weinstein, Abdullah Mubarak, Hector Nazario, Adil Habib,
Maisha N. Barnes, Alejandro Mejia, Richard Dickerman, Edward
A. Dominguez, Stephen Cheng
519: HMGB1 and nucleosomes as biomarkers of clinical
outcome in human liver transplantation
Antônio Márcio F. Andrade, Marcus V. Andrade, Agnaldo S.
Lima, Luciana C. Faria
520: Improved but persistent poor functional
performance at 1 year after liver transplantation:
Predictors of performance and opportunities for
intervention
Sarah Uttal, Lisa B. VanWagner, Brittany Lapin, Amanda
Jichlinkski, Joshua Lee, Madeleine Heldman, Brian Poole, Tanvi
Subramanian, Eduardo A. Bustamante, Suvai Gunasekaran,
Christopher S. Tapia, Annapoorani Veerappan, She-Yan Wong,
Josh Levitsky
521: Younger Hepatitis C Virus (HCV) Liver Transplant
(LT) Recipients have Significantly Reduced Graft Survival
Varun Saxena, Jennifer L. Dodge, John P. Roberts, Norah Terrault
522: Impact of portal vein thrombosis prior to liver
transplantation: a multi-center retrospective cohort study
NOVEMBER 8
Constantine J. Karvellas, Filipe S. Cardoso, Malcolm M. Wells,
SATURDAY
Fayaz A. Handoo, Lukasz Kwapisz, Mansour G. Alghanem,
Norman Kneteman, Paul Marotta, Bandar Al-Judaibi
523: Treatment with mTOR inhibitors after liver
transplantation enables a sustained increase in
regulatory T-cells while preserving their suppressive
capacity
Kaldoun Ghazal, Fabien Stenard, Clement Barjon, Lynda
Aoudjehane, Fabiano Perdigao, Olivier Scatton, Yvon Calmus,
Filomena Conti
524: Cardiovascular Risk in Liver Transplant Patients
Tommaso Di Maira, Lorena Puchades, Angel Rubin, Carmen
Vinaixa, María García Eliz, Fernando San Juan, Rafael López
Andujar, Erica Villa, Martin Prieto, Marina Berenguer
525: Long-Term Transplant Outcomes: The Role of Pre-
Transplant Depression
Shari S. Rogal, Gautam Mankaney, Viyan Udawatta, Christopher
B. Hughes, Amit D. Tevar, Mark Sturdevant, Abhinav Humar,
Andrea DiMartini
526: C4d is Present in Portal Venules in Plasma Cell
Hepatitis and May Also be Used as a Predictor for its
Development
Anshu Trivedi, Thomas D. Schiano, Stephen C. Ward, Swan N.
Thung, M. Isabel Fiel, Josh Levitsky
Presenters in Attendance 5:30 – 7:00 PM
 108A POSTER SESSIONS
Poster Sessions
527: Probiotic decreases post-liver transplant infection:
A meta analysis
Tarek Sawas, Shadi Al Halabi, Mubarak W. Sayyar, Won Kyoo
Cho
528: Should Patients Check (WWW.SRTR.ORG) Before
They Get a Liver Transplant?
Bashar M. Attar, David Van Thiel
529: Liver allograft provides immunoprotection for the
cardiac allograft in combined heart-liver transplantation
Tina W. Wong, John M. Stulak, Mark D. Stegall, Julie Heimbach,
Timucin Taner
530: Everolimus with early withdrawal or reduced dose
Calcineurin-Inhibitors (CNI) improves renal function in
Liver Transplant (LT) Recipients: A Meta analysis
Frahad Sahebjam, Sahil Mittal, Gagan K. Sood
531: Portal vein thrombosis is a risk factor for early
mortality and graft loss post liver transplantation:
Analysis of the UNOS database.
Marwan Ghabril, Saurabh Agrawal, Marco A. Lacerda, Eric S.
Orman, Raj Vuppalanchi, Craig Lammert, Howard C. Masuoka,
Samer Gawrieh, Suthat Liangpunsakul, Naga P. Chalasani, A.
Joseph Tector, Paul Y. Kwo
532: The association between early anemia and
the development of renal insuffiency after liver
transplantation
Dilip Moonka, Wadih Chacra, Mohammad Elbatta, Aishwarya
Kuchipudi, Alexander Weick, Charlotte Burmeister, George Divine
NOVEMBER 8
533: Impact of mTOR inhibition on expression of
SATURDAY
immune regulatory molecules by circulating dendritic
cells and regulatory T cells in stable liver transplant
patients
Antonino Castellaneta, Antonio Massaro, Maria Rendina,
Francesca D’Errico, Sonia Carparelli, Angus W. Thomson, Alfredo
Di Leo
534: Abusive drinking after liver transplantation for
pure alcoholic cirrhosis is associated with significant
allograft fibrosis
Marika Rudler, Géraldine Rousseau, Pascal Lebray, Corinne
Vezinet, Daniel Eyraud, Jean-Christophe Vaillant, Thierry Poynard,
Dominique Thabut
535: Early evaluation of regulatory T cells to predict
severity of HCV recurrence after liver transplantation
Kaldoun Ghazal, Morales Olivier, Clement Barjon, Geraldine
Dahlqvist, Lynda Aoudjehane, Laurissa Ouaguia, Yvon Calmus,
Delhem Nadira, Filomena Conti
536: Predictors of Delirium after Liver Transplantation
and its Relationship to Outcomes
Koki Yamada, Max Marquez, Khalid Mumtaz, Eberhard L. Renner
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
537: Bacterial antigen translocation persists after liver
transplantation in peripheral blood of patients with
decompensated cirrhosis
Gonzalo Rodriguez-Laiz, Pedro Zapater, Paola Melgar, Mariano
Franco, Cándido Alcázar, Sonia Pascual, Pablo Bellot, Jose María
Palazón, Jose Such, Félix Lluis, Ruben Frances
538: Early Liver Transplantation in Severe Alcoholic
Hepatitis: the U.S. Experience
Brian P. Lee, David W. Victor, R. Mark Ghobrial, Mary E. Rinella,
Zhiping Li
539: Deleterious Effect of Body Mass Index and Prior
Abdominal Surgery on Liver Transplant Complications
Angel Alsina, Jian Zheng, Alexia M. Makris, Jason Shim, Edson S.
Franco, Chris Albers, Nyingi M. Kemmer
540: Primary Non Function after liver transplant in
children in the PELD era: Analysis of UNOS database
Jaime Chu, Rachel A. Annunziato, Christie DiPietrantonio, Ailie M.
Posillico, Ronen Arnon
541: Pro-Atherogenic Lipoproteins And Metabolic
Biomakers Drive Serum Cardiovascular Risk In Liver
Transplant Recipients
Ravi Chhatrala, Mohammad B. Siddiqui, R. Todd Stravitz, Carolyn
Driscoll, Arun J. Sanyal, Robert A. Fisher, Carol Sargeant, Fareed
R. Riyaz, Velimir A. Luketic, Scott Matherly, Richard K. Sterling,
Puneet Puri, Mohammad S. Siddiqui
542: Coronary artery calcium score in evaluating
cardiovascular risk 1 and 4 years after liver transplant
Livia M. Linhares, Mario R. Alvares-da-Silva, Claudia P. Oliveira,
José Tadeu Stefano, Eloisa M. Gebrim, Flair J. Carrilho, Luiz C.
D`Albuquerque
543: Control of Diabetes Mellitus in Liver Transplant
Recipients:a multicentric spanish study
Beatriz Rodríguez-Medina, Diego Alvarez de Sotomayor, Carla
Satorres, Jose Ignacio Herrero, Trinidad Serrano, Manuel De la
Mata, Carmen Vinaixa, Victoria Aguilera, Angel Rubin, Martin
Prieto, Marina Berenguer
544: Non-coronary causes account for the majority
of early major adverse cardiac events after liver
transplantation
Lisa B. VanWagner, Bing Bing Weitner, Tanvi Subramanian,
Sarah Uttal, Alfred W. Rademaker, Josh Levitsky, Donald M. Lloyd-
Jones, Anton I. Skaro
545: Sphincter of Oddi Dysfunction after Liver
Transplantation: Experience in a High Volume
Transplant Center
Alejandro Fernandez Simon, Diego S. Royg, Oriol Sendino,
Claudio Zulli, Cristina Rodriguez de Miguel, Domingo Balderramo,
Gonzalo Crespo, Jordi Colmenero, Josep Llach, Miquel Navasa,
Andres Cardenas
546: Hyperhomocysteinemia is Associated with
Reduced Survival after Liver Transplantation
Rahima A. Bhanji, Mang M. Ma, Aldo J. Montano-Loza
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
547: Use of mTOR inhibitor is associated with increased
frequency of late anastomotic biliary strictures and need
for repeat ERCP in Orthotopic liver transplant recipients.
Cheri Ogwo, Satheesh Nair, Jason M. Vanatta, James Eason,
Sanjaya K. Satapathy
548: Sexual Functioning in Patients With End-Stage
Liver Disease Before and After Liver Transplantation (LT)
Beatriz Rodríguez-Medina, Diego Alvarez de Sotomayor, Carla
Satorres, Agustin Ramos-Prol, Carmen Vinaixa, Angel Rubin, María
García Eliz, Victoria Aguilera, Martin Prieto, Marina Berenguer
549: Adherence to Immunosuppressive therapy in Adult
and Adolescent Liver Transplant Recipients in a Multi-
Ethnic Asian Centre: A Questionnaire Survey
Kieron B. Lim, Juanda Leo Hartono, Yock Young Dan, Maung
Aye Thwin, Poh Seng Tan, Charlene Soon, Alfred W. Kow,
Krishnakumar Madhavan, Seng Gee Lim
550: Orthotopic liver transplantation for hepatocellular
carcinoma after successful downstaging: results from
the Belgian multicentre cohort
Jonas Schreiber, Jan P. Lerut, Chris Verslype, Hans Van Vlierberghe,
Valerio Lucidi, Olivier Detry, Luisa Vonghia, Francesco Puleo,
Eric Trépo, Milton E. Inostroza, Hélène Poels, Roberto Troisi,
Jean Delwaide, Sven M. Francque, Vincent Donckier, Christophe
Moreno
551: Outcomes for Patients with Decompensated
Cirrhosis Transferred from Outlying Hospitals to a
Tertiary Care Liver Transplant Center
Chad Cornish, Michael Winter, Thomas D. Rodgers, Gopal A.
Ramaraju, Benedict Maliakkal, Jonathan Huang
552: MELD score does not impact the outcomes of
simultaneous liver and kidney transplantation
Mohsen Hasanin, Siddharth Bansal, Yong-Fang Kuo, Ashwani K.
Singal, Russell H. Wiesner
553: WITHDRAWN
554: Diabetes Mellitus is associated with Lower Survival
following Simultaneous Liver Kidney Transplantation
Ryan B. Perumpail, Robert Wong, Andrew M. Su, Jane Tan, John
Scandling, Aijaz Ahmed
555: Histological correlates of ERCP confirmed biliary
anastomotic strictures
Fazal Yahya, Pamela B. Sylvestre, Saradasri Karri, Satheesh Nair,
Jason Vanatta, James Eason, Sanjaya K. Satapathy
556: Pre-operative renal failure predicts reduced
survival following liver transplantation but not liver
specific graft failure or death
Francis P. Robertson, Pulathis Siriwardana, Paul R. Bessell, Rafael
Diaz-Nieto, Nancy Rolando, Brian R. Davidson
557: Long term outcomes of patients with new portal
vein thrombosis occurring after liver transplantation
Scott Duncan, Laxmi B. Parsa, Nader Dbouk
Poster Viewing: 2:00 – 7:30 PM
109A
558: Evolving renal function in the post-operative
period correlates with over all graft survival following
liver transplantation
Francis P. Robertson, Pulathis Siriwardana, Paul R. Bessell, Rafael
Diaz-Nieto, Nancy Rolando, Brian R. Davidson
559: Listing practices for Morbidly Obese Patients at
Liver Transplant Centers in the United States
Dina Halegoua-De Marzio, She-Yan Wong, Jonathan M. Fenkel,
Cataldo Doria, David A. Sass
560: Racial/Ethnic Disparities in Simultaneous Liver
Kidney Transplantation: An Analysis from the UNOS
Database
Ryan B. Perumpail, Robert Wong, Andrew M. Su, Robert Isom,
John Scandling, Aijaz Ahmed
561: The mTOR inhibitor everolimus is safe within the
first month after liver transplantation
Indhira Perez Medrano, Manuel Rodríguez-Perálvarez, Marta
Guerrero Misas, Mercedes Muñoz Nuñez, Víctor M. González
Cosano, María Muñoz Garcia-Borruel, Antonio Poyato, Pilar
Barrera Baena, Enrique Fraga Rivas, Gustavo Ferrín, Guadalupe
Costan Rodero, Juan Carlos Pozo Laderas, Marina Sánchez Frías,
Ruben Ciria, Javier Briceño, Jose Luis Montero, Manuel De la Mata
562: Magnetic Resonance Cholangiopancreatography is
Significantly Superior to Ultrasound in the Diagnosis of
Biliary Anastomotic Strictures After Liver Transplantation
Anoop Prabhu, James Park, Jawad Ahmad
563: Primary Sclerosing Cholangitis is a Risk Factor for
Developing Intra-abdominal Thrombosis Following Liver
NOVEMBER 8
Transplantation
SATURDAY
Paul Reynolds, Elnaz Jafarimehr, Xiao Jing Wang, Ram M.
Subramanian
564: Prevalence and risk factors of metabolic syndrome
after liver transplantation: a single centre experience
Veronica Pepe, Giacomo Germani, Alberto Ferrarese, Alberto
Zanetto, Ilaria Bortoluzzi, Elena Nadal, Francesco P. Russo, Marco
Senzolo, Enrico Gringeri, Umberto Cillo, Patrizia Burra
565: 20 year followup of liver transplantation for HCV+
patients. Rustgi V, Landsittel D, Humar A, Hughes C,
Malik S, Behari J, Jazwinski A, Chopra K. The Thomas
Starzl Transplant Institute, Univ of Pittsburgh
Vinod K. Rustgi, Doug Landsittel, Abhinav Humar, Christopher B.
Hughes, Shahid M. Malik, Jaideep Behari, Alison Jazwinski, Kapil
B. Chopra
566: Serum aspartate transaminase levels on the third
post-operative day correlate with overall survival
and liver specific survival at 10 years following liver
transplantation
Francis P. Robertson, Paul R. Bessell, Rafael Diaz-Nieto, Nancy
Rolando, Brian R. Davidson
Presenters in Attendance 5:30 – 7:00 PM
 110A POSTER SESSIONS
Poster Sessions
567: Clinical impact of cholestasis after liver
transplantation: a retrospective cohort study
Constantine J. Karvellas, Filipe S. Cardoso, Andrew Mason,
Norman M. Kneteman, Glenda Meeberg, Aldo J. Montano-Loza
568: Analytic Morphomics Identifies Predictors of New-
Onset Diabetes After Transplantation
Valerie Vaughn-Sandler, David C. Cron, Michael Terjimanian,
Zachary Gala, Stewart C. Wang, Grace L. Su, Michael Volk
569: Everolimus treatment start POD 1 in combination
with low dose CNI is safe and effective post liver
transplantation
Martina Sterneck, Antonio Galante, Gesa Pamperin, Martina
Koch, Jun Li, Lutz Fischer, Bjoern Nashan
570: Non-adherence related mortality in adolescents
and young people after Liver transplantation
Marianne Samyn, Nigel Heaton, Michael A. Heneghan, Anil
Dhawan
571: Model to Predict Long-term Survival after Liver
Transplantation
Giuliano Testa, Giovanna Saracino, James F. Trotter, Greg J.
McKenna, Richard Ruiz, Nicholas Onaca, Tiffany Anthony, Peter
T. Kim, Marlon F. Levy, Robert M. Goldstein, Goran Klintmalm
572: Combined Heart and Liver Transplantation:
Analysis of a Single-Center Experience
Abimbola Aderinto, Maha R. Boktour, Mina Elnemr, Andrea M.
Cordero-Reyes, Jerry Estep, Sherilyn Gordon Burroughs, Ashish
Saharia, Barry Trachtenberg, Arvind Bhimaraj, Rafik M. Ghobrial,
Howard P. Monsour
NOVEMBER 8
SATURDAY
Infections and Acute on Chronic Liver
Failure
573: Clinical and prognostic relevance of albumin
dimers in patients with cirrhosis: a novel identified
structural alteration of the molecule
Maurizio Baldassarre, Marco Domenicali, Ferdinando A.
Giannone, Marina Naldi, Maristella Laggetta, Daniela Patrono,
Carlo Bertucci, Mauro Bernardi, Paolo Caraceni
574: The empirical antibiotic treatment of nosocomial
spontaneous bacterial peritonitis in patients with
decompensated liver cirrhosis: results of a randomized
controlled clinical trial
Salvatore Piano, Freddy Salinas, Filippo Morando, Marta Cavallin,
Antonietta Romano, Silvia Rosi, Marialuisa Stanco, Silvano
Fasolato, Antonietta Sticca, Marco Senzolo, Patrizia Burra, Enrico
Gringeri, Umberto Cillo, Angelo Gatta, Paolo Angeli
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
575: Determinants and prognostic significance of
bacterial infections occurring in patients with HBV- or
HCV-related compensated cirrhosis. A multicenter
prospective cohort study in 1672 patients (ANRS CO12
CirVir)
Pierre Nahon, Valérie Bourcier, Richard Layese, Nabila Talmat,
Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique
G. Larrey, Victor de Ledinghen, Denis Ouzan, Fabien Zoulim, Jean
Claude Trinchet, Françoise Roudot-Thoraval
576: The detection of bacterial DNA by in situ
hybridization method may prove the evidence of
bacterial translocation in patients with decompensated
liver cirrhosis
Shingo Usui, Hirotoshi Ebinuma, Po-sung Chu, Nobuhito Taniki,
Yuko Wakayama, Nobuhiro Nakamoto, Yoshiyuki Yamagishi,
Kazuo Sugiyama, Hidetsugu Saito, Takanori Kanai
577: ‘Eastern type’ of Acute-on-chronic Liver Failure
(ACLF) is similar in pathophysiologic, diagnostic and
prognostic criteria to the ‘Western type’: A comparison
of Chinese hospitalized patients with Hepatitis B with
CANONIC data
Hai Li, Marco Pavesi, Bo Zeng, Liu-Ying Chen, Shu-Ting Li, De-Kai
Qiu, Richard Moreau, Pere Gines, Vicente Arroyo, Rajiv Jalan
578: Utility Of A Modified PIRO (Predisposition, Injury,
Response, Organ Failure) Model For Predicting Kidney
Failure In Patients With ACLF- A Multinational Cohort
Study
Rakhi Maiwall, Shiv K. Sarin, Chandan K. Kedarisetty, Richard
Moreau, Suman Kumar, Zaigham Abbas, Deepak N. Amarapurkar,
Ankit Bhardwaj, Ajeet S. Bhadoria, Chhagan Bihari, Amna S. Butt,
Chan Albert, Yogesh K. Chawla, Abdulkadir Dokmeci, Hasmik
Ghazinyan, Saeed S. Hamid, Cho Mong, George K. Lau, Guan
Huei Lee, Laurentius A. Lesmana, Mamun A. Mahtab, Qin Ning,
Viniyendra Pamecha, Diana A. Payawal, Archana Rastogi, Salimur
Rahman, Mohamed Rela, Amrish Sahney, Vivek A. Saraswat,
Samir R. Shah, Gamal Shiha, Barjesh C. Sharma, Manoj Kumar,
Soek Siam Tan, Chitranshu Vashishtha, Ashok Choudhary, Man
Fung Yuen, Osamu Yokosuka
579: Gene-specific control of inflammation during
lipopolysaccharide tolerance is altered in immune cells
from patients with advanced cirrhosis
Mikhael Giabicani, Emmanuel Weiss, Pierre-Emmanuel Rautou,
Magali Fasseu, Catherine Paugam-Burtz, Dominique Valla,
Francois Durand, Sophie Lotersztajn, Richard Moreau
580: Systemic Inflammatory Response Syndrome (SIRS)
- a potential clinical marker for early sepsis and
survival in Acute on chronic liver failure (ACLF)
Ashok K. Choudhury, Chitranshu Vashishtha, Chandan K.
Kedarisetty, Shiv K. Sarin
581: Genetic polymorphism of mannose binding lectin
2: a potential new risk factor for spontaneous bacterial
peritonitis in cirrhotic patients
Cornelius Engelmann, Janett Fischer, Sandra Krohn, Adam Herber,
Albrecht Boehlig, Danilo Deichsel, Stephan Boehm, Thomas Berg
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
582: Overexpression Of The Genetic Effector Pathway
Of Inflammasome In Peripheral Blood Mononucleated
Cells (Pbmc) Of Patients With Acute On Chronic Liver
Failure
Elisabetta Gola, Alessandra Brocca, Salvatore Piano, Antonietta
Sticca, Filippo Morando, Silvia Rosi, Marta Cavallin, Marialuisa
Stanco, Antonietta Romano, Silvano Fasolato, Angelo Gatta, Paolo
Angeli
583: CD64 Expression may be a Promising Marker for
Early Diagnosis of Sepsis in Hospitalized Patients with
Cirrhosis
Sakkarin Chirapongsathorn, Jody C. Olson, Stacy C. League,
Siddharth Singh, Sarah Jenkins, Roshini Abraham, Patrick Kamath
584: Improving survival for patients with cirrhosis
admitted to United Kingdom critical care units
Mark J. McPhail, Francesca Parrott, Julia Wendon, David A.
Harrison, Kathy M. Rowan, William Bernal
585: The Economic Burden and Mortality of Patients
with Acute on Chronic Liver Failure (ACLF) in the United
States
Alina M. Allen, W. Ray Kim, James P. Moriarty, Nilay Shah,
Patrick S. Kamath
586: Mortality risk associated with Acute on Chronic
Liver Failure varies dependent on inciting event: a
NACSELD study
Patrick S. Kamath, Jacqueline G. O’Leary, K. Rajender Reddy,
Florence Wong, Siddharth Singh, Michael B. Fallon, Guadalupe
Garcia-Tsao, Scott W. Biggins, Benedict Maliakkal, Ram M.
Subramanian, Heather M. Patton, Leroy Thacker, Jasmohan S.
Bajaj
587: The impact of nutritional status on infections in
liver cirrhosis
Aung Kaung, Ken D. Nguyen, Amit Rajaram, Phillip Zakowski,
Tram T. Tran, Vinay Sundaram
588: Delay in appropriate antimicrobial therapy
increases mortality in cirrhotics with spontaneous
bacterial peritonitis and septic shock
Constantine J. Karvellas, Juan G. Abraldes, Yaseen Arabi, Anand
Kumar
589: Prognostic Value of Procalcitonin in patients with
Spontaneous Bacterial Peritonitis: Preliminary Results
from a Multicenter Study in Argentina
Sebastian Marciano, Natalia Sobenko, Alfredo Martinez, Manuel
Mendizabal, Luis A. Gaite, Federico Piñero, Leila Haddad,
Marcelo O. Silva, Ezequiel Ridruejo, Oscar G. Mandó, Diego H.
Giunta, Adrian Gadano
590: CLIF-SOFA score and serum sodium are
independent predictors of short term survival in
decompensated cirrhosis. A prospective study
Gustavo Pereira, Flavia F. Fernandes, Vanessa L. Zenatti, Camila
M. Alcântara, Tatiana Valdeolivas, Zulane D. Veiga, Daniela M.
Mariz, João Luiz Pereira
Poster Viewing: 2:00 – 7:30 PM
111A
591: Alpha 2a adrenergic receptor antagonism
abrogates innate immune dysfunction and hepatic
inflammatory cytokine generation in a rodent model of
Acute-on-Chronic Liver Failure (AoCLF): Proof of concept
for a new target for therapy
Vikram Sharma, Junpei Soeda, Jane MacNaughtan, Abeba
Habtesion, Pamela Leckie, Nathan Davies, Rajiv Jalan, Rajeshwar
Mookerjee
592: Pathophysiological basis of Hepatic
Encephalopathy (HE) in patients with Acute-on-chronic
liver failure (ACLF): A prospective, longitudinal study
determining the role of ammonia, inflammation and
cerebral oxygenation
Rohit Sawhney, Peter Holland-Fischer, Rajeshwar Mookerjee,
Matteo Rosselli, Banwari Agarwal, Rajiv Jalan
593: Inhibition of MER receptor tyrosine kinase in
patients with acute on chronic liver failure: a potential
target for immunotherapy?
Christine Bernsmeier, Oltin T. Pop, Evangelos Triantafyllou,
Chris J. Weston, Stuart M. Curbishley, Vishal C. Patel, Arjuna
Singanayagam, Wafa Khamri, Christopher Willars, William
Bernal, Georg Auzinger, Michael A. Heneghan, Yun Ma, Wayel
Jassem, Nigel Heaton, David H. Adams, Mark R. Thursz, Alberto
Quaglia, Julia Wendon, Charalambos G. Antoniades
594: Acquired Hemophagocytic Lymphohistiocytosis
(HLH) mimicking acute hepatic insult presenting as Acute
on chronic liver failure (ACLF) is associated with high
mortality
Ankur Jindal, Ashok Choudhary, Shiv K. Sarin
NOVEMBER 8
595: Prognosis of cirrhotic patients admitted in Intensive
SATURDAY
care Unit: A Meta-analysis
Delphine Weil, Heng-Chih Pan, Eric Levesque, Bertrand Sauneuf,
Eleni Theocharidou, Evangelos Cholongitas, Constantine J.
Karvellas, René Robert, Arnaud Galbois, Jérôme Fichet, Rodrigo
Cavallazzi, Jean Paul Cervoni, Gaël Piton, Thierry Thevenot, Gilles
Capellier, Vincent Di Martino
596: Chronic Liver Failure Sequential Organ Failure
Assessment (CLIF-SOFA) is better than the Asia-Pacific
Association for the Study of Liver (APASL) criteria for
defining Acute-on-Chronic Liver Failure (ACLF) and
Predicting Outcome
Radha K. Dhiman, Tarana Gupta, Swastik Agrawal, Ajay K.
Duseja, Yogesh K. Chawla
597: Copeptin: a marker of circulatory derangement,
is independently associated with outcome in patients
admitted for acute decompensation of cirrhosis
Hein W. Verspaget, Amorós Àlex, Rajiv Jalan, Daniel Benten,
Francois Durand, Johan van der Reijden, Bart Van Hoek, Minneke
Coenraad
Presenters in Attendance 5:30 – 7:00 PM
 112A POSTER SESSIONS
Poster Sessions
598: High enrichment of circulating mononuclear cells
with transcripts encoding CXCL neutrophil-attracting
chemokines is a predictor of death in patients with
decompensated cirrhosis
Emmanuel Weiss, Rakhi Maiwall, Pierre-Emmanuel Rautou, Magali
Fasseu, Mikhael Giabicani, Francois Durand, Dominique Valla,
Didier Lebrec, Sophie Lotersztajn, Richard Moreau
599: Percutaneous Cholecystostomy (PC) for Acute
Cholecystitis (AC) in Advanced Cirrhosis is Associated
with High Morbidity and Poor Survival
Caitlin Sullivan, Charles Gabbert, Melissa Saul, Kapil B. Chopra,
Adam Slivka, Dhiraj Yadav
600: Epidemiologic trends in mortality of cirrhosis in the
intensive care unit: a large, Australasian, multi-centre
cohort
Avik Majumdar, Michael J. Bailey, William W. Kemp, Stuart K.
Roberts, David Pilcher
601: Bacterial translocation in liver failure: a possible
mechanism of impaired innate immune responses and
immuneparesis?
Vishal C. Patel, Susanne Knapp, Glory Y. Lai, Christine Bernsmeier,
Arjuna Singanayagam, Mark J. McPhail, Christopher Willars,
William Bernal, Georg Auzinger, Michael A. Heneghan, Krishna
Menon, Wayel Jassem, Parthi Srinivasan, Andreas Prachalias,
Hector Vilca-Melendez, Nigel Heaton, Mark R. Thursz, Julia
Wendon, Charalambos G. Antoniades
602: Number Needed to reTap: Assessing the Utility of
Repeat Diagnostic Paracentesis in Spontaneous Bacterial
Peritonitis
NOVEMBER 8
Aparna Goel, Mollie A. Biewald, Gopi Patel, Shirish Huprikar,
SATURDAY
Thomas D. Schiano, Gene Y. Im
603: Prognostic significance of Insulin-like growth
factor-1 (IGF-1) serum levels in patients admitted for
acute decompensation of cirrhosis
Bruno S. Colombo, Marcelo F. Ronsoni, Pedro E. Soares e Silva,
Leonardo Fayad, Letícia M. Wildner, Maria Luiza Bazzo, Esther B.
Dantas-Correa, Janaína L. Narciso-Schiavon, Leonardo L. Schiavon
604: Prognostic value of C-reactive protein in patients
with cirrhosis: external validation from the CANONIC
cohort
Jean Paul Cervoni, Amorós Àlex, Richard Moreau, Vicente Arroyo,
Rajiv Jalan, Faouzi Saliba, Francois Durand, Julia Wendon, Thierry
Gustot, Paolo Angeli, Pere Gines, Thierry Thevenot, Vincent Di
Martino
605: Factors associated with low cardiac T2* MRI in
liver transplant (LT) candidates at risk for iron overload
Moises Nevah Rubin, Monika Sarkar, Karen Ordovas, Oren K.
Fix, Neil Mehta
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
Inflammation and Immunobiology:
Animal Models
606: Involvement of the TNF and FasL produced by
CD11b Kupffer cells/macrophages in CCl4-induced
acute hepatic injury
Hiroyuki Nakashima, Atsushi Sato, Masahiro Nakashima, Masami
Ikarashi, Kiyoshi Nishiyama, Manabu Kinoshita, Shuhji Seki
607: Acid sphingomyelinase inhibits growth of
metastatic liver tumor
Yosuke Osawa, Jun Imamura, Kiminori Kimura
608: Dose-limiting toxicity of in vivo TLR7 ligation
differs according to the kinetics of systemic and hepatic
inflammation after LCMV infection
Thomas Vanwolleghem, Dowty Movita, Martijn D. van de Garde,
Florence Herschke, Gregory C. Fanning, Harry L. Janssen, Andre
Boonstra
609: Cytotoxic CD4+ Cells Play a Pivotal Role in
Cyclophosphamide-Mediated Cytotoxicity against
Hepatoma without Antigen Priming
Tatsushi Naito, Tomohisa Baba, Naofumi Mukaida, Yasunari
Nakamoto
610: Activation of cellular innate immunity during
primary Hepacivirus infection
Cordelia Manickam, R. Keith Reeves
611: DSS-induced colitis and simultaneous hepatic
inflammation lead to immunological tolerance in the
murine liver
Nobuhito Taniki, Nobuhiro Nakamoto, Hirotoshi Ebinuma, Hiroko
Murata, Yuko Wakayama, Po-sung Chu, Shingo Usui, Akihiro
Yamaguchi, Takeru Amiya, Hidetsugu Saito, Takanori Kanai
612: A novel mouse model of hepatocyte apoptosis-
induced sterile liver inflammation and wound healing
response
Heng-Fu Bu, Fangyi Liu, Xiao Wang, Pauline M. Chou, Catherine
Marek, Ke Tian, Peng Wang, Hua Geng, M. S. Rao, Suhail
Akhtar, Monique E. De Paepe, Xiao-Di Tan
613: Administration of antisense oligodeoxynucleotides
to nerve growth factor attenuates inflammation and
liver damage in acute liver damage models
Rafael Bruck, Einav Hubel, Isabel Zvibel
614: High fat diet impairs hepatic microRNAs related to
inflammation and macrophage infiltration contributing
to nonalcoholic steatohepatitis in a mouse model with
metabolic syndrome
Priya Handa, Vicki Morgan-Stevenson, Bryan D. Maliken, Yu Li,
James E. Nelson, Matthew M. Yeh, Kris V. Kowdley
615: Murine natural killer cells transiting through the
liver demonstrate hyporesponsiveness to activation
receptor mediated stimulation
Claire Meyer, Sandeep K. Tripathy
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
616: Characterization of the liver:lung axis in alcohol-
induced lung damage
Veronica L. Massey, Lauren G. Poole, Edilson Torres-Gonzalez,
Robin H. Schmidt, Michael L. Merchant, Keith C. Falkner, Jeffrey
D. Ritzenthaler, Jesse Roman, Gavin E. Arteel
617: DSS-induced Chronic Colitis Aggravates
Inflammation and Fibrogenesis in Mice with CCl4-
induced Hepatic Fibrosis
Xiaolan Zhang, Yufeng Liu, Guochao Niu, Libo Zheng
Innate Immunity and Adaptive
618: Beta-hydroxybutyrate and niacin protect
the murine liver from acute inflammatory injury via
activation of the Gpr109 receptor
Rafaz Hoque, Ahmad Farooq, Fred Gorelick, Wajahat Z. Mehal
619: Type III interferons, including IFNL4, drive
interferon-stimulated gene (ISG) pre-activation and the
interferon-refractory state
Jordan J. Feld, Vera A. Cherepanov, Nicholas Anand, Sonya A.
MacParland, Tawnya Hansen, Harry L. Janssen, Matthew Kowgier,
Ian McGilvray
620: Iron decreases IL-4- mediated STAT6
phosphorylation, Arginase-1 production and M2
activation, while increasing NF-KB phosphorylation,
INOS protein levels and M1 activation in primary
murine macrophages
Priya Handa, Vicki Morgan-Stevenson, Kris V. Kowdley
621: Role of NADPH oxidase 4 in hepatic inflammation
and TGFβ response mediated by Toll-like receptor 4
Bhargav Koduru, Rui-Ming Liu, Nicole L. Corder, Katrin Schroder,
Ralf P. Brandes, Jinah Choi
622: MicroRNA-155 deficiency attenuates chronic
alcohol induced hepatic and intestinal inflammation in
mice
Shashi Bala, Dora Lippai, Timea Csak, James V. Zatsiorsky, Donna
Catalano, Karen Kodys, Gyongyi Szabo
623: Human Mucosal Associated Invariant T
cells express high levels of MDR-1 and maintain
innate effector function following exposure to
immunosuppressive MDR-1 substrates
Joannah R. Fergusson, Lucy J. Walker, Paul Klenerman
624: Circulating monocytes from chronic HCV-infected
patients display a pro-fibrotic phenotype mediated by
IL-1β and correlates with liver fibrosis
Banishree Saha, Karen Kodys, Gyongyi Szabo
625: Glycine minimizes hepatic innate immune
responses and autoimmunity caused by double-
stranded RNA
Akira Uchiyama, Kenichi Ikejima, Kumiko Arai, Kazuyoshi Kon,
Kyoko Fukuhara, Tomonori Aoyama, Shunhei Yamashina, Sumio
Watanabe
Poster Viewing: 2:00 – 7:30 PM
113A
626: Neutrophil toll-like receptor 9 expression and
plasma lactoferrin in acute alcoholic hepatitis and the
susceptibility to fungal infection
Jennifer M. Ryan, Godhev K. Manakkat Vijay, (Robin) Daniel
Abeles, Thomas Tranah, Laura J. Blackmore, Victoria T. Kronsten,
Lee J. Markwick, Antonio Riva, Nikhil Vergis, Nicholas J. Taylor,
Shilpa Chokshi, Yun Ma, John G. O’Grady, Debbie Shawcross
627: TLR3/4 Signaling is Mediated via the MyD88-NF-
κB-CXCR4/7 Pathway in Human Alcoholic Hepatitis
and Non Alcoholic Steatohepatitis, Where Mallory-Denk
Bodies Form
Samuel W. French, Hui Liu, Barbara A. French, Brittany C. Tillman,
Jun Li
628: Liver Injury and Inflammation Leads to Profound
Hepatic Natural Killer Cell Dysfunction and Predisposes
the Liver to Metastatic Disease
Justin B. Mendel, Aryn Price, Arash Grakoui
629: Role of interactions of circulating monocytes in
vascular sprouting during liver regeneration in mice
Pedro Melgar-Lesmes, Elazer R. Edelman
630: Distinctive phenotypic features of human mucosal-
associated invariant T cells in the liver
Kentaro Tominaga, Toru Setsu, Satoshi Yamagiwa, Naruhiro
Kimura, Hiroki Honda, Hiroteru Kamimura, Masaaki Takamura,
Minoru Nomoto
631: Large scale biomarker profiling reveals distinct
cytokine and chemokine signatures distinguishing
different acute and chronic hepatitis virus infections
NOVEMBER 8
Svenja Hardtke, Julia Hengst, Katja Deterding, Michael P. Manns,
SATURDAY
Falk S. Christine, Markus Cornberg, Heiner Wedemeyer, Verena
Schlaphoff
632: Functional features of antigen-specific T-cell
receptors reflected clinical responses of α-fetoprotein-
derived peptides vaccine treatment for advanced
hepatocellular carcinoma
Hidetoshi Nakagawa, Eishiro Mizukoshi, Eiji Kobayashi, Takeshi
Terashima, Masaaki Kitahara, Noriho Iida, Hiroyuki Kishi, Atsushi
Muraguchi, Shuichi Kaneko
633: Immunomodulatory Effects of OK432-Stimulated
Monocyte-Derived Dendritic Cell Injection into
Hepatocellular Carcinoma after Radiofrequency
Ablation
Masaaki Kitahara, Eishiro Mizukoshi, Hidetoshi Nakagawa,
Noriho Iida, Hajime Sunagozaka, Kuniaki Arai, Tatsuya
Yamashita, Shuichi Kaneko
634: Identification of a Novel HLA-A2 Restricted
Immunotherapeutic Target Derived from an EGFR
Mutated Antigen for the Treatment of Metastatic Liver
Tumors
Kazuya Ofuji, Toshiaki Yoshikawa, Yoshitaka Tada, Manami
Shimomura, Yasunari Nakamoto, Tetsuya Nakatsura
Presenters in Attendance 5:30 – 7:00 PM
 114A POSTER SESSIONS
Poster Sessions
635: The dynamic changes of Th1/Th2/Th17 cytokines
in serum of patients with acute-on-chronic liver failure
Li Jin, Yingli He, Dan Du, Yuanyuan Li, Ruitian Yi, Jing Wang,
Tianyan Chen, Yingren Zhao
636: Regulation of hepatic inflammation by the
macrophage-expressed, sulfated steroid transporter,
Slc10a6
Astrid Kosters, Demesew Abebe, Julio Felix, Saul J. Karpen
Living Donors and Split Transplant
637: Living donor liver transplantation in high model
for end-stage liver disease score
Murat Dayangac, Murat Akyildiz, Yalcin Erdogan, Gokhan
Gungor, Yaman Tokat
638: Priming hepatocytes to G2 enhances liver
regeneration in elderly mice
Fatima K. Rehman, Toshiyuki Hata, Zhaoyu Li, Guojun Bu, Justin
H. Nguyen
639: Cadaveric versus Living donor Liver Transplant
Survival in Relation to MELD Score
Mohammed Al Sebayel, Almoutaz Hahim, Faisal A. Abaalkhail,
Hussien Elsiesy, Hamad M. Al-bahili, Saleh Alabbad, Mohamed
Shoukri, Markus U. Boehnert, Dieter C. Broering
640: Hepatocellular Carcinoma is associated with Lower
Survival following Living Donor Liver Transplantation in
the U.S
Ryan B. Perumpail, Robert Wong, Andrew M. Su, Clark A.
NOVEMBER 8
SATURDAY
Bonham, Carlos O. Esquivel, Aijaz Ahmed
641: Effect of Fully Laparoscopic Left Hepatectomy on
Donor Interest in Living Donor Liver Transplantation
(LDLT)
Anna Yegiants, Darby Santamour, Tarek Mansour, Joseph F. Pisa,
Jean C. Emond, Benjamin Samstein
642: “Patient positioning” in living liver donors –
reinventing the wheel each time
Daniela Ladner, Robert A. Fisher, James V. Guarrera, Elizabeth A.
Pomfret, Mary Ann Simpson, Donna Woods
643: Liver regeneration after right lobe donor
hepatectomy: serial changes of HGF, TNF α, IL6,
Interferon α, Interferon γ, TGF β1 and Thrombopoietine
Shridhar Sasturkar, Shreya Sharma, Paul David, Shiv K. Sarin,
Nirupma Trehanpati, Viniyendra Pamecha
644: Donor Safety in Live Left-Lobe Liver Donation
Roger Patron-Lozano, Manuel Rodriguez Davalos, James E. Tooley,
Armando Salim Munoz-Abraham, Peter S. Yoo, Brett E. Fortune,
Stephen M. Luczycki, Michael L. Schilsky, David C. Mulligan,
Sukru Emre
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
645: Impact of Donor Minimal Histological Changes on
the Outcome of Living Donor Liver Transplantation
Naglaa A. Allam, Wael Abdel-Razek, Nermine Ehsan, Asmaa
Gomaa, Deena El-Azab, Imam Waked
646: Surgical and Percutaneous Ablation are Both
Safe and Effective in Patients with Small Hepatocellular
Carcinoma
Jonathan M. Schwartz, Corbett Shelton, Aws Aljanabi, Mustafa
A. Alani, Dina Ginzberg, Akiva J. Marcus, Javier Chapochnick-
Friedmann, Sarah Bellemare, Yosef Golowa, Jacob Cynamon,
Andreas Kaubisch, Nitin Ohri, Milan Kinkhabwala
647: Role of Portocaval Shunt for Patients with
Glycogen Storage Disease Type I in the Era of Liver
Transplantation : Reappraisal of Portocaval Shunt for
Growth
YoungRok Choi, Nam-Joon Yi, Suk-won Suh, Jeong-moo Lee,
Hyeyoung Kim, Hae Won Lee, Kwang-Woong Lee, Kyung-Suk Suh
648: Success of meso-Rex bypass in the management of
extrahepatic portal vein obstruction in children
Andrew Wehrman, Nadia Ovchinsky, Adam Griesemer, Steven J.
Lobritto, Mercedes Martinez, Tomoaki Kato, Jean C. Emond
649: PET/CT Positivity Has Lower Survival in Adult
Living Donor Liver Transplantation for Hepatocellular
Carcinoma
Murat Akyildiz, Arzu Oezcelik, Gokhan Gungor, Nergis Ekmen,
Necdet Guler, Onur Yaprak, Yalcin Erdogan, Gulen B. Dogusoy,
Murat Dayangac, Yildiray Yuzer, Yaman Tokat
650: Adult Living Donor Liver Transplantation From
Donors with Gilbert’s Syndrome: is it Safe?
Murat Akyildiz, Gokhan Gungor, Necdet Guler, Arzu Oezcelik,
Tonguc Utku Yilmaz, Onur Yaprak, Yalcin Erdogan, Murat
Dayangac, Yildiray Yuzer, Yaman Tokat
651: Laparoscopic Liver Resection in the Pediatric
Population: A Single Center Case Series
Ashley Walther, Shrawan Gaitonde, Greg Tiao, Maria H. Alonso,
Jaimie D. Nathan
652: Novel colonoscopy preparation of organic
coconut water with Miralax and Dulcolax in split doses
for decompensated cirrhotics. A randomized double
blinded open labelled clinical pilot single centered
observational study. COSMIC Study
Patrick Basu, Niraj J. Shah, David Lee, M. Aloysius, Frank G.
Gress
653: The technical success rate and clinical efficacy of
Hepatic Vein Stenting of Hepatic Vein Outflow Stenosis
complicating Orthotropic Liver Transplant
Faiz Francis, Thomas Lowe, Matthew Johnson, David Agarwal,
Daniel E. Wertman, Sabah Butty, Thomas Casciani
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
Mechanisms of Injury
654: Elevated plasma DNA in patients with NASH and
reduced liver injury in mice with absence of TLR9 on
Kupffer cells
Irma Garcia-Martinez, Xinshou Ouyang, Nicola Santoro, Mark J.
Shlomchik, Wajahat Z. Mehal
655: Thalidomide Pretreatment Improves Cell
Engraftment and Liver Repopulation Independently
of Chemokines/Cytokines/Receptors Expressed after
Neutrophil or Kupffer cell Activation
Preeti Viswanathan, Sorabh Kapoor, Brigid Joseph, Ekaterine
Berishvili, Sanjeev Gupta
656: Low dose digoxin protects from NASH and
alcoholic hepatitis in mice by inhibiting a ROS-HIF-1α-
inflammasome pathway
Xinshou Ouyang, Ji-Yuan Zhang, Dechun Feng, Shi-Ying Cai, Irma
Garcia-Martinez, Fu-Sheng Wang, Bin Gao, Wajahat Z. Mehal
657: A distinct role for the TLR9 pathway in immune
activation and tolerance during acute liver injury in mice
Nobuhiro Nakamoto, Hirotoshi Ebinuma, Nobuhito Taniki, Yuko
Wakayama, Po-sung Chu, Akihiro Yamaguchi, Takeru Amiya,
Hidetsugu Saito, Takanori Kanai
658: Sonic hedgehog in microparticles from apoptotic T
cells modulate vascular endothelial function via a rho-
kinase pathway
Samantha A. Canipe, Nicole Feilen, Didier Dréau, Mark G.
Clemens
659: Chronic dietary iron overload in genetically obese
mice causes nonalcoholic steatosis, whereas acute iron
excess leads to increased inflammation and reduced
steatosis
Priya Handa, Vicki Morgan-Stevenson, Bryan D. Maliken, James E.
Nelson, Matthew M. Yeh, Kris V. Kowdley
660: NLRP3 inflammasome driven liver injury and
fibrosis: roles of IL- 17 and TNF-alpha
Alexander Wree, Matthew D. McGeough, Maria E. Inzaugarat,
Carla A. Pena, Alejandra Cherñavsky, Hal M. Hoffman, Ariel E.
Feldstein
661: PAD4-mediated neutrophil extracellular trap
formation increases liver ischemia/reperfusion injury in
mice
Samer Tohme, Hai Huang, Allan Tsung
662: Visceral Adipose Levels of mRNA Encoding GATA3
and FOXP3 Transcription Factors and CSF1 Marker
of Macrophage Infiltration Negatively Correlate with
Histologically Assessed Inflammatory Scores in Liver
Biopsies
Maria Keaton, Katherine Doyle, Lei Wang, Zahra Younoszai,
Rohini Mehta, Zachary D. Goodman, Aybike Birerdinc, Ancha
Baranova, Zobair Younossi
Poster Viewing: 2:00 – 7:30 PM
115A
663: A novel method for anti-TNF based-oral
immunotherapy: Oral administration of a plant cell-
expressed recombinant anti-TNF fusion protein for
treating of fatty liver disease
Yoseph Shaaltiel, Yehudit Shabat, Ami Ben Ya’acov, Sveta Gingis-
Velitski, Einat Almon, David Aviezer, Yaron Ilan
664: Liver lymphocytes from NLG4-/- (KO) mice
showed chronic oxidative stress with reduced
respiratory burst response
Johnny Amer, Sarit Doron, Ahmad Salhab, Rifaat Safadi
665: Warm ischemia and reperfusion causes
liver microcirculatory injury and acute endothelial
dysfunction. Simvastatin prevents these deleterious
events
Diana Hide, Marti Ortega-Ribera, Sergi Vila, Carmen Peralta,
Juan Carlos Garcia-Pagan, Jaime Bosch, Jordi Gracia-Sancho
Metabolic and Genetic Diseases
666: Analysis of surgical interruption of the
enterohepatic circulation as a treatment for pediatric
cholestasis: a retrospective, multi-institutional study
Kasper S. Wang, Benjamin L. Shneider, Colleen G. Azen, Ronen
Arnon, Lee M. Bass, Molly A. Bozic, Mary L. Brandt, Matthew S.
Clifton, Patrick A. Dillon, Annie Fecteau, Paula M. Hertel, Shinjiro
Hirose, Kishore Iyer, Binita M. Kamath, Saul J. Karpen, Frederick
M. Karrer, Nanda Kerkar, Kathleen M. Loomes, Cara Mack, Peter
Mattei, Alexander G. Miethke, Douglas Mogul, Philip Rosenthal,
Kyle A. Soltys, Riccardo Superina, Dylan Stewart, Greg Tiao,
Yumirle P. Turmelle, Karen West
NOVEMBER 8
SATURDAY
667: Oxidative Stress Caused by Nocturnal Hypoxia
is Related to the Severity of Pediatric Non-Alcoholic
Fatty Liver Disease
Shikha Sundaram, Ann C. Halbower, Zhaoxing Pan, Kristen N.
Robbins, Kelley E. Capocelli, Jelena Klawitter, Ronald J. Sokol
668: Monitoring of bile acid urine profile with Liquid
Chromatography-Tandem Mass Spectrography (LC-MS/
MS) allows achievement and maintenance of metabolic
control with minimal doses of chenodeoxycholic acid
in patients affected by 3β-hydroxy-Δ5-C27-steroid
dehydrogenase/isomerase deficiency
Giorgia Curia, Paola Gaio, Francesca Parata, Giuseppe
Giordano, Graziella Guariso, Mara Cananzi
669: Predictive factors of response to non-transplant
treatment strategies in progressive familial intrahepatic
cholestasis type II
Sharat Varma, Xavier Stephenne, Nicole Revencu, Isabelle
Scheers, Raymond Reding, Françoise Smets, Etienne M. Sokal
Presenters in Attendance 5:30 – 7:00 PM
 116A POSTER SESSIONS
Poster Sessions
670: Phase I/II clinical trial of Heterologous Human
Adult Liver-derived Progenitor Cells (HHALPC, hepastem)
in urea cycle disorders (UCD) and Crigler-Najjar
syndrome (CN): six months follow-up results
Etienne M. Sokal, Patrick J. McKiernan, Emmanuel Jacquemin,
Giuliano Torre, Pierre Broue, Francois Eyskens, Dries Dobbelaere,
Carlo Dionisi-vici, Paul Gissen, Philippe Clapuyt, Daniele Pariente,
Marc Yudkoff, Doreen Dekker, Joelle J. Thonnard, Beatrice A. De
Vos, Françoise Smets
671: Post-Developmental Genetic Screening for
Zebrafish Models of Inherited Liver Diseases
Seok-Hyung Kim, Simon Wu, Josh Gamse, Kevin Ess
672: Genetic, clinical, and histopathologic features of
intermediate tight junction protein 2 deficiency
Melissa Sambrotta, A. S. Knisely, Richard J. Thompson
673: The Burden of Pruritus on Patients with Alagille
Syndrome: Results from a Qualitative Study with
Pediatric Patients and their Caregivers
Linda Abetz-Webb, Ciara Kennedy, Bonnie Hepburn, Martha
Gauthier, Nathan Johnson, Sharon Medendorp, Alejandro
Dorenbaum, Benjamin L. Shneider, Binita M. Kamath
674: A Comparison of Controlled Attenuation
Parameter and Liver Biopsy to Assess Hepatic Steatosis
in Pediatric Patients
Nirav K. Desai, Sarah Harney, Roshan Raza, Paul D. Mitchell,
Maureen M. Jonas
675: Hepatic mast cell infiltration is associated with
progression of congenital hepatic fibrosis in the PCK rat
NOVEMBER 8
Pingping Fang, James Weemhoff, Seth Septer, Briana Holt,
SATURDAY
Udayan Apte, Michele Pritchard
676: Silent progression of liver disease and
development of cirrhosis in children several years after
cranial tumor resection
Anita K. Pai, Shengmei Zhou, Mark Krieger, Sophoclis
Alexopoulos, Yuri Genyk, Nanda Kerkar
677: Serial Enhanced Liver Fibrosis Test (ELF) to monitor
disease progression in Pediatric Non-Alcoholic Fatty
Liver Disease
Jeremy K. Rajanayagam, Andrew W. Lee, Patrick J. McKiernan
Viral and Autoimmune Hepatitis
678: Predicting future outcome in infancy-acquired
chronic hepatitis B – importance of quantitative HBeAg
and HBsAg plasma levels, HBV DNA viral load and
IP10 plasma levels
Mary Horner, Matthew J. Bruce, Sanjay Bansal, Sarah Tizzard,
Diego Vergani, Phillip M. Harrison, Kosh Agarwal, Giorgina Mieli-
Vergani, Ivana Carey
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
679: Association Between Hepatitis C Virus Infection
with Insulin Resistance and Total Cholesterol Levels in
Children and Youth
Aymin Delgado-Borrego, Roshan Raza, Michelle Godbee, Andrea
Barreto, Elsa Yumar, Betania Negre, David A. Ludwig, Maureen
M. Jonas, Raymond Chung
680: Differences in clinical characteristics of children
with chronic hepatitis B (CHB) by adoption status:
findings from the Hepatitis B Research Network (HBRN)
Simon C. Ling, Yona K. Cloonan, Philip Rosenthal, G. Johnson,
Karen F. Murray, Sarah J. Schwarzenberg, Norberto Rodriguez-
Baez, Jeffrey Teckman, Kathleen B. Schwarz
681: APRI, FIB-4 and Fibroscan in Prediction of
Significant Fibrosis in Adolescent Cancer Survivors in a
Resource Limited Country
Manal H. El-Sayed, Dalia N. Toaima, Fatma A. Marzouk, Amira
Mohsen, Aisha Elsharkawy, Gamal E. Esmat, Alaa El-Haddad
682: Pegylated Interferon Therapy in Chronic Hepatitis
B Infection- Is it the best option available in Children?
Vikrant Sood, Sanjeev K. Verma, Seema Alam, Rajeev Khanna,
Dinesh Rawat
683: Can expression of interferon-stimulated genes in
pre-treatment liver biopsy of chronic hepatitis B patients
predict therapy response and long-term HBV infection
outcome?
Ivana Carey, Kate Childs, Sanjay Bansal, Sarah Tizzard, Matthew
J. Bruce, Mary Horner, Diego Vergani, Kosh Agarwal, Giorgina
Mieli-Vergani
Viral Hepatitis and Liver Transplant
684: Impact of EGF, IL28B, and PNPLA3
polymorphisms on the outcome of allograft hepatitis C:
a multicenter study
Jessica L. Mueller, Lindsay Y. King, Kara B. Johnson, Tian Gao,
Lauren D. Nephew, Darshan Kothari, Mary Ann Simpson, Lan
Wei, Kathleen E. Corey, Joseph Misdraji, Joon Hyoek Lee, Bryan
C. Fuchs, Kenneth K. Tanabe, Frederic D. Gordon, Michael P.
Curry, Raymond T. Chung
685: Genetic polymorphisms of toll–like receptors
1 and 9 are associated with increased risk of severe
hepatitis C virus recurrence after liver transplantation
Ana Maria Duca, María J. Cítores, Sara de la Fuente, Isolina
Baños, Ana B. Cuenca, Valentin Cuervas-Mons
686: The influence of mTor-Inhibitors on HCV
replication after liver transplantation
Eva-Maria Ecker, Alexandra Frey, Katja Piras-Straub, Andreas
Walker, Guido Gerken, Kerstin Herzer
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
687: Hepatitis C Treatment Does Not Affect Waiting
Time for Liver Transplantation in Hepatitis C Positive
Patients
Mohannad Dugum, Nizar N. Zein, Naim Alkhouri, Rocio Lopez,
Brigette Bevly, Charles M. Miller, Teresa Diago, Ibrahim A.
Hanouneh
688: Sofosbuvir and ribavirinin in hcv-infected patients
listed for liver transplantation: a cost-effectiveness
analysis
Paolo A. Cortesi, Lorenzo G. Mantovani, Antonio Ciaccio, Matteo
Rota, Giancarlo Cesana, Mario Strazzabosco, Luca S Belli
689: Hepatitis E Virus (HEV) Infection is Rare Cause of
Hepatitis Among US Liver Transplant Recipients
Norah Terrault, Ronald E. Engle, Jennifer L. Dodge, Chris Freise,
Averell H. Sherker, Patrizia Farci, Robert H. Purcell
690: Characteristics of Post Transplantation Hepatitis
E Virus Infection Among Solid Organ Transplant
Recipients at a North American Transplant Center
Paul K. Sue, Nora Pisanic, Christopher D. Heaney, Kenrad Nelson,
Kathleen B. Schwarz, Alexandra Valsamakis, Michael Forman,
Annette M. Jackson, John R. Ticehurst, Robert A. Montgomery,
Wikrom Karnsakul
691: Validation of The Hepatitis Aggressiveness Score
in a Liver Transplant Population with Recurrent Hepatitis
C Zobair Younossi, Maria Stepanova, Sammy Saab, Gregory
Alberto Unzueta, Roger K. Moreira, Giovanni DePetris, Maxwell L.
Smith, Yu-Hui H. Chang, Meng-Ru Cheng, Angela Eyshou, Juan F.
Gallegos-Orozco, Bashar Aqel, Hugo E. Vargas
692: Living donor liver transplantation for hepatitis C
virus-positive recipients in Japan: a nationwide survey
Tomohiro Tanaka, Nobuhisa Akamatsu, Yasuhiko Sugawara,
Junichi Kaneko, Sumihito Tamura, Taku Aoki, Yoshihiro Sakamoto,
Kiyoshi Hasegawa, Norihiro Kokudo
693: Performance Characteristics of the Procleix HEV
Assay on the Fully Automated Procleix Panther System
Edgar Ong, Alanna Janssen, Robin Cory, Maria Babizki, Tim Shin,
Andre Lindquist, Ngoc-Anh Hoang, Lee P. Vang, Lisa Danzig,
Jeffrey M. Linnen
694: Sofosbuvir as the backbone of treatment for
HCV after liver transplantation: a real-life multicenter
experience
Rohit Satoskar, Joseph Ahn, Helen S. Te, Adam Deising, Andrew
Aronsohn, Suzanne Robertazzi, Thomas D. Schiano
695: The Impact of Pre-Transplant Obesity and
Diabetes on Survival Following Liver Transplantation
among Hepatitis C Virus Patients With and Without
Hepatocellular Carcinoma
Robert J. Wong, Ramsey Cheung, Edward W. Holt, Aijaz Ahmed
Poster Viewing: 2:00 – 7:30 PM
117A
696: Long-Term Results of Prophylaxis of De Novo
Hepatitis B Virus (HBV) Infection With Lamivudine in
HBsAg-negative Naive Recipients of anti-HBc-positive
Liver Grafts: A 13-year Single-center Experience
Martin Prieto, María García Eliz, Ana M. Braithwaite, Angel
Rubin, Victoria Aguilera, Salvador Benlloch, Marina Berenguer,
Carmen Vinaixa
697: Reinfection prophylaxis with entecavir
monotherapy is successful and safe in patients with
hepatitis B virus infection after liver transplantation
Kerstin Herzer, Ingmar Mederacke, Guido Gerken, Frank Lehner,
Juergen Klempnauer, Michael P. Manns, Karsten Wursthorn
698: Accessibility to Liver Transplantation for HIV-
HCV Coinfected Patients with End Stage Liver Disease:
the French Prospective Multicenter ANRS HC EP 25
PRETHEVIC COHORT
Maria Ostos, Moana Gelu-Simeon, Laetitia A. Johnson, Elina
Teicher, Hélène Fontaine, Pierre Tattevin, Isabelle Poizot-Martin,
Stephanie Dominguez, David Zucman, Julie Chas, Pascal P.
Crenn, Anne Gervais, Karine Lacombe, Philippe Morlat, Rodolphe
Anty, Faroudy Boufassa, Inga Bertucci, Georges-Philippe Pageaux,
Laurence Meyer, Jean-Charles Duclos-Vallée
699: Hepatitis C Virus Infection is an Independent
Predictor of Post-Liver Transplant Diabetes: Data from
the U.S. Scientific Registry of Transplant Recipients
Trimble, Alita Mishra, Shirley K. Kalwaney, Zahra Younoszai,
Fatema Nader, Linda Henry
700: Sustained Virologic Responses with Nitazoxanide
NOVEMBER 8
Therapy in Recurrent Hepatitis C (genotype 1) Infection
SATURDAY
Post Liver Transplantation
Marshall E. McCabe, Saurabh Agrawal, Marco A. Lacerda, A.
Joseph Tector, Paul Y. Kwo, Marwan Ghabril
701: Early Safety and Efficacy Profiles of Renal
Transplant Recipients with Chronic Hepatitis C Treated
with Sofosbuvir and Ribavirin
Genevieve Huard, Brian Kim, Anna Patel, Badr Aljarallah, Ponni
Perumalswami, Joseph A. Odin, Sara Geatrakas, Jawad Ahmad,
Douglas Dieterich, Vinay Nair, Thomas D. Schiano, Gene Y. Im
702: T Regulatory Cells in De Novo Hepatitis B Virus
Infection after Liver Transplantation
Yinjie Gao, Min Zhang, Jingmin Zhao, Hanwei Li
703: The long-term efficacy of combination of nucleos(t)
ide analogue treatment and low dose hepatitis b
immunoglobulin on posttransplant HBV recurrence
Ramazan Idilman, Murat Akyildiz, Onur Keskin, Ali Tuzun,
Tonguc U. Yilmaz, Necdet Guler, Onur Yaprak, Gokhan Gungor,
Yalcin Erdogan, Murat Dayangac, Deniz Balci, Kubilay Cinar,
Acar Tuzuner, Selcuk Hazinedaroglu, Yaman Tokat, Sadik Ersoz,
Abdulkadir Dokmeci
Presenters in Attendance 5:30 – 7:00 PM
 118A POSTER SESSIONS
Poster Sessions
704: Efficacy of protease inhibitor in combination with
pegylated interferon and ribavirin to treat hepatitis C
after living donor liver transplantation
Satoshi Miuma, Tatsuki Ichikawa, Hisamitsu Miyaaki, Naota
Taura, Kazuhiko Nakao
705: Post-transplant Treatment of Severe Recurrent
Hepatitis C (HCV) with Daclatasvir and Sofosbuvir Plus
or Minus Ribavirin
Natalie H. Bzowej, Shobha Joshi, George Therapondos, Nigel
Girgrah, Gia Tyson, Inna Goldvarg-Abud, Jennifer B. Scheuermann,
Humberto E. Bohorquez, Ari J. Cohen, Ian C. Carmody, Trevor W.
Reichman, David S. Bruce, George E. Loss
706: Sofosbuvir + Simeprevir is Safe in Liver Transplant
Recipients
Fredric D. Gordon, Andreana L. Kosinski, Sheila J. Coombs,
Pauline Goucher, Emad S. Aljahdli, Elizabeth A. Pomfret
707: Telbivudine is associated with improvement of
renal function in patients after liver transplantation
Evangelos Cholongitas, Themistoklis Vasiliadis, Ioannis Goulis,
Ioannis Fouzas, Vasileios Papanikolaou, Evangelos A. Akriviadis
NOVEMBER 8
SATURDAY
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
708: Survey on Pre- and Post-Transplant Management
of Hepatitis C: Response from Medical Directors of US
Transplant Programs
Paul J. Gaglio, Carly E. Glick, John F. Reinus
709: Liver transplantation for patients with HCV-related
end-stage liver disease and undetectable HCV-RNA: the
Turin Centre experience
Alessandro Risso, Francesco Tandoi, Silvia Martini, Renato
Romagnoli, Mauro Salizzoni
710: Safety and Efficacy of Hepatitis C Therapy with
Sofosbuvir and Simeprevir after Liver Transplantation
Julio A. Gutierrez, Alla Grigorian, Andres F. Carrion, Michael
D. Schweitzer, Danny J. Avalos, Kalyan R. Bhamidimarri, Adam
Peyton
711: The Combination of Simeprevir and Sofosbuvir
for the Treatment of HCV Infection in Patients Post Liver
Transplant With Significant Fibrosis
Idrees Suliman, Renee Pozza, Yaseen Kady, Catherine Hill,
Thomas
    A. Couturier, Preeti Reshamwala, Tarek Hassanein
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
Poster Session 2
Sunday, November 9
POSTER VIEWING: 8:00 AM - 5:30 PM
Hall C
Presenters in attendance:
12:30 - 2:00 PM
Those posters identified as AASLD Presidential Poster of Distinction
by a ribbon icon have received review scores that place them
within the top 10 percent of all posters. We encourage you to
make them a priority as you visit the poster sessions.
Acute Liver Failure
712: The Mortality of Acute-on-Chronic Liver Failure
by APASL vs. EASL-CLIF definition: A Multicenter,
Retrospective Cohort Study in Korea (KACLiF Study)
Tae Yeob Kim, Dong Joon Kim, Do Seon Song, Dong Hyun Sinn,
Eileen L Yoon, Joo Hyun Sohn, Chang wook Kim, Young Kul Jung,
Ki Tae Suk, Jin Mo Yang, Heon Ju Lee
713: Predicting Progression from Acute Liver Injury to
Acute Liver Failure Using a Machine Learning Algorithm
Jaime L. Speiser, David G. Koch, William M. Lee
714: Development and Validation of the CLIF-C
AD score for the prognosis of patients with acute
decompensation (AD) of cirrhosis not fulfilling diagnostic
criteria for acute-on-chronic liver failure (ACLF)
Rajiv Jalan, Marco Pavesi, Faouzi Saliba, Alex Amorós, Javier
Fernandez, Peter Holland-Fischer, Rohit Sawhney, Rajeshwar
Mookerjee, Paolo Caraceni, Tania M. Welzel, Richard Moreau,
Pere Gines, Francois Durand, Paolo Angeli, Carlo Alessandria,
Wim Laleman, Jonel Trebicka, Didier Samuel, Stefan Zeuzem,
Thierry Gustot, Alexander L. Gerbes, Julia Wendon, Mauro
Bernardi, Vicente Arroyo
715: Hyperammonaemia and systemic inflammation is
associated with intracellular lactate accumulation
Anne M. Witt, Fin Stolze Larsen, Peter N. Bjerring
716: Alginate biocompatibility for use in tissue
engineering and cell therapy applications: biological
responses to hydrogel-encapsulated HepG2 cells in
vitro - leukocyte cytokine release and peripheral blood
mononuclear cell proliferation
Jordi G. Molina, Graham Wright, Sam Coward, Hardeep Kalsi,
Eloy Erro, Barry Fuller, Clare Selden
717: Implanted human bone mesenchymal stem cells
rescue fulminant hepatic failure within one week
through paracrine and transdifferentiation in pigs
Jun Li, Dongyan Shi, Jianing Zhang, Ding Wenchao, Jiaojiao Xin,
Qian Zhou, Hongcui Cao, Xin Chen, Lanjuan Li
Poster Viewing: 8:00 AM – 5:30 PM
119A
718: Assessment of adrenal function in patients with
severe acute hepatitis: a growing interest of serum
free cortisol and salivary cortisol. A prospective
observational multicenter study
Thibault Degand, Elisabeth Monnet, Francois Durand, Emilie
Grandclement, Philippe Ichai, Franck Schillo, Arnaud Agin,
Alexandre Louvet, Jérôme Dumortier, Gilles Dumoulin, Vincent Di
Martino, Thierry Thevenot
719: Characterization of Acute-on-Chronic Liver Failure
And Prediction of Mortality in Patients with Alcoholic
Hepatitis
Hwi Young Kim, Yong Jin Jung, Byeong Gwan Kim, Kook Lae Lee,
Won Kim
720: Acute Liver Decompensation Following
Radioembolization For Liver Cancer: A Retrospective
Study
Michael Min, Totianna Prudhomme, Eduardo Ehrenwald, Jill May,
Kai Hanson, Andrew J. Henn, Joseph Leach, Coleman Smith
721: Improved survival of hepatocytes in co-culture with
mesenchymal stromal cells following exposure to acute
liver failure serum: the role of paracrine factors
Emer Fitzpatrick, Sunitha Vimalesvaran, Celine Filippi, Ragai R.
Mitry, Tracey Dew, Charalambos G. Antoniades, Anil Dhawan
722: Alpha fetoprotein: A biomarker for the recruitment
of progenitor cells in the liver of the patients with acute
liver injury/acute liver failure
Keisuke Kakisaka, Kojiro Kataoka, Yuji Suzuki, Yasuhiro
Miyamoto, Yasuhiro Takikawa
723: The Safety of Therapeutic Plasma Exchange in
Pediatric End Stage Liver Disease
Amy S. Arrington, Moreshwar S. Desai, Ayse Akcan Arikan, Jun
Teruya, Poyyapakkam R. Srivaths
724: Acetaminophen (APAP)-induced Acute Liver Failure
(ALF) Leads to Activation Of Endogenous Hepatic Stem/
Progenitor Cells with Inability to Complete Hepatic
NOVEMBER 9
Regeneration
SUNDAY
Nicole Pattamanuch, Preeti Viswanathan, Sriram Bandi, Leslie E.
Rogler, Charles E. Rogler, Sanjeev Gupta
725: TNF-α Induces Receptor Interacting Protein-3
Kinase to Mediate Necrotic Cell Death in Acute-on-
Chronic Liver Failure
Arshi Khanam, Nirupma Trehan Pati, Archana Rastogi, Shiv K.
Sarin
726: The Usefulness of Prognostic Factors of Acute-on-
Chronic Liver Failure in Patients with Liver Cirrhosis:
A Multicenter, Retrospective Cohort Study in Korea
(KACLiF Study)
Do Seon Song, Dong Joon Kim, Tae Yeob Kim, Dong Hyun Sinn,
Eileen L Yoon, Joo Hyun Sohn, Chang wook Kim, Young Kul Jung,
Ki Tae Suk, Jin Mo Yang, Heon Ju Lee
Presenters in Attendance 12:30 – 2:00 PM
 120A POSTER SESSIONS
Poster Sessions
727: Acute Liver Failure related to Drug reaction with
eosinophilia and systemic symptoms (DRESS): Outcome
and Predictive Factors for improvement
Philippe Ichai, Camille Besch, Catherine Guettier, Claire Francoz,
Laurence Valeyrie-Allanore, Sylvie Roussin-Bretagne, Olivier Roux,
Alexia Letierce, Faouzi Saliba, Florent Artru, Marc Boudon, Teresa
Maria Antonini, Francois Durand, Didier Samuel
728: A non-invasive method for enumerating cell
number in three dimensional cell cultures; the integrated
variable cell count, a tool for regenerative medicine,
enabling quality assurance of cell therapy applications
Eloy Erro, Hyun Woo Yu, Dominic Davis, James T. Bundy, Aurelie
Le lay, Humphrey Hodgson, Barry Fuller, Clare Selden
729: Arterial ammonia concentration determined
by point of care testing in acute liver failure; clinical
associations and utility in prediction of complications
and outcome
Vishal C. Patel, Beatriz Mateos Muñoz, Elizabeth Sizer,
Charalambos G. Antoniades, Christopher Willars, Georg
Auzinger, Julia Wendon, William Bernal
730: Impaired Neutrophil Function Aggravates Liver
Injury and Correlates with Clinical Severity Indices in
Acute-on-Chronic Liver Failure
Arshi Khanam, Nirupma Trehan Pati, Peggy Riese, Archana
Rastogi, Carlos A. Guzman, Shiv K. Sarin
731: Genome editing with Cas9 in adult mice corrects a
liver disease mutation and phenotype
Hao Yin
732: LDH in the determination of cause in acute liver
failure, revisited
Michelle Gottfried, Kurt Kleinschmidt, William M. Lee
733: Liver failure determines the extra-hepatic organ
failure and outcome in patients with acute-on-chronic
liver failure: Analysis of 1363 patients of AARC Data
Base
NOVEMBER 9
Chandan K. Kedarisetty, Shiv K. Sarin, Lovkesh Anand, Zaigham
SUNDAY
Abbas, Deepak N. Amarapurkar, Ankit Bhardwaj, Ajeet S.
Bhadoria, Chhagan Bihari, Amna S. Butt, Ashok Choudhary,
Chan Albert, Yogesh K. Chawla, Abdulkadir Dokmeci, Hitendra
K. Garg, Hasmik Ghazinyan, Saeed S. Hamid, Ankur Jindal,
Naveen Kumar, Avinash Kumar, Guan Huei Lee, Laurentius A.
Lesmana, Mamun A. Mahtab, Rakhi Maiwall, Qin Ning, Devraj
Rangegowda, Archana Rastogi, Amrish Sahney, Samir R. Shah,
Gamal Shiha, Barjesh C. Sharma, Manoj Kumar, Saggere M.
Shasthry, Soek Siam Tan, Chitranshu Vashishtha, Man-Fung Yuen,
Osamu Yokosuka
734: Higher thyroid-stimulating hormone,
triiodothyronine and thyroxine values are associated
with better outcome in acute liver failure
Olympia Anastasiou, Jan-Peter Sowa, Paul P. Manka, Christian D.
Fingas, Wing-Kin Syn, Antonios Katsounas, Dagmar Führer, Robert
K. Gieseler, Lars Bechmann, Guido Gerken, Lars C. Moeller, Ali
Canbay
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
735: Ambient temperature short-term preservation
of liver cells for bioengineering applications using
perfluorodecalin as an oxygen source
Darren L. Scroggie, Eloy Erro, James T. Bundy, Aurelie Le lay,
Dominic Davis, Sunil R. Modi, Barry Fuller, Clare Selden
736: Hepatocyte Krüppel-Like-Factor 6 expression
is upregulated in acute liver injury and represses
hepatocyte proliferation
Svenja Sydor, Jan Best, Paul P. Manka, Martin Schlattjan, Thomas
Schreiter, Diana Vetter, Andreas Paul, Scott L. Friedman, Guido
Gerken, Ali Canbay, Lars Bechmann
737: Impaired monocyte and macrophage function in
Hepatitis E Virus (HEV) infected pregnant women with
Acute Liver Failure
Rashi Sehgal, Paul David, Ashish Vyas, Arshi Khanam, Ankit
Bhardwaj, Preety Rawal, Syed Hissar, Sharda Patra, Shubha S.
Trivedi, Shyam Kottilil, Shiv K. Sarin, Nirupma Trehanpati
738: Increased neutrophil actin production and
translocation of myeloperoxidase in patients with
acetaminophen-induced acute liver failure may
contribute to multiorgan failure
Godhev K. Manakkat Vijay, Gema Vizcay-Barrena, Thomas
Tranah, Leanne Glover, Vishal C. Patel, Christine Bernsmeier,
Jennifer M. Ryan, Laura J. Blackmore, Xiaohong Huang, Victoria
T. Kronsten, Nicholas J. Taylor, William Bernal, Georg Auzinger,
Christopher Willars, Julia Wendon, Yun Ma, Barbara Bain, Alice
Warley, Debbie Shawcross
739: Granulocyte-colony stimulating factor for acute-
on-chronic liver failure: systematic review and meta-
analysis of randomized control trials
Victoria J. Ornelas-Arroyo, Desiree Vidaña-Pérez, Guadalupe
Delgado-Sánchez, Indira R. Mendiola Pastrana, Camilo Noreña-
Herrera, Tonatiuh Barrientos-Gutierrez, Eva Juárez Hernández,
Nahum Méndez-Sanchéz, Misael N. Uribe-Esquivel, Norberto C.
Chavez-Tapia
740: Etiology, Clinical Features and Outcome of Acute
Liver Failure in Japan
Nobuaki Nakayama, Hirohito Tsubouchi, Satoshi Mochida
741: Secretory Leukocyte Protease Inhibitor (SLPI)
promotes hepatic resolution responses in acute liver
failure (ALF)
Evangelos Triantafyllou, Oltin T. Pop, Evaggelia Liaskou, Christine
Bernsmeier, Wafa Khamri, Zania Stamataki, Yun Ma, Mark R.
Thursz, Julia Wendon, Alberto Quaglia, Chris J. Weston, Stuart M.
Curbishley, David H. Adams, Charalambos G. Antoniades
742: Characterization of disease-specific biomarkers in
hepatitis B virus-related acute-on-chronic liver failure
and their predictive value for mortality
Jun Li, Jiaojiao Xin, Ding Wenchao, Qian Zhou, Longyan Jiang,
Dongyan Shi, Lanjuan Li
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
743: Traditional prognostic factors do not differentiate
between survivors and non-survivors in pediatric liver
failure patients on renal support
Ayse Akcan Arikan, Keila L. de la Garza, Poyyapakkam R. Srivaths,
Alyssa Riley, Kathleen Thompson, Ryan Himes, Moreshwar S.
Desai
744: Inclusion of Admission Red Cell Distribution Width
(RDW) and Mean Corpuscular Volume (MCV) improves
predictive accuracy of prognostic models of Acute Liver
Failure (ALF)
Kimberly A. Forde, Thure Caire, Craig Newcomb, R. Todd Stravitz
745: Pre-existing liver diseases lead acute HEV infection
to progressive liver failure
Jong-Hon Kang, Takeshi Matsui, Kazumasa Nagai, Akiko
Tomonari, Kazunari Tanaka, Kunihiko Tsuji, HIroyuki Maguchi,
Yoshiyasu Karino, Itaru Ozeki, Shuhei Hige, Tomoaki Nakajima,
Takumi Ohmura, Kazuaki Takahashi, Masahiro Arai, Shunji
Mishiro
746: A pilot study to determine the efficacy and safety
of ribavirin in patients of acute severe hepatitis E
Rahul Gupta, Sandeep S. Sidhu, Varun Mehta, Ajit Sood
747: Granulocyte colony stimulating factor (G-CSF) to
treat acute (on chronic) liver failure: effect on immune
and stem cell mobilisation
Cornelius Engelmann, Katrin Splith, Thomas Berg, Moritz Schmelzle
748: C/EBP homologous protein (CHOP) promotes
hepatocyte death by ERO1α signaling during acute liver
failure
Ling Lu, Jianhua Rao, Haoming Zhou, Xuehao Wang
749: The clinical and immunological chracteristics of
acute liver failure with autoimmune features – for early
diagnosis and proper treatment–
Hirotoshi Ebinuma, Hidetsugu Saito, Yoshiyuki Yamagishi,
Nobuhiro Nakamoto, Po-sung Chu, Yuko Wakayama, Nobuhito
Taniki, Akihiro Yamaguchi, Shunsuke Shiba, Shingo Usui, Kazuo
Sugiyama, Takanori Kanai
750: Increased CD11b+CD163+ macrophages caused
liver injury in acute liver Failure (ALF) non-survivors
Rashi Sehgal, Arshi Khanam, Ashish Vyas, Shiv K. Sarin, Nirupma
Trehanpati
751: Micro RNAs miR-106a, miR-122 and mir-197
are increased in severe acute viral hepatitis with
coagulopathy
Lukas Weseslindtner, Iris F. Macheleidt, Hannah Eischeid, Robert
Paul Strassl, Theresia Popow-Kraupp, Harald Hofer, Margarete
Odenthal, Heidemarie Holzmann
Poster Viewing: 8:00 AM – 5:30 PM
121A
Basic Fibrosis
752: Raf kinase inhibitor 1 (Rkip1): a potential
modifier of fibrogenesis in liver and heart
Rabea A. Hall, Andrey Kazakov, Ulrich Laufs, Michael Boehm,
Frank Lammert
753: The Role of Toll Like Receptor 4 signaling by
Hepatic Stellate Cells in Hepatocarcinogenesis
Jinsheng Guo, Yangyang Ouyang, Chengzhao Lin, Yujing Wu,
Yuanqing Zhang, Yirong Cao, Shiyao Chen, Jiyao Wang, Scott
L. Friedman
754: Highly Efficient Gene Targeting of a LncRNA in
Human LX-2 Hepatic Stellate Cells using TALENs
Daniel L. Motola, Kaveh Daneshvar, Samuel R. York, Alan Mullen,
Raymond T. Chung
755: The role of Fyn in hepatic stellate cells activation
and liver fibrosis
Yin Ying Lu, Guanghua Rong, Dechun Feng, Chunping Wang,
Xiujuan Chang, Xudong Gao, Yan Chen, Jianhui Qu, Zhen Zeng,
Hong Wang, Bin Gao, Yongping Yang
756: A Hepatic Stellate Cell Expression Signature
Identifies Novel Cell Markers and Predicts Outcomes in
Chronic Liver Disease
David Zhang, Hsin I Chou, Yujin Hoshida, Scott L. Friedman
757: Grb2-associated binder 1 protects against
liver fibrosis via suppression of CCL5 production from
hepatocytes
Yuichi Yoshida, Takashi Kizu, Kunimaro Furuta, Satoshi Ogura,
Mayumi Egawa, Norihiro Chatani, Yoshihiro Kamada, Shinichi
Kiso, Tetsuo Takehara
758: The peripherally-restricted CB1 antagonist
AM6545 reduces liver fibrogenesis via growth
inhibitory effects for hepatic myofibroblasts and anti-
inflammatory properties
NOVEMBER 9
Jinghong Wan, Aida Habib, Jasper Lodder, Arthur Brouillet, Fouad
SUNDAY
Lafdil, Adrien Guillot, Catherine Pavoine, Richard Moreau, Ariane
Mallat, Sophie Lotersztajn
759: MicroRNA-155 (miR-155) deficiency attenuates
liver fibrosis and not liver injury or inflammation in an
animal model of steatohepatitis
Timea Csak, Shashi Bala, Dora Lippai, Karen Kodys, Donna
Catalano, Gyongyi Szabo
760: The adiponectin peptide agonist ADP355
attenuates CCl4-mediated liver fibrosis: therapeutic
implications by multiple molecular mechanisms in vivo
and in vitro
Pradeep Kumar, Tekla Smith, Khalidur Rahman, Natalie Thorn,
Frank A. Anania
Presenters in Attendance 12:30 – 2:00 PM
 122A POSTER SESSIONS
Poster Sessions
761: The interaction of beta-Arrestin-2 with AT1-
receptor signalling in liver fibrosis
Robert Schierwagen, Judith Heinzen, Sabine Klein, Frank E.
Uschner, Kanishka Hiththetiya, Christian P. Strassburg, Tilman
Sauerbruch, Jonel Trebicka
762: Identification of long noncoding RNAs induced
in hepatic stellate cell myofibroblasts
Samuel R. York, Chan Zhou, Jennifer Y. Chen, Kaveh Daneshvar,
Alan Mullen
763: Genetic or pharmacologic inhibition of
microRNA-21 does not prevent liver fibrosis or
hepatocellular carcinoma in mice
J Matias Caviglia, Myoung Kuk Jang, Geum-Youn Gwak, Ingmar
Mederacke, Xueru Mu, Dianne H. Dapito, Robert F. Schwabe
764: Pharmacological inhibition of apoptosis signal-
regulating kinase 1 (ASK1) in a murine model of NASH
with pre-existing disease blocks fibrosis, steatosis, and
insulin resistance
Satyajit Karnik, Michael Charlton, Yury Popov, Zachary D.
Goodman, Michelle Nash, Maisoun Sulfab, Vivian Barry, Erik
G. Huntzicker, Dorothy French, Kelvin Li, Martin Decaris, Claire
Emson, Scott M. Turner, David Breckenridge, Daniel Tumas
765: Inhibition of MAP3K5, Apoptosis signal-
regulating kinase 1, with an oral small molecule
inhibitor blocks hepatic fibrosis and steatosis in murine
models of NASH and PSC
Satyajit Karnik, Michael Charlton, Michelle Nash, Maisoun
Sulfab, Vivian Barry, Erik G. Huntzicker, Dorothy French, David
Breckenridge, Britton Corkey, Gregory Notte, James E. Nelson,
Kris V. Kowdley, Daniel Tumas
766: Differential roles of C5a receptors C5aR and
C5L2 in liver and kidney fibrosis
Ina V. Martin, Tammo Ostendorf, Jürgen Floege, Frank Lammert,
Susanne N. Weber
NOVEMBER 9
767: Coniferyl Ferulate Attenuated Liver Fibrosis
SUNDAY
Through Inhibition Of Transforming Growth Factor-Β
Receptor
Ya N. Zhou, Wen W. Fu, Ping Liu
768: Lysyl oxidase activity contributes to collagen
stabilization during liver fibrosis progression and limits
hepatic fibrosis reversal in mice
Susan B. Liu, Naoki Ikenaga, Deanna Sverdlov, Zhen-Wei Peng,
Detlef Schuppan, Yury Popov
769: Deficiency of stress induced heat shock
transcription factor 1 (HSF1) Exacerbates Liver Fibrosis:
Regulation of Inflammatory Cytokines and Fibrogenesis
Pranoti Mandrekar, Arlene Lim
770: Cthrc1 alleviates cholestatic liver fibrosis through a
negative feedback loop with p-smad3 in mice
Zhaolian Bian, Qi Miao, Wei Zhong, Xiong Ma
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
771: ‘Lucky grandchildren’: Inbred mice whose
grandparents developed liver fibrosis appear to be
protected against the same disease
Andrea Schmetz, Frank Lammert, Susanne N. Weber
772: Signaling via the osteopontin and high-mobility
group box-1 axis drives the fibrogenic response to liver
injury
Elena Arriazu, Xiaodong Ge, Tung Ming Leung, Aritz Lopategi,
Yongke Lu, Raquel Urtasun, Neil D. Theise, Natalia Nieto
773: Sortilin deficiency affects fibrosis differently in
hepatocellular versus cholangiocyte models of liver
injury
Rafael Bruck, Einav Hubel, Tamar Thurm, Isabel Zvibel
774: Linagliptin mediated DPP-4 inhibition ameliorates
inflammation and fibrosis in models of NASH and
biliary fibrosis
Xiao-Yu Wang, Shih-Yen Weng, Yong Ook Kim, Thomas Klein,
Detlef Schuppan
775: The Hippo pathway effector YAP is an early
regulator of hepatic stellate cell activation
Inge Mannaerts, Sofia B. Leite, Stefaan Verhulst, Lien F. Thoen,
Sofie Claerhout, Georg Halder, Leo A. van Grunsven
776: Toll-like Receptor 3 Accelerates Liver Fibrosis by
Enhancing IL-17 Production in Mice
Wonhyo Seo, Hyuk-Soo Eun, Young-Sun Lee, Hyon-Seung Yi, Jong-
Min Jeong, So Yeon Kim, Yoo Kyung Kang, Jin Yong Kim, Byung
Jun Choi, Won-Il Jeong
777: Deletion of the cytoplasmic domain of Tissue
Factor ameliorates liver fibrosis and decreases TGFβ
expression in a murine model of cirrhosis
Virginia Knight, Jorge Tchongue, Dinushka Lourensz, Alison X. Liu,
Peter Tipping, William Sievert
778: Platelets as a novel target in liver fibrosis:
extrahepatic supply of PDGF-B by platelets drives
hepatic stellate cell activation and biliary liver fibrosis
progression
Shuhei Yoshida, Naoki Ikenaga, Susan B. Liu, Deanna Sverdlov,
Masahiko Shimada, Maki Tobari, Tetsuya Hamano, Takayoshi
Nishino, Atsushi Mitsunaga, Detlef Schuppan, Yury Popov
779: Anti-fibrotic and anti-inflammatory activity of
the adenosine receptor 2b antagonist, GS-6201, in a
murine model of PSC
Satyajit Karnik, Yong Ook Kim, Michelle Nash, Maisoun Sulfab,
Dewan Zeng, Hongyan Zhong, Simon C. Robson, Detlef Schuppan,
Daniel Tumas
780: Role of LARP6 and nonmuscle myosin in
partitioning of collagen mRNAs to the ER membrane
Hao Wang, Yujie Zhang, Lela Stefanovic, Branko Stefanovic
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
781: Differential roles of non-receptor tyrosine kinase
Fak family members in TGF-β-mediated fibrogenic
signaling in hepatic stellate cells
Jonghwa Kim, SoHee Kang, Soohyun Park, Ju-Yeon Cho, Won
Sohn, Geum Youn Gwak, Byung Chul Yoo, David A. Brenner,
Yong-Han Paik
782: Liver injury and pro-fibrotic markers, but not frank
fibrosis, are enhanced in Has3-/- mice after carbon
tetrachloride exposure: potential role for enhanced
matrix metabolism
Jennifer M. McCracken, Krutika T. Deshpande, Michele Pritchard
783: Hepatic Stellate Cells Express the Hepatocyte-
enriched Transcription Factor, Hepatocyte Nuclear
Factor 4α
Marzena Swiderska-Syn, Guanhua Xie, Jason D. Coombes,
Gregory A. Michelotti, Anna Mae Diehl
784: Activation of JNK modulates the profibrogenic
actions of myostatin in hepatic stellate cells (HSC)
Alessandra Caligiuri, Wanda Delogu, Angela Provenzano, Chiara
Rosso, Elisabetta Bugianesi, Fabio Marra
785: Role of gamma-ketoaldehydes as novel mediators
of experimental fibrogenesis and stellate cells activation
Lisa Longato, Dipok K. Dhar, Sean S. Davies, Jackson L. Roberts,
Tu Vinh Luong, Brian Davidson, Giuseppe Fusai, Jude A. Oben,
Kevin Moore, Massimo Pinzani, Krista Rombouts
786: Keratinocyte growth factor inhibits hepatic
inflammation and fibrosis in murine models of hepatic
injury
Barbara Czech, Claus Hellerbrand
787: The Role of Receptor-Mediated Endocytosis
of H-ferritin in Induction of NFkappaB-dependent
Proinflammatory Signalling in Hepatic Stellate Cells
Manuel A. Fernandez-Rojo, Anita Burgess, Amber Glanfield, Diem
Hoang-Le, Grant A. Ramm
788: Alternative regulation of macrophages activation
by IL-4 receptor alpha in fibrosis progression and
reversal
Shih-Yen Weng, Santosh Vijayan, Xiao-Yu Wang, Kornelius
Padberg, Yong Ook Kim, Brombacher Frank, Detlef Schuppan
789: Hepatic stellate cell activation is regulated by
neuropilin-synectin mediated autophagic degradation of
PDGFR-α
Mary Drinane, Usman Yaqoob, Debabrata Mukhopadhyay,
Shengbing Huang, Frank A. Sinicrope, Sheng Cao, Vijay Shah
790: microRNA-194 regulates the expression of TNF-α,
IL-1α and IL-6 via modulating akt/NF-κB pathway in
hepatic stellate cells
Pushpendra K. Sahu, Satendra Kumar, Parul Gupta, Senthil K.
Venugopal
Poster Viewing: 8:00 AM – 5:30 PM
123A
791: Pharmacological modulation of IL-4Ralpha
regulates liver fibrosis progression and regression by
tuning M2 macrophage polarization
Shih-Yen Weng, Xiao-Yu Wang, Santosh Vijayan, Kornelius
Padberg, Yong Ook Kim, Jeff R. Crosby, Michael L. McCaleb,
Detlef Schuppan
792: Development of Sonic hedgehog transgenic mouse
models using hydrodynamics-based transfection
Sook In Chung, Hye Lim Ju, Kwang-Hyub Han, Weonsang S. Ro
793: Human neutrophil peptide-1 exacerbates hepatic
fibrosis associated with Kuppfer cell activation and
hepatocyte apoptosis in a murine model of alcoholic
liver disease
Rie Ibusuki, Hirofumi Uto, Kozono Masaya, Kohei Oda, Akihiko
Oshige, Kotaro Kumagai, Seiichi Mawatari, Tsutomu Tamai,
Akihiro Moriuchi, Hirohito Tsubouchi, Akio Ido
794: Epigallocatechin gallate treatment
decreases osteopontin expression and attenuates
N-Nitrosodimethylamine induced hepatic fibrosis in rats
Joseph George, Mikihiro Tsutsumi
795: Iron excess exacerbates proinflammatory and
fibrogenic gene expression in genetically obese mice
and in primary human hepatic stellate cells in response
to TNF- α or TGF-β
Priya Handa, Vicki Morgan-Stevenson, Bryan D. Maliken, James E.
Nelson, Matthew M. Yeh, Kris V. Kowdley
796: Modulating Tumor-Stromal Interactions by
Targeting Adenosine Monophosphate-Activated
Kinase (AMPK) in Human Hepatic Stellate Cells and
Hepatocellular Carcinoma
Katrin Schölzel, Lisa Longato, Tu Vinh Luong, Brian Davidson,
Giuseppe Fusai, Massimo Pinzani, Krista Rombouts
797: A new communication system regulating
extracellular matrix in liver fibrosis: RANK/RANKL/
OPG
NOVEMBER 9
Leonie Beljaars, Carian E. Boorsma, Burak Guney, Klaas Poelstra,
SUNDAY
Barbro N. Melgert
798: Markers of extracellular matrix remodeling can
elucidate the matrix turnover profile of the fibrotic liver
Niels Ulrik B. Hansen, Federica Genovese, Diana J. Leeming,
Morten A. Karsdal
Clinical Steatohepatitis
799: Role of Genetic Polymorphisms in the Development
of Nonalcoholic Fatty Liver Disease (NAFLD) and
Steatohepatitis (NASH)
Fernando Bril, Marina Kawaguchi-Suzuki, Reginald Frye, Paola
Portillo Sanchez, Maryann Maximos, Song Lai, Jean Hardies,
Fermin Tio, Kenneth Cusi
Presenters in Attendance 12:30 – 2:00 PM
 124A POSTER SESSIONS
Poster Sessions
800: Low serum vitamin D concentration in patients with
nonalcoholic fatty liver disease is not associated with
increased mortality: Results from the National Health
and Nutrition Examination Survey 18-year mortality
follow-up data
Ivo C. Ditah, Albert Ndzengue, Zeenat Y. Bhat, Chijioke Enweluzo,
Chobufo M. Ditah, Callistus Ditah, Michael Charlton, Patrick S.
Kamath
801: Prevalence of nonalcoholic fatty liver disease and
its association with aging
Ainara Cano, Cristina Alonso, Itziar Mincholé, David Balgoma,
Pablo Ortiz, Maria L. Martinez-Chantar, Shelly C. Lu, Jose M.
Mato
802: Hepatic Steatosis as a Component of Spinal and
Bulbar Muscular Atrophy (SBMA, Kennedy’s Disease)
Hawwa Alao, Derrick Fox, Angela Kokkinis, Colleen Hadigan,
Christopher Grunseich, Kenneth Fischbeck, Yaron Rotman
803: Protease-Activated Receptor-2 (PAR2)–A Novel
Therapeutic Target in Nonalcoholic Steatohepatitis
(NASH)
Andrew M. Shearer, Karyn Austin, Srijoy Guha, Nga Nguyen,
Richard Looby, Allyson Clappin, James Baleja, Lidija Covic, Athan
Kuliopulos
804: Cardiovascular Death in Recipients of Liver
Transplants with Nonalcoholic Steatohepatitis: An
Analysis of the UNOS Database
Emily H. Wong, Jason Vanatta, Donna Hathaway, Elizabeth A.
Tolley, Satheesh Nair, James Eason, Sanjaya K. Satapathy
805: Progression to hepatic steatosis and fibrosis by
serum biomarkers is frequent in HIV mono-infection and
is associated with black ethnicity, poor HIV control and
hyperglycemia: a 7-year study of 1,291 cases
Giada Sebastiani, Kathleen C. Rollet-Kurhajec, Norbert Gilmore,
Costas Pexos, Richard Lalonde, Marina B. Klein
806: Histological Severity And Glycemic Stage Drive The
NOVEMBER 9
Evolution Of Atherogenic Risk Profile In Nonalcoholic
SUNDAY
Fatty Liver Disease
Mohammad S. Siddiqui, Kavish Patidar, Ankit V. Patel, Velimir A.
Luketic, Sherry L. Boyett, Michael O. Idowu, R. Todd Stravitz, Scott
Matherly, Puneet Puri, Richard K. Sterling, Arun J. Sanyal
807: Validation of surrogate indexes of peripheral and
hepatic insulin resistance and evaluation of their utility
as non-invasive predictors of histological features in
patients with Non-Alcoholic Fatty Liver Disease
Chiara Rosso, Ester Vanni, Lavinia Mezzabotta, Roberto Gambino,
Francesca Saba, Federico Salomone, Ramy Ibrahim Kamal
Jouness, Melania Gaggini, Emma Buzzigoli, Chiara Saponaro,
Fabrizia Carli, Gian Paolo Caviglia, Maria Lorena Abate,
Antonina Smedile, Mario Rizzetto, Maurizio Cassader, Amalia
Gastaldelli, Elisabetta Bugianesi
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
808: Progression of early atherosclerotic vascular
damage in patients with NAFLD and in controls of
general population during 10 years of follow up
Anna Ludovica Fracanzani, Giuseppina Pisano, Silvia Tiraboschi,
Marianna Porzio, Rosa Lombardi, Cristina Bertelli, Luca Valenti,
Andrea Baragetti, Liliana Grigore, Alberico Catapano, Silvia
Fargion
809: 5-aminolevulinic acid combined with ferrous iron
protects from ischemia-reperfusion injury in mouse
steatotic liver model by inducing carbon monoxide
generation
Shao-Wei Li, Terumi Takahara, Toshiro Sugiyama, Kazuhiro
Tsukada, Tohru Tanaka, Xiao-Kang Li
810: Oral glucose tolerance test predicts hepatic fibrosis
in nonalcoholic fatty liver disease patients without overt
diabetes mellitus
Sohji Nishina, Hideyuki Hyogo, Miwa Kawanaka, Teruki Miyake,
Masanori Abe, Satoyoshi Yamashita, Hiroshi Tobita, Shuichi Sato,
Yoichi Hiasa, Kazuaki Chayama, Keisuke Hino
811: Natural history of NAFLD: A study of 108 patients
with paired liver biopsies
Stuart McPherson, Elsbeth Henderson, Timothy Hardy, Alastair D.
Burt, Chris Day, Quentin M. Anstee
812: Role of Genetic Polymorphisms on the
Improvement of Liver Histology after Pioglitazone
Treatment in Patients with Nonalcoholic Fatty Liver
Disease (NAFLD)
Marina Kawaguchi-Suzuki, Fernando Bril, Kenneth Cusi, Taimour
Langaee, Yan Gong, Reginald Frye
813: The Protease Fibroblast Activation Protein (FAP) in
Liver Disease
Mark D. Gorrell, Kathryn H. Williams, Ana Julia Vieira de Ribeiro,
Sumaiya Chowdhury, Elizabeth J. Hamson, Oliver Schilling, Emilia
Prakoso, Nicholas A. Shackel, Susan V. McLennan, William W.
Bachovchin, Fiona M. Keane, Geoffrey W. McCaughan, Amany
Zekry, Stephen Twigg
814: Association of Hepatic Nuclear Hormone Receptor
Expression Profiles with Features of Hepatic Histology in
Children with Nonalcoholic Fatty Liver Disease
Joel E. Lavine, Michael Downes, Kevin P. May, Ruth Yu, Jeffrey B.
Schwimmer, Cynthia A. Behling, Elizabeth M. Brunt, Mark L. van
Natta, James Tonascia, Ronald M. Evans
815: There is substantial phenotypic variability in lean
versus obese subjects with NAFLD across the world: The
Global NASH Study
Angelo H. Paredes, Lawrence Serfaty, Claudia P. Oliveira, Abhijit
Chowdhury, Sherry L. Boyett, Mohammad S. Siddiqui, Arun J.
Sanyal
816: Prevalence and Risk Factors for Advanced Liver
Fibrosis in Adults Undergoing Intestinal Transplantation
Genevieve Huard, M. Isabel Fiel, Jang Moon, Lauren Schwartz,
Kishore Iyer, Thomas D. Schiano
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
817: Racial disparities in nonalcoholic fatty liver
disease related mortality among US Adults: Results of
the National Health and Nutrition Examination Survey
18-year mortality follow-up data
Ivo C. Ditah, Taiwo N. Ngwa, Albert Ndzengue, Zeenat Y. Bhat,
Chijioke Enweluzo, Callistus Ditah, Michael Charlton, Patrick S.
Kamath
818: Steatosis Assessment By Cap™ Using Xl Probe
Victor de Ledinghen, Christophe Corpechot, Julien Vergniol, Pierre
Bedossa, Andrew R. Hall, Olivier Chazouillères, Yves Menu, Amar
P. Dhillon, Valerie Paradis
819: Distinction between non-alcoholic steatohepatitis
and simple steatosis according to the controlled
attenuation parameter and liver stiffness value using
transient elastography in patients with non-alcoholic
fatty liver disease: a Korean multicenter study
Young Eun Chon, Soo Young Park, Hana Park, Ja Kyung Kim, Jae
Young Jang, Chun Kyon Lee, Kwang-Hyub Han, Seung Up Kim
820: Non- Viral Liver Disease Burden In HIV Positive
Individuals: An Observational Retrospective Cohort
Study
Natalie Shur, Martin Fisher, Yvonne Gilleece, Sumita Verma
821: Patients with Non-Alcoholic Steatohepatitis are at
High Risk of Developing Post-Transplant Diabetes
Zobair Younossi, Maria Stepanova, Sammy Saab, Kelly E. Hoyle,
Rebecca Cable, Alita Mishra, Stephen C. Clement, Sharon L. Hunt
822: Population incidence of nonalcoholic fatty liver
disease: A prospective study using serial proton-
magnetic resonance spectroscopy and transient
elastography
Vincent W. Wong, Grace LH Wong, David K. Yeung, Winnie C.
Chu, Henry Lik-Yuen Chan
823: Prediction of 10-year clinical outcomes in NASH
by non-invasive fibrosis and steatosis tools, hepatic
venous pressure gradient (HVPG) and liver histology
Giada Sebastiani, Marc Deschenes, Rasha Alshaalan, Maria
Rubino, Philip Wong, Peter Metrakos, Maged Peter Ghali
824: Liver Fat and Insulin Resistance as Major
Determinants of Plasma Alanine Aminotransferase
Levels in Nonalcoholic Fatty Liver Disease
Maryann Maximos, Fernando Bril, Paola Portillo Sanchez, Romina
Lomonaco, Diane Biernacki, Amitabh Suman, Michelle Weber,
Beverly Orsak, Kenneth Cusi
825: Plasma cytokeratin-18 in a healthy population:
how does it correlate with metabolic risk factors,
alcohol consumption, steatosis and elastography
Sofia Carvalhana, Jorge Leitão, Ana C. Alves, Mafalda Bourbon,
Helena Cortez-Pinto
Poster Viewing: 8:00 AM – 5:30 PM
125A
826: Serum autotaxin levels are independently
associated with hepatic steatosis in morbidly obese
women
Vikrant Rachakonda, Valerie L. Reeves, Jules Aljammal, James P.
DeLany, Petra Kienesberger, Erin E. Kershaw
827: Circulating Cholesteryl Ester Transfer Protein is
Associated with Percentage of Collagen Deposition in
Patients with Nonalcoholic Fatty Liver Disease
Elzafir Elsheikh, Zahra Younoszai, Munkhzul Otgonsuren, Fanny
Monge, Lakshmi Alaparthi, Brian P. Lam, Sharon L. Hunt, Zachary
D. Goodman, Zobair Younossi
828: Body Fat Distribution and the Risk of Incident and
Remittent Nonalcoholic Fatty Liver Disease: Prospective
Cohort Study
Donghee Kim, Goh Eun Chung, Min-Sun Kwak, Won Kim, Yoon
Jun Kim, Jung-Hwan Yoon
829: Dynamicity of Adiposity determine evolution
of non-alcoholic fatty liver even in lean subjects: a
prospective cohort study
Pankaj Singh, Kausik Das, Debashis Misra, Gautam Ray, Amal
Santra, Abhijit Chowdhury
830: Lesser risk of advanced liver fibrosis in morbidly
obese patients
Fabio Nascimbeni, Judith Aron-Wisnewsky, Pierre Bedossa, Joan
Tordjman, Raluca Pais, Thierry Poynard, Karine Clément, Vlad
Ratziu
831: Altered Fasting and Postprandial Serum Bile Acids
in Patients with Non-Alcoholic Steatohepatitis (NASH)
Brian C. Ferslew, Curtis K. Johnston, Eleftheria Tsakalozou,
Mingming Su, Guoxiang Xie, Wei Jia, Kim L. Brouwer, Alfred S.
Barritt
832: HLA Class II Alleles Are Strongly Associated
with Non-alcoholic Fatty Liver Disease (NAFLD), Non-
alcoholic Steatohepatitis (NASH) and Fibrosis
Azza Karrar, Zheng Li, Ali M. Moosvi, Siddharth Hariharan, Yun
NOVEMBER 9
Fang, Maria Stepanova, Zachary D. Goodman, Zobair Younossi
SUNDAY
833: Serum soluble CD163 is associated with
steatohepatitis and advanced fibrosis in non-alcoholic
fatty liver disease
Eoin R. Feeney, Jessica L. Mueller, Kyle Malecki, Lindsay Y. King,
Joseph Misdraji, Kathleen E. Corey, Raymond T. Chung
834: Serum levels of apoptosis inhibitor of macrophage
(AIM) are associated with hepatic fibrosis and insulin
resistance in patients with nonalcoholic fatty liver
disease
Kohei Oda, Hirofumi Uto, Yoshio Sumida, Takeshi Okanoue,
Seiichi Mawatari, Rie Ibusuki, Hiroka Onishi, Haruka Sakae, Kaori
Ono, Eriko Toyokura, Akihiko Oshige, Dai Imanaka, Tsutomu
Tamai, Akihiro Moriuchi, Hirohito Tsubouchi, Akio Ido
Presenters in Attendance 12:30 – 2:00 PM
 126A POSTER SESSIONS
Poster Sessions
835: Moderate-Vigorous Physical Activity (MVPA)
Volume is an Important Factor for Management of Non-
Alcoholic Fatty Liver Disease: A Retrospective Study
Sechang Oh, Takashi Shida, Rina So, Takehiko Tsujimoto, Kiyoji
Tanaka, Junichi Shoda
836: Performance of FibroMax (SteatoTest, ActiTest,
FibroTest) in patients with NAFLD for predicting liver
lesions (Steatosis, Activity and Fibrosis) assessed by SAF
scoring system and FLIP algorithm
Mona Munteanu, Fabio Nascimbeni, Pierre Bedossa, Marion
Houot, Frederic Charlotte, Yen Ngo, Raluca Pais, Olivier Deckmyn,
Vlad Ratziu, Thierry Poynard
837: Adverse outcomes of pregnancy in mothers with
NAFLD and their offspring
Hannes Hagström, Jonas F. Ludvigsson, Anders Ekbom, Rolf W.
Hultcrantz, Olof Stephansson, Knut Stokkeland
838: Survey of Diagnostic and Treatment Patterns
of NAFLD and NASH in the United States: Real Life
Practices Differ From Published Guidelines
Zurabi Lominadze, Stephen A. Harrison, Michael Charlton, Rohit
Loomba, Brent A. Neuschwander-Tetri, Stephen H. Caldwell, Kris
V. Kowdley, Mary E. Rinella
839: The features and differences of GLP-1 analogues
and DPP-4 inhibitors as treatments for non-alcoholic
fatty liver disease patients with type 2 diabetes mellitus
Takamasa Ohki, Isogawa Akihiro, Koki Sato, Nobuo Toda
840: Metabolic Stressors Associated with Progressive
Nonalcoholic Fatty liver Disease and Liver
Transcriptional Activity of Alanine and Aspartate
Aminotransferases
Silvia Sookoian, Gustavo O. Castaño, Tomas Fernández Gianotti,
Romina Scian, Carlos J. Pirola
841: Irisin is associated with physical activity level
and hepatic steatosis grade in non-alcoholic fatty liver
disease subjects
NOVEMBER 9
Rina So, Sechang Oh, Takashi Shida, Kiyoji Tanaka, Junichi Shoda
SUNDAY
842: Is liver stiffness measurement (LSM) by Fibroscan
better than FIB4 score for prediction of clinically
significant fibrosis in patients with NAFLD?
Raj Vuppalanchi, Samer Gawrieh, Regina Weber, Naga P.
Chalasani
843: Endoscopic Duodenal–Jejunal Bypass Liner
(Endobarrier) Improves Hepatic Parameters of
Nonalcoholic Fatty Liver Disease in Obese Uncontrolled
type 2 Diabetes Mellitus Patients
Oranit Cohen-Ezra, Gabriella Segal-Lieberman, Alon Lang, Maor
Lahav, Yeroham Kleinbaum, Sima Katsherginsky, Keren Tsaraf,
Ziv Ben Ari
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
844: Fetuin-A negatively correlates with liver and
vascular fibrosis in NAFLD subjects
Yoshihiro Kamada, Motoya Sato, Yuri Takeda, Sachiho KIda,
Yuka Ohara, Hironobu Fujii, Maaya Akita, Kayo Mizutani, Yuichi
Yoshida, Makoto Yamada, Hidetaka Hougaku, Tetsuo Takehara,
Eiji Miyoshi
845: Clinical validation of the FLIP algorithm and the
SAF score in Non-Alcoholic Fatty Liver Disease
Fabio Nascimbeni, Pierre Bedossa, Larysa Fedchuk, Raluca
Pais, Sven M. Francque, Dominique G. Larrey, Guruprasad P.
Aithal, Lawrence Serfaty, Mihai Voiculescu, Pascal Lebray, Thierry
Poynard, Klaudia M. Traudtner, Vlad Ratziu
846: Serum Vitamin D Deficiency is Associated with
Nonalcoholic Steatohepatitis in Adults
James E. Nelson, Laura Wilson, Christian Roth, Matthew M. Yeh,
Kris V. Kowdley
847: Hepatic copper and PNPLA3 in patients with non-
alcoholic fatty liver disease
Albert Stättermayer, Stefan Traussnigg, Elmar Aigner, Christian
Kienbacher, Petra E. Steindl-Munda, Christian Datz, Fritz Wrba,
Michael Trauner, Peter Ferenci
848: Impact of Liver Histology on Hepatic Elastography
in Non-alcoholic Fatty Liver Disease
Ranesh Palan, William W. Kemp, Bastiaan DeBoer, Jeffrey M.
Hamdorf, Michael J. House, Gerry C. MacQuillan, George Garas,
Helena Ching, Ross Mac Nicholas, Stuart K. Roberts, Matthew T.
Kitson, Gary P. Jeffrey, Leon Adams
849: The association of soluble lectin-like oxidized LDL
receptor 1 (sLOX-1) level with histological severity in
NAFLD patients
Hiroshi Ishiba, Yoshio Sumida, Saiyu Tanaka, Kazuyuki Kanemasa,
Yuya Seko, Akira Okajima, Tasuku Hara, Hiroyoshi Taketani, Kanji
Yamaguchi, Michihisa Moriguchi, Hironori Mitsuyoshi, Kohichiroh
Yasui, Yoshito Itoh, Masahito Minami
850: Combination of Geniposide and Chlorogenic Acid
May Reverse NASH Pathogenesis by Improving Gut
Barrier Function
Qin Feng, Susan S. Baker, Wensheng Liu, Ricardo A. Arbizu,
Ghanim Aljomah, Maan Khatib, Colleen A. Nugent, Robert D.
Baker, Yiyang Hu, Lixin Zhu
851: The serum levels of SDF-1α correlated with the
fibrosis and suggested the appearance of hepatic
progenitor cells in the advanced stage of NASH
Wataru Ando, Hiroaki Yokomori, Yutaka Inagaki, Isao Okazaki,
Yutaka Suzuki, Tsutsui Nobuhiro, Eigoro Yamanouchi, Hiroki
Tanabe, Hajime Kuroda, Soichi Kojima, Mitsuko Hara, Masaya
Oda, Takako Komiyama
852: Should we screen diabetic patients for fatty liver
and advanced fibrosis? A prospective study with 2080
controlled attenuation parameter and liver stiffness
measurements
Raymond Kwok, Grace LH Wong, Henry Lik-Yuen Chan, Juliana C.
Chan, Alice P. Kong, Vincent W. Wong
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
853: Four simple risk factors predict post-transplant
cardiac mortality in patients with nonalcoholic
steatohepatitis
Lisa B. VanWagner, Brittany Lapin, Donald M. Lloyd-Jones, Anton
I. Skaro, Mary E. Rinella
854: Patients with non-alcoholic fat liver disease
(NAFLD) with lower levels of free serum copper and
ceruloplasmin have different clinical and biochemical
characteristics
Vinicius Nunes, Adriana R. Andrade, Ana Luiza V. Guedes,
Claudia P. Oliveira, Marcio A. Diniz, Jose Estefano, Daniel F.
Mazo, Eduardo Luiz R. Cancado
855: Tai chi ameliorates patient centered outcomes and
markers of systemic inflammation and liver injury in
subjects with nonalcoholic fatty liver disease
Angelo H. Paredes, Jo L. Robins, Jamie L. Sturgill, Mohammad S.
Siddiqui, Arun J. Sanyal
856: Atherogenic Dyslipidemia in the Setting of Insulin
Resistance Contributes to Cardiovascular Risk in Patients
with Nonalcoholic Fatty Liver Disease
Fernando Bril, John Sninsky, Arthur M. Baca, Robert H. Superko,
Paola Portillo Sanchez, Margaret C. Lo, Beverly Orsak, Kenneth
Cusi
857: High Density Lipoprotein Dysfunction in Patients
with Nonalcohol Steatohepatitis
Arthur J. McCullough, Jaividhya Dasarathy, Ling Li, Gregory
Brubaker, Belinda Willard, Srinivasan Dasarathy, Jonathan D.
Smith, Takhar Kasumov
858: Meta-Analysis Of Randomized Controlled Trials
Comparing Current Pharmacologic Agents Vs. Placebo
In Non-Alcoholic Fatty Liver Disease
Ahmed Akhter, Adnan Said
859: Bile acid serum levels in adolescents with NAFLD:
a biomarker for progression?
Jörg Jahnel, Zoehrer Evelyn, Günter Fauler, Hubert Scharnagl,
Tatjana Stojakovic, Valerio Nobili
860: Oxidative stress-inducible factors promote liver
fibrosis in patients with Non-Alcoholic Fatty Liver
Disease
Lavinia Mezzabotta, Chiara Rosso, Ester Vanni, Roberto
Gambino, Ramy Ibrahim Kamal Jouness, Francesca Saba,
Federico Salomone, Melania Gaggini, Emma Buzzigoli, Chiara
Saponaro, Fabrizia Carli, Gian Paolo Caviglia, Maria Lorena
Abate, Antonina Smedile, Mario Rizzetto, Maurizio Cassader,
Amalia Gastaldelli, Elisabetta Bugianesi
Poster Viewing: 8:00 AM – 5:30 PM
127A
861: Comparison of NAFLD Fibrosis Score (NFS)
and transient elastography (Fibroscan®), alone and
in combination, as non-invasive methods for the
evaluation of fibrosis in non-alcoholic fatty liver disease
(NAFLD)
Edric Hee, William W. Kemp, Bastiaan de Boer, Jeffrey M.
Hamdorf, Gerry C. MacQuillan, George Garas, Helena Ching,
Ross Mac Nicholas, Stuart K. Roberts, Matthew T. Kitson, Gary P.
Jeffrey, Leon Adams
862: Nonalcoholic Fatty Liver Disease Is Associated with
Left Ventricular Diastolic Dysfunction
Jeong-Hoon Lee, Donghee Kim, Goh Eun Chung, Min-Sun Kwak,
Yoon Jun Kim, Jung-Hwan Yoon, Hyo-Suk Lee
863: The relationship between ALT and liver histology
changes with age in NAFLD
Boon Bee George Goh, Mangesh Pagadala, Jaividhya Dasarathy,
Aynur Unalp, Ruth Sargent, Carol A. Hawkins, Achuthan
Sourianarayanane, Amer Khiyami, Lisa M. Yerian, Rish Pai,
Srinivasan Dasarathy, Arthur J. McCullough
864: Non-alcoholic fatty liver disease (NAFLD)
recurrence after liver transplant (OLT) for non-alcoholic
steatohepatitis(NASH)
Norio Kawamura, Mustafa Nazzal, Galal El-Gazzaz, Mario
Spaggiari, Masato Fujiki, Teresa Diago, Federico N. Aucejo, Koji
Hashimoto, Cristiano Quintini, Charles Winans, Bijan Eghtesad,
Charles M. Miller, John J. Fung, Naim Alkhouri, Dympna Kelly
865: Degree of hepatic fibrosis assessed using transient
elastography is independently related with coronary
artery calcification in nonalcoholic liver disease
Seng Chan You, Seung Up Kim, Beom Kyung Kim, Jun Yong Park,
Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han
866: Associations Between Helicobacter pylori, Leptin,
and Nonalcoholic Fatty Liver Disease (NAFLD)
Joseph Roberts, William LeBlanc, Kiran Bambha
867: Nonalcoholic Fatty Liver Disease Is Associated
NOVEMBER 9
With Arterial Stiffness Measured by Cardio-Ankle
SUNDAY
Vascular Index
Donghee Kim, Goh Eun Chung, Su-Yeon Choi, Min-Sun Kwak,
Won Kim, Yoon Jun Kim, Jung-Hwan Yoon
868: Extremely low awareness and under-diagnosis of
NAFLD in a population-based sample
Lisa B. VanWagner, Mary E. Rinella, Hongyan Ning, Donald M.
Lloyd-Jones, Cora E. Lewis, Miriam B. Vos
869: Assessment of glycemic variability by continuous
glucose monitoring system in patients with nonalcoholic
fatty liver disease
Makiko Taniai, Etsuko Hashimoto, Kazuhisa Kodama, Tomomi
Kogiso, Katsutoshi Tokushige, Keiko Shiratori
Presenters in Attendance 12:30 – 2:00 PM
 128A POSTER SESSIONS
Poster Sessions
870: Is fatty liver in diabetes a risk factor for HCC and
cardiovascular disease? Prospective 10-year cohort
study
Masataka Seike, Koichi Honda, Junya Oribe, Mizuki Endo, Mie
Yoshihara, Masanori Tokoro, Masao Iwao, Hiroki Syo, Kazunari
Murakami
871: Risk of severe fibrosis is associated with age at
menopause in nonalcoholic fatty liver disease (NAFLD)
Jagpal S. Klair, Ju Dong Yang, Manal F. Abdelmalek, Cynthia D.
Guy, Ryan M. Gill, Katherine P. Yates, Aynur Unalp-Arida, Joel E.
Lavine, Jeanne M. Clark, Anna Mae Diehl, Ayako Suzuki
872: Autoimmunity to Human Heat Shock Protein-70
is Associated with the Presence of Coronary Artery
Disease in Patients with Nonalcoholic Fatty Liver Disease
Elzafir Elsheikh, Zahra Younoszai, Munkhzul Otgonsuren, Maria
C. Albano, Ingrid Schneider, Hussain Allawi, Brian P. Lam, Yousef
Fazel, Michael L. Campbell, Thomas Jeffers, Spencer Frost, Bryan
Raybuck, Zobair Younossi
873: Performance and limitations of five steatosis
biomarkers in patients with Non-alcoholic Fatty Liver
Disease
Fabio Nascimbeni, Larysa Fedchuk, Raluca Pais, Frederic
Charlotte, Chantal Housset, Paola Loria, Vlad Ratziu
874: A deficiency in 25-OH vitamin D is associated with
increased steatohepatitis in alcoholic patients
Clémence M. Canivet, Rodolphe Anty, Stephanie Patouraux,
Antonio Iannelli, Patricia Panaia-Ferrari, Imed Ben Amor, Anne-
Sophie Schneck, Marie-Christine M. Saint-Paul, Jean Gugenheim,
Philippe Gual, Albert Tran
875: Association between Type 2 Diabetes Genetic
Susceptibility Loci and Hepatocellular Carcinoma
in Patients with Type 2 Diabetes as Determined by
Fibroscan
Masaaki Korenaga, Misuzu Ueyama, Nao Nishida, Keiko
Korenaga, Takumi Kawaguchi, Hideyuki Hyogo, Hiroshi Aikata,
NOVEMBER 9
Erina Kumagai, Yoshihiko Aoki, Masaya Sugiyama, Masatoshi
Imamura, Kazumoto Murata, Tatsuya Kanto, Naohiko Masaki,
SUNDAY
Masashi Mizokami
876: NAFLD: A marker of severe Acute Pancreatitis
Sarfaraz A. Jasdanwala, Shivank Madan, Rajagopalan
Sivaprasad, Capecomorin Pitchumoni
877: Berberine with Alfa Lipoic Acid (ALA) in Non
Alcoholic Steato-hepatitis (NASH). A randomized double
blinded placebo control trial. A Clinical pilot – The
BANISH Trial
Patrick Basu, Niraj J. Shah, M. Aloysius
878: Elevated biomarker-indicated liver disease
and pro-inflammatory cytokines are associated with
environmental PCB exposure in Anniston, Alabama
Heather B. Clair, Keith C. Falkner, Banrida Wahlang, Russell A.
Prough, Matthew C. Cave
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
879: Patients with type 2 diabetes mellitus (T2DM) and
normal plasma aminotransferases are at high risk of
nonalcoholic fatty liver disease (NAFLD)
Paola Portillo Sanchez, Fernando Bril, Maryann Maximos, Romina
Lomonaco, Diane Biernacki, Beverly Orsak, Joan Hecht, Kenneth
Cusi
880: Effects of Liraglutide on Carotid Intima-Media
Thickness in Patients with Type-2 Diabetes and Non-
Alcoholic Fatty Liver Disease: An 8-Month Prospective
Pilot Study
Angelo M. Patti, Manfredi Rizzo, Rosaria V. Giglio, Dragana
Nikolic, Antonino Terranova, Melchiorre Cervello, Alessandra
Ferlita, Valeria A. Giannone, Giovanna Aurilio, Valentina Mistretta,
Lydia Giannitrapani, Maurizio Soresi, Giuseppe Montalto
881: Oleuropein counteracts systemic inflammation and
hepatic immune cells infiltration in a mouse model of
NAFLD
Alessia Longo, Mario Arciello, Barbara Barbaro, Gabriele Toietta,
Roberta Maggio, Carmela Viscomi, Clara Balsano
882: Serum concentration of CDCA and TCDCA are
independently associated with Insulin sensitivity in a
large blood donor population
Alberto Porro, Francesco Azzaroli, Simoni Patrizia, Domenico
Fiorillo, Cecilia Camborata, Paolo Cecinato, Federica Buonfiglioli,
Davide Festi, Silvia Spinozzi, Paolo Parini, Rosario Arena, Marco
Montagnani, Rocco Maurizio Zagari, Franco Bazzoli, Aldo Roda,
Giuseppe Mazzella
883: The Development of a Non-invasive Model to
Predict the Presence of Nonalcoholic Steatohepatitis in
Patients with Nonalcoholic Fatty Liver Disease
Danny Issa, George Boon-Bee Goh, Rocio Lopez, Mangesh R.
Pagadala, Jaividhya Dasarathy, Achuthan Sourianarayanane, Ruth
Sargent, Carol A. Hawkins, Amer Khiyami, Lisa M. Yerian, Rish
Pai, Srinivasan Dasarathy, Naim Alkhouri, Arthur J. McCullough
884: Normal ALT and advanced liver fibrosis in
morbidly obese patients undergoing bariatric surgery
Fabio Nascimbeni, Judith Aron-Wisnewsky, Pierre Bedossa, Joan
Tordjman, Raluca Pais, Thierry Poynard, Vlad Ratziu
885: Central obesity is associated with portal vein
thrombosis
Julie Laurent, Camille Christol, Jean Bernard Ruidavets, Jean
Ferrieres, Marie Angele Robic, Jean-Marie Peron, Jean-Pierre
Vinel, Christophe Bureau
886: The quantitative amount of hepatic steatosis in
NAFLD patients predicts the risk of developing diabetes:
a prospective study with up to 25 years of follow-up
Patrik S. Nasr, Mattias Ekstedt, Ulrik L. Mathiesen, Stergios
Kechagias
887: Cryptogenic cirrhosis category masks three
quarters of NASH patients getting liver transplant
Angela Dolganiuc, Vikas Khullar, Virginia C. Clark, Roberto J.
Firpi
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
888: LUM002 Positive Metabolic Profile Shown after
Administration of 10mg For 28 Days in Type 2 Diabetes
Mellitus Patients Leading to Potential Treatment for
Patients with Nonalcoholic Steatohepatitis (NASH)
Renger Tiessen, Ciara Kennedy, Bradley T. Keller, Nancy Levin,
Lisette Acevedo, Dee Wynne, Bronislava Gedulin, Andre A. van
Vliet, Elizabeth Olek, Alejandro Dorenbaum
889: Apolipoprotein A-V Gene Expression in Non-
Alcoholic Steatohepatitis
Qin Feng, Susan S. Baker, Wensheng Liu, Robert D. Baker, Yiyang
Hu, Lixin Zhu
890: U.S. Physician Survey of Current Practices
in the Diagnosis and Treatment of Nonalcoholic
Steatohepatitis (NASH)
Stephen A. Harrison, Sheldon Y. Okada, Cathy A. Su, Matthew
Paulson, Jeffrey D. Bornstein, Arun J. Sanyal
891: Wfa-M2bp Levels Are Usefull Indicators Of
Progression And Inprovement For Monitoring Liver
Fibrosis In Patients With Nonalcoholic Steatohepatitis
Miwa Kawanaka, Ken Nishino, Jun Nakamura, Takahito Oka,
Noriyo Urata, Daisuke Goto, Mitsuhiko Suehiro, Hirofumi
Kawamoto, Gotaro Yamada
892: Vitamin D level is not associated with liver
histology in non-alcoholic steatohepatitis
Matthew T. Kitson, Stephen Casey, Alan Pham, Adam Gordon,
William W. Kemp, Peter Button, Stuart K. Roberts
893: Clinical and Histologic Differences Between HIV-
associated NAFLD and Primary NAFLD: A Case-control
Study
Irine Vodkin, Mark A. Valasek, Ricki Bettencourt, Edward R.
Cachay, Rohit Loomba
894: Non-alcoholic fatty liver disease Intermittent
Fasting Time Intervention (NIFTI): Fasting without calorie
restriction improves hepatic transient elastography,
visceral adiposity and insulin resistance compared to
standard care
Alexander Hodge, Alexandra Mack, Caroline Tuck, Jorge
Tchongue, Darcy Q. Holt, William Sievert, Gregory T. Moore
895: African American Race and Hepatitis C Virus are
associated with Lower Survival in Morbidly Obese
Patients following Liver Transplantation: An Analysis of
UNOS Data
Ryan B. Perumpail, Robert Wong, Andrew M. Su, Christina Chou,
Aijaz Ahmed
896: Acoustic structure quantification (ASQ): a
new ultrasound-based approach for non-invasive
quantification of liver fat content
Thomas Karlas, Joachim Berger, Nikita Garnov, Franziska Lindner,
Harald Busse, Rima Chakaroun, Bettina Relke, Michael Tröltzsch,
Volker Keim, Johannes Wiegand
Poster Viewing: 8:00 AM – 5:30 PM
129A
897: High-dose vitamin D supplementation does not
improve liver histology or metabolic profile in non-
alcoholic steatohepatitis – a pilot study
Matthew T. Kitson, Alan Pham, Adam Gordon, William W. Kemp,
Peter Button, Stuart K. Roberts
898: Comparison of M and XL FibroScan® probes for
diagnosis of clinically significant fibrosis in patients with
non-alcoholic fatty liver disease
Raj Vuppalanchi, Samer Gawrieh, Regina Weber, Naga P.
Chalasani
Experimental Hepatocarcinogenesis
899: iNOS overexpression activates the Ras pathway
in hepatocellular carcinoma, and targeted inhibition of
iNOS suppresses Ras signaling and tumor growth
Michael Li, Yujin Hoshida, Scott L. Friedman, Andrew Sikora
900: Sharpin promotes invasion of hepatocellular
carcinoma through trans-activating Versican expression
Yasuo Tanaka, Keisuke Tateishi, Takuma Nakatsuka, Yotaro Kudo,
Yoshinari Asaoka, Ryosuke Tateishi, Kazuhiko Koike
901: Genome-wide DNA methylation analysis in
hepatocellular carcinoma: Identification and validation
of STEAP4 as a novel methylated gene
Kohichiroh Yasui, Taichiro Nishikawa, Kanji Yamaguchi, Michihisa
Moriguchi, Yoshio Sumida, Hironori Mitsuyoshi, Shinji Tanaka,
Shigeki Arii, Yoshito Itoh
902: Persistent Effects of Rapamycin on the Genetic
Signature of Preneoplastic Foci in a Rat Model of
Progenitor-Derived Hepatocellular Carcinoma (HCC)
Adeola O. Adebayo, Heather Francois-Vaughn, Kate E. Brilliant,
Philip A. Gruppuso, Jennifer A. Sanders
903: Diet Associated Obesity Enhances Development of
Hepatocellular Carcinoma Through Tenascin-C/Toll-like
NOVEMBER 9
Receptor 4 Signaling
SUNDAY
Jennifer H. Benbow, Kyle J. Thompson, Amber C. Smith, Tracy L.
Walling, Catherine R. Culberson, Iain H. McKillop, Ting Li, Laura
W. Schrum
904: Activation of the TGFβ/SMAD Pathway Underlies
a Novel Tumor Promoting Role of Sulfatase1 in
Hepatocellular Carcinoma
Renumathy Dhanasekaran, Chunling Hu, Gang Chen, Abdul M.
Oseini, Catherine D. Moser, Toin H. van Kuppevelt, Wei Zhou,
Jan van Deursen, Taofic Mounajjed, Martin E. Fernandez-Zapico,
Lewis R. Roberts
905: Identification of Hypermethylation and Non-
Synonymous Mutations in Genes Down-Regulated
during the Process of Hepatocarcinogenesis in a Model
of Chronic Hepatitis B
Yasunari Nakamoto, Taro Yamashita, Katsushi Hiramatsu,
Tomoyuki Nemoto, Hiroyuki Suto, Shuichi Kaneko
Presenters in Attendance 12:30 – 2:00 PM
 130A POSTER SESSIONS
Poster Sessions
906: The role of the tumor microenvironment for
the CSC phenotype and progression of liver cancer:
mechanistic findings and prognostic implications
Michael Fischer, Stefan Heinrich, Jesper B. Andersen, Martin F.
Sprinzl, Ines Gockel, Marcus A. Woerns, Snorri S. Thorgeirsson,
Peter R. Galle, Hauke Lang, Jens U. Marquardt
907: Branched-chain amino acids prevent hepatic
fibrosis and development of hepatocellular carcinoma in
a non-alcoholic steatohepatitis mouse model
Kai Takegoshi, Masao Honda, Hikari Okada, Naoto Matsuzawa,
Hisashi Takabatake, Toshinari Takamura, Takuji Tanaka, Shuichi
Kaneko
908: p53 does not only suppress tumor development,
but also regulates essential survival pathways in chronic
liver injury
Laura E. Buitrago, Silke Marhenke, Thomas Longerich, Michelle C.
Barton, Robert Geffers, Michael P. Manns, Arndt Vogel
909: Curcumin targets stem-like liver cancer cells by
NF-kB mediated inhibition of histone deacetylases
Jens U. Marquardt, Luis E. Gómez-Quiroz, Lucrecia O. Arreguin
Camacho, Frederico Pinna, Yun-Han Lee, Mitsuteru Kitade, Jesper
B. Andersen, Kai Breuhahn, Peter R. Galle, Valentina M. Factor,
Snorri S. Thorgeirsson
910: Antitumor effect of the novel sphingosine
kinase-2 inhibitor ABC294640 is enhanced by
inhibition of autophagy and by sorafenib in human
cholangiocarcinoma cells
Xiwei Ding, Roongruedee Chaiteerakij, Catherine D. Moser, Albert
Ndzengue, Hassan M. Shaleh, Gang Chen, Ying Li, Yanling
Zhou, Shengbing Huang, Frank A. Sinicrope, Melanie B. Thomas,
Charles D. Smith, Lewis R. Roberts
911: FABP4 but not FABP5 Promotes Human HCC Cell
Line Proliferation In Vitro
Shayan S. Nazari, Ryan Z. Swan, Iain H. McKillop, Kyle J.
Thompson
NOVEMBER 9
912: Preclinical Evaluation of a Selective Low-Density
SUNDAY
Lipoprotein-Docosahexaenoic Acid Nanomedicine: A
Promising Alternate Treatment Strategy for Unresectable
Hepatocellular Carcinoma
Ian Corbin, Xiaodong Wen, Lacy Reynolds, Rohit Mulik, Jorge A.
Marrero
913: Peretinoin, an acyclic retinoid, suppresses
steatohepatitis and development of tumorigenesis by
activated Atg16L1-dependent autophagy in mice fed an
atherogenic high-fat diet
Hikari Okada, Masao Honda, Kai Takegoshi, Naoto Matsuzawa,
Taro Yamashita, Yoshio Sakai, Toshinari Takamura, Takuji Tanaka,
Shuichi Kaneko
914: IL-33 Facilitates Oncogene Driven
Cholangiocarcinoma in Mice
Daisaku Yamada, Sumera Rizvi, Nataliya Razumilava, Steven F.
Bronk, Jun Li, Jorge A. Bezerra, Xin Chen, Gregory J. Gores
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
915: Role of Reptin in the regulation of DNA double
strand breaks repair in human hepatocellular
carcinoma
Anne-Aurélie Raymond, Véronique Neaud, Jean Rosenbaum
916: A potential role for type XVIII collagen as a
suppressor of hepatocellular carcinoma
Michael Duncan, Renumathy Dhanasekaran, Priyanka Thakur,
Lewis R. Roberts
917: Two microRNA polymorphisms are associated with
hepatitis B virus-related but not hepatitis C virus-related
hepatocellular carcinoma in the Japanese population
Daiki Miki, Hidenori Ochi, C. Nelson Hayes, Hiromi Abe,
Tomokazu Kawaoka, Atsushi Ono, Sakura Akamatsu, Takashi
Nakahara, Noriaki Seki, Eisuke Murakami, Yizhou Zhang, Takuro
Uchida, Yohji Honda, Keiichi Masaki, Hiromi Kan, Masataka
Tsuge, Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami,
Hiroshi Aikata, Michiaki Kubo, Kazuaki Chayama
918: The Molecular Basis of the Anti-Cyclin D1
Intrabody-Induced Inhibition of Hepatocellular
Carcinoma Progression
Yan Wu, An Cui, Hanwei Li, Weiwei Tang, Ying Zhang, Ning
Yang, Guannan Shen, Cynthia Ju, Guiying Li
919: Enhancing effect of retinoids on anti-cancer drugs
by regulating the metabolic pathways of hepatocellular
carcinoma cells
Goshi Shiota, Keita Kanki
920: CXCR4 inhibition in combination with anti-PD1
immunotherapy results in an effective immune response
during treatment with sorafenib in hepatocellular
carcinoma
Thomas Reiberger, Rakesh R. Ramjiawan, Yunching Chen, Mei
R. Ng, Tai Hato, Elizabeth C. Unan, Tejaswini P. Reddy, Yuhui
Huang, Hiroki Ochiai, Peigen Huang, Andrew X. Zhu, Rakesh K.
Jain, Dan G. Duda
921: Impact of connective tissue growth factor in Ras
pathway-activated hepatocytes on the development of
hepatocellular carcinoma
Yuki Makino, Hayato Hikita, Tsukasa Kawaguchi, Takahiro
Kodama, Minoru Shigekawa, Yugo Kai, Yasutoshi Nozaki, Tasuku
Nakabori, Yoshinobu Saito, Satoshi Tanaka, Ryotaro Sakamori,
Takuya Miyagi, Tomohide Tatsumi, Tetsuo Takehara
922: TSU-68 ameliorates the aggressiveness of
hepatocellular carcinoma through inhibition of
microenvironmental PDGF receptor signaling
Yasumasa Hara, Taro Yamashita, Naoki Oishi, Kouki Nio,
Takehiro Hayashi, Yoshimoto Nomura, Mariko Yoshida, Tomoyuki
Hayashi, Tomomi Hashiba, Hikari Okada, Masao Honda, Shuichi
Kaneko
923: miR-133b inhibits hepatocellular carcinoma cell
growth through suppression of MET proto-oncogene
Takayuki Kogure, Yasuteru Kondo, Jun Inoue, Yu Nakagome,
Osamu Kimura, Tomoaki Iwata, Tatsuki Morosawa, Yasuyuki
Fujisaka, Tooru Shimosegawa
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
924: Spink3 and Tff3 are overexpressed in autophagy-
deficient mice and may contribute to hepatocellular
carcinoma development
Michael C. Wallace, Youngmin A. Lee, Luke A. Noon, Kemal M.
Akat, Marie-Luise Berres, Scott L. Friedman
925: HCV NS5A blocks MG132-induced apoptosis in
hepatocytes through the inhibition of NF-κB activation
Xia Jiang, Tatsuo Kanda, Shuang Wu, Yuki Haga, Reina Sasaki,
Masato Nakamura, Shingo Nakamoto, Fumio Imazeki, Osamu
Yokosuka
926: Liver fibrosis enhances tumorigenicity of hepatoma
cells and makes them resistant to chemotherapy
Benoit Lacoste, Benoît Dupont, Grégory Merlen, Marc Bilodeau
927: Polo-Like Kinase 3 is associated with improved
Overall Survival in Cholangiocarcinoma
Benjamin Juntermanns, Svenja Sydor, Gernot M. Kaiser, Andreas
Paul, Hideo A. Baba, Ali Canbay, Christian Dominik Fingas
928: Notch signal-activated hepatoma cells are
associated with Jagged1 genomic abnormality, and
Notch inhibitors efficiently suppress EpCAM+ liver
cancer stem cells
Kazunori Kawaguchi, Masao Honda, Taro Yamashita, Kouki Nio,
Hikari Okada, Masashi Nishikawa, Kuniaki Arai, Yoshio Sakai,
Tatsuya Yamashita, Eishiro Mizukoshi, Shuichi Kaneko
929: Activation of mitochondrial pathway of apoptosis
in hepatocytes increases oxidative stress in hepatocytes
leading to liver tumorigenesis
Hayato Hikita, Tomohide Tatsumi, Yoshinobu Saito, Satoshi
Tanaka, Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu,
Tetsuo Takehara
930: Difference in pattern of somatic mutations
between primary sclerosing cholangitis (PSC)-related
cholangiocarcinoma (CCA) and non-PSC related CCA
Roongruedee Chaiteerakij, Emily G. Barr Fritcher, Jesse Voss,
Fergus J. Couch, Kevin C. Halling, Lewis R. Roberts, Benjamin R.
Kipp
931: Loss of heterozygosity at 5q13.2 and 8p23.1 in
dysplastic hepatocytes of cirrhotic liver are common
events in hepatocellular carcinoma
Zhang Zhao, Guang-Yong Chen, Jiang Long, Jian Huang
932: Sorafenib induces conversion to RAF dependence
and ERK activation as a mechanism of rapidly acquired
resistance in hepatocellular carcinoma
Rakesh R. Ramjiawan, Thomas Reiberger, Yunching Chen,
Annique M. Duyverman, Peigen Huang, Keith Flaherty, Andrew X.
Zhu, Rakesh K. Jain, Dan G. Duda
Poster Viewing: 8:00 AM – 5:30 PM
131A
933: Reduction in nuclear S100A4 in
Cholangiocarcinoma by low dose paclitaxel inhibits
tumor invasiveness and hematogenous metastatization
by interfering with Rho-A and Cdc42
Gaia Spagnuolo, Massimiliano Cadamuro, Luisa Sambado,
Stefano Indraccolo, Giorgia Nardo, Antonio Rosato, Carlo Spirli,
Mario Strazzabosco, Luca Fabris
934: Galnt1 Modifies Cell Surface O-Glycosylation
And Regulates Malignant Phenotypes In Hepatocellular
Carcinoma
Yao-Ming Wu, Miao-Juei Huang, Min-Chuan Huang
935: Role of histone demethylase Kdm3a in liver
tumorigenesis
Takuma Nakatsuka, Keisuke Tateishi, Yotaro Kudo, Keisuke
Yamamoto, Ryota Takahashi, Koji Miyabayashi, Yoshinari
Asaoka, Yasuo Tanaka, Hideaki Ijichi, Kazuhiko Koike
936: FAK is required for c-Met/β-catenin-driven
hepatocarcinogenesis
Na Shang, Maribel Arteaga, Jimmy Stauffer, Scott Cotler, Jiwang
Zhang, Wei Qiu
937: Inhibitory role of peroxisome proliferator-activated
receptor-β/δ in hepatocarcinogenesis in mice and in
vitro
Bo Shen, Ai min Li, Yu Qiang Nie, Yu-Jui Yvonne Wan, Yan Lei Du,
Yu Yuan Li, Gui Jia Shen
938: Germline variants of highly point-mutated genes in
hepatocellular carcinoma do not have strong effects on
HCV-related hepatocarcinogenesis
Daiki Miki, Hidenori Ochi, C. Nelson Hayes, Atsushi Ono, Sakura
Akamatsu, Yuji Urabe, Keiichi Masaki, Hiromi Abe, Tomokazu
Kawaoka, Takashi Nakahara, Noriaki Seki, Eisuke Murakami,
Yizhou Zhang, Takuro Uchida, Yohji Honda, Hiromi Kan,
Masataka Tsuge, Nobuhiko Hiraga, Michio Imamura, Yoshiiku
Kawakami, Hiroshi Aikata, Michiaki Kubo, Kazuaki Chayama
939: Statins interfere on TCTP and PI3K/AKT/
NOVEMBER 9
mTOR pathway and inhibit hepatocellular carcinoma
SUNDAY
progression
Marta García-Valdecasas, Antonio Gil-Gómez, Angela Rojas,
Jordi Muntané, Farncisco Javier PAdillo Ruiz, Manuel Romero-
Gomez, Jose Antonio Del Campo
940: Role of Fatty Acid-Binding Protein 4 in liver
carcinogenesis related to metabolic syndrome
Aurelie Sannier, Samira Laouirem, Mouna Mebarki, Miguel
Albuquerque, Jacques Belghiti, Pierre Bedossa, Valerie Paradis
941: Hepatic steatosis and high circulating free fatty
acid levels promote growth and invasiveness of
hepatocellular carcinoma
Andreas Koch, Claus Hellerbrand
Presenters in Attendance 12:30 – 2:00 PM
 132A POSTER SESSIONS
Poster Sessions
942: Antioxidative selenoenzyme glutathione
peroxidase 4 affects tumour vascularisation in a mice
model of hepatocellular carcinoma
Nataliya Rohr-Udilova, Dagmar Stoiber, Eva Bauer, Wen Li,
Martha Seif, Hubert Hayden, Gerald Timelthaler, Klaus Stolze,
Regina Brigelius-Flohe, Robert Eferl, Markus Peck-Radosavljevic
943: Interplay of adenosinergic signaling and TTK
mitotic kinase inhibition limits hepatocellular cancer cell
growth
Ruoyu Miao, Yan Wu, Haohai Zhang, Huandi Zhou, Xiaofeng
Sun, Eva Csizmadia, Lian He, Yi Zhao, Chengyu Jiang, Haitao
Zhao, Simon C. Robson
944: Impaired function of CD4+ follicular helper T(Tfh)
cells associated with progression of hepatocellular
carcinoma
Yiqiong Jia, Lifeng Wang, Zheng Zhang, Fu-Sheng Wang
945: The possibility of cancer stem cells among EpCAM-
positive cells of hepatocellular carcinoma
Osamu Kimura, Yasuteru Kondo, Takayuki Kogure, Jun Inoue, Yu
Nakagome, Tatsuki Morosawa, Tomoaki Iwata, Yasuyuki Fujisaka,
Teruyuki Umetsu
946: Platelet-Derived Growth Factor D-Induced
Secretion of Vascular Endothelial Growth Factor-C
by Cancer-associated Fibroblasts stimulates
lymphangiogenesis in Cholangiocarcinoma
Massimiliano Cadamuro, Marta Vismara, Simone Brivio, Mario
Strazzabosco, Luca Fabris
947: Targeting the raft-associated Akt signaling in
hepatocellular carcinoma
Jingmin Zhao, Yuan Liu, Jiyun Lv, Jian-Fei Shi, Jin Li, Mei Yang,
Xiaodong Guo, Zhiwei Li, Hong-Bo Wang, Shaogeng Zhang,
Zhenwen Liu, Jin-Biao Ding, Dong-Ping Xu
948: Hepatocyte specific Bid depletion reduces tumor
development via suppression of inflammation related
compensatory proliferation
NOVEMBER 9
Alexander Wree, Casey Johnson, Joan Font-Burgada, Michael
SUNDAY
Karin, Ariel E. Feldstein
949: Insulin treatment improves disorder of glycolipid
metabolism, but accelerates the progression of
hepatocellular carcinoma in DIAR-nSTZ mice, which is a
hepatocellular carcinoma model based on diabetes
Hayato Baba, Koichi Tsuneyama, Takeshi Nishida, Johji Imura
950: Hepatitis B virus X protein priors to induce
expression of alpha-fetoprotein to activate PI3K/mTOR
signal pathway in liver cells
Mingyue Zhu, Junli Guo, Hua Xia, Xieju Xie, Mengsen Li
951: Cell cycle-dependent regulation of FGFR4 in
cholangiocarcinoma
Ashley M. Mohr, Mary A. Smith, Sathish Kumar Natarajan, Cody
J. Wehrkamp, Carol A. Casey, Justin L. Mott
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
Hepatitis C: Approved Therapeutic
Agents
952: Significant Reduction of Hepatocellular
Carcinoma Risk in Chronic Hepatitis C Patients with Peg-
interferon plus Ribavirin Therapy: A Five-year Clinical
Cohort Study
Mei-Hsuan Lee, Yong Yuan, Ming-Lung Yu, Wan-Long Chuang, Jia-
Horng Kao, Chen-Hua Liu, Sheng-Nan Lu, I-Shyan Sheen, Gilbert J.
L’Italien, Hwai-I Yang, Chien-Jen Chen
953: Early Assessment of Hepatitis C Virologic
Response of US Veterans Receiving Sofosbuvir-based
Therapy
Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A.
Mole
954: Cost-effectiveness of sofosbuvir for the
treatment of chronic hepatitis C infected patients in the
UK
Sandrine Cure, Ines Guerra, Geoffrey M. Dusheiko
955: Safety and Efficacy of Sofosbuvir (SOF) in
Combination with Simeprevir (SIM) + Ribavirin (RBV)
in Patients with Genotype 1: Interim Results of a
Prospective, Observational Study
Mark S. Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie,
Alexander Kuo, K. Rajender Reddy, Joseph K. Lim, Giuseppe
Morelli, Jordan J. Feld, Robert S. Brown, Lynn M. Frazier, Michael
W. Fried, David R. Nelson, Ira M. Jacobson
956: Safety and efficacy of Simeprevir +
Sofosobuvir with or without Ribavirin in Patients with
Decompensated Genotype 1 Hepatitis C induced
Cirrhosis
Apurva A. Modi, Hector Nazario, Stevan A. Gonzalez,
Manjushree Gautam, Jeffrey S. Weinstein, Parvez S. Mantry,
Maisha Barnes, Adil Habib, Jean L. McAfee, Olga Teachenor,
Lauren Tujague, James F. Trotter
957: Short duration response-guided treatment is
effective for most individuals with recent hepatitis C
infection: the ATAHC II Study
Marianne Martinello, Margaret Hellard, David Shaw, Kathy
Petoumenos, Tanya L. Applegate, Jason Grebely, Barbara Y.
Yeung, Laurence Maire, David M. Iser, Andrew R. Lloyd, Alexander
J. Thompson, Joe Sasadeusz, Paul Haber, Gregory J. Dore, Gail
Matthews
958: Decrease of Cirrhosis and Hepatocellular
Carcinoma (HCC) in African Americans (AA) Following
Successful Treatment for Chronic Hepatitis C (CHC)
Naveen Reddy, Paul Naylor, Zaher Hakim, Redwan Asbahi,
Karthik Ravindran, Murray N. Ehrinpreis, Milton G. Mutchnick
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
959: Sofosbuvir plus Ribavirin in the Treatment
of Egyptian Patients with Chronic Genotype 4 HCV
Infection
Gamal E. Esmat, Gamal Shiha, Rabab F. Omar, Mohamad
Hassany, Radi Hammad, Marwa Khairy, Waleed Samir, Reham
Soliman, Diana M. Brainard, Deyuan Jiang, Kathryn Kersey,
Steven J. Knox, Benedetta Massetto, John G. McHutchison, Wahid
H. Doss
960: Performance of Simeprevir- and Sofosbuvir-
based HCV Treatment in Real World Clinical Practice
Kian Bichoupan, Rachana Yalamanchili, Keith M. Sigel, Alyson
Harty, Michel Ng, Alicia Stivala, Donna Fanelli, Donald
Gardenier, David B. Motamed, Badr Aljarallah, David Sachs,
Michael Linderman, Viktoriya Khaitova, Meena B. Bansal, Priya
Grewal, Ritu Agarwal, Charissa Y. Chang, Jennifer Leong,
Gene Y. Im, Lawrence Liu, Joseph A. Odin, Nancy Bach, David
C. Perlman, Jonathan Yeh, Albert Min, Henry C. Bodenheimer,
Donald P. Kotler, Scott L. Friedman, Thomas D. Schiano, Ponni
Perumalswami, Douglas Dieterich, Andrea D. Branch
961: Resistance Analysis of Treatment-Experienced
HCV Genotype 1 Infected Patients Retreated with
Sofosbuvir
Hongmei Mo, Brian Doehle, Viktoria Gontcharova, Ramakrishna
K. Chodavarapu, Bittoo Kanwar, Ira M. Jacobson, Stanislas Pol,
Diana M. Brainard, John G. McHutchison, Michael D. Miller
962: Reducing Polymorphisms Consisting of (TA)n
Dinucleotide Repeat Near IL28B Gene Interact with the
Deviation of IL28B SNPs and Affect the Effectiveness of
PegIFN/RBV, but not PegIFN/RBV/TVR
Masaaki Korenaga, Masaya Sugiyama, Yoshihiko Aoki, Keiko
Korenaga, Yoko Yamagiwa, Masatoshi Imamura, Nao Nishida,
Kazumoto Murata, Tatsuya Kanto, Naohiko Masaki, Masashi
Mizokami
963: Efficacy and safety of sofosbuvir plus simeprevir in
patients with advanced HCV cirrhosis
Camelia I. Capraru, Magdalena Kuczynski, Danie La, Diana
Kaznowski, Matthew Kowgier, David K. Wong, Joshua Juan,
Hemant Shah, Alnoor Ramji, Harry L. Janssen, Jordan J. Feld
964: Burden of Side Effects Associated with Treatment
of Hepatitis C
Ami R. Buikema, Lisa C. Rosenblatt, Fang Liu, Boris Gorsh, John C.
White, Bruce E. Sill
965: Impact of host and therapeutic factors and
resistant associated variants on response to interferon
based- direct acting antiviral treatment in difficult-to-
treat chronic hepatitis C patients
Mina Nakagawa, Yasuhiro Asahina, Miki Taniguchi, Takako
Watanabe, Yuki Nishimura-Sakurai, Yasuhiro Itsui, Seishin Azuma,
Sei Kakinuma, Yujiro Tanaka, Mamoru Watanabe
Poster Viewing: 8:00 AM – 5:30 PM
133A
966: Safety, Anti-Viral Efficacy and Pharmacokinetics
(PK) of Sofosbuvir (SOF) in Patients with Severe Renal
Impairment
Edward J. Gane, Richard A. Robson, Maurizio Bonacini, Benedict
Maliakkal, Lin Liu, Karim Sajwani, Luisa M. Stamm, Diana M.
Brainard, John G. McHutchison, Catherine A. Stedman, Eric Lawitz
967: Plasma and Intracellular Ribavirin
Pharmacokinetics and Concentration-Effect Analyses in
Chronic Hepatitis C Virus Genotype 1 Patients Receiving
Sofosbuvir plus Ribavirin in the NIAID SPARE Trial
Joseph E. Rower, Eric G. Meissner, Leah C. Jimmerson, Anu
Osinusi, Zayani Sims, Tess L. Petersen, Lane Bushman, Pamela
Wolfe, John G. McHutchison, Shyam Kottilil, Jennifer J. Kiser
968: Baseline vitamin D level and sustained virologic
response to interferon-based antiviral therapy in chronic
hepatitis C: a systematic review and meta-analysis
Matthew T. Kitson, Christoph Sarrazin, Pierluigi Toniutto, Guy D.
Eslick, Stuart K. Roberts
969: Delayed early HCV RNA response during IFN-free
therapy with sofosbuvir in interferon-ineligible patients
with advanced cirrhosis
Katja Deterding, Christoph Hoener zu Siederdissen, Kerstin Port,
Janina Kirschner, Lisa Sollik, Carola Mix, Michael P. Manns,
Markus Cornberg, Heiner Wedemeyer
970: Response to IFN-based antiviral therapy
and long term effect of HCV eradication in Mixed
Cryoglobulinemia, with or without symptoms: a
prospective, controlled, open-label, long term, cohort
study
Laura Gragnani, Alessia Piluso, Elisa Fognani, Monica Monti,
Barbara Boldrini, Teresa Urraro, Alessio Fabbrizzi, Umberto
Arena, Stefania Moscarella, Jessica Ranieri, Cristina Stasi,
Giacomo Laffi, Anna Linda Zignego
971: Efficacy and safety of telaprevir based triple
therapy in coinfected patients with advanced fibrosis.
Final results of the spanish cohort
NOVEMBER 9
Miguel A. von Wichmann, Ana Moreno, Luis F. López Cortés,
SUNDAY
Enrique Ortega, Jose Antonio Mira, Carmen Quereda, Marisa L.
Montes, Maria Tellez, Miguel García del Toro, José A. Iribarren,
Angela M. Camacho, Luz Martin-Carbonero, Joseba Portu, José-
Ramón Blanco, Koldo Aguirrebengoa, Juan Berenguer, Juan
Gonzalez García, Manuel Márquez Solero
972: Safety and Effectiveness of Sofosbuvir (SOF) in
Combination with Simeprevir (SIM) or Ribavirin (RBV)
for the Treatment of Hepatitis C Virus (HCV) Recurrence
after Liver Transplant (LT)
Glen A. Lutchman, Nghia H. Nguyen, Tiffany I. Hsiao, Vinh D.
Vu, Vincent Chen, Aijaz Ahmed, Tami Daugherty, Gabriel Garcia,
Radhka Kumari, W. Ray Kim, Mindie H. Nguyen
Presenters in Attendance 12:30 – 2:00 PM
 134A POSTER SESSIONS
Poster Sessions
973: 97% Sustained Virologic Response in Japanese
Patients with Chronic Genotype 2 Hepatitis C Virus
Infection Receiving Sofosbuvir in Combination with
Ribavirin for 12 Weeks: Results from a Phase 3
Multicenter Study
Masao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, Hitoshi
Mochizuki, Namiki Izumi, Fusao Ikeda, Hidenori Toyoda, Osamu
Yokosuka, Kazushige Nirei, Takuya Genda, Takeji Umemura,
Tetsuo Takehara, Naoya Sakamoto, Yoichi Nishigaki, Kunio
Nakane, Nobuo Toda, Tatsuya Ide, Mikio Yanase, Keisuke
Hino, Juan Betular, Bing Gao, Akinobu Ishizaki, Masa Omote,
Diana M. Brainard, Steven J. Knox, William T. Symonds, John G.
McHutchison, Hiroshi Yatsuhashi, Masashi Mizokami
974: Modeling treatment scale up effect on hepatitis
C prevalence among persons who inject drugs in
metropolitan Chicago
Desarae Echevarria, Alexander Gutfraind, Basmattee Boodram,
Marian E. Major, Scott Cotler, Harel Dahari
975: Efficacy of sofosbuvir and simeprevir-based
regimens for 304 HCV treatment-experienced patients
in a real-life setting; data from the TRIO network
Bruce R. Bacon, Douglas Dieterich, Steven L. Flamm, Kris V.
Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, Naoky Tsai
976: High Response Rate and Good Tolerability of
Genotype 6 Chronic Hepatitis C Patients to Pegylated
Interferon alfa combining Ribavirin in China
Lai Wei, ZhiLiang Gao, Qing Mao, Dazhi Zhang, Jianning Jiang,
Guozhong Gong, Zhibiao Yin, Qing Xie, Jian Sun, Huiying Rao,
Bo Feng, Ruifeng Yang, Haiying Zhang
977: Poor Sustained Virologic Response (SVR) in a
Multicenter Real-Life Cohort of Chronic Hepatitis C (CHC)
Patients Treated with Pegylated Interferon (PEG IFN)
and Ribavirin (RBV) plus Telaprevir (TVR) or Boceprevir
(BOC)
Kevin P. Vo, Philip Vutien, Matthew J. Akiyama, Vinh D. Vu, Joy I.
Piotrowski, Nghiem B. Ha, James M. Wantuck, Marina Roytman,
NOVEMBER 9
Ramsey Cheung, Jiayi Li, Naoky Tsai, Mindie H. Nguyen
SUNDAY
978: Treatment safety and efficacy of Boceprevir-based
triple therapy in genotype 1 hepatitis C: the Australian
multicentre Boceprevir real world experience (SABRE-C)
Anouk T. Dev, Joanne Mitchell, Kevan Polkinghorne, Richard
Skoien, Katherine Stuart, Wendy Cheng, Alice Lee, Miriam T.
Levy, John Lubel, Saroja Nazareth, Alan J. Wigg, Sherryne L.
Warner, Stuart K. Roberts
979: DDRGK1 variants are associated with platelet
decline during peginterferon and ribavirin therapy in
Caucasian patients with chronic HCV infection
Raoel Maan, Adriaan J. van der Meer, Willem Pieter Brouwer,
Elisabeth P. Plompen, Milan J. Sonneveld, Robert Roomer,
Annemiek A. van der Eijk, Zwier M. Groothuismink, Bettina E.
Hansen, Bart J. Veldt, Harry L. Janssen, Andre Boonstra, Robert
J. de Knegt
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
980: Impact of latest direct antiviral agents (DAAs) on
the cure rate and cost of hepatitis C infection treatment:
a meta-analysis
Siddharth Bansal, Mohamed G. Shoreibah, Brendan M. McGuire,
Ashwani K. Singal, Bhupinderjit S. Anand
981: A real life experience with COSMSOS regimen
in Genotype 1 chronic hepatitis C treatment: including
patients with East Asian ancestry and decompensated
cirrhosis
Marina Roytman, Resham Ramkissoon, Leena K. Hong, Leslie
Huddleston, Ruby Trujillo, Peter Poerzgen, Todd B. Seto, Naoky
Tsai
982: Sofosbuvir plus Ribavirin for the Treatment of
Russian Patients with Chronic HCV Genotype 1 or 3
Infection
Vladimir Chulanov, Konstantin Zhdanov, Kathryn Kersey,
Yanni Zhu, Benedetta Massetto, Sergey Zhuravel, Svetlana
Romanova, Elena Nurmukhametova, Viacheslav Morozov,
Galina Kozhevnikova, Larisa Gogova, Natalia Geyvandova,
Natalia Gankina, Evgenii Chesnokov, Eduard Z. Burnevich, Elena
Bessonova, Djamal Abdurakhmanov, Diana M. Brainard, John G.
McHutchison, Igor G. Bakulin, Vasily Isakov
983: Evaluation of efficacy of sofosbuvir and
simeprevir-based regimens in a real-life population of
345 HCV patients with cirrhosis; data from the TRIO
network
Steven L. Flamm, Bruce R. Bacon, Douglas Dieterich, Kris V.
Kowdley, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi
984: Interferon based therapies (IBT) against hepatitis
C (HCV) in previous kidney transplant (KT) recipients on
hemodialysis (HD) do not seem to increase the risk of
graft intolerance syndrome (GIS)
Javier-Enrique Hernandez Blanco, Josep M. Barrera, Sabela Lens,
Zoe Mariño, Francesc Maduell, Josep-Maria Campistol, Xavier
Forns, Maria-Carlota Londono
985: Telaprevir combination therapy in treatment-naïve
and -experienced patients co-infected with HCV/HIV
(INSIGHT STUDY): sustained virologic response at 12
weeks final analysis
Marisa L. Montes, Mark Nelson, Pierre-Marie Girard, Joe
Sasadeusz, Andrzej Horban, Beatriz Grinsztejn, Natalia
Zakharova, Antonio Rivero, Erkki Lathouwers, Katrien Janssen, Sivi
Ouwerkerk-Mahadevan, James Witek
986: Protease inhibitors impair renal function in HCV-
infected immunocompetent patients
Carlos Fernández-Carrillo, Juan Manuel Pascasio, Martin Prieto, J.
L. Montero, Javier Crespo, Inmaculada Fernández, Xavier Forns,
Javier García-Samaniego, Manuel Romero-Gomez, Juan Turnes,
J. Javier Moreno, Elba Llop, Cristina Serrano-Millan, Maria Buti,
Jose Luis Calleja
987: MCNs, reach and treat the HCV patients other
pathways can’t!
Jan Tait, Brian P. Stephens, Shirley Cleary, Paul G. McIntyre, John
F. Dillon
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
988: Analysis of HCV-RNA decrease until one week
after the start of the triple therapy including protease
inhibitor in patients chronically infected with hepatitis C
virus genotype 1
Satoru Hashimoto, Rumiko Nakao, Ayako Mine, Yuki Kugiyama,
Ryu Sasaki, Shigemune Bekki, Akira Saeki, Shinya Nagaoka,
Seigo Abiru, Kazumi Yamasaki, Atsumasa Komori, Hiroshi
Yatsuhashi
989: Inosine Triphosphatase and Interleukin 28B
Genetic Variants to Predict Sustained Virologic Response
in Hemodialysis Patients with Hepatitis C Virus
Genotype 1 or 2 Infection who Received Peginterferon
alfa-2a plus Low-Dose Ribavirin: Data Analysis from
HELPER-1 and HELPER-2 Trials
Chen-Hua Liu, Chun-Jen Liu, Chung-Feng Huang, Jou-Wei Lin,
Chia-Yen Dai, Cheng-Chao Liang, Jee-Fu Huang, Peir-Haur Hung,
Hung-Bin Tsai, Meng-Kun Tsai, Chih-Yuan Lee, Shih-I Chen, Sheng-
Shun Yang, Tung-Hung Su, Hung-Chih Yang, Pei-Jer Chen, Ding-
Shinn Chen, Wan-Long Chuang, Ming-Lung Yu, Jia-Horng Kao
990: Safety and Efficacy of Simeprevir, Sofosbuvir
and Riabviirn Combination Therapy in Liver Transplant
Recipients with Severe Recurrent HCV
Satheesh Nair, Nader Dbouk, Shilpa Lingala, Sanjaya K.
Satapathy
991: Effects of Ribavirin on Red Blood Cell
Concentrations of Endogenous Purines in Patients with
Hepatitis C Virus Undergoing Ribavirin-Based Treatment
Leah C. Jimmerson, James R. Burton, Fafa Baouchi, Aimee E.
Truesdale, Angie Price, Michelle Ray, Lane Bushman, Kyle
Hammond, Jacob Langness, Sarah Tise, Gregory T. Everson,
Jennifer Kiser
992: The Effect of Rifampin on the Pharmacokinetics of
Sofosbuvir in Healthy Volunteers
Kimberly L. Garrison, Yi Wang, Diana M. Brainard, Karim
Sajwani, Anita Mathias
993: Simeprevir and Sofosbuvir with modified doses
of Ribavirin (RBV) therapy on Telaprevir experienced
Co infected (with HIV) cirrhotics with chronic hepatitis
C (CHC) A randomized open label clinical pilot study:
STOP C
Patrick Basu, Niraj J. Shah, M. Aloysius
994: Real-World Data on HIV positive Patients with HCV
Genotype 1,2 and 3 on Sofosbuvir- and Simeprevir-
containing Regimens
David P. Del Bello, Kian Bichoupan, Rachana Yalamanchili,
Alyson Harty, Michel Ng, Alicia Stivala, Donald Gardenier,
Viktoriya Khaitova, Nadim Salomon, Donna Mildvan, David C.
Perlman, Lawrence U. Liu, Joseph A. Odin, Thomas D. Schiano,
Ponni Perumalswami, Daniel S. Fierer, Douglas Dieterich, Andrea
D. Branch
Poster Viewing: 8:00 AM – 5:30 PM
135A
995: Real World Experience with Sofosbuvir and
Simeprevir combination treatment in patients with HCV
genotype 1
Ming V. Lin, Neliswa A. Gogela, Jessica L. Wisocky, Michael
Thiim, Daniel S. Pratt, Karin L. Andersson, Nikroo Hashemi, Anna
E. Rutherford, Kathleen E. Corey, Lee F. Peng, Dahlene N. Fusco,
Arthur Y. Kim, Alan Mullen, Judith A. Bloom, Raymond T. Chung
996: Simeprevir plus Sofosbuvir for Patients with
Recurrence of Genotype 1 Hepatitis C Infection after
Liver Transplantation
Susan J. Ripper, Edward W. Holt, Stewart Cooper, Adil E. Wakil,
Timothy J. Davern, Raphael Merriman, Jennifer Guy, R. Todd
Frederick
997: The impact of plasma ribavirin concentration
on the efficacy of the interferon-sparing regimen,
sofosbuvir and ribavirin
Marianne Martinello, Maryam Alavi, Gregory J. Dore, Ana
Schteinman, Richard O. Day, Kenneth Williams, Gail Matthews
998: A real life experience with sofosbuvir-based
regimens, including patients with multiple factors
previously associated with inferior treatment response
Christina Wu, Marina Roytman, Leena K. Hong, Leslie Huddleston,
Ruby Trujillo, Alvin Cheung, Peter Poerzgen, Naoky Tsai
999: Higher sustained virologic response (SVR) in
patients with early virologic response (EVR) and
hepatitis C genotype 4 (HCV-4) compared to genotype
1 (HCV-1) with pegylated interferon and ribavirin (PEG
IFN+RBV): a comparative analysis from a meta-analysis
Brittany E. Yee, Derek Lin, Nghia H. Nguyen, Bing Zhang, Philip
Vutien, Carrie R. Wong, Glen A. Lutchman, Mindie H. Nguyen
1000: Renal Impairment under Triple Therapy with
Boceprevir in German Real-Life: Evidence for a Pivotal
Role for Peginterferon/Ribavirin Backbone, Female
Gender and Age >50 Years
Peter Buggisch, Hanns F. Loehr, Gerlinde Teuber, Hermann
Steffens, Michael R. R. Kraus, Christine John, Peter R. Geyer,
NOVEMBER 9
Bernd Weber, Thomas Witthoeft, Andreas Herrmann, Mark Hoesl,
SUNDAY
Uwe Naumann, Elmar Zehnter, Dagmar Hartmann, Bernd Dreher,
Manfred Bilzer
1001: Relevance of early virological assessment during
triple therapy combining telaprevir or boceprevir with
pegylated interferon/ribavirin in chronic hepatitis C
patients - The ANRS CO20 CUPIC study
François Bailly, Victor Virlogeux, Cécilie Dufour, Pierre Pradat,
Christophe Hezode, Dominique G. Larrey, Laurent Alric, Didier
Samuel, Marc Bourlière, Sophie Metivier, Jean-Pierre Zarski,
Hélène Fontaine, Veronique Loustaud-Ratti, Lawrence Serfaty, Jean-
Pierre Bronowicki, Ventzislava Petrov-Sanchez, Fabrice Carrat,
Fabien Zoulim
1002: Successful treatment of post liver transplant
patients with genotype 1 hepatitis C virus with
sofosbuvir and simeprevir
Carmi S. Punzalan, Curtis Barry, Isabel Zacharias, Julie Rodrigues,
Savant Mehta, Adel Bozorgzadeh, Graham Barnard
Presenters in Attendance 12:30 – 2:00 PM
 136A POSTER SESSIONS
Poster Sessions
1003: Safety and Efficacy of Simeprevir and Sofosbuvir
in Patients with Decompensated Cirrhosis
Shilpa Lingala, Sanjaya K. Satapathy, Nader Dbouk, Satheesh
Nair
1004: Urgent Treatment With Sofosbuvir Based
Regimen For Hepatitis C Genotype 1 Patients With
Severe Renal Insufficiency (GFR <30ml/min)
Kalyan R. Bhamidimarri, Julio A. Gutierrez, Alla Grigorian, Adam
L. Peyton, Cynthia Levy, Christopher O’Brien, Paul Martin
1005: Significant interindividual variability in Telaprevir
exposure in patients undergoing anti-HCV therapy -
need for “real world” PK studies to identify vulnerable
populations
Omar El-Sherif, Sujan Dilly Penchala, Laura J. Else, Suzanne
Norris, Saye H. Khoo
1006: Outcomes from the Irish national hepatitis C
prospective treatment registry
Emma Gray, Aisling O’Leary, Cathal Walsh, Colm J. Bergin,
Suzanne Norris
1007: Meta-analysis: Predictors for response-guided
therapy (RGT) in hepatitis C genotype 4 (HCV-4) patients
treated with pegylated interferon and ribavirin (PEG
IFN+RBV)
Brittany E. Yee, Nghia H. Nguyen, Bing Zhang, Philip Vutien,
Carrie R. Wong, Glen A. Lutchman, Mindie H. Nguyen
1008: A real life experience of Simeprevir, pegylated-
interferon and ribavirin therapy revealed high rate of
rapid virological response regardless of age, fibrosis
and NS3 polymorphisms
Shoko Suzuki, Namiki Izumi, Masayuki Kurosaki, Jun Itakura,
Kaoru Tsuchiya, Hiroyuki Nakanishi, Takanori Hosokawa, Yutaka
Yasui, Nobuharu Tamaki, Nobuhiro Hattori, Yu Asano, Shuya
Matsuda, Natsuko Nakakuki, Hitomi Takada, Koichi Gondou
1009: The impact of an inosine triphosphatase
polymorphism on bilirubin increases in patients with
NOVEMBER 9
hepatitis C virus infection treated with simeprevir,
SUNDAY
pegylated interferon plus ribavirin
Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Naoki Morishita,
Naoki Harada, Ryoko Yamada, Takayuki Yakushijin, Yukiko Saji,
Sadaharu Iio, Akira Yamada, Eiji Mita, Hideki Hagiwara, Hiroyuki
Fukui, Masami Inada, Shinji Tamura, Harumasa Yoshihara, Atsuo
Inoue, Yasuharu Imai, Hayato Hikita, Ryotaro Sakamori, Takuya
Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Akinori Kasahara,
Norio Hayashi, Tetsuo Takehara
1010: Efficacy and safety of telaprevir-based triple
therapy for patients aged 66 years and older with
genotype 1b chronic hepatitis C
Satoshi Yamagiwa, Toru Ishikawa, Shunsuke Tsubata, Nobuo
Waguri, Soichi Sugitani, Hiroto Wakabayashi, Masaaki
Takamura, Masato Igarashi, Minoru Nomoto
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1011: Interferon Induced Low Blood Cell Counts
Are Associated With Bleeding and Infection in Liver
Transplant Recipients on Hepatitis C Treatment
Ludi Koning, Kymberly D. Watt, Bettina E. Hansen, Julie Heimbach,
Robert J. de Knegt, Michael Charlton
1012: Analysis of the liver function and hepatic
reserve improvement effect, and liver carcinogenesis
suppressant effect of the Daclatasvir/Asnaprevir
combination therapy
Yoshiyasu Karino, Shuhei Hige, Itaru Ozeki, Tomoaki Nakajima,
Mutuumi Kimura, Tomohiro Arakawa, Yasuaki Kuwata, Takahiro
Sato, Takumi Ohmura, Joji Toyota
1013: Quality of Life for HCV-infected Patients
during Treatment: Are IFN-free Better than IFN-based
Regimens?
Jillian Nickerson, Kian Bichoupan, Alyson Harty, Jeffrey J. Weiss,
Ponni Perumalswami, Thomas D. Schiano, Douglas Dieterich,
Andrea D. Branch
1014: The risk factors for hepatocellular carcinoma
development in patients with hepatitis C virus
eradication
Masafumi Naito
1015: Frequency and Impact of Thyroid Dysfunction
on Early Virologic Response in Patients Undergoing
Boceprevir Triple Therapy for HCV Genotype 1 Infection
Peter Buggisch, Hanns F. Loehr, Gerlinde Teuber, Hermann
Steffens, Michael R. R. Kraus, Christine John, Peter R. Geyer,
Bernd Weber, Thomas Witthoeft, Andreas Herrmann, Mark Hoesl,
Uwe Naumann, Elmar Zehnter, Dagmar Hartmann, Bernd Dreher,
Manfred Bilzer
1016: Serious Adverse Events and Hepatic
Decompensation in Hepatitis C Virus infected Patients on
Sofosbuvir- and/or Simeprevir-based Therapies
Ponni Perumalswami, Kian Bichoupan, Rachana Yalamanchili,
Alyson Harty, Donald Gardenier, Michel Ng, David B. Motamed,
Viktoriya Khaitova, Nancy Bach, Charissa Y. Chang, Gene Y.
Im, Jennifer Leong, Lawrence Ku, Thomas D. Schiano, Douglas
Dieterich, Andrea D. Branch
1017: Influence of ribavirin plasma concentration on
the virological response and safety in patients with HCV
genotype 1 infection treated by combination therapy
with telaprevir or boceprevir
Marie Julia, Peggy Gandia, Mathieu Guivarch, Laura Coimet-
Berger, Florence Abravanel, Delphine Bonnet, Laurent Alric
1018: No differences of response to telaprevir based
therapy in cirrhotic and non cirrhotic patients with RVR:
a real life data from South Italy
Marcello Persico, Mario Masarone, Silvia Camera, Valerio Rosato,
Rocco Granata, Giovan Giuseppe Di Costanzo, Carmine Coppola,
Nicola Coppola, Angelo Salomone Megna, Ivan Gentile, Antonio
De Luna, Alessandro Federico, Davide F. Precone, Ernesto Claar,
Filomena Morisco
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1019: Orexigenic ghrelin secretion in HCV-infected
patients with telaprevir- or simeprevir-based triple
therapy
Toru Aoyama, Sumiko Nagoshi, Ryuichi Yamamoto, Naomi
Yamaguchi, Shino Ohno, Koji Yakabi
1020: Evaluation of liver fibrosis by acoustic radiation
force impulse (ARFI) imaging in hemodialysis patients
with chronic hepatitis C
Naoki Harada, Naoki Hiramatsu, Tsugiko Oze, Naoki Morishita,
Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Takayuki
Yakushijin, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi,
Akinori Kasahara, Norio Hayashi, Tetsuo Takehara
1021: Ultra-deep sequencing analysis of resistant
variants in chronic hepatitis C patients treated with
simeprevir, peginterferon and ribavirin
Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, Yuki Tahata,
Naoki Harada, Ryoko Yamada, Takatoshi Nawa, Hayato Hikita,
Takayuki Yakushijin, Takuya Miyagi, Yuichi Yoshida, Tomohide
Tatsumi, Akira Yamada, Eiji Mita, Toshifumi Ito, Masami Inada,
Yasuharu Imai, Michio Kato, Tetsuo Takehara
1022: Daclatasvir, Simeprevir and Ribavirin as a new
IFN-free triple regimen for HCV recurrence after liver
transplantation: First results of safety and efficacy in 6
patients
Angela Papadopoulos-Köhn, Jörg Timm, Ali Canbay, Christoph
Jochum, Guido Gerken, Kerstin Herzer
1023: Final results of Boceprevir Early-Access For
Advanced Fibrosis/Cirrhosis In Asia-Pacific HCV
Genotype 1 Non-Responders/Relapser Patients (Beacon
Study)
Wattana Sukeepaisarnjaroen, Tri H. Pham, Tawesak Tanwandee,
Saroja Nazareth, Sam Galhenage, Lindsay Mollison, Leanne
Totten, Alan J. Wigg, Rosalie Altus, Anton Colman, Brenda
Morales, Susan Mason, Tracey L. Jones, Nadine Leembruggen,
Vince Fragomelli, Cheryl Sendall, Richard Guan, Dede Sutedja,
Soek Siam Tan, Yock Young Dan, Yin-Mei Lee, Widjaja Luman,
Eng Kiong Teo, Yin Min Than, Teerha Piratvisuth, Seng Gee Lim
1024: Delayed early HCV RNA response during IFN-
free therapy with sofosbuvir in interferon-ineligible
patients with advanced cirrhosis
Katja Deterding, Christoph Hoener zu Siederdissen, Kerstin Port,
Janina Kirschner, Lisa Sollik, Carola Mix, Michael P. Manns,
Markus Cornberg, Heiner Wedemeyer
1025: Treating Advanced Hepatitis C Virus with New
Direct Acting Antiviral Medications, a VA Experience
Joel P. Wedd, Becky Ashcraft, Kristin Babson, Nancy Boyd,
Marsha Costelow, Anthony Pepe, Yvette Tong, Hugo R. Rosen,
John Redington
1026: Ultra Rapid Virological Response as a Predictor
of Favorable Treatment Outcome for Acute Hepatitis C
Infection in Patients on Maintenance Hemodialysis
Syed M. Hassan, Arzoo Saeed, Muhammad Osama Butt, Nasir
Hassan Luck, Syed Mudassir Laeeq, Zaigham Abbas
Poster Viewing: 8:00 AM – 5:30 PM
137A
1027: Single Center Experience with Simeprevir/
Sofosbuvir Combination Therapy for Recurrent Hepatitis
C Virus Infection in Liver Transplant Recipients
Neil Crittenden, Eric G. Davis, Luis S. Marsano, Craig J. McClain,
Ashutosh Barve, Barbra A. Goshko, Robert R. Tatum, Michael G.
Hughes, Christopher M. Jones, Michael R. Marvin, Matthew C.
Cave
1028: Safety and efficacy of all-oral sofosbuvir-
based regimens to treat HCV recurrence post-liver
transplantation
Mohammed Eyad Yaseen Alsabbagh, Ibrahim A. Hanouneh, Binu
V. John, John K. Guirguis, Bijan Eghtesad, John J. Fung, Nizar N.
Zein, Naim Alkhouri
1029: Post-Liver Transplant Treatment of Hepatitis
C with a combination of Sofosbuvir, Simeprevir, +/-
Ribavirin at a High Volume Academic Transplant Center
Ryan M. Ford, Anjana Pillai, Nicole Cheng, Nikita M. Young,
Samir Parekh, JP Norvell, Ram Subramanian, James Spivey
1030: Early Viral Kinetics during Interferon-free
Sofosbuvir containing Treatment Regimen in a Real-life
Cohort of Chronic Hepatitis C Patients
Karin Kozbial, Robert Paul Strassl, Ramona Al Zoairy, Andreas
Maieron, Rudolf E. Stauber, Michael P. Strasser, Hermann Laferl,
Thomas Bamberger, Albert Staettermayer, Heinz M. Zoller, Peter
Knoflach, Katharina Staufer, Markus Peck-Radosavljevic, Petra E.
Steindl-Munda, Wolfgang Vogel, Peter Ferenci, Harald Hofer
1031: Factors associated with virologic response in
triple therapy with simeprevir, pegylated interferon and
ribavirin in Japanese patients with chronic hepatitis C
Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Ryoko
Yamada, Naoki Harada, Naoki Morishita, Yuki Tahata, Hayato
Hikita, Ryotaro Sakamori, Takuya Miyagi, Yuichi Yoshida,
Tomohide Tatsumi, Akira Yamada, Masahide Oshita, Hideki
Hagiwara, Eiji Mita, Toshifumi Ito, Yukinori Yamada, Taizo
Hijioka, Shinji Tamura, Kazuhiro Katayama, Harumasa Yoshihara,
Yasuharu Imai, Michio Kato, Norio Hayashi, Tetsuo Takehara
NOVEMBER 9
1032: Severe anemia with Sofosbuvir based therapy for
SUNDAY
Hepatitis C (HCV) recurrence post Liver transplantation
on mycophenolate mofetil (MMF)
Hussien Elsiesy, Aziza A. Ajlan, Ahmed Aljedai, Rania Alarieh,
Waleed K. Al-Hamoudi, Delal Alkortas, Mohammed Al Sebayel,
Dieter C. Broering, Faisal A. Abaalkhail
1033: Beneficial effect of treatment individualization for
patients with chronic hepatitis C receiving peginterferon
alfa-2a and ribavirin in a large non-interventional
cohort study
Wolf P. Hofmann, Stefan Mauss, Elmar Zehnter, Dietrich Hueppe,
Heike Pfeiffer-Vornkahl, Ulrich Alshuth, Eckart Schott
1034: Serum granulysin levels as a predictor of serious
telaprevir-induced dermatological reactions
Goki Suda, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka,
Naoya Sakamoto
Presenters in Attendance 12:30 – 2:00 PM
 138A POSTER SESSIONS
Poster Sessions
1035: Treatment of HCV in the SOF era: experience in
difficult to treat patients in a US liver transplant center
K Tuesday Werner, Amy E. Chervenak, Lorrie A. Hartel, Bashar
Aqel, Vijayan Balan, Thomas J. Byrne, Elizabeth J. Carey, Hugo E.
Vargas, Jorge Rakela
1036: Sustained Virological Response in Diabetic
Patients with Chronic Hepatitis C
Umit B. Dogan, Mustafa S. Akin, Gunay Camuz
1037: Clinical utility of NS3/4A protease inhibitor-
resistant variant detection for prediction of treatment
efficacy in HCV genotype 1
Norio Akuta, Fumitaka Suzuki, Yushi Sorin, Taito Fukushima,
Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya
Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Mariko Kobayashi,
Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
1038: Sofosbuvir-based therapy under real life
conditions in Germany
Peter Buggisch, Holger Hinrichsen, Stefan Mauss, Karl-Georg
Simon, Dietrich Hueppe, Joerg Petersen
1039: Treatment of Previously Untreated Patients with
Chronic HCV Genotype 1 Infection with Boceprevir in
German Real-Life: High End of Treatment Response >
90% in Patients with Early Virologic Response
Peter Buggisch, Hanns F. Loehr, Gerlinde Teuber, Hermann
Steffens, Michael R. R. Kraus, Christine John, Peter R. Geyer,
Bernd Weber, Thomas Witthoeft, Andreas Herrmann, Mark Hoesl,
Uwe Naumann, Elmar Zehnter, Dagmar Hartmann, Bernd Dreher,
Manfred Bilzer
1040: Treatment of Acute Hepatitis C (HCV) Infection
with Pegylated Interferon and Ribavirin (P/R) in Patients
Co-infected with Human Immunodeficiency Virus (HIV):
a systematic review and meta-analysis
Bing Zhang, Benjamin Yip, Nghia H. Nguyen, Brittany E. Yee,
Walid S. Ayoub, Mindie H. Nguyen, Glen A. Lutchman
1041: IFNL4/IL-28B haplotype structure and
NOVEMBER 9
predictability of their variations for spontaneous and
SUNDAY
treatment-induced clearance of HCV infection in the
Japanese population
Hidenori Ochi, Daiki Miki, C. Nelson Hayes, Hiromi Abe, Michiaki
Kubo, Kazuaki Chayama
1042: Estimated Glomerular Filtration Rate (eGFR) at
Baseline Strongly Predicts the Frequency of Anemia
in Patients Undergoing Boceprevir Triple Therapy in
German Real-Life
Gerlinde Teuber, Peter Buggisch, Hanns F. Loehr, Hermann
Steffens, Michael R. R. Kraus, Christine John, Peter R. Geyer,
Bernd Weber, Thomas Witthoeft, Andreas Herrmann, Mark Hoesl,
Uwe Naumann, Elmar Zehnter, Dagmar Hartmann, Bernd Dreher,
Manfred Bilzer
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1043: Interferon ineligible naive chronic hepatitis
C genotype I subjects treated with Simeprevir and
Sofosbuvir in special population (psychiatric). An open
label prospective clinical pilot study; INSPIRE C study
Patrick Basu, Niraj J. Shah, M. Aloysius, Robert S. Brown
1044: Final efficacy and safety of telaprevir, Peg-IFN-
alfa-2a, and ribavirin in combination with darunavir/
ritonavir-based HAART in HCV/HIV-1 co-infected
patients (INSIGHT substudy)
Marisa L. Montes, Enrique Ortega, Andrzej Horban, Mark
Nelson, Jacques Durant, Katrien de Backer, Katrien Janssen, Sivi
Ouwerkerk-Mahadevan
Hepatotoxicity: Drug Metabolism
1045: Lysosomal Iron Mobilization in Hepatotoxicity
after Acetaminophen in Vivo in Mice
Jiangting Hu, Hartmut Jaeschke, John J. Lemasters
1046: A common UGT1A haplotype of genetic
variants reduces the transcriptional responsiveness
towards the anti-cancer drug irinotecan
Sandra Kalthoff, Anja Winkler, Christian P. Strassburg
1047: ‘Dual function of Jnk1 and Jnk2 in hepatocytes
is indispensable against drug-induced liver injury’
Francisco Javier Cubero, Wei Hu, Gang Zhao, Jin Peng, Yulia
Nevzorova, Malika Al Masaoudi, Lars Bechmann, Mark V.
Boekschoten, Michael Muller, Nikolaus Gassler, Ali Canbay,
Christian Liedtke, Christian Trautwein
1048: Activation of AMPK prevents and reverses
drug induced mitochondrial and hepatocellular damage
in collagen sandwich culture of hepatocytes
Dong Fu, Geoffrey C. Farrell, Ghada Haydar
1049: Human mercapto-albumin of chronic liver disease
patients contributes to alterations in the functional
properties of human serum albumin
Hiroko Setoyama, Motohiko Tanaka, Hideaki Naoe, Takehisa
Watanabe, Masakuni Tateyama, Kotaro Fukubayashi, Youko
Yoshimaru, Takeshi Kawasaki, Satomi Fujie, Kazuhiro Izumi,
Hiroshi Watanabe, Toru Maruyama, Yutaka Sasaki
1050: Amoxicillin-clavulanate induced DILI: 113 cases
from the US Drug-Induced Liver Injury Network (DILIN)
Andrew deLemos, Marwan Ghabril, Don C. Rockey, Jiezhun Gu,
Huiman X. Barnhart, Mark W. Russo, Herbert L. Bonkovsky
1051: The Non-nucleoside Reverse Transcriptase
Inhibitor Efavirenz-induces an inflammatory response in
hepatic cells controlled by autophagy
Ana Blas-García, Fernando Alegre, Miriam Polo, Dolores Ortiz-
Masiá, Haryes A. Funes, Alberto Martí-Rodrigo, Nadezda
Apostolova, Juan V. Esplugues
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1052: The Long-Term Follow-up of 140 Patients
with Drug-Induced Liver Injury (DILI): Emphasis on
Phenotypes and Chronic Risk Factors
Wenjing Zhu, Xinyan Zhao, Tailing Wang, Hong Ma
1053: Pharmacological Inhibition of M1 Muscarinic
Receptors (M1R) Reduces Oxidative Stress in AML12
Hepatocytes
Ravirajsinh Jadeja, Sandeep Khurana
1054: Risk factors for chronicity in idiosyncratic drug-
induced liver injury (DILI)
I. Medina-Cáliz, B. Garcia-Muñoz, Mercedes Robles Diaz, C.
Stephens, Andrés González-Jiménez, Miren García-Cortés, A.
Ortega, Ramón Hidalgo, Maria Carmen Fernandez, Manuel
Romero-Gomez, J. M. Navarro, Hacibe Hallal, Ramon Planas, S.
Avila, S. Blanco, Agustin Castiella, E. Zapata, Miguel Jimenez, J.
M. Moreno-Planas, German Soriano, Carlos Guarner, E. Roman,
Joaquin Primo, A. Aldea, Martin Prieto, M. I. Lucena, Raul J.
Andrade
1055: Drug-induced Liver Injury (DILI) Associated
with Stevens-Johnson Syndrome or Toxic Epidermal
Necrolysis (SJS/TEN): Characteristics and Outcome
Harshad Devarbhavi, Sujata Raj, Keyur A. Sheth, Karnam
Ravikiran, Rajvir Singh, Venu H. Aradya, T. R. Vijaykumar,
Mallikarjun Patil, Adarsh Ck
1056: Characteristics of Efavirenz drug induced liver
injury - a cohort analysis
Mark W. Sonderup, Helen Wainwright, Mashiko Setshedi, C. W.
Spearman
1057: Endoplasmic Reticulum stress inhibitors diminish
acetaminophen toxicity
Annelies Paridaens, Yves-Paul Vandewynckel, Eliene Bogaerts,
Anja Van den Bussche, Hans Van Vlierberghe, Anja M. Geerts,
Isabelle Colle
1058: Brincidofovir (CMX001) Dose and Plasma
Exposure Correlates with Serum Alanine
Aminotransferase Elevations
Tom Brundage, Herve Mommeja-Marin, Marion Morrison,
Katherine J. Van Sickle
1059: Histological Changes That Reliably Differentiate
Autoimmune Hepatitis from Drug-Induced Autoimmune
Hepatitis: Important Role of Liver Biopsy
Sadhna Dhingra, Thomas D. Schiano, Jawad Ahmad, Joseph A.
Odin, M. Isabel Fiel
1060: The effect of acetaminophen on primary
hepatocytes isolated from transgenic mice with different
apolipoprotein E genotypes
Vojtech Mezera, Otto Kucera, Alena Moravcova, Eva Peterova,
David Rychtrmoc, Tomas Rousar, Ondrej Sobotka, Zuzana
Cervinkova
Poster Viewing: 8:00 AM – 5:30 PM
139A
1061: Hep-114, a Novel Drug Candidate with Potent
Activity against Toxic Liver Injury: Preliminary Phase 2
Results
George Tets
Hepatotoxicity: Mechanisms
1062: CD44 deficency exacerbates murine
acetaminophen(APAP) hepatotoxicity in association with
enhanced hepatic inflammation and impaired clearance
of hyaluronan fragments
Jo Suda, Luoluo Yang, Neil Kaplowitz, Zhang-Xu Liu
1063: Acetaminophen (APAP) Hepatotoxicity Leads
To DNA Damage-Induced Arrest of Injured Cells In G0/
G1 Through Involvement Of Cell Cycle Regulators
Preeti Viswanathan, Sriram Bandi, Sanjeev Gupta
1064: Liver fibrogenesis is controlled by innate
immune activation pathways in hepatocyte apoptosis
Arvin Iracheta-Vellve, Jan Petrasek, Abhishek Satishchandran,
Karen Kodys, Evelyn A. Kurt-Jones, Katherine A. Fitzgerald,
Gyongyi Szabo
1065: Sumoylation regulates Cytochrome P450 2E1
(CYP2E1) expression in alcoholic liver disease
Maria Lauda Tomasi, Minjung Ryoo, Diana Arsene
1066: Exposure to Vinyl Chloride Metabolites
Exacerbates Liver Injury Caused by High Fat Diet in
Mice
Lisanne C. Anders, Amanda N. Douglas, Adrienne M. Bushau,
Keith C. Falkner, Gavin E. Arteel, Matthew C. Cave, Craig J.
McClain, Juliane I. Beier
1067: Cholestatic Drug reactions are more likely to
cause persistent liver injury and impaired Quality of
Life during prolonged follow-up: Results from the DILIN
Prospective study
NOVEMBER 9
Robert J. Fontana, Paul H. Hayashi, Rajender Reddy, David E.
SUNDAY
Kleiner, Thomas Phillips, Huiman X. Barnhart, Jayant A. Talwalkar,
Naga P. Chalasani, William M. Lee, Andrew Stolz, Timothy J.
Davern, Paul B. Watkins, Jose Serrano
1068: Microsomal prostaglandin E synthase-1
(mPGES-1) prevents Fas-induced liver injury
Lu Yao, Chang Han, Tong Wu
1069: New insight into the role of liver in viral
hemorrhagic fever
Gavin E. Arteel, Juliane I. Beier, Jenny Jokinen, Patrick S. Whang,
Amah M. Martin, Nikole L. Warner, Igor S. Lukashevich
1070: Oxaloacetic Acid Protects the Liver Against
Warm Ischemia
Grégory Merlen, Benoit Lacoste, Benoît Dupont, Valérie-Ann
Raymond, Marc Bilodeau
Presenters in Attendance 12:30 – 2:00 PM
 140A POSTER SESSIONS
Poster Sessions
1071: Acetaldehyde Suppresses Interferon Alpha
Signaling In HCV-infected Hepatoma Cells By Impairing
Protein Methylation
Murali Ganesan, Lee K. Jaramillo, Kusum K. Kharbanda, Dean J.
Tuma, Natalia A. Osna
1072: A novel oral form of pentamidine (OCZ103)
blocks TNF-mediated mouse liver injury from GalN/LPS
Enpeng Zhao, Ghulam Ilyas, Yu Lin, Kathryn Tanaka, Francois
Ravenelle, Mark J. Czaja
1073: Hepatic Stellate Cells Are Activated In A Rac1
Dependent Mechanism After Engulfment Of Isoniazid
Exposed Dying Hepatocytes – Role In Drug Induced
Fibrogenesis
Suman Santra, Abhijit Chowdhury, Debasree Bishnu, Gopal K.
Dhali, Amal Santra
1074: Moderate (2% v/v) ethanol feeding delays liver
regeneration and enhances hepatic profibrotic markers
after carbon tetrachloride-induced liver injury in mice
Krutika T. Deshpande, Shinlan Liu, Michele Pritchard
1075: Early growth response 1 attenuates ethanol-
accelerated, carbon tetrachloride-induced profibrotic
signatures in liver: Novel role for NAD(P)H
dehydrogenase, quinone 1
Briana Holt, Krutika T. Deshpande, Michele Pritchard
1076: Profiles of serum microRNAs in acute drug-
induced liver injury and their prognostic significance
Mark W. Russo, James Norton, William Anderson, Nury
Steuerwald, Huiman X. Barnhart, Naga P. Chalasani, Robert J.
Fontana, Paul H. Hayashi, Jose Serrano, Herbert L. Bonkovsky
1077: Type XVIII collagen regulates hepatocyte cell
survival and the anti-oxidant response during elevated
oxidative stress conditions, in vitro
Ravirajsinh Jadeja, Priyanka Thakur, Sandeep Khurana, Michael
Duncan
NOVEMBER 9
1078: Severe liver and kidney injury in mouse models
SUNDAY
of acute-on-chronic alcoholic hepatitis
Shinji Furuya, Takeki Uehara, Yuki Kato, Oksana Kosyk, Gemma
Odena, Hiroshi Kono, Ramon Bataller, Ivan Rusyn
1079: A New Approach To The Mechanism Of
Paracetamol Hepatotoxicity: Liver 5-Ht7 Receptors
Zekai Halici, Elif Cadirci, Beyzagul Polat, Emre Karakus, Yasin
Bayir, Abdulmecit Albayrak, Deniz Unal
1080: Identification of alcohol-induced tubulin
acetylation sites by mass spectrometry
Jennifer L. Groebner, Dean J. Tuma, Pamela L. Tuma
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1081: Killer Ig-like receptors (KIR) profiles and HLA
class I ligands in amoxicillin-clavulanate-induced
hepatotoxicity
C. Stephens, Antonia Moreno-Casares, MAngel López-Nevot,
Miren García-Cortés, I. Medina-Cáliz, Hacibe Hallal, German
Soriano, Francisco. Ruiz-Cabello, Manuel Romero-Gomez, M. I.
Lucena, Raul J. Andrade
1082: Intrahepatic Neurons: Chronological Changes
after Liver Transplantation, and their Associations with
Liver Diseases
Kei Mizuno, Keigo Murakami, Tomohiro Katsumi, Kyoko Tomita,
Chikako Sato, Kazuo Okumoto, Yuko Nishise, Hisayoshi
Watanabe, Takafumi Saito, Naoki Kawagishi, Yoshiyuki Ueno
1083: What is the possible pathogen of the patients
with fever, elevated serum enzymes and inflammatory
markers, changes of WBC, PLT and Lymphocytes?
Jie Cai, Xiling Guo, Yin Chen, Yiyue Ge, Lunbiao Cui, Yali Weng
Imaging of Steatohepatitis
1084: Diagnosis and Quantification of Fatty Liver with
Quantitative Ultrasound using MRI-Derived Proton
Density Fat Fraction as Reference in Patients with and
without NAFLD
Steven C. Lin, Elhamy Heba, Tanya Wolfson, Brandon Ang,
Anthony C. Gamst, Aiguo Han, John W. Erdman, William D.
O’Brien, Michael P. Andre, Claude B. Sirlin, Rohit Loomba
1085: Multi-parametric MRI can diagnose
steatohepatitis and cirrhosis in patients with NAFLD
Michael Pavlides, Rajarshi Banerjee, Elizabeth M. Tunnicliffe, Jane
Collier, Lai Mun Wang, Fleming A. Kenneth, Stefan Neubauer,
Eleanor Barnes
1086: Visceral Adiposity but not Hepatic Steatosis
is Associated with Coronary Artery Calcification: a
Prospective Cohort Study
Kathleen Jacobs, Sharon S. Brouha, Ricki Bettencourt, Claude B.
Sirlin, Rohit Loomba
1087: T2* magnetic resonance imaging is more
sensitive than histology and serum ferritin for the
assessment of iron overload in patients with NAFLD
Michael Pavlides, Rajarshi Banerjee, Elizabeth M. Tunnicliffe, Lai
Mun Wang, John D. Ryan, Jeremy F. Cobbold, Stefan Neubauer,
Eleanor Barnes
Steatohepatitis
1088: Recipient but not Donor Adiponectin rs266729
Polymorphism is Linked to Post-Transplant Steatosis in
Patients Transplanted with Chronic Hepatitis C Infection
Binu V. John, Ari Garber, Taylor Aiken, Dawn Thomas, Dongxing
Chen, Venkata Rajesh Konjeti, Rocio Lopez, Stanley Mistak, Nizar
N. Zein, Medhat Askar
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1089: Notch-mediated epithelial/mesenchymal
interaction influences non-alcoholic steatohepatitis
(NASH) progression
Carola M. Morell, Romina Fiorotto, Marica Meroni, Aileen Raizner,
Massimiliano Cadamuro, Emanuele Albano, Mario Strazzabosco
1090: Hepatic Overexpression of Thioesterase
Superfamily Member 1 (Them1) Accelerates Glucose
Intolerance in High Fat Fed Mice: Pathogenic Role in
Non-Alcoholic Fatty Liver Disease (NAFLD)
Cafer Ozdemir, David E. Cohen
1091: Palmitic acid lipotoxicity is determined by the
interaction of JNK with mitochondrial Sab (SH3BP5)
Sanda Win, Tin A. Than, Carmen Garcia-Ruiz, Jose Fernandez-
Checa, Neil Kaplowitz
1092: Distinct CD4+ T cell subset composition in
peripheral blood and hepatic tissue of patients with
NAFLD, NASH and healthy controls
Monika Rau, Anne-Kristin Schilling, Ilona Hering, Jan Meertens,
Theodor Kudlich, Christian Jurowich, Niklas Beyersdorf, Andreas
Geier
1093: Dynamics of Hepatic Lipid Composition,
and Mitochondrial Function during the Evolution of
Fast Food-Induced NASH – From the First Mouthful to
Steatofibrosis
Anuradha Krishnan, Tasduq Abdullah, Toafic Mounajjed, Stella
Hartono, Andrea L. McConico, Thomas A. White, Ian Lanza,
Nathan K. LeBrasseur, k Sreekumaran Nair, Gregory J. Gores,
Michael Charlton
1094: Lipotoxicity-Induced Extracellular Vesicles
Activate Macrophages Through TRAIL Signaling
Petra Hirsova, Steven Bronk, Nathan W. Werneburg, Anuradha
Krishnan, Gregory J. Gores
1095: Circulating extracellular vesicles with a specific
Proteome and liver microRNAs are novel biomarkers for
liver injury in fatty liver disease
Davide Povero, Akiko Eguchi, Hongying Li, Casey Johnson,
Alexander Wree, Milos Lazic, Karen Messer, Ariel E. Feldstein
1096: Hepatocyte-derived mitochondrial DNA acts as
a “danger signal” to promote inflammation and fibrosis
in non-alcoholic steatohepatitis
Naoki Ikenaga, Makoto Miyamoto, Susan B. Liu, Zhen-Wei Peng,
Shuhei Yoshida, Konstantin Khrapko, Henry Koziel, Yury Popov
1097: Characterization Of A Diet-Induced Mouse
Model Of Nonalcoholic Fatty Liver Disease With
Reproducible Progression To Advanced Fibrosis And
Hepatocellular Carcinoma
Amon Asgharpour, Tommy Pacana, Robert Vincent, Sophie C.
Cazanave, Faridoddin Mirshahi, Mulugeta Seneshaw, Kalyani
Daita, Puneet Puri, Arun J. Sanyal
Poster Viewing: 8:00 AM – 5:30 PM
141A
1098: Targeting of Kupffer cells with anti-CD163
antibody-dexamethasone-conjugate strongly reduces
liver inflammation in rats with fructose-induced non-
alcoholic steatohepatitis (NASH)
Pia Svendsen, Jonas H. Graversen, Henning Gronbaek, Holger J.
Møller, Hendrik V. Vilstrup, Søren K. Moestrup
1099: Regulation of the microRNA-clock gene
network by melatonin during alcoholic liver injury
Ying Wan, Yuyan Han, Kelly McDaniel, Heather L. Francis, Haibo
Bai, Julie Venter, Nan Wu, Morgan Quezada, Shannon S. Glaser,
Gianfranco Alpini, Fanyin Meng
1100: Impaired metabolic compensation in adipose
tissues and functional alignment by complemented stem
cells in mice with progressive nonalcoholic fatty liver
disease
Taichiro Nishikawa, Kohichiroh Yasui, Hisakazu Nakajima,
Satoru Sugimoto, Ikuyo Itoh, Kazuki Koudou, Tomoki Nakajima,
Kanji Yamaguchi, Michihisa Moriguchi, Yoshio Sumida, Hironori
Mitsuyoshi, Masahito Minami, Yoshito Itoh
1101: TRAIL Receptor Signaling Promotes Hepatocyte
Apoptosis and Liver Inflammation in a Mouse Model of
Steatohepatitis
Leila Idrissova, Harmeet Malhi, Nathan W. Werneburg, Nathan
K. LeBrasseur, Steven F. Bronk, Christian Dominik Fingas, Tamar
Tchkonia, Tamar Pirtskhalava, Christian Liedtke, Christian
Trautwein, Niklas Finnberg, Wafik S. El-Deiry, James L. Kirkland,
Gregory J. Gores
1102: Liver-specific deletion of augmenter of liver
regeneration (ALR) induces accelerated steatohepatitis in
mice
Chandrashekhar R. Gandhi, J. Richard Chaillet, Michael A.
Nalesnik, Sudhir Kumar, Anil Dangi, Robert Ferrell, Tong Wu,
Senad Devanovic, Donna B. Stolz, Jiang Wang, Thomas Starzl
1103: Effects of liver-specific loss of lipin 1-mediated
phosphatidate phosphohydrolase activity
NOVEMBER 9
Nisreen Soufi, George G. Schweitzer, Zhouji Chen, Connie Gan,
SUNDAY
Kyle McCommis, Brian Finck
1104: Free-fatty acids activate cytokine expression in
cholangiocytes
Mary A. Smith, Sathish Kumar Natarajan, Justin L. Mott
1105: miR-451 inhibits Palmitic acid-induced
proinflammatory cytokine IL-8 expression through
AMPK/AKT pathway in non-alcoholic steatohepatitis
Wonhee Hur, Jung-Hee Kim, Joon Ho Lee, Sung Woo Hong,
Seung Kew Yoon
1106: HCV infection increases JNK phosphorylation
and accentuates hepatocyte lipoapoptosis
Hiroko Takaki, Yuko Akazawa, Hisamitsu Miyaaki, Satoshi
Miuma, Naota Taura, Hidetaka Shibata, Takuya Honda, Tsutomu
Kanda, Yoko Kido, Kazuhiko Nakao
Presenters in Attendance 12:30 – 2:00 PM
 142A POSTER SESSIONS
Poster Sessions
1107: eNOS dysfunction in Steatosis/Steatohepatitis
Mario Masarone, Albino Carrizzo, Alessandro Federico, Valerio
Rosato, Carmine Vecchione, Marcello Persico
1108: Bcl-3 modulates hepatic glucose and lipid
metabolism through insulin-signaling in a murine model
of non-alcoholic fatty liver disease (NAFLD)
Nadine Gehrke, Amrit Mann, Yvonne Alt, Arno Schad, Ari
Waisman, Peter R. Galle, Marcus A. Woerns, Jörn M. Schattenberg
1109: Involvement of CXCL1-S100A8 loop via
CXCR2 in the development of nonalcoholic fatty liver
disease
Kaori Mukai, Takuya Miyagi, Yoshinobu Yokoyama, Teppei
Yoshioka, Kumiko Nishio, Akira Nishio, Yoshiki Onishi, Satoshi
Aono, Yoshinobu Saito, Satoshi Tanaka, Hayato Hikita, Ryotaro
Sakamori, Naoki Hiramatsu, Harumasa Yoshihara, Yasuharu Imai,
Tomohide Tatsumi, Tetsuo Takehara
1110: Increased expression of Rubicon by high fat
diet suppresses autophagic flux and induces apoptosis
by increasing endoplasmic reticulum stress in mice: a
possible mechanism for pathogenesis of NASH
Satoshi Tanaka, Hayato Hikita, Yasutoshi Nozaki, Yugo Kai,
Tasuku Nakabori, Yoshinobu Saito, Ryotaro Sakamori, Takuya
Miyagi, Naoki Hiramatsu, Tomohide Tatsumi, Tetsuo Takehara
1111: Treatment with the FXR-TGR5 dual agonist INT-
767 decreases NAFLD-NASH in mice fed a Western diet
Xiaoxin Wang, Yuhuan Luo, Cherelle Parker, Rachel McMahan,
Hugo R. Rosen, David J. Orlicky, Luciano Adorini, Moshe Levi
1112: Aging Promotes Chronic Plus Binge Ethanol
Feeding-Induced Liver Injury by Inhibiting Sirt1-
Autophagy
Teresa Ramirez, Yongmei Li, Dechun Feng, Huan Xu, Bin Gao
1113: Generation of a TALEN-mediated stem cell model
to study non-alcoholic fatty liver disease associated with
a PNPLA3 polymorphism
NOVEMBER 9
Nidhi Goyal, Maria P. Ordonez, Lawrence S. Goldstein
SUNDAY
1114: NAFLD progression to NASH is associated with
cumulative danger signals, M1 macrophage phenotype
and increased microRNA-155 expression that
contributes to fibrosis in a high fat/cholesterol/sugar
diet feeding in mice
Michal Ganz, Timea Csak, Shashi Bala, Banishree Saha, Gyongyi
Szabo
1115: Thioesterase Superfamily Member 1 (Them1)
Suppresses Thermogenesis and Contributes to Diet-
Induced Obesity and Non-Alcoholic Fatty Liver Disease
(NAFLD)
Kosuke Okada, Katherine B. Leclair, Yongzhao Zhang, Susan J.
Hagen, David E. Cohen
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1116: Notch1 reprograms mitochondria metabolism
for hepatic macrophage M1 activation in ASH through
upregulation of pyruvate dehydrogenase (PDH) activity
and mtDNA transcription
Jun Xu, Feng Chi, Vasu Punj, WN Paul Lee, Samuel W. French,
Hidekazu Tsukamoto
1117: The association between dietary cholesterol,
hepatic cholesterol crystals and experimental NASH
George N. Ioannou, Alan Chait, Savitha Subramanian, W. G.
Haigh, Matthew M. Yeh, Christopher Savard
1118: Reduced Lipoapoptosis, Hedgehog Pathway
Activation, and Fibrosis in Caspase-2 deficient Mice
with Nonalcoholic Steatohepatitis
Mariana V. Machado, Gregory A. Michelotti, Thiago A. Pereira,
Leandi Kruger, Marzena Swiderska-Syn, Gamze Karaca,
Guanhua Xie, Cynthia D. Guy, Kelly Lindblom, Erika Johnson,
Sally Kornbluth, Anna Mae Diehl
1119: The Pivotal Role Played by Lipocalin-2 in
Experimental Alcohol-Induced Fatty Liver Injury in Mice
Alvin Jogasuria, Bin Gao, Min You
1120: Whole Exome Sequencing of Extreme Phenotypes
of NAFLD Identifies Potential Genetic Risk Factors for
Advanced Hepatic Fibrosis
Thomas J. Urban, Cynthia A. Moylan, Matthew Rein, Manal F.
Abdelmalek, David B. Goldstein, Anna Mae Diehl
1121: Fibroblast Growth Factor 21 Deficiency
Exacerbates Chronic Alcohol-Induced Hepatic Steatosis
and Injury in Mice
Cuiqing Zhao, Liming Liu, Fengyuan Li, Craig J. McClain, Wenke
Feng
1122: Diet-induced nonalcoholic fatty liver disease is
associated with sarcopenia and decreased serum insulin
growth factor-1
Alex Ruiz, Daniel Cabrera, Pablo Quintero, Margarita Pizarro,
Nancy Solis, Javiera Torres, Claudio Cabello-Verrugio, Enrique
Brandan, Francisco Barrera, Marco Arrese
1123: The protective role of CAR and PXR in Aroclor
1260-induced Steatohepatitis
Banrida Wahlang, Keith C. Falkner, Ming Song, Heather B. Clair,
Russell A. Prough, Matthew C. Cave
1124: Mechanism analysis of microRNA-27b causing
the fatty liver formation and insulin resistance at the
same onset
Takaomi Kessoku, Yasushi Honda, Yuji Ogawa, Wataru Tomeno,
Kento Imajo, Hironori Mawatari, Satoru Saito, Koichiro Wada,
Yuichiro Eguchi, Atsushi Nakajima
1125: Sevelamer improves hepatic steatosis and
modulates inflammation in a Western Diet mouse model
of non-alcoholic fatty liver disease (NAFLD)
Brett McGettigan, Rachel McMahan, Cara Porsche, David J.
Orlicky, Xiaoxin Wang, Yuhuan Luo, Moshe Levi, Hugo R. Rosen
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1126: L-carnitine improves high-fat diet-induced
steatohepatitis through insulin sensitization and
regulation of lipid metabolism
Kazuyoshi Kon, Kenichi Ikejima, Hiromi Kusama, Maki Morinaga,
Kumiko Arai, Akira Uchiyama, Tomonori Aoyama, Shunhei
Yamashina, Sumio Watanabe
1127: TIGAR is a ‘Mitochondrial-Preload’ Regulator that
Modulates Insulin Signaling and Fatty Acid Metabolism
in the Liver
Zoltan Derdak, Asa Ohsaki, Zohra Kalani, Ragheb Harb, Jack R.
Wands
1128: Human subcutaneous and visceral fat
inflammatory gene signatures accurately predict
histological severity of non-alcoholic fatty liver disease
Johannie du Plessis, Jos van Pelt, Hannelie Korf, Chantal Mathieu,
Matthias A. Lannoo, Gary K. Fetter, Simon Nayler, Tessa van der
Merwe, Luc van Gaal, Sven M. Francque, Frederik Nevens, Schalk
Van Der Merwe
1129: Osteopontin mediates fibrogenic effects of leptin
and enhances NASH progression
Jason D. Coombes, Steve S. Choi, Paul P. Manka, Marco A.
Briones-Orta, Marzena Swiderska-Syn, Naoto Kitamura, Rasha
Younis, Shanna Bitencourt, Laurent Dollé, Roger Williams, Leo A.
van Grunsven, Anna Mae Diehl, Ali Canbay, Wing-Kin Syn
1130: Suppression of Liver Monoacylglycerol
Acyltransferase 1 Reduces Triacylglycerol Content, but
not Inflammation and Injury in Livers of Mice with Non
Alcoholic Steatohepatitis
Nisreen Soufi, Angela Hall, Sara Collier, James Mathews,
Elizabeth M. Brunt, Carolyn J. Albert, Mark Graham, David A.
Ford, Brian Finck
1131: COX 7a2 Inhibition in Mitochondrial Complex
IV Induces Hepatic Oxidative Stress and Iron Metabolic
Disorder in C57BL/6N Mouse
Masaaki Korenaga, Mihoko Tsuji, Miyuki Kondo, Erina Kumagai,
Misuzu Ueyama, Keiko Korenaga, Kazumoto Murata, Tatsuya
Kanto, Naohiko Masaki, Masashi Mizokami
1132: Down regulation of CD98 receptors via siRNA
loaded nanoparticles attenuate NAFLD signs in mice
liver
Jenniffer L. Stetler, Brandon S. Canup, Qiang Ma, Russell P. Pucket,
Hamed Laroui
1133: Hepatocyte-specific deletion of UBXD8 induces
periportal steatosis after high-fat diet feeding
Norihiro Imai, Michitaka Suzuki, Yoji Ishizu, Teiji Kuzuya, Takashi
Honda, Kazuhiko Hayashi, Masatoshi Ishigami, Toyoshi Fujimoto,
Hidemi Goto
1134: Hepatic Xbp1 deficiency exacerbates high fat/
high fructose diet-induced injury in the murine liver
Xiaoying Liu, Anne S. Henkel, Brian E. LeCuyer, Richard Green
Poster Viewing: 8:00 AM – 5:30 PM
143A
1135: Long-term histological and biochemical
analyses of a mouse model of NASH using low-density
lipoprotein receptor knockout mice with choline-
deficient diet
Yuichiro Amano, Fumi Shimizu, Ayako Harada, Masami Suzuki,
Shuntarou Tsuchiya, Osamu Isono, Mari Asada, Mayumi Imai,
Shigemitsu Imai, Hiroshi Nagabukuro, Ryuichi Tozawa
1136: Resveratrol improve the pathogengesis of
nonalchoholic steatohepatitis with serum CD14 of high
value
Takaomi Kessoku, Yasushi Honda, Yuji Ogawa, Wataru Tomeno,
Kento Imajo, Hironori Mawatari, Satoru Saito, Atsushi Nakajima
1137: Association of IL-33/sST2 Axis with Non
Alcoholic Steatohepatitis (NASH) Severity
Gihan Naguib, Jason L. Eccleston, Koji Fujita, Niharika Samala,
Mary Walter, Yaron Rotman
1138: Pirfenidone improves NASH features induced by
high fat/carbohydrate diet in mice
Jose Macias-Barragan, Jose Vera-Cruz, Jesus Garcia-Banuelos,
David A. Lopez-de la Mora, Cibeles Sanchez-Roque, Krista
Rombouts, Fabio Marra, Massimo Pinzani, Juan Armendáriz-
Borunda
1139: Genetic characterization of variants and genes
at hepatic steatosis genome wide association study
associated loci
Yue Chen, Andrew W. Tai, Elizabeth K. Speliotes
1140: A Diet-Induced Mouse Model With Development
Of Severe Nash
Yong Ook Kim, Rambabu Surabattula, Kyoung-Sook Park, Shih-
yen Weng, Detlef Schuppan
1141: Beneficial effects of mineralocorticoid receptor
blockade in experimental non-alcoholic steatohepatitis
Margarita Pizarro, Nancy Solis, Pablo Quintero, Juan C. Roa,
Rene Baudrand, Carlos B. Fardella, Arnoldo Riquelme, Marco
Arrese
NOVEMBER 9
SUNDAY
1142: Plasma Amino Acid Metabolome In Human
Nonalcoholic Fatty Liver Disease Demonstrates Highly
Enriched Lysine Degradation Pathway With High
Arginine And Proline Pathway Impact
Puneet Puri, Andrew R. Joyce, Velimir A. Luketic, Mohammad
S. Siddiqui, Sherry L. Boyett, Jolene Schlosser, Carol Sargeant,
Kalyani Daita, Hae-Ki Min, Faridoddin Mirshahi, Arun J. Sanyal
1143: Effects of the Selective Estrogen Receptor
Modulator, Raloxifene, on Nonalcoholic Steatohepatitis
in Ovariectomized Mice
Fangqiong Luo, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya,
Takashi Honda, Kazuhiko Hayashi, Hidemi Goto
Presenters in Attendance 12:30 – 2:00 PM
 144A POSTER SESSIONS
Poster Sessions
1144: Oral Administration of Tributyrin Attenuates
Chronic Ethanol-Induced Hepatic Steatosis, Inflammation
and Injury
Hridgandh Donde, Jingwen Zhang, Smita Ghare, Leila Gobejishvili,
Swati Joshi-Barve, Vatsalya Vatsalya, Craig J. McClain, Shirish
Barve
1145: Metformin decreases lipid droplets accumulation
and inhibits intracellular inflammation by targeting a
new EZH2-phosphoSTAT3-miRNAs pathway in an in
vitro model of vescicular steatosis
Natalia Pediconi, Silvia Di Cocco, Debora Salerno, Laura Belloni,
Silvia Piconese, Vincenzo Barnaba, Massimo Levrero
1146: CD36 regulates hepatic lipid metabolism and the
development hepatic steatosis in mice
Camella Wilson, Jennifer L. Tran, Derek Erion, Maria Febbraio,
Ethan J. Weiss
1147: Hepatic steatosis impairs acidification of
autolysosomes via suppression of vacuolar ATPase
subunit in lysosomes
Eisuke Nakadera, Shunhei Yamashina, Yoshihiro Inami, Kousuke
Izumi, Tomonori Aoyama, Akira Uchiyama, Kazuyoshi Kon,
Kenichi Ikejima, Sumio Watanabe
1148: TLR7 signaling negatively regulates the
development of alcoholic steatohepatitis
Hiroshi Matsushita, Yoon Seok Roh, Bi Zhang, Shuang Liang,
Ekihiro Seki
1149: High-energy diets containing starch:oleate as
model carbohydrates:fats cause more hepatic steatosis
and liver pathology in mice than other macronutrient
combinations
Caroline C. Duwaerts, Andrew Pierce, Scott M. Turner, Carine
Beysen, Mark D. Fitch, James P. Grenert, Jacquelyn J. Maher
1150: Suppressive effects of group IVA phospholipase
A2-deficiency on the liver injury and hepatic fibrosis
induced by oxidative stress in mice
NOVEMBER 9
Shiho Kanai, Keiichi Ishihara, Satoshi Akiba
SUNDAY
1151: Pathological feature, oxidative DNA damage and
epigenetic alteration of tumor suppressor genes in non-
alcoholic fatty liver disease
Naoshi Nishida, Norihisa Yada, Hirokazu Chishina, Tadaaki
Arizumi, Masahiro Takita, Satoshi Kitai, Tatsuo Inoue, Satoru
Hagiwara, Yasunori Minami, Kazuomi Ueshima, Toshiharu
Sakurai, Masatoshi Kudo
1152: Prospective Assessment of the Abundance of
Drug Metabolizing Enzymes in the P450 Pathway in
Patients with Non Alcoholic Fatty Liver Disease (NAFLD)
Bashar Aqel, Paul Langlais, Hugo E. Vargas, Elizabeth J. Carey,
Michael Leonard, Lawrence J. Mandarino
1153: Hedgehog pathway regulates hepatic
inflammation in mice with nonalcoholic steatohepatitis
Hyunjoo Kwon, Kyoungsub Song, Chang Han, Tong Wu
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1154: In vitro treatment of HepG2 cells with saturated
fatty acids reproduces mitochondrial dysfunction found
in non-alcoholic steatohepatitis
José A. Solís-Herruzo, Pablo Solís-Muñoz, Daniel Fernández-
Moreira, Teresa Muñoz-Yagüe, Inmaculada García-Ruiz
1155: GFT505 reverses NASH pathology, obesity and
insulin resistance in the foz/foz model
Isabelle A. Leclercq, Vanessa Legry, Benoit Noel, Rémy Hanf,
Dean W. Hum, Robert Walczak
1156: Oral supplementation of BCAA alleviates hepatic
steatosis and liver injury associated with NASH
Takashi Honda, Masatoshi Ishigami, Fangqiong Luo, Yoji Ishizu,
Teiji Kuzuya, Kazuhiko Hayashi, Yoshiharu Shimomura, Hidemi
Goto
1157: L-carnitine prevents progression of non-alcoholic
steatohepatitis in a mouse model with upregulation of
mitochondrial pathway
Hisashi Ishikawa, Akinobu Takaki, Kazuhide Yamamoto
1158: Deletion of both p62 and Nrf2 spontaneously
leads to development of steatohepatitis in mice
Kentaro Akiyama, Eiji Warabi, Kosuke Okada, Miho Ikeuchi,
Tetsuya Ueda, Katsumi Kose, Junichi Shoda
1159: Effect of G-CSF on non- alcoholic fatty liver
disease model
Ho Hyun Nam, Dae Won Jun, Waqar K. Saeed, Sunmin Kim, Tae
Yeob Kim, Joo Hyun Sohn, Min Young Kim, Eun Kyung Kim
1160: M1 Polarization bias and subsequent NASH
progression is attenuated by nitric oxide donor DETA
NONOate via inhibition of CYP2E1 induced oxidative
stress
Ratanesh K. Seth, Suvarthi Das, Sahar Pourhoseini, Diptadip
Dattaroy, Stephen Igwe, Julie Basu Ray, Gregory A. Michelotti,
Anna Mae Diehl, Saurabh Chatterjee
1161: Blood ethanol levels in children and mice with
NAFLD: Connection of insulin resistance and ethanol
elimination
Anna Janina Engstler, Marion Duerr, Eva Weiss, Vanessa T. Rist,
Ina B. Maier, Chengjun Jin, Cathrin Sellmann, Ina Bergheim
1162: Genome-wide analysis reveals predisposing
nonalcoholic fatty liver disease related DNA methylation
loci in peripheral white cells
Ruinan Zhang, Qin Pan, Feng Shen, Guangyu Chen, Chanyan
Zhu, Jiafa Lu, Jiayu Wu, Yiming Chen, Jian-Gao Fan
1163: Expression of Cell Death-Inducing DFF45-Like
Effector (CIDE) Family of Proteins in Patients with
Obesity Associated Non-Alcoholic Fatty Liver Disease
(NAFLD)
Rohini Mehta, Katherine Doyle, Thomas Jeffers, Drew Venuto,
Aybike Birerdinc, Zobair Younossi
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1164: Functional Genomic Screen Identifies Novel
Mediators of Hepatocyte Lipotoxicity
Steven Bronk, Ying Peng, James A. Blau, Matthew J. Hangauer,
Michael McManus, Gregory J. Gores, Yi Guo
1165: Hepatocyte specific keap-1 deletion selectively
reduces triglyceride accumulation but not inflammation
in a diet-induced model of nonalcoholic steatohepatitis
Pierluigi Ramadori, Hannah K. Drescher, Fabienne Schumacher,
Stephanie Erschfeld, Athanassios Fragoulis, Christoph Wruck,
Christian Trautwein, Daniela C. Kroy, Konrad L. Streetz
1166: Establishment of repeated liver biopsy technique
in experimental mice
Koichi Tsuneyama, Takahiko Nakajima, Hayato Baba, Takeshi
Nishida, Shinichi Hayashi, Shigeharu Miwa, Johji Imura
1167: Does Citrulline prevent high fat high fructose-
induced non-alcoholic fatty liver disease?
Prasanthi Jegatheesan, Stéphanie Beutheu, Kim Freese, Gabrielle
Ventura, Wassila Ouelaa, Perrine Marquet-de-Rougé, Jean-Pascal
De Bandt
1168: Long-term plus multiple binge ethanol feeding
induces steatohepatitis and fibrosis in aged mice
Hua Wang, Ming-Jiang Xu, Adeline Bertola, Bin Gao
Transport, Bilirubin, Cholesterol, Lipids
and Bile Salts
1169: IL-1β generated by LPS-activated CCR2-
positive Hepatic Macrophages regulates expression of
Hepatocellular Sterol and Bile Transport Systems
Padade Vue, Karim C. El Kasmi, Aimee Anderson, Michael W.
Devereaux, Natarajan Balasubramaniyan, Frederick J. Suchy,
Ronald J. Sokol
1170: Short-term sleep deprivation and Western diet
alters the circadian rhythms of CYP7A1 and hepatic
clock genes, and lipid metabolism
Jessica M. Ferrell, Shannon M. Boehme, John Chiang
1171: Enterohepatic biomarkers of microbial
pathogenesis in Clostridium difficile infection
Mary Elizabeth M. Tessier, Petri T. Urvil, Cana Ross, Toni-Ann
Mistretta, Shaji K. Chacko, Michael Francis, Joseph Sorg, Alex G.
Peniche, Sara M. Dann, Kevin W. Garey, Tor Savidge
Poster Viewing: 8:00 AM – 5:30 PM
145A
1172: Hepatoprotective Effects of Farnesoid X Receptor
in a Mouse Chronic Alcohol Feeding Model
Bo Kong, Le Zhan, Jianliang Shen, Tanya Forostyan, Li Wang,
Wen-Xing Ding, Grace L. Guo
1173: Long non-coding (Lnc) RNA H19 is a critical
modulator of bile acid homeostasis
Yuxia Zhang, Hiroyuki Tsuchiya, Olivier Barbier, Rana Smalling,
James Cox, Don Delker, Curt H. Hagedorn, Li Wang
1174: FGF19 Exchange Across the Gut and Liver in
Humans
Kiran V. Koelfat, Frank Schaap, Johanne G. Bloemen, Peter L.
Jansen, Cornelis H. Dejong, Steven Olde Damink
1175: TUDC-dependent translocation of MRP2 to
the plasma membrane or retrieval from the plasma
membrane is determined by MKK3 status
Christopher M. Schonhoff, Se Won Park, Cynthia R. Webster,
Mohammed S. Anwer
1176: Defining the Effect of a Human Gut Microbiota on
Bile Acid Metabolism and FXR Signaling in Gnotobiotic
Mice
Annika Wahlström, Hanns-Ulrich Marschall, Petia Kovatcheva-
Datchary, Maria Johansson, Marcus Ståhlman, Fredrik Bäckhed
1177: Bile acids modulate pancreatic islet α cells to
promote glucose homeostasis
Divya P. Kumar, Sunila Mahavadi, Faridoddin Mirshahi, John R.
Grider, Karnam S. Murthy, Arun J. Sanyal
1178: Hepatic Xbp1 regulates bile acid homeostasis
and bile salt injury
Xiaoying Liu, Anne S. Henkel, Brian E. LeCuyer, Eric Zhang,
Richard Green
1179: 3-Dimensional Culturing of Hepatocytes Increases
Fluorescent Bile Acid Accumulation and Sensitivity to
Drug Induced Cell Death
John W. Murray, Allan W. Wolkoff
NOVEMBER 9
SUNDAY
1180: Cyclic AMP reverses taurolithocholate-induced
internalization of MRP2 in part by inhibiting TLC/PKCε/
MARCKS phosphorylation pathway
Se Won Park, Christopher M. Schonhoff, Cynthia R. Webster,
Mohammed S. Anwer
1181: Regulation of Multidrug and Toxin Extrusion
Pump-1 (MATE-1) in Cholestasis
Priscilla C. Encarnacao, Carol J. Soroka, James L. Boyer, Meena
Ananthanarayanan
Presenters in Attendance 12:30 – 2:00 PM
 146A POSTER SESSIONS
Poster Sessions
Poster Session 3
Monday, November 10
POSTER VIEWING: 8:00 AM - 5:30 PM
Hall C
Presenters in attendance:
12:30 - 2:00 PM
Those posters identified as AASLD Presidential Poster of Distinction
by a ribbon icon have received review scores that place them
within the top 10 percent of all posters. We encourage you to
make them a priority as you visit the poster sessions.
Alcohol: Clinical and Basic Mechanisms
1182: Apolipoprotein (apo)AV deficiency
exacerbates alcoholic liver injury, leading to a gradual
progression from simple steatosis to steatohepatitis, and
then to liver fibrosis in ethanol-fed mice
David Q. Wang, Ornella de Bari, Bin Gao, Helen H. Wang,
Piero Portincasa, Linda S. Zhang, David A. Ford, Brent A.
Neuschwander-Tetri, Patrick Tso
1183: Deletion of GSTA4 increases mitochondrial
oxidative stress contributing to increased hepatocellular
damage during chronic ethanol consumption
Colin T. Shearn, Kelly E. Mercer, Kristofer S. Fritz, James J.
Galligan, Bridgette Engi, David J. Orlicky, Piotr Zimniak, Martin J.
Ronis, Dennis R. Petersen
1184: Toll-Like Receptor 2 and 9 mediates alcoholic
steatohepatitis via CXCL1 production and neutrophil
recruitment
Yoon Seok Roh, Bi Zhang, Shuang Liang, Hiroshi Matsushita,
Ekihiro Seki
1185: FOXO3-dependent macrophage apoptosis
protects the liver from alcoholic injury
Zhuan Li, Jie Zhao, Sudhakiranmayi Kuravi, Josiah Cox, James
Helzberg, Irina Tikhanovich, Steven A. Weinman
1186: Progression of hepatic steatosis (HS) to
steatohepatitis (SH) stage in alcoholic liver disease (ALD)
in mice is largely dependent on Large-conductance
calcium-activated potassium (MaxiK) channels
Tracie C. Lo, Keisaku Sato, Angela Dolganiuc
NOVEMBER 10
1187: Sterile and Infection-Associated SIRS Predict
MONDAY
Multiple Organ Dysfunction in Alcoholic Hepatitis:
Diagnostic Value of Procalcitonin
Javier Michelena, Jose Altamirano, Juan G. Abraldes, Silvia Affò,
Oriol Morales-Ibanez, Pau Sancho-Bru, Marlene Dominguez,
Vicente Arroyo, Pere Gines, Juan Caballeria, Ramon Bataller
1188: Cannabinoïd CB2 receptor protects from
alcoholic liver disease via an autophagy-dependent
pathway in Kupffer cells
Timothé Denaës, Jasper Lodder, Marie-Noële Chobert, Jean-Michel
Pawlotsky, Sophie Lotersztajn, Fatima Teixeira-Clerc
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1189: Farnesoid X Receptor (FXR) Regulates FoxO3
Activation in Ethanol-Induced Autophagy and Liver
Injury
Sharon Manley, Hong-Min Ni, Jessica A. Williams, Grace L. Guo,
Wen-Xing Ding
1190: Dysbiosis-induced intestinal inflammation
activates TNFR-1 and mediates alcoholic liver disease in
mice
Peng Chen, Peter Starkel, Jerrold R. Turner, Samuel B. Ho, Bernd
Schnabl
1191: Pharmacological activation of aldehyde
dehydrogenase 2 reverses alcohol-induced hepatic
steatosis and cell death in mice
Wei Zhong, Wenliang Zhang, Qiong Li, Guoxiang Xie, Qian Sun,
Xiuhua Sun, Xiaobing Tan, Xinguo Sun, Zhanxiang Zhou
1192: Lipid-derived aldehyde, acrolein, is a critical
mediator of alcohol-induced gut-liver injury in alcoholic
liver disease
Wei-Yang Chen, Jingwen Zhang, Shirish Barve, Craig J. McClain,
Swati Joshi-Barve
1193: Functional role of cellular senescence in alcoholic
liver injury
Kelly McDaniel, Yuyan Han, Heather L. Francis, Haibo Bai, Julie
Venter, Nan Wu, Morgan Quezada, Ying Wan, Shannon S.
Glaser, Gianfranco Alpini, Fanyin Meng
1194: Alcohol stimulates release of hepatocyte derived
extracellular vesicles leading to macrophage activation
Vikas K. Verma, Patrick S. Kamath, Patricia C. Contreras, Gregory
J. Gores, Vijay Shah
1195: Monocyte Oxidative Burst defect is associated
with susceptibility to Infection in Alcoholic Hepatitis and
is restored by N-Acetylcysteine
Nikhil Vergis, Wafa Khamri, Jennifer M. Ryan, Debbie Shawcross,
Yun Ma, Charalambos G. Antoniades, Mark R. Thursz
1196: Ductular bilirubinostasis predicts the evolution to
acute-on-chronic liver failure in patients suspected with
severe alcoholic steatohepatitis
Len D. Verbeke, Tania Roskams, Chris Verslype, David Cassiman,
Schalk Van Der Merwe, Werner Van Steenbergen, Geert Maleux,
Alexander Wilmer, Wim Laleman, Frederik Nevens
1197: Serum metabolomic profiling in acute alcoholic
hepatitis identifies multiple dysregulated pathways
Vikrant Rachakonda, Charles Gabbert, Amit Raina, Shahid M.
Malik, Lauren N. Bell, Sara J. Cooper, Jaideep Behari
1198: Phosphodiesterase 4 (PDE4) plays a significant
role in alcohol induced dysregulation of lipid
metabolism and development of hepatic steatosis
Diana Avila, Jingwen Zhang, Craig J. McClain, Shirish Barve,
Leila Gobejishvili
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1199: Hepatic Gap Junction Inhibition Protects Against
Liver Injury and Inflammation in a Murine Model of
Alcoholic Steatohepatitis
Jay Luther, Kevin R. King, John Garber, Ricard Masia, Daniel L.
Motola, Martin L. Yarmush, Raymond T. Chung, Suraj J. Patel
1200: NOX4 regulates CCR2 mRNA stability in hepatic
stellate cells in alcoholic liver injury
Yu Sasaki, Joy Jiang, Tzu-I Chao, Jijing Tian, Natalie Torok
1201: Association of Two Novel Bitter Taste Receptor
2R38 (TAS2R38) Haplotypes with Alcohol Intake among
the Population of West Mexico
Oscar O. Ramos-Lopez, Sonia Roman, Claudia Ojeda-Granados,
Maricruz Sepulveda-Villegas, Rafael Torres-Valadez, Maria Elena
Trujillo-Trujillo, Karina Gonzalez-Aldaco, Erika Martinez-Lopez,
Arturo Panduro
1202: Alcoholic Cirrhosis is Associated with Neuro-
Inflammation and Impaired White Matter Integrity
despite Controlling for MELD score and Hepatic
Encephalopathy
Vishwadeep Ahluwalia, James Wade, Douglas M. Heuman,
Richard K. Sterling, Scott Matherly, Mohammad S. Siddiqui,
Velimir A. Luketic, R. Todd Stravitz, Arun J. Sanyal, Puneet Puri,
Melanie White, Nicole Noble, James Hovermale, Edith A. Gavis,
Jasmohan S. Bajaj
1203: Carriage of the Ile148Met Mutation in PNPLA3
has a Detrimental Effect on Survival In Patients with
Alcohol-Related Cirrhosis
Michael J. Way, Harriet M. Gordon, Jonathan C. Marshall,
Andrew McQuillin, Marsha Y. Morgan
1204: Unfolded Protein Response (UPR) and calcium-
dependent endoplasmic reticulum stress modulate
development of alcohol-induced liver disease in mice
Keisaku Sato, Tracie C. Lo, Angela Dolganiuc
1205: The Worsening Profile of Acute Alcoholic
Hepatitis in the United States
Tuyet A. Nguyen, Arun J. Sanyal, Jonathan P. DeShazo
1206: Fat-specific Protein 27/CIDE-C Promotes Liver
Injury in Chronic Plus Binge Ethanol Fed-mice And
Human Alcoholic Hepatitis
Ming-Jiang Xu, Yan Cai, José T. Altamirano, Binxia Chang,
Hua Wang, Adeline Bertola, Gemma Odena, Jim Lu, Kimihiko
Matsusue, Shioko Kimura, Frank J. Gonzalez, Ramon Bataller,
Bin Gao
1207: Distinct Intestinal Microbiome Signature In Obese
Subjects With Alcoholic Versus Nonalcoholic Fatty Liver
Disease
Puneet Puri, Mohammad S. Siddiqui, Sherry L. Boyett, Carol C.
Sargeant, Jolene Schlosser, Larry D. White, Richard K. Sterling,
R. Todd Stravitz, Scott Matherly, Velimir A. Luketic, Faridoddin
Mirshahi, Kalyani Daita, Masoumeh Sikaroodi, Andrew R. Joyce,
Patrick M. Gillevet, Arun J. Sanyal
Poster Viewing: 8:00 AM – 5:30 PM
147A
1208: Interleukin-1 receptor inhibition facilitates
recovery from liver inflammation and injury and
promotes regeneration of hepatocytes in alcoholic
hepatitis in mice
Jan Petrasek, Arvin Iracheta-Vellve, Shashi Bala, Timea Csak,
Karen Kodys, Evelyn A. Kurt-Jones, Gyongyi Szabo
1209: Imaging Mass Spectrometry (IMS) Visualization
of Hepatic Lipid Profiles in Experimental Steatohepatitis
Induced by Chronic Ethanol, Tobacco Nitrosamine
(NNK), or Both Exposures In Long Evans Rats
Emine Yalcin, Kavin M. Nunez, Ming Tong, Shannon Cornett,
Suzanne M. de la Monte
1210: 9(S)-hydroxy-octadecadienoic acid (HODE)
enhances interleukin-1β production of PBMCs from
alcoholic liver cirrhosis patients by activation of TRPV1
Qifa Xie, Mohammad K. Mohammad, Matthew C. Cave, Shirish
Barve, Irina Kirpich, Craig J. McClain
1211: Transient Receptor Potential Vanilloid 1 Gene
Deficiency Ameliorates Hepatic Injury in a Mouse Model
of Chronic-Binge-Induced Alcoholic Liver Disease
Irina Kirpich, Keith C. Falkner, Juliane I. Beier, Gavin E. Arteel,
Christopher Ramsden, Ariel E. Feldstein, Craig J. McClain
1212: Hepatic Stellate Cell Selective Deletion
of Neuropilin-1 is Protective against Alcoholic
Steatohepatitis in Mice
Douglas A. Simonetto, Vikas K. Verma, Jung Hee Kwon, Usman
Yaqoob, Thiago de Assuncao, Sheng Cao, Tatiana Kisseleva,
David A. Brenner, Vijay Shah
1213: Nuclear receptor SHP is a key regulator of
circadian clock mediated hyperhomocysteinemia
induced by alcohol
Hiroyuki Tsuchiya, Yuxia Zhang, Sangmin Lee, Rana Smalling, Li
Wang
1214: Calcineurin and NFAT drive the development of
steatosis component of alcoholic liver disease (ALD) in
mice by regulating Calcium-dependent signaling
Keisaku Sato, Tracie C. Lo, Angela Dolganiuc
1215: Zinc Sulfate for Alcoholic Cirrhosis (ZAC) Clinical
Trial - Interim Analysis of Clinical Parameters, Intestinal
Permeability and Liver Fibrosis Biomarkers
Ming Song, Mohammad K. Mohammad, Keith C. Falkner, Craig J.
NOVEMBER 10
McClain, Matthew C. Cave
MONDAY
1216: Decreased dietary fat attenuates ethanol induced
oxidative stress and upregulation of antioxidant
responses
Colin T. Shearn, David J. Orlicky, Rebecca Smathers-McCullough,
Kenneth N. Maclean, Dennis R. Petersen
Presenters in Attendance 12:30 – 2:00 PM
 148A POSTER SESSIONS
Poster Sessions
1217: Predictors of mortality and comparison of
prognostic models in 220 patients with alcoholic
hepatitis: a prospective study
Venu H. Aradya, Harshad Devarbhavi, Karnam Ravikiran, Keyur
A. Sheth, T. R. Vijaykumar, Rajvir Singh, Adarsh Ck, Mallikarjun
Patil
1218: Translational Bioenergetics: A novel biomarker in
the management of patients with alcoholic liver disease
Ashwani K. Singal, Philip A. Kramer, Saranya Ravi, Toni Seay,
Balu Chacko, Degui Zhi, Victor Darley-Usmar
1219: Betaine attenuates chronic ethanol-induced
disruption of intestinal epithelial integrity
Sarah Bligh, Kusum K. Kharbanda, Paul G. Thomes
1220: Pharmacological Restoration of WNT/β-Catenin
Signaling Attenuates Alcoholic Liver Disease Progression
in a Rat Model
Chiung-Kuei Huang, Tunan Yu, Zoltan Derdak, Suzanne M. de la
Monte, Jack R. Wands, Miran Kim
1221: Does the Alcoholic Pancreatitis CLDN2 High-Risk
Locus Predispose to Liver Disease?
Alison Jazwinski, Jyothsna Talluri, Gautam Mankaney, Jessica
LaRusch, David C. Whitcomb, Jaideep Behari
1222: Kupffer cell-specific calcium signaling drives
inflammation in alcoholic liver disease (ALD) in mice
Tracie C. Lo, Keisaku Sato, Angela Dolganiuc
1223: The inflammasome in alchohoic hepatitis: its
relationship with Mallory-Denk body formation
Cindy Peng, Barbara A. French, Brittany C. Tillman, Samuel W.
French
1224: Interactions between the gut permeability, blood
endotoxemia and liver injury in alcoholic patients
during detoxification
Irina Kirpich, John Umhau, Vatsalya Vatsalya, Melanie Schwandt,
Monte Phillips, Thomas Lionetti, Keith C. Falkner, Lucy Zhang,
Catey Harwell, David George, Markus Heilig, Craig J. McClain
1225: Repeated validation of AshTest as a non-invasive
alternative to liver biopsy in patients with suspicion of
severe acute alcoholic hepatitis (AH)
Marika Rudler, Sarah Mouri, Frederic Charlotte, Philippe Cluzel,
Yen Ngo, Mona Munteanu, Dominique Thabut, Thierry Poynard
NOVEMBER 10
MONDAY
1226: Metabolomics studies in Patients with Liver
Disease Identify Novel Plasma Analytes in Alcoholic
Hepatitis
Ibrahim A. Hanouneh, Stephanie Marshall, Zhen Wang, Raed
Dweik, Nizar N. Zein, David Grove, Laura E. Nagy, Arthur J.
McCullough, Rocio Lopez, Stanley L. Hazen, J. Mark Brown
1227: Does the Alcoholic Liver Disease/ Non-alcoholic
fatty liver disease Index (ANI) predict mortality in
Alcoholic Hepatitis?
Traci Murakami, Cristian E. Dominguez, Varun Takyar, Krunal
Patel, Thomas D. Boyer, Shahid Habib
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1228: Alcoholic versus non-alcoholic fatty liver:
Indistinguishable histology but distinct differences in
function and content of proteins involved in vesicle
trafficking and receptor-mediated endocytosis
Karuna Rasineni, Daniel Penrice, Edward N. Harris, Cliff I. Stains,
Jon Beck, Benita L. McVicker, Mark A. McNiven, Carol A. Casey
1229: Potential Contributions of the Tobacco-Specific
Nicotine-Derived Nitrosamino Ketone (NNK) in the
Pathogenesis of Steatohepatitis in a Chronic-Binge Rat
Model of Alcoholic Liver Disease (ALD)
Valerie Zabala, Ming Tong, Teresa Ramirez, Emine Yalcin, Silvia
Balbo, Elizabeth Silbermann, Chetram Deochand, Stephen Hecht,
Suzanne M. de la Monte
1230: Comparative Evaluation of Prediction Models in
Severe Alcoholic Hepatitis
Gene Y. Im, Aparna Goel, Thomas D. Schiano, Scott L. Friedman
1231: Zinc Sulfate for Alcoholic Cirrhosis (ZAC) Clinical
Trial - Interim Analysis of Liver Injury/Inflammation
Biomarkers
Mohammad K. Mohammad, Ming Song, Keith C. Falkner, Craig J.
McClain, Matthew C. Cave
1232: Serum fibroblast growth factor 19 levels are
increased in subjects with alcoholic cirrhosis and
positively associated with serum total bile acid levels
Cuiqing Zhao, Mohammad K. Mohammad, Liming Liu, Keith
C. Falkner, Zhanxiang Zhou, Craig J. McClain, Wenke Feng,
Matthew C. Cave
1233: Sarcopenia as a prognostic factor in patients with
severe alcoholic hepatitis
Do Seon Song, JinMo Yang, U Im Chang, Sang Wook Choi, Se
Hyun Cho, Joon-Yeol Han
1234: Hepatic cell proliferation and outcome in
alcoholic hepatitis: histology, gene expression and
effect of stem cell therapy
Nicolas Lanthier, Laura Rubbia-Brandt, Nathalie Lin-Marq, Sophie
Clément, Jean-Louis Frossard, Nicolas Goossens, Laurent Spahr
Basic Hepatobiliary Neoplasia
1235: Genetic profiling of circulating tumor cells in
hepatocellular carcinoma
Jennifer Au, Angel E. Dago, Kelly Bethel, Peter Kuhn, Randolph L.
Schaffer
1236: A Cell surface β-Hydroxylase is a biomarker and
therapeutic target for hepatocellular carcinoma
Arihiro Aihara, Chiung-Kuei Huang, Mark Olsen, Qiushi Lin,
Waihong Chung, Qi Tang, Xiaoqun Dong, Jack R. Wands
1237: Nodular regenerative hyperplasia: expression
pattern of glutamine synthetase and a potential role for
hepatic progenitor cells
Marie-Christine Guilbert, Geneviève Soucy, Dominique Trudel,
Bich N. Nguyen
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1238: Histopathologic Features as Surrogate Markers of
Molecular Classification of Hepatocellular Carcinoma
Poh Seng Tan, Anu Venkatesh, Stephen C. Ward, Claudia Canasto-
Chibuque, Anna Koh, Venugopalan Nair, Manjeet Deshmukh,
Shigeki Nakagawa, Xiaochen Sun, Masahiro Kobayashi,
Hiromitsu Kumada, Yujin Hoshida
1239: TPU0114 suppresses Bcl-xl to induce apoptosis in
human hepatocellular carcinoma
Tomoyuki Hayashi, Taro Yamashita, Naoki Oishi, Kouki Nio,
Takehiro Hayashi, Yasumasa Hara, Yoshimoto Nomura, Mariko
Yoshida, Tomomi Hashiba, Hikari Okada, Koji Miyanouchi,
Shuichi Kaneko
1240: Differential EGFR regulation in metastatic and
primary unresectable hepatoblastoma
Sarangarajan Ranganathan, Mylarappa Ningappa, Chethan
Ashokkumar, Brandon W. Higgs, Qing Sun, Lori Schmitt, Hakon
Hakonarson, Rakesh Sindhi
1241: Discovery of Novel DNA Methylation Markers for
the Detection of Cholangiocarcinoma by Methylome-
Wide Analysis
Mohammed M. Aboelsoud, William R. Taylor, Tracy C. Yab,
Patrick H. Foote, Douglas W. Mahoney, Thomas C. Smyrk, Lewis
R. Roberts, David Ahlquist, John B. Kisiel
1242: Clinical significance of serum cytokeratin 19
fragment (CYFRA 21-1) in biliary tract cancers: a
reliable biomarker for gallbladder carcinoma and
intrahepatic cholangiocarcinoma
Li Huang, Wei Chen, Peiwen Liang, Wenjie Hu, Kunsong Zhang,
Bin Chen, Yuyan Han, Fanyin Meng, Sharon DeMorrow, Xiaoyu
Yin, Jiaming Lai, Lijian Liang
1243: CD90+ and CD133+ Cancer Stem Cells Correlate
with Transcription Factor FOXM1 and Glycolytic Enzyme
Hexokinase II (HKII) Immunolevels, and Markers for
Oxidative and Nitrosative Stress Correlate with Disease
Progression in Hepatocellular Carcinoma
Lily Mei, Katherine M. Choi, Rajender Mulpuri, Dragana Kopanja,
Hari Sreedhar, Michael J. Walsh, Ming Jin, Costica Aloman,
Charmaine Stewart, Nissim Hay, Pradip Raychaudhuri, Grace
Guzman
1244: Identification of new tissue biomarkers to predict
biologic features of hepatocellular carcinoma
Yoriko Nomura, Sachiko Ogasawara, Jun Akiba, Hironori Kusano,
Masamichi Nakayama, Osamu Nakashima, Hirohisa Yano
1245: Metabolomic Analysis by 1H-NMR Spectroscopy
of Human Tissues reveals different metabolic
biomarkers of Hepato-Cellular Carcinoma according to
the underlying liver disease
Camille Teilhet, Daniel Morvan, Juliette Joubert-Zakeyh, Pierre
J. Déchelotte, Denis Pezet, Emmanuel Buc, Bruno Pereira, Anne-
Sophie Biesse, Géraldine Lamblin, Sylvie Massoulier, Michel
Peoc’h, Jack Porcheron, Marie-Paule Vasson, Aïcha Demidem,
Armando Abergel
Poster Viewing: 8:00 AM – 5:30 PM
149A
1246: Cartilage oligomeric matrix protein (COMP): A
novel non-invasive marker for assessing liver cirrhosis
and risk of progression to hepatocellular carcinoma
Gary L. Norman, Nikolaos Gatselis, Zakera Shums, Christos
Liaskos, Dimitrios P. Bogdanos, George K. Koukoulis, George N.
Dalekos
1247: Serum levels of advanced glycation end products
and pigment epithelium derived factor in patients with
hepatocellular carcinoma derived from non-alcoholic
steatohepatitis
Hiromi Kan, Hideyuki Hyogo, Hiroshi Aikata, Tomoki Kobayashi,
Takayuki Fukuhara, Noriaki Naeshiro, Yohji Honda, Tomokazu
Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura,
Yoshiiku Kawakami, Kazuaki Chayama
1248: Adenomatous polyposis coli-binding protein EB1
as an important predictive factor for the prognosis and
recurrence in hepatocellular carcinoma
Takeshi Aiyama, Tatsuya Orimo, Hideki Yokoo, Takanori Ohata,
Kanako Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Kenji
Wakayama, Tatsuhiko Kakisaka, Yosuke Tsuruga, Hirofumi
Kamachi, Toshiya Kamiyama, Akinobu Taketomi
1249: The expression of arginase-1, keratin (K)
8, and K18 and clinicopathologic significance of
phosphorylation K8 in combined hepatocellular-
cholangiocarcinoma, stem cell subtypes-intermediate-
cell type
Jun Akiba, Osamu Nakashima, Hirohisa Yano
1250: Performance of biomarkers for diagnosis of
hepatocellular carcinoma –alpha fetoprotein, protein
induced by vitamin K absence, osteopontin and
Dickkopf-1
Jong Ho Lee, Eun Sun Jang, Yun Suk Choi, Philippe Leissner,
Christian Brechot, Jung Wha Chung, Jin Wook Kim, Sook-Hyang
Jeong
1251: Cancer stem cell, TGF-β gene signatures, and
epithelial-mesenchymal transition are features of late
rather than early hepatocarcinogenesis
Hyungjin Rhee, Jeong Eun Yoo, Ei Yong Ahn, Luca Di Tomaso,
Bogdan Pintea, Massimo Roncalli, Young Nyun Park
1252: Oxidative stress in leucocytes of patients with
advanced hepatocellular carcinoma
Paloma Lluch, Laia Navarro López, Gloria Segarra, Guadalupe
NOVEMBER 10
Herrera, María Mora, Joan Tosca, Miguel Angel Serra, Pascual
MONDAY
Medina
1253: Serum Dickkopf-1 as a biomarker for the
diagnosis of hepatocellular carcinoma with stem cell
features
Hajime Sunagozaka, Taro Yamashita, Naoki Oishi, Takehiro
Hayashi, Hajime Takatori, Tetsuro Shimakami, Kazuya Kitamura,
Kuniaki Arai, Takashi Kagaya, Yoshio Sakai, Tatsuya Yamashita,
Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Presenters in Attendance 12:30 – 2:00 PM
 150A POSTER SESSIONS
Poster Sessions
1254: Fatty Acid Binding Protein 5 promotes tumor
progression through epithelial-mesenchymal transition
in hepatocellular carcinoma
Takanori Ohata, Hideki Yokoo, Toshiya Kamiyama, Kenji
Wakayama, Tatsuya Orimo, Tatsuhiko Kakisaka, Yosuke Tsuruga,
Hirofumi Kamachi, Akinobu Taketomi
1255: The Autophagy-Related Marker P62 Is Useful For
Diagnosis In Human Hepatocellular Carcinoma
Changjae Hur, Byoung Kuk Jang, Jeong Min Kim, Kyung Ho Yang,
Hye min Park, Sang Min Lee, Eun Sung Choi, Jung Min Lee, Woo
Jin Chung, Jaeseok Hwang, Yoo Na Kang, Koo Jeong Kang
1256: A gene signature derived from sorafenib resistant
liver cancer cells identifies HCC patients with poor
prognosis
Jeroen Dekervel, Dusan Popovic, Hannah van Malenstein, Petra
Windmolders, Ashenafi S. Bulle, Bart De Moor, Frederik Nevens,
Chris Verslype, Jos van Pelt
1257: Effect of metabolic syndrome on patients with
viral hepatitis treated with local regional therapy for
hepatocellular carcinoma
Fei Wen Chen, Jacob George, Amany Zekry
1258: CUX1 downregulation causes apoptosis in HIF1-
alpha expressing HCC
Carmen Rothmund, Pietro Di Fazio, Heidi Griesmann, Benjamin
Kuehnemuth, Thomas Gress, Patrick Michl, Thaddaeus T.
Wissniowski
1259: Consecutive increment of serum alpha-feto
protein level is a useful surrogate marker in predicting
hepatocellular carcinoma in liver cirrhosis patients
Heechul Nam, Hae Lim Lee, Jung Suk Oh, Young Joon Lee, Ho
Jong Chun, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Biliary Atresia and Cholestasis
1260: C5aR distinguishes subsets of hepatic myeloid
and lymphoid cells promoting epithelial injury in
experimental biliary atresia
Pranavkumar Shivakumar, Stephanie Walters, Janet Pfister, Rachel
M. Sheridan
1261: The association of tetra-hydroxylated bile acids
with good prognosis in infantile intrahepatic cholestasis
NOVEMBER 10
Chee-Seng Lee, Kimura Akihiko, Jia-Feng Wu, Yen-Hsuan Ni,
MONDAY
Hong-Yuan Hsu, Mei-Hwei Chang, Huey-Ling Chen
1262: Portal hypertension in children; review of
management in the era of non-invasive prediction
markers
Anastasios Grammatikopoulos, Peter Witters, Dominic A. Hughes,
Palaniswamy Karthikeyan, Somashekara H Ramakrishna, Mark
Davenport, Anil Dhawan
1263: WITHDRAWN
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
Cellular and Molecular Biology
1264: The Small GTPase Rab7 as a Central Regulator
of Hepatocellular Lipophagy
Barbara Schroeder, Ryan J. Schulze, Shaun Weller, Arthur C.
Sletten, Carol A. Casey, Mark A. McNiven
1265: Characterization of Microtubule-based Motility
of Autophagic Vesicles from Mouse Liver
Xintao Wang, Eloy Bejarano-Fernandez, John W. Murray, Ana
Maria Cuervo, Allan W. Wolkoff
1266: Ca2+-depletion impairs transcytotic vesicle
fusion with the apical membrane by altering the SNARE
docking and fusion machinery in WIF-B cells
Alfonso Lopez Coral, Pamela L. Tuma, Julia F. Omotade
1267: Dual rab17 species have distinct biochemical
properties
Anneliese C. Striz, Pamela L. Tuma
1268: Insulin resistance of CD56dim NK cells
decrease NK killing ability in NASH patients with
advanced fibrosis
Johnny Amer, Sarit Doron, Ahmad Salhab, Rifaat Safadi
1269: C-Myc is a central regulator of liver
regeneration in mice with chronic liver injury
Stephanie Klett, Kristin Hanak, Bruno Guigas, Robert Geffers,
Jessica Endig, Laura E. Buitrago, Silke Marhenke, Michael P.
Manns, Arndt Vogel
1270: TIGAR Overexpression Increases
Chemosensitivity in Sorafenib-resistant Hepatocellular
Carcinoma Cells
Zoltan Derdak, Ragheb Harb, Jack R. Wands
1271: Mitoferrofluor – A New Approach to
Determine Mitochondrial Chelatable Iron
Andaleb Kholmukhamedov, Christopher C. Lindsey, Craig C.
Beeson, John J. Lemasters
1272: Concomitant loss of beta-catenin and gamma-
catenin in liver disrupts junctional integrity leading to
cholestasis, fibrosis and mortality
Lili Zhou, Kari Nejak-Bowen, Satdarshan (Paul) S. Monga
1273: The new platelet activating receptor C-type
Lectin Receptor -2 plays an essential role in the liver
regeneration after partial hepatectomy in mice
Hiroshi Kono, Hideki Fujii
1274: Betaine Mitigates Acetaldehyde-Induced Gut
Barrier Dysfunction
Paul G. Thomes, Sandra L. Todero, Dean J. Tuma, Kusum K.
Kharbanda
1275: Hepatocytes maintain their karyotype in spite of
being polyploid
Kristin Knouse, Angelika Amon
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1276: All-in-one liver cell preparation: high quality of
functional primary human hepatocytes, liver sinusoidal
endothelial cells, Kupffer cells and hepatic stellate cells
Melanie Lutterbeck, Catherine I. Real, Kathrin Skibbe, Joerg Timm,
Andreas Paul, Guido Gerken, Joerg F. Schlaak, Ruth Broering
1277: Nuclear receptor SHP and FOXA1 are novel
modulators of homocysteine metabolism via regulating
BHMT and CTH expression
Hiroyuki Tsuchiya, Kerry-Ann da Costa, Sangmin Lee, Barbara
Renga, Yuxia Zhang, Rana Smalling, Hartmut Jaeschke, Steven H.
Zeisel, Fiorucci Stefano, Li Wang
1278: The role of NF-kB in inflammation-induced
and obstructive cholestasis
Natarajan Balasubramaniyan, Meena Ananthanarayanan,
Frederick J. Suchy
1279: Enlarged livers in a human hepatocyte
repopulated mouse model are due to aberrant bile
acid signaling: potential mechanism underlying the
“hepatostat”
Willscott E. Naugler, Markus Grompe
1280: Yap reprograms glutamine metabolism
and supports growth during liver development and
tumorigenesis
Andrew G. Cox, Katie L. Hwang, Sebastian Beltz, Kimberley
Evason, Keelin O’Connor, Kristin Brown, Evan C. Lien, Sagar
Chhangawala, Yariv Houvras, Didier Y. Stainier, Wolfram
Goessling
1281: Increased circulating TGFβ1 following liver
failure suppresses neural IGF-1 that contributes to
hepatic encephalopathy
Matthew McMillin, Cheryl Galindo, Gabriel A. Frampton, Sharon
DeMorrow
1282: Endothelial nitric oxide synthase is a key
mediator of extracellular ATP-mediated mitogenic
signaling and proliferation of hepatocytes
Yu Mei, Sundararajah Thevananther
1283: Mechanisms of PKC-mediated enhancement of
HIF-1alpha activity and its inhibition by Vitamin K2 in
Hepatocellular carcinoma cells
Jinghe Xia, Iwata Ozaki, Sachiko Matsuhashi, Jingyan Qi, Shinji
Iwane, Hirokazu Takahashi, Yuichiro Eguchi, Toshihiko Mizuta,
Keizo Anzai
1284: PKCδ facilitates cAMP-induced NTCP
translocation and negatively regulates p38 MAPK
activation in mouse hepatocytes
Se Won Park, Christopher M. Schonhoff, Cynthia R. Webster,
Mohammed S. Anwer
Poster Viewing: 8:00 AM – 5:30 PM
151A
1285: Osteopontin isoforms are upregulated in human
cholangiocarcinoma cells and modulate levels of the
TGF-β repressor, SnoN
Marco A. Briones-Orta, Jason D. Coombes, Naoto Kitamura, Paul
P. Manka, Roger Williams, Ali Canbay, Salvatore Papa, Wing-Kin
Syn
1286: Post-translational modification of ERK mediates
impaired skeletal muscle protein synthesis during
hyperammonemia of cirrhosis
Gangarao Davuluri, Michela Giusto, Sathyamangla V. Naga
Prasad, Srinivasan Dasarathy
1287: Modulation of bile acid receptor TGR5 : novel
therapy for heart failure
Moreshwar S. Desai, Zainuer Shabier, Jorge Coss-Bu, Sundararajah
Thevananther, David D. Moore, Saul J. Karpen, Daniel J. Penny
1288: Steatogenesis in adult-onset type II citrullinemia
is associated with down-regulation of PPAR alpha
Takefumi Kimura
1289: Targeting activated Wnt/β-catenin signaling by
XAV939 and its derivative WXL-8 in hepatocellular
carcinoma
Li Ma, Xiaolin Wang, Wei Wei, Mei-Sze Chua, Samuel K. So
1290: Lysophosphatidic Acid Signaling Mediates
Human Hepatoma Cell Motility
Valentina Zuckerman, Eugene Sokolov, Jacob H. Swet, David A.
Iannitti, Iain H. McKillop
1291: PNPLA3 (rs738409), LYPLA1 (rs12137855),
and NCAN (rs2228603) are associated with elevated
transaminase levels in Mexican adults
Yvonne N. Flores, Manuel Bañuelos, Manuel Quiterio, Hal F. Yee,
Zuo-Feng Zhang, Rafael Velázquez-Cruz, Jorge Salmerón
1292: Evaluation of Yes associated protein as a
therapeutic target in primary liver malignancies
Haibo Bai, Qing-feng Zhu, Gianfranco Alpini, Robert A. Anders
1293: Interactions between Hedgehog and
inflammatory signaling reproduce aspects of biliary
atresia
Zenobia Cofer, Shuang Cui, Valerie Sapp, Randolph P. Matthews
1294: Inhibition of miR-122 Mediates the
NOVEMBER 10
Pathogenesis of Alcoholic Liver Disease
MONDAY
Abhishek Satishchandran, Nicita Mehta, Arvin Iracheta-Vellve, Jia
Li, Shashi Bala, Donna Catalano, Li Zhong, Jun Xie, Guangping
Gao, Gyongyi Szabo
1295: Expression of the Myc dominant interfering
miniprotein Omomyc prevents human hepatocellular
carcinoma cell growth
Barbara Barbaro, Cristiana Porcu, Gabriele Toietta, Roberta
Maggio, Mauro Savino, Sergio Nasi, Clara Balsano
Presenters in Attendance 12:30 – 2:00 PM
 152A POSTER SESSIONS
Poster Sessions
1296: Integrative role of histone lysine demethylase
LSD2 in hepatic energy metabolism: possible epigenetic
mechanism of nonalcoholic fatty liver disease
Katsuya Nagaoka, Shinjiro Hino, Yutaka Sasaki, Mitsuyoshi
Nakao
1297: Iron-overload alters lipid metabolism and Ras
signaling independent of oxidative stress in mouse liver
tissue by whole RNA sequencing
Hiroki Tanaka, Takaaki Ohtake, Lynda Addo, Masayo Yamamoto,
Yasumichi Toki, Koji Sawada, Shunsuke Nakajima, Takumu
Hasebe, Katsuya Ikuta, Katsunori Sasaki, Yoshihiro Torimoto,
Mikihiro Fujiya, Yutaka Kohgo
1298: Suppression of Dual Specificity Phosphatase I
inhibits Hepatitis C Virus Replication
Jung Eun Choi, Jung Hyun Kwon, Seung Kew Yoon, Sang Wook
Choi
1299: Endoplasmic reticulum stress activates the hepatic
activator protein 1 complex via mitogen activated
protein kinase-dependent signaling pathways
Shantel Olivares, Richard Green, Anne S. Henkel
1300: The pivotal role of anti-angiogenic activity in the
in vivo antitumor effects of type I interferon
Hirayuki Enomoto, Tohru Tsujimura, Masao Honda, Chikage
Nakano, Kunihiro Hasegawa, Ryo Takata, Tomoko Aoki, Kenji
Hashimoto, Akio Ishii, Tomoyuki Takashima, Yoshiyuki Sakai,
Nobuhiro Aizawa, Naoto Ikeda, Yoshinori Iwata, Hironori Tanaka,
Masaki Saito, Shuichi Kaneko, Hiroko Iijima, Shuhei Nishiguchi
1301: A pivotal role of KLF5 in regulation of cancer
stem-like cells in hepatocellular carcinoma
Mitsuteru Natsuizaka, Osamu Maehara, Fumiyuki Sato, Yoshimasa
Kubota, Goki Suda, Jun Itoh, Seiji Tsunematsu, Yoko Tsukuda,
Katsumi Terashita, Masato Nakai, Takuya Sho, Koji Ogawa,
Shunsuke Ohnishi, Naoya Sakamoto
1302: Characterization of Exosomal microRNA
(miRNA) Content Following Hepatic Injury And Roles
in Cytoprotection After Uptake of Exosomes By Injured
Hepatocytes
Yogeshwar Sharma, Tatyana Tchaikovskaya, Preeti Viswanathan,
David B. Rhee, Pilib Ó Broin, Tatyana Gorbacheva, Alexander Y.
Maslov, Aaron Golden, Sanjeev Gupta
1303: Heat Shock Factor 1 (HSF1) Involvement In
NOVEMBER 10
Tumour Recurrence After Radiofrequency Ablation In An
MONDAY
Animal Model Of Secondary Liver Cancer
Francesca Zanieri, Vinicio Carloni, Sara Omenetti, Claudio
Amabile, Nevio Tosoratti, Simone Cassarino, Sriram Saravanan
Shanmuga Velandy, Mark Kester, Massimo Pinzani, Krista
Rombouts
1304: Establishment of Liver-Targeting Delivery System
Using Hepatitis E Virus-Like Particles
Jung-Hee Kim, Wonhee Hur, Eun Byul Lee, Jung Eun Choi, Seung
Kew Yoon
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1305: Efficient and Safe HCC-specific Gene Therapy
and Its Possible Role of Immunogenic Cell Death via
Adenovirus Harboring mTERT-targeting Trans-splicing
Ribozyme, Liver-specific Promoter and MicroRNA
Regulation in Immunocompetent Mouse
Jin-Sook Jeong, Sang Young Han, Seong-Wook Lee, Mi Ha Ju,
Kyung Sook Cho
1306: Suppression of HCV replication by exosome-
mediated miR-199* delivery
Guohua Lou, Yanning Liu, Zhi Chen
1307: The efficiency of portal venous port-catheter
system as a route of siRNA delivery for the liver
metastasis
Toshio Kokuryo, Yukihiro Yokoyama, Masato Nagino
Cellular Immunobiology
1308: Plasma Microparticles Modulate
Vascular Inflammation and Liver Regeneration via
Ectonucleotidase-Dependent Levels of MicroRNA 142-3P
Stephanie Kuhn, Katrin Splith, Ines Kämmerer, Cindy Hegewald,
Linda Feldbrügge, Jan Schulte am Esch, Sven Jonas, Simon C.
Robson, Moritz Schmelzle
1309: Matrix-embedded endothelial cells
rescue median lobe from ischemia and switch
M1 macrophages to M2 phenotype after partial
hepatectomy in mice
Pedro Melgar-Lesmes, Elazer R. Edelman
1310: Serum transcriptomic analysis of liver transplant
recipients with hepatitis C: mild versus severe disease
Obaid S. Shaikh, Yue Chen, Chengli Shen, Phalguni Gupta
1311: Effect of continuous hypothermic oxygenated
machine perfusion(CHOP) on liver graft from donors
after cardiac death (DCD) following liver transplantation
Ling Lu, Jianhua Rao, Haoming Zhou, Xuehao Wang
1312: A novel model for reperfusion of the human liver
following organ preservation
James H. Avruch, Bote G. Bruinsma, Pepijn D. Weeder, Gautham
V. Sridharan, Heidi Yeh, Korkut Uygun, James F. Markmann
1313: Ischemic postconditioning (IPostC) in fibrotic livers
following warm ischemia: a new strategy to protect the
liver against ischemia-reperfusion injury
Julia Schewe, Ingrid Liss, Lisa Selzner, Marie-Christine Makeschin,
Burkhard Göke, Alexander L. Gerbes, Christian J. Steib
1314: TLR4 activation, ER stress induction and
autophagy inhibition: a tripartite synergy in interleukin
23 induction during liver ischemia and reperfusion
injury
Ling Lu, Jianhua Rao, Haoming Zhou, Xuehao Wang
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1315: Progressive biliary fibrosis stimulates liver
repopulation by either stem/progenitor cells or mature
hepatocytes
Mladen Yovchev, Joseph Locker, Michael Oertel
Clinical Hepatobiliary Neoplasia
1316: Analysis of Immune Responses in Patients
Vaccinated with Alpha-Fetoprotein-Derived Peptides in
the Treatment of Hepatocellular Carcinoma
Eishiro Mizukoshi, Tatsuya Yamashita, Kuniaki Arai, Hajime
Sunagozaka, Kazumi Fushimi, Hidetoshi Nakagawa, Noriho Iida,
Masaaki Kitahara, Shuichi Kaneko
1317: Prognostic Effect of Statins on Hepatocellular
Carcinoma in Presence and Absence of Metformin
intake
Reham Abdel-Wahab, Hesham M. Hassabo, Ahmed El Antably,
Kanwal Raghav, Ahmed O. Kaseb, H. Franklin Herlong, Young
Kwang Chae, Gehan Botrus, Harrys A. Torres, Ahmed S. Shalaby,
Manal Hassan
1318: Hepatocellular Carcinoma: Hospitalizations and
financial burden in the United States
Raxitkumar Jinjuvadia, Augustine Salami, Suthat Liangpunsakul,
Reena Salgia
1319: The risk of hepatocellular carcinoma (HCC)
in patients with HCV cirrhosis is predicted by a
polymorphism of MERTK gene
Vincenza Calvaruso, Stefania Grimaudo, Rosaria Maria Pipitone,
Maria Grazia Bavetta, Giuseppe Cabibbo, Elisabetta Conte,
Fabrizio Bronte, Antonio Craxì, Vito Di Marco
1320: Liver Transplantation for HIV-Infected Patients
with Hepatocellular Carcinoma (HCC)
Heather L. Platt, Caitlin C. Citti, Beatriz Minguez, Ting-Yi Chen,
Meritxell Ventura-Cots, Maria D. Hernandez, Ziba Jalali, Maaz
B. Badshah, Michael Yin, Ayse Aytaman, Mark Nelson, Jürgen K.
Rockstroh, Matthew B. Goetz, Myron Schwartz, Douglas Dieterich,
Judith Aberg, Yujin Hoshida, Norbert Bräu
1321: The management and prognosis of patients with
hepatocellular carcinoma: What has changed during 20
years?
Sun Young Yim, Yeon Seok Seo, Chang Ho Jung, Tae Hyung Kim,
Jae Min Lee, Hyonggin An, Ji Hoon Kim, Hyung Joon Yim, Jong
Eun Yeon, Kwan Soo Byun, Soon Ho Um, Ho Sang Ryu
1322: Predicting Survival of HIV-Infected Patients with
Liver Cancer – the SHILCA Score and Staging Model
Ting-Yi Chen, Nicolás Merchante, Caitlin C. Citti, Heather L. Platt,
Maaz B. Badshah, Meritxell Ventura-Cots, Esperanza Merino,
Luciana Kikuchi, Mamta K. Jain, Francisco Rodríguez-Arrondo,
Beatriz Minguez, Michael Yin, Ayse Aytaman, Cristina Tural,
Myron Schwartz, Douglas Dieterich, Judith Aberg, Juan Pineda,
Jorge A. Marrero, Morris Sherman, Yujin Hoshida, Norbert Bräu
Poster Viewing: 8:00 AM – 5:30 PM
153A
1323: Role of Occult HBV Infection in the Development
of non-B, non-C Hepatocellular Carcinoma: Analysis
from a Large Retrospective Multicenter Cohort Study
Ryosuke Tateishi, Takeshi Okanoue, Kiwamu Okita, Kendo
Kiyosawa, Masao Omata, Hiromitsu Kumada, Norio Hayashi,
Kazuhiko Koike
1324: The Effect of HBV DNA Level on The Development
of Hepatocelluar Carcinoma in Patients with Hepatitis
B Virus-associated Liver Cirrhosis during Entecavir
Treatment: A Multicenter Study
Oh Sang Kwon, Jong Eun Yeon, Jeong Han Kim, So Young Kwon,
Sang Jun Suh, Yun Soo Kim, Ju Hyun Kim
1325: Real Life Treatment of Hepatocellular Carcinoma:
Impact of Deviation from Guidelines Recommendation
Zahraa Alkhatib, Asmaa Gomaa, Eman A. Rewisha, Imam Waked
1326: Intrahepatic cholangiocarcinoma in patients with
nonalcoholic fatty liver disease
Takayoshi Nishioka, Shogo Tanaka, Shigekazu Takemura,
Takahiro Uenishi, Hiroji Shinkawa, Takatsugu Yamamoto,
Masahiko Kinoshita, Genya Hamano, Sayaka Tanaka, Yuko
Kuwae, Masahiko Ohsawa, Kenichi Wakasa, Shoji Kubo
1327: Validation for retreatment strategy and
survival analysis after second session of transarterial
chemoembolization in patient with hepatocellular
carcinoma
Yang J. Yoo, Ji Hoon Kim, Ji Hye Je, Seong Hee Kang, Hae Rim
Kim, Sang Jun Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon
Yim, Jong Eun Yeon, Kwan Soo Byun
1328: Wnt/beta-catenin signaling activates different
target genes depending on stem/maturational status
and HNF4α expression in hepatocellular carcinoma
Taro Yamashita, Masao Honda, Shuichi Kaneko
1329: N.I.A.C.E score: a new tool to better distribute
advanced hepatocellular carcinoma (BCLC C). Results
from four French cohorts comprising 703 patients
Xavier Adhoute, Guillaume Penaranda, Jean-Frédéric Blanc, Julien
Edeline, Guillaume Conroy, Paul Castellani, Valerie Oules, Olivier
Bayle, Olivier Monnet, Bernard L. Pol, Patrick Beaurain, Herve
Perrier, Jean-Luc Raoul, Jean-Pierre Bronowicki, Marc Bourlière
1330: Specialty Care is Associated with Early Diagnosis
of Hepatitis C-related Hepatocellular Carcinoma in U.S.
NOVEMBER 10
Veterans
MONDAY
Janice H. Jou, Lauren A. Beste, Yin Yang, Michael F. Chang,
Andrew J. Muir
1331: Circulating SCCA-IgM complex is a useful
biomarker to predict the outcome of therapy in HCC
patients
Maria Guarino, Giovan Giuseppe Di Costanzo, Andrea Gallotta,
Giorgio Fassina, Raffaella Tortora, Concetta Tuccillo, Francesco
Auriemma, Nicola Caporaso, Filomena Morisco
Presenters in Attendance 12:30 – 2:00 PM
 154A POSTER SESSIONS
Poster Sessions
1332: The combined use of sorafenib and branched
chain amino acids enhances antitumor effect in the
treatment of hepatocellular carcinoma
Yoshiki Onishi, Tomohide Tatsumi, Satoshi Aono, Seiichi Tawara,
Akira Nishio, Takatoshi Nawa, Atsuo Takigawa, Hayato Hikita,
Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu, Tetsuo
Takehara
1333: Prospective evaluation of the performance of per
ERCP bile aspiration combined to endobiliary brushing
in the diagnosis of malignant strictures of the biliary
tract
Roth Gael, Bichard Philippe, Fior-Gozlan Michele, Auroux Jean,
Christian Letoublon, Ivan Bricault, Vincent Leroy, Thomas Decaens
1334: The outcomes of transarterial infusion of
epirubicin and cisplatin combined with systemic infusion
of 5-fluorouracil compared to TACE using doxorubicin
for unresectable hepatocellular carcinoma
Sung Won Lee, Jung Hyun Kwon, Soon woo Nam, Jeong Won
Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
1335: Comparison of Safety and Efficacy of
Chemoembolization for unresectable Hepatocellular
Carcinoma: Doxorubicin-Eluting Beads versus
conventional TACE in Patients With and Without
Transjugular Intrahepatic Portosystemic Shunt
Ali Faramarzalian, KV Narayanan Menon, Baljendra Kapoor,
Amanjit Gill, Gordon McLennan, Amit Gupta, Benjamin Tritle,
Mark J. Sands, Federico N. Aucejo, Robert J. Pelley, Bassam
Estfan, Nancy Obuchowski
1336: Percutaneous thermal ablation for hepatocellular
carcinoma: A systematic review and meta-analysis
Mohamed A. Chinnaratha, Anthony Chuang, Robert Fraser,
Richard J. Woodman, Alan J. Wigg
1337: Serum dickkopf-1, osteopontin and midkine as
novel biomarkers for the diagnosis and pre-clinical
diagnosis of hepatocellular carcinoma
Roslyn Vongsuvanh, Jacob George, Tristan J. Iseli, Simone I.
Strasser, Geoffrey W. McCaughan, David van der Poorten
1338: Surveillance for Hepatocellular Carcinoma with
Magnetic Resonance Imaging Using a Liver-Specific
Contrast Agent Gadoxetic Acid and Ultrasonography in
High-Risk Patients with Cirrhosis
Young-Suk Lim, So Yeon Kim, Jae Ho Byun, Hyung Jin Won, So
NOVEMBER 10
Jung Lee, Seungbong Han, Jihyun An, Han Chu Lee, Yung Sang
MONDAY
Lee
1339: Epithelial to mesenchymal transition affects the
stemness of primary liver cancers
Naoki Oishi, Juling Ji, Taro Yamashita, Qinghai Ye, Shuichi
Kaneko, Xin W. Wang
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1340: Comparison of acute healthcare costs and effects
of Trans-arterial chemo-embolization using conventional
technique with drug eluting beads
Farooq A. Khan, Eleftherios Floros, Guruprasad P. Aithal, Mahal
Gurpreet, Martin W. James, Zergham Zia, Stephen D. Ryder,
Richard O’Neill
1341: Gross appearance of hepatocellular carcinoma
reflects expression of cancer stem cells, epithelial-
mesenchymal transition and hypoxia related genes
Hyungjin Rhee, Deuk Chae Na, Young Nyun Park
1342: Diffusion-weighted MRI is suitable to predict
malignant potential in small hepatocellular carcinoma
Shusuke Okamura, Tatsuyuki Tonan, Shuji Sumie, Masahito
Nakano, Manabu Satani, Ryoko Kuromatsu, Takuji Torimura
1343: Yttrium-90 radioembolization for HCC in the
transplant setting: feasibility, clinical and pathological
considerations. Can we give a better chance for locally
advanced HCC?
Raffaella Lionetti, Andrea Laurenzi, Giovanni Vennarecci, Roberto
Santoro, Marzia Montalbano, Ubaldo Visco Comandini, Elisa Busi
Rizzi, Rosa Sciuto, Pierluca Piselli, Lucia Rosalba Grillo, Gianpiero
D’Offizi, Giuseppe M. Ettorre
1344: Clinical characteristics of hepatocellular
carcinoma in elderly patients: A retrospective,
multicenter study
Naota Taura, Hisamitsu Miyaaki, Kazuhiko Nakao
1345: Hepatocellular carcinoma incidence in chronic
hepatitis C patients according to sustained virologic
response (SVR) and fluctuation of Alfa feto-protein levels
during antiviral treatment
Tuul Purevsambuu, Simona Bota, Florian Hucke, Harald Hofer,
Peter Ferenci, Wolfgang Sieghart, Markus Peck-Radosavljevic
1346: A nationwide all-inclusive analysis demonstrates
a decrease in adjusted survival of incident-cases of
hepatocellular carcinoma (HCC) among HIV+ patients
Nathalie GOUTTE, Philippe Sogni, Noelle Bendersky, Bruno
Falissard, Olivier Farges
1347: First generation protease inhibitor-based triple
therapy and risk of hepatocellular carcinoma
Jonathan M. Fenkel, Gloria Francis, Doris H. Chan, Dina Halegoua-
De Marzio, David A. Sass, Steven K. Herrine, Jesse M. Civan
1348: The Optimal Method for Measuring Intrahepatic
Hepatocellular Carcinomas in Liver Transplant
Candidates Undergoing Lipiodolized Transarterial
Chemoembolization
Hyung-Don Kim, Ju Hyun Shim, Yeonjung Ha, Mi-Jung Jun, Young
Joo Yang, Seung Bum Lee, Gi Ae Kim, Jee Eun Yang, Eui Ju Park,
Jihyun An, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee,
Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1349: Increased incidence but improved survival for
biliary tract cancers in Ontario from 1994-2012: A
population-based study
Jennifer A. Flemming, Senthuran Tharmalingam, Sulaiman Nanji,
Jina Zhang-Salomons, Christopher Booth
1350: Surveillance for hepatocellular carcinoma is
associated with better survival: Results from a large
cohort in the Netherlands
Suzanne van Meer, Robert A. de Man, Minneke Coenraad, Dave
Sprengers, Carin M. Van Nieuwkerk, Martijn van Oijen, Heinz-
Josef Klümpen, Peter L. Jansen, Peter D. Siersema, Karel J. van
Erpecum
1351: Impact of advanced age on the short- and long-
term postoperative outcomes in patients undergoing
hepatectomy for hepatocellular carcinoma
Hiroaki Motoyama, Akira Kobayashi, Takahide Yokoyama, Akira
Shimizu, Norihiko Furusawa, Hiroshi Sakai, Noriyuki Kitagawa,
Takuma Arai, Tomoki Shirota, Shinichi Miyagawa
1352: Systematic Identification of Long Intergenic Non-
coding RNAs expressed in Hepatocellular Carcinoma
Yuji Zhang, Asha Nair, Lewis R. Roberts, Tushar Patel
1353: ω-3 Polyunsaturated Fatty Acids Regulate the
Expression of 15-PGDH through miRNA26a and
miRNA26b in Cholangiocarcinoma
Lu Yao, Chang Han, Kyoungsub Song, Kyu Lim, Tong Wu
1354: Analytic Morphomics Improves the Prediction of
Survival in Patients with Hepatocellular Carcinoma
Peng Zhang, Pratima Sharma, Pranab Barman, Neehar D. Parikh,
Sampath kumar Santhanam Ethiraj, Venkat Krishnamurthy, Lu
Wang, Stewart C. Wang, Grace L. Su
1355: The Effect of Demographics and Socio-Economic
Factors on Survival in Metastatic Neuroendocrine
Tumors: a Surveillance, Epidemiology and End Results
(SEER) Population Study
Minzhi Xing, Nima Kokabi, Juan C. Camacho, Hyun S. Kim
1356: Clinical outcomes of early to intermediate
hepatocellular carcinoma treated with Trans-Arterial
chemoembolization versus Radiofrequency ablation
Wei Rong, Benjamin Tay, Jia Chen Lim, Alfred W. Kow, Shridhar
G. Iyer, Kin Yong, Stephen Stephen, Chern Hao Chong, Maureen
Da Costa, Krishnakumar Madhavan, Seng Gee Lim, Yock Young
Dan
1357: Inflammatory bowel disease (IBD) is a risk factor
for extrahepatic cholangiocarcinoma (ECC) in subjects
without underlying primary sclerosing cholangitis (PSC)
Hassan M. Ghoz, Esha Baichoo, Benyam D. Addissie, Lewis R.
Roberts, Roongruedee Chaiteerakij
Poster Viewing: 8:00 AM – 5:30 PM
155A
1358: There are significant differences in the risk factors
for perihilar cholangiocarcinoma (CCA) compared to
distal CCA: Rationale for approaching them as distinct
entities
Hassan M. Ghoz, Esha Baichoo, Benyam D. Addissie, Lewis R.
Roberts, Roongruedee Chaiteerakij
1359: Radiofrequency ablation of solid tumors in
combination with bortezomib causes ER-stress
Thaddaeus T. Wissniowski, Deike Strobel, Daniel Neureiter,
Thomas Gress, Patrick Michl, Pietro Di Fazio
1360: Clinical outcomes of intraoperative
radiofrequency ablation for primary hepatocelluar
carcinoma ineligible for percutaneous radiofrequency
ablation or surgical resection
Eun Chung, Jung Hyun Kwon, Soon woo Nam, Young Woon Kim,
Sung Won Lee, Young chul Yoon
1361: Ten-Year Outcomes of Cryoablation Therapy
for Small Hepatocellular Carcinoma and Child–Pugh
Class A or B Cirrhosis: A Single Center Large Cohort
Experience
Guanghua Rong, Wenlin Bai, Zheng Dong, Chunping Wang, Yin
Ying Lu, Ke-Qin Hu, Yongping Yang
1362: Prognostic factors for patients with recurrent
hepatocellular carcinoma following liver transplant. A
Euro-American study
Gonzalo Sapisochin, Nicolas Goldaracena, Santiago Astete,
Duncan Davidson, Rafael Ehab, Lluis Castells, Charbel Sandroussi,
Itxarone Bilbao, Les Lilly, Cristina Dopazo, Anand Ghanekar, Ian
McGilvray, Mark Cattral, Markus Selzner, David Grant, Ramon
Charco, Paul Greig
1363: Prognostic Significance of Hepatic Venous
Pressure Gradient in the Prediction of Hepatocellular
Carcinoma
Eun Jin Kim, Ki Tae Suk, Hyo Sun Kim, Sang Hyun Park, Chang
Seok Bang, Ji Won Park, Choong Kee Park, Sung Eun Kim,
Hyoung Su Kim, Myoung Kuk Jang, Sang Hoon Park, Myung Seok
Lee, Dong Joon Kim
1364: Eukaryotic elongation factor 2 is a prognostic
marker and its kinase a potential drug target in
hepatocellular carcinoma
Leona L. Pott, Henning Reis, Barbara Sitek, Hideo A. Baba
NOVEMBER 10
1365: A Prospective Randomized Study Comparing
MONDAY
Radiofrequency Ablation and Hepatic Resection for
Hepatocellular Carcinoma
Hae Won Lee, Kyung-Suk Suh, Hyeyoung Kim, YoungRok Choi,
Suk-Won Suh, Jaehong Jeong, Nam-Joon Yi, Kwang-Woong Lee
1366: Increased level of nucleolin confers to aggressive
tumor progression and poor prognosis in patients with
hepatocellular carcinoma after hepatectomy
Xiaodong Guo, Lingxiang Yu, Jinghui Dong, Ruisheng Li, Boan Li,
Huiqiang Liu, Mei Yang, Jingmin Zhao
Presenters in Attendance 12:30 – 2:00 PM
 156A POSTER SESSIONS
Poster Sessions
1367: A retrospective review of Hepatocellular
Carcinoma surveillance in 3 United Kingdom teaching
hospitals
Henry House, Nowlan Selvapatt, Ashley S. Brown
1368: ABSTRACT Survival of hepatocellular carcinoma
in patients with normal liver versus underlying cirrhosis:
Results from a large cohort in the Netherlands
Suzanne van Meer, Karel J. van Erpecum, Joanne Verheij, Minneke
Coenraad, Dave Sprengers, Carin M. Van Nieuwkerk, Heinz-Josef
Klümpen, Peter L. Jansen, Peter D. Siersema, Robert A. de Man
1369: A preclinical study of EpCAM-targeted therapy
for human hepatocellular carcinoma with stem cell
features
Shinji Tanaka, Kousuke Ogawa, Satoshi Matsumura, Arihiro
Aihara, Daisuke Ban, Takanori Ochiai, Takumi Irie, Atsushi Kudo,
Shigeki Arii, Minoru Tanabe
1370: Screening and Management of Hepatocellular
Carcinoma. Report of a Global Survey
Dalbir S. Sandhu, Antonio J. Sanchez
1371: Calculating the growth rate of small
hepatocellular carcinoma: implications for surveillance
and treatment
Ian A. Rowe, Debashis Haldar, Diarmaid D. Houlihan, Shishir
Shetty, Hynek Mergental, Tahir Shah
1372: Subgroup Analysis of Patients with HIV+HCC
Among a Cohort of 2322 Veterans Diagnosed with
Hepatocellular Carcinoma (HCC) from 2008-2010
David E. Kaplan, Ayse Aytaman, Michelle Baytarian, Kathryn
D’Addeo, Feng Dai, Rena K. Fox, Kristel K. Hunt, Astrid Knott, Rajni
Mehta, Marcos Pedrosa, Christine Pocha, Melissa Skanderson,
Adriana Valderama, Tamar H. Taddei
1373: Treatment outcome of Radiofrequency ablation
as first line treatment for Hepatocellular carcinoma
in Milan criteria : Analysis of 510 patients in a single
center
Se Young Jang, Soo Young Park, Won Young Tak, Young Oh
Kweon, Su Hyun Lee, Jung Gil Park
1374: High alpha-fetoprotein levels and presence of
clinically significant portal hypertension represent risk
factors for hepatocellular carcinoma development in
cirrhotic patients
NOVEMBER 10
Simona Bota, Florian Hucke, Matthias Pinter, Mattias Mandorfer,
MONDAY
Thomas Reiberger, Arnulf Ferlitsch, Michael Trauner, Wolfgang
Sieghart, Markus Peck-Radosavljevic
1375: Impact of surveillance on the survival of
patients with hepatocellular carcinoma: results from a
longitudinal study in Taiwan
Diana Chirovsky, Kristen Hassmiller Lich, Alfred S. Barritt, Pei-Jer
Chen, Stephanie B. Wheeler, Lucinda S. Orsini, Andrea K. Biddle
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1376: Hypercoagulability in cirrhotic patients with
hepatocellular carcinoma (HCC) and portal vein
thrombosis (PVT)
Alberto Zanetto, Alberto Ferrarese, Kryssia I. Rodriguez, Veronica
Pepe, Mariangela Fadin, Claudia M. Radu, Sabrina Gavasso,
Alessandro Vitale, Umberto Cillo, Fabio Farinati, Francesco P.
Russo, Giacomo Germani, Elena Nadal, Paolo Simioni, Patrizia
Burra, Marco Senzolo
1377: Clinical outcomes in patients who develop
hepatocellular carcinoma after hepatitis C viral
eradication by antiviral therapy
Kaoru Tsuchiya, Yutaka Yasui, Nobuharu Tamaki, Shoko Suzuki,
Takanori Hosokawa, Hiroyuki Nakanishi, Jun Itakura, Yuka
Takahashi, Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi
1378: Absence of thrombocytopenia is correlated with
decreased survival in patients with advanced liver
disease and hepatocellular carcinoma
Marco Senzolo, Alessandro Vitale, Edoardo G. Giannini, Teh-Ia
Huo, Franco Trevisani, Fabio Farinati
1379: Beneficial effects of oral branched-chain amino
acid supplementation after local therapy for liver cancer
Shunsuke Nojiri, Kei Fujiwara, Noboru Shinkai, Etsuko Iio, Takashi
Joh
1380: Doubling Time of Des-gamma-carboxy
Prothrombin Can be Useful as a Prognostic Marker for
Hepatocellular Carcinoma
Nobuyuki Matsumoto, Hiroki Ikeda, Yohei Noguchi, Ryuta
Shigefuku, Kotaro Matsunaga, Chiaki Okuse, Michihiro Suzuki,
Fumio Itoh
1381: Role of Primovist-MR Imaging on Preoperative
Assessment of the Risk of Postoperative Liver Failure in
Patients with Hepatocellular Carcinoma
Sin-Il Kim, Young-Joo Jin, Soon Gu Cho, Ah Rhm Woo, Jin-Woo
Lee, Young Soo Kim
1382: Obesity and alfa-fetoprotein predict presence of
histopathologic features associated with hepatocellular
carcinoma recurrence after liver transplantation
Vinay Sundaram, Anish V. Patel, Alagappan A. Annamalai, Walid
S. Ayoub, Tram T. Tran, Andrew S. Klein
1383: Tumor volume doubling time in hepatocellular
carcinoma: a systematic literature review and meta-
analysis
Diana Chirovsky, Andrea K. Biddle, Richard C. Semelka, Kristen
Hassmiller Lich, Stephanie B. Wheeler, Lucinda S. Orsini, Alfred
S. Barritt
1384: Adherence to Hepatocellular Carcinoma
Diagnostic Guidelines: Single Veterans Affairs Medical
Center (VAMC) Experience
Thoetchai Peeraphatdit, Niyada Naksuk, Paola Ricci
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1385: Early response prediction of hepatocellular
carcinoma to conventional transcatheter
chemoembolization using intraprocedual plain cone-
beam CT
Yasunori Minami, Masatoshi Kudo
1386: Phase 2 trial of temozolomide and veliparib
combination therapy for sorafenib-refractory advanced
hepatocellular carcinoma (HCC)
Aiwu R. He, Narayan Shivapurkar, Anteneh A. Tesfaye, HongKun
Wang, Michael J. Pishvaian, Brandon G. Smaglo, John Marshall,
Karen Dorsch-Vogel, Jaydeep Kachhela
1387: WITHDRAWN
1388: Additive anti-Tumor Response to the Rabbit VX2
Hepatoma by Combined Radio Frequency Ablation and
Toll like Receptor 9 Stimulation
Barbara Behm, Pietro Di Fazio, Daniel Neureiter, Thomas Gress,
Patrick Michl, Detlef Schuppan, Thaddaeus T. Wissniowski
1389: Survival Benefit of Long-Term Sorafenib
Treatment in Patients with Advanced Hepatocellular
Carcinoma in Indonesia: Multicenter experience
Cosmas R. Lesmana, Rino A. Gani, Levina S. Pakasi, Irsan Hasan,
Agus S. Waspodo, Lianda Siregar, Poernomo Budi, Laurentius A.
Lesmana
1390: Trends and Patterns of Treatment for
Hepatocellular carcinoma in Korea
Youngmi Hong, Mong Cho, Ki Tae Yoon, Daehwan Kang,
Hyungwook Kim, Cheol Woong Choi, SuBum Park, Jeong Heo,
Hyun Young Woo, Won Lim
1391: HIV Viral Load Independently Predicts Survival
in HIV-Infected Patients With Hepatocellular Carcinoma
(HCC)
Caitlin C. Citti, Heather L. Platt, Maaz B. Badshah, Ting-Yi Chen,
Luciana Kikuchi, Meritxell Ventura-Cots, Noami Chaudhary,
Sonja Marcus, Michael Yin, Ayse Aytaman, Judith Aberg, Myron
Schwartz, Douglas Dieterich, Yujin Hoshida, Norbert Bräu
1392: Complete response at the first chemoembolization
is still the most robust factor for favorable outcome in
hepatocellular carcinoma
Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park,
Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han
1393: Radiofrequency ablation for initial recurrent
hepatocellular carcinoma after curative treatment:
Compared with primary cases
Takayuki Fukuhara, Hiroshi Aikata, Yohji Honda, Hiromi Kan,
Tomoki Kobayashi, Noriaki Naeshiro, Daisuke Miyaki, Tomokazu
Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura,
Hideyuki Hyogo, Yoshiiku Kawakami, C. Nelson Hayes, Kazuaki
Chayama
Poster Viewing: 8:00 AM – 5:30 PM
157A
1394: Retrospective Cohort study for liver
carcinogenesis prediction using VF map score : Virtual
Touch Quantification(VTQ), Fasting blood glucose(FBG),
male, age, platelet
Tomoko Aoki, Shuhei Nishiguchi, Chikage Nakano, Kenji
Hashimoto, Akio Ishii, Tomoyuki Takashima, Nobuhiro Aizawa,
Yoshiyuki Sakai, Naoto Ikeda, Hironori Tanaka, Yoshinori Iwata,
Hirayuki Enomoto, Masaki Saito, Jiro Fujimoto, Seiichi Hirota,
Hiroko Iijima
1395: Prognostic value of the Barcelona Clinic Liver
Cancer staging subclassification system for conventional
transarterial chemoembolization
Yutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, Koichi Gondou,
Natsuko Nakakuki, Hitomi Takada, Shuya Matsuda, Yu Asano,
Nobuhiro Hattori, Nobuharu Tamaki, Shoko Suzuki, Takanori
Hosokawa, Hiroyuki Nakanishi, Jun Itakura, Namiki Izumi
1396: Autophagy may be an early event in the stepwise
carcinogenesis via biliary intraepithelial neoplasia in
cholangiocarcinoma associated with hepatolithiasis
Motoko Sasaki, Takeo Nitta, Yasunori Sato, Yasuni Nakanuma
1397: In vitro validation of human glypican-3 specific
chimeric antigen receptors for hepatocellular carcinoma
Yonghai Li, David E. Kaplan
1398: The role of gut commensal bacteria in anti-tumor
effect of chemotherapy for hepatocellular carcinoma
Noriho Iida, Eishiro Mizukoshi, Tatsuya Yamashita, Shuichi
Kaneko
1399: Management of hepatocellular carcinoma in
elderly patients: an Italian “in field” experience
Elena Dionigi, Mauro Borzio, Angelo Rossini, Anna Toldi,
Giampiero Francica, Fabio Fornari, Andrea Salmi, Fabio Farinati,
Susanna Vicari, Massimo Marignani, Giancarlo Parisi, Fulvia
Terracciano, Ilario de Sio, Rodolfo Sacco
1400: Vascularization of hepatocellular adenomas and
carcinomas by co-option of portal tracts
Ashley E. Stueck, Masayuki Nakano, Ian R. Wanless
1401: Prognostic Assessment of Patients with Untreated
Hepatocellular Carcinoma
Edoardo G. Giannini, Fabio Farinati, Francesca Ciccarese, Anna
Pecorelli, Gian Ludovico Rapaccini, Mariella Di Marco, Eugenio
Caturelli, Marco Zoli, Franco Borzio, Franco Trevisani
NOVEMBER 10
MONDAY
1402: Clinical Impact of Additional Interferon
Administration on Sorafenib-treated Patients with
Recurrent Advanced Hepatocellular Carcinoma
Hisakazu Doi
1403: How Is BCLC Stage C HCC Treated In Real-Word
Practice And What Outcomes Are Obtained?
Sasan Roayaie, Ghalib Jibara, Parissa Tabrizian, Joong-Won Park,
Jijin Yang, Lunan Yan, Guohong Han, Francesco Izzo, Minshan
Chen, Jean-Frédéric Blanc, Phillip Johnson, Masatoshi Kudo, Lewis
R. Roberts, Morris Sherman
Presenters in Attendance 12:30 – 2:00 PM
 158A POSTER SESSIONS
Poster Sessions
1404: Characteristics and prognosis of hepatocellular
carcinoma after sustained virological response to
interferon therapy for hepatitis C
Koichi Honda, Masataka Seike, Junya Oribe, Mizuki Endo, Mie
Yoshihara, Hiroki Syo, Masao Iwao, Masanori Tokoro, Tetsu Mori,
Tsutomu Yamashita, Toyokichi Muro, Kazunari Murakami
1405: The decrease of alpha-fetoprotein and/or the
decrease of tumor stain on contrast enhanced CT
images after 2 weeks of sorafenib treatment predict
prognosis in patients with advanced hepatocellular
carcinoma
Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda,
Kazuhiko Hayashi, Tetsuya Ishikawa, Hidemi Goto
1406: Incidental Microscopic Bile Duct Tumor Thrombi in
Hepatocellular Carcinoma after Curative Hepatectomy:
A Matched Study
Jong Man Kim, Ju-Yeon Cho, Geum Youn Gwak, Choon Hyuck
D. Kwon, Moon Seok Choi, Joon Hyeok Lee, Jae Won Joh, Seung
Woon Paik, Cheol Keun Park, Byung Chul Yoo
1407: Staged Doxorubicin Eluting Bead Transarterial
Chemoembolization Therapy for Unresectable
Hepatocellular Carcinoma Confers to Survival
Advantage with Preservation of Quality of Life
Minzhi Xing, Hasmukh J. Prajapati, Grant R. Webber, Hyun S. Kim
1408: Factors affecting tolerability of Yttrium-90
Radioembolization in patients with advanced
hepatocellular carcinoma – A large single center
analysis
Bahar Madani, Ashwini P. Mehta, Parvez S. Mantry, Carlos G.
Fasola, Aden Tadelle, Islam Shahin, Alejandro Mejia, Hector
Nazario, Jeffrey S. Weinstein, Maisha Barnes, Adil Habib,
Abdullah Mubarak, Steve Cheng
1409: Transarterial chemoembolization (TACE) caused
hypoxia may trigger a progenitor cell phenotype in
hepatocellular carcinoma (HCC)
Jinping Lai, Beatrice Knudsen, Maha Guindi
1410: Does Liver Regeneration Increase the
Postoperative Recurrence after Curative Resection of
Hepatocellular Carcinoma?
Jin Ho Lee, Gi Hong Choi, Dai Hoon Han, Jin Sub Choi
1411: Cancer Registries Underestimate Hepatocellular
NOVEMBER 10
Carcinoma Incidence: An Independent Population-Based
MONDAY
Epidemiological Study
Thai Hong, Alexander J. Thompson, Paul Gow, Michael A. Fink,
Anouk T. Dev, Virginia H. Knight, Marno C. Ryan, Ian Kronborg,
Niranjan J. Arachchi, Stuart K. Roberts, William W. Kemp,
Amanda J. Nicoll, John Lubel, Helen Farrugia, Vicky Thursfield,
Paul V. Desmond, Sally Bell
1412: Statins and metformin use improve prognosis
after diagnosis of hepatocelullar carcinoma
Javier Ampuero, Raquel Calle, Blanca Figueruela, Paula Ferrero,
Emilio Suarez, Manuel Romero-Gomez
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1413: Interleukin-8 level as predictive marker
for treatment response after transarterial
chemoembolization in hepatocellular carcinoma
Joohan Park, Soon Sun Kim, Hyo Jung Cho, Sun Young Park, Seon
Joo Ahn, Jae Youn Cheong, Sung Won Cho
1414: Predisposing factors for development of
hepatocellular carcinoma in chronically infected
hepatitis C virus patients who underwent pegylated
interferon plus ribavirin
Sin-Il Kim, Young-Joo Jin, Jihye Jang, Jin-Woo Lee, Young Soo Kim
1415: Does a Multidisciplinary Team (MDT) change
management in Hepatocellular Carcinoma (HCC)? A
Single Center Experience
Pierre M. Gholam, Anthony B. Post, Stanley M. Cohen, Kenneth
J. Woodside, Vanessa Humphreville, Badar Muneer, Edmund Q.
Sanchez, Christopher T. Siegel
1416: Selective Internal Radiation Therapy(SIRT) Using
Yttrium-90 In Patients With Advanced Hepatocellular
Carcinoma: A Large Single Center Experience
Bahar Madani, Ashwini P. Mehta, Parvez S. Mantry, Carlos G.
Fasola, Aden Tadelle, Islam Shahin, Alejandro Mejia, Hector
Nazario, Jeff Weinstein, Maisha Barnes, Adil Habib, Abdullah
Mubarak, Steve Cheng
1417: Array-based gene expression analysis of M1/
M2-polarized macrophages during treatment with multi-
kinase inhibitor Sorafenib
Martin F. Sprinzl, Jens U. Marquardt, Brigitte Bartsch, Hauke Lang,
Arndt Weinmann, Peter R. Galle
1418: Nuclear to Cytoplasmic Translocation of FOXO3
Determines the Sensitivity of Human Hepatocellular
Carcinoma to Doxorubicin
Josiah Cox, Anusha Vittal, Maura O’Neil, Zhuan Li, Sudhakiranmayi
Kuravi, Brian Bridges, Ahmad B. Abdulkarim, Steven A. Weinman
1419: Heterogeneity in risk factors and treatment
allocation, but comparable clinical presentation and
survival with hepatocellular carcinoma (HCC) among the
three largest Asian sub-populations in California
Channa R. Jayasekera, Lily H. Kim, James M. Wantuck, Benjamin
Yip, Mindie H. Nguyen
1420: Biphenotypic Tumors: Assessing Outcomes of
Hepatic Directed Therapies
Kathryn Fowler, Nael Saad, Elizabeth M. Brunt, Manik Amin,
Neeta Vachharajani, Maria Bernadetta Doyle, Benjamin Tan,
William C. Chapman
1421: Aberrant expression of microRNA according to
aging is participating in hepatocarcinogenesis
Yoshiki Murakami, Saori Itami, Hidenori Toyoda, Takashi Kumada,
Toshihito Tanahashi, Etsushi Kawamura, Atsushi Hagihara,
Sawako K. Uchida, Hiroyasu Morikawa, Masaru Enomoto, Akihiro
Tamori, Norifumi Kawada, Y-h Taguchi
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1422: Prognostic influence of spontaneous tumor
rupture on resectable hepatocellular carcinoma
Chan Albert, Ronnie T. Poon, Tan To Cheung, Kenneth S. Chok,
Sheung Tat Fan, Chung Mau Lo
1423: Occurrence of Hepatocellular Carcinoma Is
Comparable in Chronic HBV Infectors Treated with
Different Nucleos(t)ide Analogues: A 6-year Retro- and
Prospective Real World Cohort Study
Yuankai Wu, Xiangyong Li, Mingxing Huang, Guoli Lin, Shu-ru
Chen, Hong Shi, Yusheng Jie, Xin-Hua Li, Fangji Yang, Min Zhang,
Yunlong Ao, Yihua Pang, Yutian Chong
1424: Real-life Data of Sorafenib in Unresectable
Hepatocellular Carcinoma: Retrospective Analysis of
511 Consecutive Patients Treated with Sorafenib in a
Single Tertiary Referral Center
Yeonjung Ha, Hyung-Don Kim, Mi-Jung Jun, Young Joo Yang,
Seung Bum Lee, Jee Eun Yang, Gi Ae Kim, Eui Ju Park, Jihyun An,
Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu
Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh
1425: Etiological roles of diabetes, BMI and past
hepatitis B infection in the development of non-B non-C,
non-alcoholic hepatocellular carcinoma
Hae Lim Lee, Nam Ik Han, Sang Wook Choi, Joon-Yeol Han, Se
Hyun Cho, Jin-Mo Yang
1426: Decreased expression of PBLD correlates with a
poor prognosis and functions as a tumor suppressor in
human hepatocellular carcinoma
Aimin Li, Qun Yan, Side Liu, Yu Qiang Nie
1427: HBV DNA / Quantitative HBsAg Level Ratio,
but Not Either Quantitative HBsAg Level or HBV DNA,
Can Predict Hepatocellular Carcinoma Development in
HBeAg-Negative Chronic Hepatitis Patients with HBV
DNA ≥ 2000 IU/mL
Jem ma Ahn, Dong Hyun Sinn, Ju Yeon Cho, Won Sohn, Geum-
Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee,
Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
1428: Radiofrequency ablation with or without
transcatheter arterial chemoembolization for small
hepatocellular carcinoma; a propensity analysis
Hee Yeon Kim, Chang Wook Kim, Yu Seung Kim, Seung Kew
Yoon, Jong Young Choi, Si Hyun Bae, Chang Don Lee
1429: The importance of intrahepatic tumor in
hepatocellular carcinoma with extrahepatic spread in
patients treated with sorafenib
Won Sohn, Yong-Han Paik, Ju Yeon Cho, Jem-Ma Ahn, Dong
Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee,
Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
Poster Viewing: 8:00 AM – 5:30 PM
159A
1430: Effect of hepatitis B virus reactivation on the
recurrence of HBV-related hepatocellular carcinoma
after curative resection in patients with low viral load
Won Sohn, Yong-Han Paik, Ju Yeon Cho, Jong Man Kim, Choon
Hyuck D. Kwon, Jae Won Joh, Jem-Ma Ahn, Dong Hyun Sinn,
Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang
Cheol Koh, Seung Woon Paik, Byung Chul Yoo
1431: Sorafenib combined with hepatectomy in patients
with intermediate-stage and advanced hepatocellular
carcinoma
Lei Zhuang, Tianfu Wen, Mingqing Xu, Jiayin Yang, Wentao
Wang, Hong Wu, Lvnan Yan, Yonggang Wei, Bo Li
1432: Isolated Hepatitis B core Antibody positivity: a
potential risk factor for liver cancer
Linda L. Wong, Marina Roytman, Naoky Tsai
1433: The serum alpha-fetoprotein as predictor
of tumor recurrence after liver transplantation for
hepatocellular carcinoma
Luciana S. Schraiber, Angelo A. Mattos, Maria L. Zanotelli,
Guido Pio G. Cantisani, Ajacio B. Brandão, Claudio A. Marroni,
Guilhermo Kiss, Lucas Ernani, Livia C. Lionco
1434: Liver transplant for hepatocellular carcinoma
(HCC). Are we missing some factors in the procedure’s
outcomes? Single center 3-year experience
Rinjal Brahmbhatt, Lokesh K. Jha, Fedja A. Rochling, Daniel F.
Schafer, Timothy M. McCashland, Diana Gomez-Martin, Marco
A. Olivera-Martinez
1435: Impact of Underlying Liver Disease, Tumor
Burden and Performance Status on Survival after
Selective Internal Radiation Therapy: A Large Single
Center Experience
Parvez S. Mantry, Bahar Madani, Ashwini P. Mehta, Aden Tadelle,
Carlos Fasola, Islam Shahin, Hector Nazario, Alejandro Mejia,
Jeffrey S. Weinstein, Abdullah Mubarak, Steve Cheng
1436: Relationship between the mitochondria gene
abnormality in liver tissues in patients with chronic viral
hepatitis C and the hepatocarcinogenesis
Nobuhiro Aizawa, Chikage Nakano, Kunihiro Hasegawa, Ryo
Takata, Tomoko Aoki, Kenji Hashimoto, Akio Ishii, Tomoyuki
Takashima, Yoshiyuki Sakai, Naoto Ikeda, Hironori Tanaka,
Yoshinori Iwata, Hirayuki Enomoto, Masaki Saito, Hiroko Iijima,
Yuji Iimuro, Jiro Fujimoto, Shuhei Nishiguchi
NOVEMBER 10
MONDAY
1437: Down-staging of hepatocellular carcinoma
tumors at liver transplant centers in the United States
She-Yan Wong, Dina Halegoua-De Marzio, Jesse M. Civan
1438: Noninvasive Fibrosis Panels are more useful than
Inflammatory Markers for Prediction of Hepatocellular
carcinoma Recurrence after Radiofrequency ablation
Jeong Han Kim, Won Hyeok Choe, So Young Kwon
Presenters in Attendance 12:30 – 2:00 PM
 160A POSTER SESSIONS
Poster Sessions
Cost-Effectiveness
1439: Modeling Cost Avoidance For Preventing Disease
Progression In Hepatitis C Patients
Chris M. Kozma, Andrew Paris, George Wan
1440: Comorbidity and Resource Utilization in Older
Liver Transplant Recipients
Nyingi M. Kemmer, Chris Albers, Edson S. Franco, Husssein
Osman-Mohamed, Elizabeth Cece Fallon, Erin Parkinson, Jennifer
Horkan, Angel Alsina
1441: Insurance Approval Patterns for Second
Generation DAAs
Fredric D. Gordon, Amir A. Qamar, Patricia M. Hogan, Lois V.
Daponte, Mary Ann Simpson
1442: Patient-Reported Outcomes (PROs) in HIV-HCV
Co-infected Patients Treated with Sofosbuvir (SOF)-
containing Regimens
Zobair Younossi, Maria Stepanova, Mark S. Sulkowski, Susanna
Naggie, Sharon L. Hunt
1443: Cost-effectiveness of Telbivudine Renoprotection
in Chronic Hepatitis B Liver Cirrhosis
Yock Young Dan, Seng Gee Lim
1444: Regional disparities in total hospital charges for
the treatment of inpatients with alcoholic hepatitis in the
United States
Folasade P. May, Vineet Syan, Ashwini Lakshmanan, Vinay
Sundaram
HCV: Diagnostics, Epidemiology, and
Natural History
1445: Sustained Virologic Response with Ledipasvir
(LDV) and Sofosbuvir (SOF) Regimens Leads to
Substantial Improvement in Patient-Reported Outcomes
(PROs) Among Chronic Hepatitis C (CHC) Patients with
Early Hepatic Fibrosis as Well as Those with Advanced
Hepatic Fibrosis
Zobair Younossi, Maria Stepanova, Patrick Marcellin, Nezam H.
Afdhal, Kris V. Kowdley, Stefan Zeuzem, Sharon L. Hunt
1446: The Significance of NA5A-Y93H Mutation
NOVEMBER 10
Evaluated by a Novel Simple Assay System Using
MONDAY
Cycling Probe-Based Real-Time PCR in Patients with
HCV Infection
Yoshihito Uchida, Jun-ichi Kouyama, Kayoko Naiki, Satoshi
Mochida
1447: HCV Screening of “Baby Boomers” Increased
Significantly Following 2012 CDC Call to Action, But
Screening Rate Fell in Non-Baby Boomers: Results of a
Nationwide Lab Test Database Analysis
Carol Smyth, Jason Bhan, Tatiana Sorokina, Ajitpal S. Dhaliwal,
Nancy Reau
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1448: Check Hep C: A Community-Based Approach to
Hepatitis C Diagnosis in High-Risk Populations
Mary Ford, Ashly Jordan, Eric J. Rude, Nirah Johnson, Holly
Hagan, Fabienne Laraque, Jay K. Varma
1449: Historical and geographical trends in hepatitis C
virus (HCV) incident infection among people who inject
drugs: The International Collaboration on Incident HCV
and HIV Infection among PWID (InC3 Study)
Meghan D. Morris, Thomas M. Rice, Stephen Shiboski, Julie
Bruneau, Andrea Cox, Gregory J. Dore, Jason Grebely, Judith
A. Hahn, Arthur Y. Kim, Andrew R. Lloyd, Margaret Hellard, Lisa
Maher, Barbara H. McGovern, Maria Prins, Kimberly Page
1450: Senior Center Based Hepatitis C Screening in
Baltimore
Oluwaseun Falade-Nwulia, Risha Irvin, Ayesha M. McAdams-
Mahmoud, Shruti H. Mehta, Jackline Joy M. Lasola, Dorcas
Baker, Arnold Eppel, Patrick Chaulk, Kathleen R. Page, Mark S.
Sulkowski, David L. Thomas
1451: Impact of Hepatitis E Virus Seropositivity on
Chronic Liver Disease of Cancer Patients with Hepatitis C
Virus Infection
Andreas Kyvernitakis, Parag Mahale, Jiang Ying, Harrys A. Torres
1452: Add-on of Boceprevir in HIV-positive Patients
with Genotype 1 Acute Hepatitis C at high Risk for
Treatment Failure
Mattias Mandorfer, Sebastian Steiner, Philipp Schwabl, Berit
A. Payer, Maximilian C. Aichelburg, Gerold Lang, Katharina
Grabmeier-Pfistershammer, Michael Trauner, Markus Peck-
Radosavljevic, Thomas Reiberger
1453: The prevalence of naturally occurring resistance
mutations against NS3 protease inhibitors, NS5A
replication complex inhibitors, and NS5B polymerase
inhibitors in patients with hepatitis C virus genotype 1b
Kazuhiko Hayashi, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya,
Takashi Honda, Yoshiaki Katano, Yoshiki Hirooka, Hidemi Goto
1454: Next-generation sequencing revealed the
prevalence of multi-geno/subtypic multiple infection of
hepatitis C virus in hemophiliac patients in Japan
Masato Ogishi, Hiroshi Yotsuyanagi, Takeya Tsutsumi, Hiroyuki
Gatanaga, Kyoji Moriya, Kazuhiko Koike
1455: Health-related quality of life (HRQOL) is not
negatively impacted by therapy of MK-5172/MK-8742
during treatment of genotype (GT) 1 chronic hepatitis
C in contrast to pegylated-interferon (IFN) or ribavirin
(RBV)-containing therapy
Jean Marie Arduino, Boan Zhang, Chizoba Nwankwo, Shazia
Khawaja, Melissa Shaughnessy, Isaias N. Gendrano, Peggy
Hwang, Michael Robertson, Niloufar Mobashery, Barbara A.
Haber
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1456: Preliminary Assessment of Hepatitis C Antibody
Testing in the United States Before and After Publication
of CDC Screening Recommendations
Monina Klevens, Xiaohua Huang, Daulati Thakare, Anthony E.
Yeo, Mouneer Odeh, John W. Ward
1457: Patterns of hepatitis C virus RNA levels during
acute infection: the InC3 study
Behzad Hajarizadeh, Bart P. Grady, Kimberly Page, Arthur Y.
Kim, Barbara H. McGovern, Andrea Cox, Thomas M. Rice, Rachel
Sacks-Davis, Julie Bruneau, Meghan D. Morris, Janaki Amin, Janke
Schinkel, Tanya L. Applegate, Lisa Maher, Margaret Hellard,
Andrew R. Lloyd, Maria Prins, Gregory J. Dore, Jason Grebely
1458: Failure of Perinatal Hepatitis C Testing:
Philadelphia, 2011 - 2013
Danica Kuncio, Kendra Viner, Claire Newbern
1459: If You Build It, They Will Come: Preliminary
Results of the ACTonHCV Online Educational Program
Sue Currie, Joy A. Peter, HoChong Gilles, Vincent Keane, Janeil
Klett, Julie A. Deal, Norah Terrault, Guadalupe Garcia-Tsao
1460: HCV Awareness, Risk Assessment, and
Healthcare Utilization Among “Baby Boomers”
Presenting to the Emergency Department
Derek E. Wells, Grace N. Cain, Charles T. Prickett, Ricardo A.
Franco, Jordan M. Forsythe, Joel B. Rodgers, James W. Galbraith
1461: Improving HCV care cascade outcomes in a
community-based testing program by providing same
day confirmatory testing and patient navigation
Stacey B. Trooskin, Hwajin Lee, Joanna Poceta, Caitlin Towey,
Sophie C. Feller, Annajane Yolken, Najia Luqman, Ta-Wanda
Preston, Erin Smith, Amy Nunn
1462: The Different Incidences of HCV Genotypes Using
Two Different Regions of Classification: 5’NC and NS5B
in Vietnamese Patients at Medic Medical Center
Thu Thuy Pham Thi, Tan Dat Ho, Bao Toan Nguyen
1463: Factors Associated with Hepatitis C Treatment
Eligibility
Shari S. Rogal, Ada O. Youk, Michael K. Chapko, Barbara H.
Hanusa, Robert A. Arnold, Galen E. Switzer, Mary Ann Sevick,
Nichole K. Bayliss, Carolyn L. Zook, David S. Obrosky, Susan
Zickmund
1464: Association between (TA)n dinucleotide repeat
near IL28B gene and HCV spontaneous clearance in
Japanese and African American
Masaya Sugiyama, Satoshi Hiramine, Norihiro Furusyo, Akio
Ido, Hirohito Tsubouchi, Hisayoshi Watanabe, Yoshiyuki Ueno,
Masaaki Korenaga, Kazumoto Murata, Naohiko Masaki, Tatsuya
Kanto, Jun Hayashi, David L. Thomas, Masashi Mizokami
1465: An Innovative, Scalable and Sustainable Model
to Routinize HCV Testing and Linkage to Care in Five
Federally Qualified Health Centers
Catelyn Coyle
Poster Viewing: 8:00 AM – 5:30 PM
161A
1466: Unregulated Tattooing in an Urban Cohort: An
Analysis of Age, Gender, Risk Knowledge and Risk
Perception
Audun Lier, Amy Nunn, Sophie C. Feller, Caitlin Towey, Joanna
Poceta, Hwajin Lee, Gladys L. Thomas, Stacey B. Trooskin
1467: Overestimate of Fibrosis by FIBROSpect II in
African Americans Complicates Management of their
Chronic Hepatitis C
Paul Naylor, Maher Tama, Suhag Patel, Dhiraj Gulati, Johnny
Altawil, Karthik Ravindran, Murray N. Ehrinpreis, Milton G.
Mutchnick
1468: HCV-positive women of child-bearing age
have premature ovarian senescence, associated with
reproductive failure and more severe hepatic fibrosis
Aimilia Karampatou, Alessia Ciancio, Laura Turco, Enrica Baraldi,
Rosina Maria Critelli, Veronica Bernabucci, Simonetta Tagliavini,
Silvia Strona, Tommaso Trenti, Mario Rizzetto, Erica Villa
1469: Long-Term Impact of Hepatitis C Therapy on
Liver Fibrosis and Hepatic Events in HIV-HCV Coinfected
Patients
Pablo Labarga, José Vicente Fernández-Montero, Carmen de
Mendoza, Pablo Barreiro, Vincent Soriano
1470: Improving predictive models of risk of disease
progression among patients with chronic hepatitis C by
incorporating longitudinal data
Monica Konerman, Yiwei Zhang, Ji Zhu, Peter Higgins, Anna S.
Lok, Akbar K. Waljee
1471: FIB4 Score and Gender Predict the Incidence
of Hepatocellular Carcinoma (HCC) among Patients
with Chronic Hepatitis C Virus (HCV) Infection: Chronic
Hepatitis Cohort Study (CHeCS)
Fujie Xu, Jian Xing, Anne C. Moorman, Stuart C. Gordon, Loralee
B. Rupp, Mei Lu, Philip R. Spradling, Eyasu H. Teshale, Joseph A.
Boscarino, Vinutha Vijayadeva, Mark A. Schmidt
1472: Marijuana Use Is Not Associated With Liver
Fibrosis Progression in HCV/HIV Co-infected Women
Erin Kelly, Jennifer L. Dodge, Monika Sarkar, Audrey French, Phyllis
Tien, Marshall Glesby, Elizabeth T. Golub, Michael Augenbraun,
Michael Plankey, Marion G. Peters
1473: Performance of Cobas Taqman and Abbott
Realtime HCV RNA assays during protease inhibitor-
NOVEMBER 10
based triple therapy in patients with advanced liver
MONDAY
fibrosis and cirrhosis
Benjamin Maasoumy, Bela Hunyady, Vincenza Calvaruso,
Michael Makara, Johannes Vermehren, Attila Haragh, Simone
Susser, Birgit Bremer, Gavin A. Cloherty, Michael P. Manns,
Antonio Craxi, Heiner Wedemeyer, Christoph Sarrazin
1474: Spatial epidemiology and inter familial clustering
of hepatitis C infection: Secondary analysis of a country
wide national hepatitis survey of Pakistan
Saeed S. Hamid, Bilal Ahmed, Huma Qureshi
Presenters in Attendance 12:30 – 2:00 PM
 162A POSTER SESSIONS
Poster Sessions
1475: Hepatitis C virus network dynamics among
people who inject drugs in Vancouver, Canada
Brendan Jacka, Art Poon, Tanya L. Applegate, Mel Krajden,
Andrea Olmstead, Richard Harrigan, Brandon D. Marshall, Kora
DeBeck, M-J Milloy, Francois Lamoury, Oliver Pybus, Viviane Lima,
Gkikas Magiorkinis, Vincent Montoya, Julio Montaner, Jeffrey Joy,
Gregory J. Dore, Thomas Kerr, Evan Wood, Jason Grebely
1476: A genomic and clinical prognostic index for
hepatitis C-related early-stage cirrhosis
Lindsay Y. King, Claudia Canasto-Chibuque, Kara B. Johnson,
Shun Yip, Xintong Chen, Kensuke Kojima, Manjeet Deshmukh,
Anu Venkatesh, Poh Seng Tan, Xiaochen Sun, Augusto Villanueva,
Angelo Sangiovanni, Venugopalan Nair, Milind Mahajan,
Masahiro Kobayashi, Hiromitsu Kumada, Massimo Iavarone,
Massimo Colombo, M. Isabel Fiel, Scott L. Friedman, Josep M
Llovet, Raymond Chung, Yujin Hoshida
1477: Two hepatitis C antibody chemiluminescence
assays predict viremia by a different signal to cutoff
ratio in asymptomatic people with hepatitis C
Ana M. Contreras
1478: Birth cohort distribution and screening of viremic
HCV infections in Switzerland
Francesco Negro, Florian K. Bihl, Sarah Blach, Daniel Lavanchy,
Beat Mullhaupt, Homie Razavi, David Semela, Philip Bruggmann
1479: The global distribution and prevalence of HCV
genotypes
Janey Messina, Isla Humphreys, Abraham D. Flaxman, Anthony C.
Brown, Graham Cooke, Oliver Pybus, Eleanor Barnes
1480: Impact of HCV Triple Therapy on Liver Stiffness
Jillian Nickerson, Kian Bichoupan, Ponni Perumalswami, Douglas
Dieterich, Andrea D. Branch
1481: High Rates of Comorbidities and Polypharmacy
in Patients with Chronic Hepatitis C (CHC) in a Real-
World Setting: a Consequence of an Aging Population
Philip Vutien, Louis Brooks, Richard C. Livornese, Mindie H.
Nguyen
1482: Is the diagnostic accuracy of non-invasive
methods better than liver biopsy ? A Latent Class
Analysis on assessment of liver fibrosis in chronic
hepatitis C
Flavia F. Fernandes, Maria Lucia Ferraz, Hugo Perazzo, Luis
NOVEMBER 10
Eduardo C. Andrade, Alessandra Dellavance, Carlos Terra,
MONDAY
Gustavo Pereira, João Luiz Pereira, Frederico F. Campos, Fátima
A. Figueiredo, Renata M. Perez
1483: Impact of electronic reminder to improve hepatitis
C screening in age-appropriate patients: results of a
pilot quality improvement intervention
Thomas J. Byrne, Elizabeth J. Carey, Bashar Aqel, David D.
Douglas, Vickie Timm, Melissa Dosmann, Patricia Whitten, Monika
R. White, Jorge Rakela, Hugo E. Vargas
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1484: The impact of time on a scenario to minimize
complications of hepatitis C infection
David Semela, Sarah Blach, Florian K. Bihl, Philip Bruggmann,
Daniel Lavanchy, Francesco Negro, Homie Razavi, Beat Mullhaupt
1485: Identifying HCV Treatment Barriers Amongst High
Risk Population of Vancouver Downtown Eastside
Brian Conway, Behroz Rashidi, Shawn Sharma, Syune Hakobyan,
Osamah Alenezi, Amy Hung, Kevin Yen, Xinyang Huang, Harout
Tossonian
1486: Serum Cystatin C and NGAL levels at the start of
protease inhibitor antiviral therapy positively predict
renal dysfunction development and anaemia severity
Suman Verma, Ivana Carey, Kosh Agarwal
1487: Hepatitis C Virus (HCV) Infection in New Zealand:
Burden of Chronic Disease
Edward J. Gane, Cheryl R. Brunton, Chris Estes, Charles
Henderson, John Hornell, Sarah Radke, Homie Razavi, Catherine
A. Stedman
1488: The global burden of viremic chronic HCV
infection
Erin Gower, Chris Estes, Sarah Blach, Kathryn L. Razavi-Shearer,
Homie Razavi
1489: The relationship of Wisteria floribunda
agglutinin-positive human Mac-2 binding protein and
hepatocellular carcinoma developed after sustained
virological response against hepatitis C virus
Ryu Sasaki, Kazumi Yamasaki, Ayako Mine, Yuki Kugiyama,
Shigemune Bekki, Satoru Hashimoto, Akira Saeki, Shinya
Nagaoka, Seigo Abiru, Atsumasa Komori, Atsushi Kuno, Masaaki
Korenaga, Masashi Mizokami, Hisashi Narimatsu, Hiroshi
Yatsuhashi
1490: Non invasive markers of liver fibrosis: which one
to pick from a myriad of them! A study on 1602 liver
biopsies in patients with hepatitis C
Ragesh B. Thandassery, Anil John, Madiha E. Soofi, Saad R. Al
Kaabi
1491: HCV re-infection rates are low after long-term
follow up of acute HCV infection: The Australian Trial of
Acute Hepatitis C Recall study
Joseph S. Doyle, Gregory J. Dore, David Shaw, Jason Grebely,
Amanda Erratt, Margaret Hellard, Gail Matthews
1492: Simple serum markers models accurately predict
liver related survival, complications and HCC in chronic
HCV infection
Yi Huang, Leon Adams, Gerry C. MacQuillan, Enrico Rossi, Max
K. Bulsara, Gary P. Jeffrey
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1493: Factors associated with hepatitis C virus RNA
levels in early acute and early chronic infection: the InC3
study
Behzad Hajarizadeh, Bart P. Grady, Kimberly Page, Arthur Y.
Kim, Barbara H. McGovern, Andrea Cox, Thomas M. Rice, Rachel
Sacks-Davis, Julie Bruneau, Meghan D. Morris, Janaki Amin, Janke
Schinkel, Tanya L. Applegate, Lisa Maher, Margaret Hellard,
Andrew R. Lloyd, Maria Prins, Ronald Geskus, Gregory J. Dore,
Jason Grebely
1494: NS5A variability and dynamics of resistance-
associated mutations in HCV genotype 4 patients,
naive to treatment receiving triple therapy with
DACLATASVIR+PEG-IFN/RBV, assessed by ultra deep
sequencing
Barbara Bartolini, Raffaella Lionetti, Emanuela Giombini, Chiara
Taibi, Marzia Montalbano, Gianpiero D’Offizi, Fiona McPhee,
Eric A. Hughes, Giuseppe Ippolito, Anna Rosa Garbuglia, Maria
R. Capobianchi
1495: The impact of genetic polymorphism in PNPLA3
gene on fibrosis progression and hepatocellular
carcinoma development differs between hepatitis C and
hepatitis B
Masayuki Kurosaki, Kaoru Tsuchiya, Nobuharu Tamaki, Yutaka
Yasui, Takanori Hosokawa, Shoko Suzuki, Jun Itakura, Namiki
Izumi
1496: Cocaine/crack use is not associated with liver
fibrosis progression in HIV-HCV co-infected patients
Valerie Martel-Laferriere, Kathleen C. Rollet-Kurhajec, Joseph Cox,
Curtis Cooper, Mark Tyndall, Danielle Rouleau, Sharon Walmsley,
Marina B. Klein
1497: Response-guided Boceprevir-based Triple
Therapy in HIV/HCV-coinfected Patients: The
HIVCOBOC-RGT Study
Mattias Mandorfer, Sebastian Steiner, Philipp Schwabl, Berit
A. Payer, Maximilian C. Aichelburg, Gerold Lang, Katharina
Grabmeier-Pfistershammer, Michael Trauner, Markus Peck-
Radosavljevic, Thomas Reiberger
1498: Potential impact on mortality of HCV eradication
post-liver transplant in the era of direct anti-viral agents
Carmi S. Punzalan, Graham F. Barnard
1499: Most patients with hepatitis C virus (HCV)-
associated lymphoma present with mild liver disease at
cancer diagnosis - A call to revise indications for HCV
treatment
Harrys A. Torres, Parag Mahale
1500: Factors Associated with Spontaneous Resolution
of HCV Infection in Untreated Individuals, Philadelphia
Danica Kuncio, Amy Hueber, Claire Newbern, Kendra Viner
Poster Viewing: 8:00 AM – 5:30 PM
163A
1501: Near-infrared spectroscopy for the early
detection of prodromal phase of depression during
interferon-based therapy for patients with chronic
hepatitis C
Kazumichi Abe, Akira Wada, Sachie Oshima, Soichi Kono,
Atsushi Takahashi, Yukiko Kanno, Hiromichi Imaizumi, Manabu
Hayashi, Ken Okai, Shin-ichi Niwa, Hirooki Yabe, Hiromasa
Ohira
1502: Identifying the disease burden of hepatitis C virus
(HCV) infection and non-injection drug use: a systematic
review and meta-analysis of persons who use drugs but
do not inject
Rebecca L. Morgan, Natalie Blackburn, Anthony K. Yartel, Don
C. Des Jarlais
1503: ABCA1 SNPs rs2230806 and rs2230808 in
chronic hepatitis C are gender specific and influence
cholesterol metabolism and severity of liver disease
Joana Ferreira, Cilénia B. Costa, Ricardo Andrade, Manuel Bicho,
Fatima S. Serejo
1504: Time to hepatocellular carcinoma after
notification of hepatitis B or C infection: a population-
based cohort study, 1992–2007
Maryam Alavi, Matthew Law, Jason Grebely, Hla-Hla Thein,
Janaki Amin, Gregory J. Dore
1505: The Role Of Genetic Polymorphism Of LDL
Receptor In Egyptian Population Infected With Chronic
HCV, Regarding Response To Treatment
Mazen I. Naga, Mona A. Amin, Dina A. Algendy, Ahmed I. El
Badry, Mai M. Fawzi, Ayman R. Foda, Serag M. Esmat, Dina
Sabry, Laila A. Rashed, Samia M. Gabal, Manal Kamal
1506: Prevalence of viral hepatitis and liver fibrosis in
a population of incomers in French prisons. UCSASCAN
study
Julien Vergniol, Maylis Capdepont, Samy El Aouadi, Gildas
Le-Port, Gilles Gatineau-Sailliant, Valéry Hédouin, Catherine
Martineau, Juliette Foucher, Victor de Ledinghen
1507: Genetic variant of MICA in HCC development
among HCV patients post anti-viral therapy- a
longitudinal follow-up study
Ming-Lung Yu, Chung-Feng Huang, Chia-Yen Dai, Jee-Fu Huang,
Wan-Long Chuang
NOVEMBER 10
1508: Burden of Hepatitis C Virus and Chronic Liver
MONDAY
Disease amongst Hospitalized Inmates in Massachusetts
Alysse G. Wurcel, Michaela Superson, Kathryn Noonan, Arthur Y.
Kim, Barbara H. McGovern
1509: CDC new guidelines for testing for HCV: Does
one size fit all?
Mohamed G. Shoreibah, Cynthia E. Jordan, Shabnam Sarker,
Mary L. McCain, Arvind Tripathi, Omar Massoud
Presenters in Attendance 12:30 – 2:00 PM
 164A POSTER SESSIONS
Poster Sessions
1510: New Cut-off Points of Enhanced Liver Fibrosis
(ELF) Panel for Chronic Hepatitis C Patients
Flavia F. Fernandes, Alessandra Dellavance, Luis Eduardo C.
Andrade, Frederico F. Campos, Maria Chiara Chindamo, Joao
M. Araujo-Neto, Cristiane Villela-Nogueira, Henrique Sergio M.
Coelho, Carlos Terra, Gustavo Pereira, João Luiz Pereira, Fátima
A. Figueiredo, Renata M. Perez, Maria Lucia Ferraz
1511: Fear of a liver biopsy is the primary barrier
leading to disparities in the treatment and outcomes of
hepatitis C in Somali patients in Minnesota
Esther Connor, Albert Ndzengue, Nasra H. Giama, Jeremiah
Menk, Essa A. Mohamed, Saleh Elwir, Lewis R. Roberts, Mohamed
A. Hassan
1512: High Rates of HCV Active Infection in a Blood
Bank Study in Ghana, West Africa
Jennifer E. Layden, Richard O. Phillips, Fred S. Sarfo, Nallely Mora,
Dorcas O. Owusu, Stephanie Kliethermes, Shirley P. Owusu-Ofori,
Joseph Forbi, Ohene Opare-Sem, Kenrad Nelson, Richard Cooper
1513: Reduction of miR-20a, miR-92a and miR-122 in
patients with chronic hepatitis C and severe fibrosis
Kevin Appourchaux, Emilie Estrabaud, Philippe Broet, Martine
Lapalus, Michelle Martinot-Peignoux, Nathalie Boyer, Michel
Vidaud, Pierre Bedossa, Patrick Marcellin, Tarik Asselah
1514: Disease Burden of Chronic Hepatitis C Virus
(HCV) Infection in Ireland
Colm J. Bergin, Chris Estes, Diarmaid D. Houlihan, Homie Razavi,
Kathryn L. Razavi-Shearer, Lelia Thornton, Suzanne Norris
1515: A new serum biochemical model that accurately
predicts liver collagen proportional area
Yi Huang, Bastiaan de Boer, Leon Adams, Gerry C. MacQuillan,
Enrico Rossi, Max K. Bulsara, Gary P. Jeffrey
1516: Vitamin D binding protein gene polymorphism
rs222020, CYP2R1 can predict treatment response and
liver fibrosis of northern Chinese patients with chronic
hepatitis C
Ruqi Mei, Yu Pan, Xiumei Chi, Xiaomei Wang, Ruihong Wu,
Xiuzhu Gao, Jinglan Jin, Ge Yu, Jing Jiang, Junqi Niu
1517: Hepatitis C Virus (HCV) Infection in Argentina:
Burden of Chronic Disease
Ezequiel Ridruejo, Jorge Daruich, Chris Estes, Adrian Gadano,
Homie Razavi, Marcelo O. Silva, Federico G. Villamil, Fernando
NOVEMBER 10
Bessone
MONDAY
1518: Treatment Patterns and Clinical Outcomes of HCV
in Real World Practice in China
Huiying Rao, Hong Li, Hong Chen, Qing Xie, Shang Jia, Jun Li,
ZhiLiang Gao, Yongtao Sun, Jianning Jiang, Lunli Zhang, Lai Wei
1519: Hepatitis C lipoviral particle levels are associated
with spontaneous clearance of acute infection
David A. Sheridan, Behzad Hajarizadeh, Gail Matthews, Tanya
L. Applegate, Mark W. Douglas, Beverley Askew, Dermot Neely,
Margaret F. Bassendine, Gregory J. Dore, Andrew R. Lloyd, Jacob
George, Jason Grebely
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1520: Assessment of noninvasive hepatic fibrosis
markers among patients with chronic HCV infection and
advanced liver disease
Raoel Maan, Adriaan J. van der Meer, Jordan J. Feld, Heiner
Wedemeyer, Jean-Francois J. DuFour, Frank Lammert, Andres
Duarte-Rojo, Michael P. Manns, Stefan Zeuzem, Wolf P. Hofmann,
Harry L. Janssen, Bettina E. Hansen, Bart J. Veldt, Robert J. de
Knegt
1521: Prognostic factors of survival in HIV-
HCV coinfected patients after a first episode of
decompensation: the French prospective multicenter
ANRS HC EP 25 PRETHEVIC Cohort
Moana Gelu-Simeon, Tatiana Bayan, Maria Ostos, Elina Teicher,
Hélène Fontaine, Pierre Tattevin, Isabelle Poizot-Martin, Stephanie
Dominguez, David Zucman, Julie Chas, Pascal P. Crenn, Anne
Gervais, Karine Lacombe, Philippe Morlat, Rodolphe Anty,
Faroudy Boufassa, Inga Bertucci, Georges-Philippe Pageaux,
Laurence Meyer, Jean-Charles Duclos-Vallée
1522: Mutual Inhibition between Hepatitis B Virus (HBV)
and Hepatitis C Virus (HCV)
Ge Yu, Yu Pan, Ruihong Wu, Xiumei Chi, Xiaomei Wang, Xiuzhu
Gao, Fei Kong, Xiang-wei Feng, Jinglan Jin, Yue Qi, Junqi Niu
1523: Effect of Hemochromatosis gene mutation on HCV
response to treatment in the Egyptian population
Mazen I. Naga, Mona A. Amin, Dina A. Algendy, Ahmed I. El
Badry, Mai M. Fawzi, Ayman R. Foda, Serag M. Esmat, Dina
Sabry, Laila A. Rashed, Samia M. Gabal, Manal Kamal
1524: Hepatitis C infection is not associated with
metabolic syndrome irrespective of age, gender and
fibrosis
Chien-Wei Su, Yuan-Jen Wang, Keng-Hsin Lan, Teh-Ia Huo,
Yi-Hsiang Huang, Kuei-Chuan Lee, Han-Chieh Lin, Fa-Yauh Lee,
Jaw-Ching Wu, Shou-Dong Lee
1525: Boceprevir and telaprevir-based regimens for the
treatment of hepatitis C virus in a real world HIV/HCV
co-infected cohort
Lauren A. Beste, Pamela Green, George N. Ioannou
1526: Low albumin is independent risk factor for post-
sustained virologic response hepatocellular carcinoma
in chronic hepatitis C patients: A case control study
Qing-Lei Zeng, Bin Yang, Bing Li, Xue-Xiu Zhang, Fu-Sheng Wang
1527: HCV and HIV Co-Infection and Related Risks in
Injecting Drug Users From A Superspeciality Centre
Arun K. Sharma, Subodh Bn, Debasish Basu
1528: Audit of a universal antenatal hepatitis C virus
screening programme at a London hospital
Nowlan Selvapatt, Heather Bailey, Claire Thorne, Lay-May See,
Melanie Douglas, Mark R. Thursz, Gareth Tudor-Williams, Ashley
S. Brown
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1529: Clinical utility of the VERSANT HCV RNA 1.0
Assay (kPCR) for HCV-RNA quantification in patients
with HCV genotype 1-infection
Johannes Vermehren, Simone Susser, Dany Perner, Stefan Zeuzem,
Christoph Sarrazin
1530: Delay presentation to care is an independent
prognostic factor for clinical outcomes in patients with
chronic hepatitis C
Blaise K. Kutala, Laurent Cattan, Christine Aurière, Alexandrine Di
Pumpo, Beatrice Monnier, Nathalie Giuily, Kevin Appourchaux,
Corinne Castelnau, Patrick Marcellin, Nathalie Boyer
1531: VITRO-score (vWF-Ag/thrombocytes) predicting
mortality in HCV cirrhosis in comparison to MELD-score
Andreas Maieron, Stephanie Hametner, Silvia I. Hametner, Monika
Ferlitsch, Rainer Schöfl, Alexander Ziachehabi, Arnulf Ferlitsch
1532: Learning curve and intraobserver agreement of
liver stiffness measurement in chronic hepatitis C with or
without HIV co-infection
Hugo Perazzo, João Carlos Soares, Flavia F. Fernandes, Juliana
Fittipaldi, Sandra W. Cardoso, Beatriz Grinsztejn, Valdilea Veloso
1533: Hepatitis C virus infection in HIV-positive men
who have sex with men: Systematic review and meta-
analysis
Holly Hagan, Joshua Neuer, Ashly Jordan
1534: Urinary Metabolite Biomarker Panel for the
Detection of Hepatocellular Carcinoma in Hepatitis C
Infected Populations
Wendy S. Baker, John R. Petersen, Maen M. Masadeh, Feroze A.
Hussain, Heidi Spratt
1535: Clinical outcomes of chronic hepatitis C in Korea:
A prospective, multicenter cohort study
Kyeong Sam Ok, Sook-Hyang Jeong, Eun Sun Jang, Young Seok
Kim, Youn Jae Lee, Si Hyun Bae, Han Chu Lee, Mee-Kyung Kee,
Sung Soon Kim, Chun Kang
1536: Disease Burden of Chronic Hepatitis C Virus
(HCV) Infection in India
Pankaj Puri, Anil C. Anand, Vivek A. Saraswat, Subrat K. Acharya,
Shiv K. Sarin, Radha K. Dhiman, Rakesh Aggarwal, Shivaram P.
Singh, Deepak N. Amarapurkar, Anil Arora, Mohinish Chhabra,
Kamal Chetri, Gourdas Choudhuri, Abhijit Chowdhury, Vinod K.
Dixit, Ajay K. Duseja, Sarah Blach, Ajay K. Jain, Dharmesh Kapoor,
Premashis Kar, Abraham Koshy, Ashish Kumar, Kaushal Madan,
Sri P. Misra, Mohan V. Prasad, Aabha Nagral, Amarendra S. Puri,
Jeyamani Ramachandran, Homie Razavi, Sanjiv Saigal, Samir R.
Shah, Praveen K. Sharma, Ajit Sood, Sandeep Thareja, Manav
Wadhawan
1537: Characterization of Hepatitis C Patients who
fail to Achieve Sustained Virologic Response with
Triple Therapy (Peg-Interferon Alfa and Ribavirin with
Boceprevir or Telaprevir)
T Craig Cheetham, Yong Yuan, Fang Niu, Anupama Kalsekar,
Rulin Hechter, Kevin Chiang, Joel Hay, Lisa M. Nyberg
Poster Viewing: 8:00 AM – 5:30 PM
165A
1538: Identifying patients with chronic hepatitis C in
need of early treatment and intensive monitoring: A
systematic review of predictors and predictive models of
disease progression
Monica Konerman, Suna Yapali, Anna S. Lok
1539: Low Rates of Baby Boomer Screening for
Hepatitis C in Initial Primary Care Visits at a Tertiary
Care Center
Bonnie A. Ewald, Alysse G. Wurcel, Sonali Paul, Kathleen Viveiros
1540: Evidence for Multiple Transmission Pathways and
Geographic Variation of HCV infection in Ghana, West
Africa
Jennifer E. Layden, Richard O. Phillips, Fred S. Sarfo, Dorcas
O. Owusu, Nallely Mora, Joseph Forbi, Stephanie Kliethermes,
Shirley P. Owusu-Ofori, Ohene Opare-Sem, Kenrad Nelson,
Richard Cooper
1541: HCV genotypes and NS3-DAAs resistant
mutations in treatment naive HIV/HCV co-infected
population in the South of China
Fengyu Hu, Zhiwei Liang, Yun Lan, Xiaoping Tang, Weiping Cai
1542: Treatment of Latent Tuberculosis in Patients with
Hepatitis C and Advanced Fibrosis
Christini T. Emori, Silvia N. Uehara, Ana Cristina A. Feldner,
Antonio Eduardo B. Silva, Roberto J. Carvalho-Filho, Ivonete Silva,
Maria Lucia Ferraz
1543: Chronic Hepatitis C Infection May Be Associated
With Adverse Clinical Outcomes Following Renal
Transplantation
Charles Gabbert, Siva Talluri, Mordechai Rabinovitz
1544: Hepatitis C virus RNA and genotype, IL28B
genotype, and liver fibrosis scores in a regional cohort
of HIV-HCV co-infected patients under routine HIV care
in Asia
Nicolas Durier, Kiat Ruxrungtham, Anchalee Avihingsanon, Kinh
Nguyen Van, Bui Vu Huy, Evy Yunihastuti, Andri S. Sulaiman,
Sharifah Faridah binti Syed Omar, Ilias Adam Yee, Patricia
Morgan, David Boettiger, Gail Matthews
1545: Vitamin D status and liver stiffness in chronic
hepatitis C infection
Matthew T. Kitson, Paula Lewis, William W. Kemp, Adam Gordon,
Eldho Paul, Stuart K. Roberts
NOVEMBER 10
MONDAY
1546: Fibroscan has a low predictive performance
for hepatocellular carcinoma in HCV patients with or
without a sustained virological response
Philippe Sultanik, Damien Soudan, Samir Bouam, Jean-Francois
Meritet, Anaïs Vallet-Pichard, Hélène Fontaine, Laurence Bousquet,
Marion Corouge, Estelle Boueyre, Philippe Sogni, Stanislas Pol,
Vincent Mallet
Presenters in Attendance 12:30 – 2:00 PM
 166A POSTER SESSIONS
Poster Sessions
Health Care Delivery
1547: A value-based approach to the management
of patients with liver cirrhosis through the systematic
measurement of clinical outcome and quality of life
indicators
Stefano Okolicsanyi, Antonio Ciaccio, Paolo A. Cortesi, Matteo
Rota, Marta Gemma, Pietro Giani, Luciana Scalone, Lorenzo
G. Mantovani, Stefano Fagiuoli, Maria G. Valsecchi, Giancarlo
Cesana, Luca S Belli, Mario Strazzabosco
1548: Bi-Factor Item Response Theory (IRT) modeling
reveals that the Chronic Liver Disease Questionnaire
(CLDQ) overestimates the clinical relevance of liver
disease-specific subdomain scores
Sujit V. Janardhan, Andrew Aronsohn, Jason Morris, Robert
Gibbons, David G. Beiser
1549: CDC guidelines for hepatitis C screening have
no impact on screening or linkage to care
Mansi Kothari, Archita P. Desai, Andrew Aronsohn, K. Gautham
Reddy, Donald M. Jensen, Helen S. Te, Nancy Reau
1550: Benefit of Early Palliative Care Intervention
in End-stage Liver Disease Patients Awaiting Liver
Transplantation
Alexandra J. Baumann, David Wheeler, Marva James, Arthur
Siegel, Victor J. Navarro
1551: Barriers to Receipt of Recommended Chronic
Hepatitis B Care at a Tertiary Medical Center in
Northern California
Cara Torruellas, Moon Chen, Brian Chan, Susan Stewart, Julie
Dang, Tina T. Fung, Duke A. LeTran, Christopher L. Bowlus
1552: Inadequate Hepatitis B Care in Mothers After
Pregnancy
Ruma Rajbhandari, Anna C. Juncadella, Anna K. Rubin, Tokunbo
Ajayi, Ying Wu, Ashwin N. Ananthakrishnan, Raymond T. Chung
1553: Hospice Care Utilization Improves Outcome
of Medicare Patients Diagnosed with Hepatocellular
Carcinoma
Zobair Younossi, Li Zheng, Jessica Heintz, James N. Cooper,
Andrei Racila, Madeline Erario, Linda Henry, Alita Mishra, Sharon
L. Hunt, Gregory Trimble
1554: A quality improvement initiative decreases
NOVEMBER 10
30-day readmission rates in patients admitted to a
MONDAY
Hepatology Service
Elliot B. Tapper, Dan Finkelstein, Gail Piatkowski, Murray
Mittleman, Michelle Lai
1555: Information Technology Decision Support
Improves Hepatitis C Screening Rates But Not Diagnosis
Rates
Todd L. Burstain, Monika Ahuja, Michael D. Voigt
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1556: Predictors of 30-day Hospital Readmission after
Deceased Donor Liver Transplantation
Jessica Yu, Amy Hosmer, Tamara Parks, Christopher J. Sonnenday,
Pratima Sharma
1557: Hospice referral among veterans with cirrhosis
is infrequent and primarily utilized for malignancy, not
decompensated cirrhosis
Mina Rakoski, Grace L. Su, Anna S. Lok, Michael Volk
1558: Sero-prevalence of Hepatitis E In Patients With
Chronic Liver Disease
Niharika Samala, Elizabeth C. Wright, Joni Trenbeath, Ronald E.
Engle, Nancy Fryzek, Harvey J. Alter, Jay H. Hoofnagle, Marc G.
Ghany
1559: The impact of liver disease on the health-related
quality of life
Paolo A. Cortesi, Matteo Rota, Luciana Scalone, Paolo Cozzolino,
Giancarlo Cesana, Lorenzo G. Mantovani, Stefano Okolicsanyi,
Antonio Ciaccio, Marta Gemma, Stefano Fagiuoli, Maria G.
Valsecchi, Luca S Belli, Mario Strazzabosco
1560: Chronic liver disease related morbidity compared
to congestive heart failure and chronic obstructive
pulmonary disease
Sumeet K. Asrani, Maria A. Kouznetsova, Andrew Masica, Brett
Stauffer, James F. Trotter, Patrick Kamath, Fasiha Kanwal
1561: Variation in Liver Disease Related Mortality in the
United States
Archita P. Desai, Ricki Bettencourt, Rohit Loomba
1562: Severity of illness, referral patterns and
specialized care are important determinants of same-
center thirty day readmissions in patients with cirrhosis
Marwan Ghabril, Samuel Hohmann, Eric S. Orman, Raj
Vuppalanchi, Paul Y. Kwo, Naga P. Chalasani
1563: Healthcare Utilization Among Patients with
Cirrhosis: The Role of Inflammation, Medications, Pain,
and Depression
Shari S. Rogal, Klaus Bielefeldt, Susan Zickmund, Andrea DiMartini
1564: Predictors of Increased Healthcare Utilization
After Liver Transplantation
Shari S. Rogal, Gautam Mankaney, Viyan Udawatta, Christopher
B. Hughes, Amit D. Tevar, Mark Sturdevant, Abhinav Humar,
Andrea DiMartini
1565: Pneumonia Vaccination Prevalence in Liver
Cirrhosis
Tuyyab Hassan, Sulieman Abdal Raheem, Ripple Mehta, Omer J.
Deen, Naim Alkhouri, Annette Kyprianou
1566: Personalized Learning: A Novel Educational
Model to Prepare and Expand the Hepatitis C
Workforce
Nancy Reau, Tara G. Edmonds, Jennifer Garick, Catherine C.
Capparelli, Simi Hurst
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1567: Update from an HCV Screening Program in an
Emergency Department in the Southern US: Challenges
to Follow-up and Linkage to Care
Anne Zinski, Ricardo A. Franco, Henry E. Wang, Michael Saag,
Edgar T. Overton, Jordan M. Forsythe, Joel B. Rodgers, James W.
Galbraith
1568: Hepatitis B (HBV) knowledge in a large multi-
ethnic North American cohort with chronic hepatitis
B infection: Impact of ethnicity, migration status, and
language fluency
Mandana Khalili, Colina Yim, Donna M. Evon, Mauricio Lisker-
Melman, Harry L. Janssen, Mohamed A. Hassan, Coleman Smith,
Anna S. Lok
1569: Increased all-cause hospitalization among
hepatitis C virus (HCV)-infected persons: the Chronic
Hepatitis Cohort Study (CHeCS), 2006-2010
Eyasu H. Teshale, Jian Xing, Scott D. Holmberg, Anne C.
Moorman, Stuart C. Gordon, Loralee B. Rupp, Mei Lu, Philip
Spradling, Joseph A. Boscarino, Vinutha Vijayadeva, Mark A.
Schmidt, Fujie Xu
1570: Assessment of Readmission rates and mortality in
hospitalized Cirrhotic patients: A review of the state in
patient database
Shaheryar Siddiqui, Shivang Mehta, Sachin Batra, Victor I.
Machicao, Michael B. Fallon
1571: Vaccination Rates in Cirrhotic Liver Disease
Abhijeet Waghray, Nisheet Waghray, Annette Kyprianou, KV
Narayanan Menon
1572: A national audit on hepatocellular carcinoma
(HCC) epidemiology and management in a Western
country: survival factors including healthcare
organization and referral pattern
Nathalie GOUTTE, Philippe Sogni, Noelle Bendersky, Bruno
Falissard, Olivier Farges
1573: Fatigue of Compensated Chronic Liver Disease
is associated with Altered Sleep Pattern and Melatonin
Profile
Michele M. Tana, Hawwa Alao, Nevitt Morris, Mary Walter,
Jacob Hattenbach, Sarah Smyth, Robert Brychta, Xiongce Zhao,
Yaron Rotman
1574: AASLD Guidelines for Chronic Hepatitis B
Management: Knowledge and Adherence Among
HIV Providers and Hepatologists at a Large Academic
Medical Center
Bevin Hearn, Rachel Chasan, Kian Bichoupan, Maria Suprun,
Emilia Bagiella, Douglas Dieterich, Ponni Perumalswami, Andrea
D. Branch, Shirish Huprikar
1575: Interferon (INF)-Free Regimens for Chronic
Hepatitis C (CHC): Barriers to Treatment Candidacy and
Insurance Coverage
Zobair Younossi, Maria Stepanova, Brian P. Lam, Manirath
Srishord, Spencer Frost, Huong T. Pham, Andrei Racila, Mariam
Afendy, Thomas Jeffers
Poster Viewing: 8:00 AM – 5:30 PM
167A
1576: Overestimation of Decline in Health-Related
Quality of Life Occurs in a Third of Cirrhotic Patients
Compared to US Norms using PROMIS tools
Jasmohan S. Bajaj, Melanie White, Nicole Noble, Richard K.
Sterling, R. Todd Stravitz, Mohammad S. Siddiqui, Scott Matherly,
Arun J. Sanyal, Puneet Puri, Velimir A. Luketic, Douglas M.
Heuman, Michael Fuchs, James Wade
1577: Paradigm Shift in Access to Adult Liver
Transplantation
Nyingi M. Kemmer, Chris Albers, Edson S. Franco, Husssein
Osman-Mohamed, Erin Parkinson, Elizabeth Cece Fallon, Jennifer
Horkan, Angel Alsina
1578: Telehepatology improves provider satisfaction
and specialty care integration among rural Veterans
Affairs Primary Care Providers
Lauren A. Beste, Raimund Pichler, Maureen Germani, Michael F.
Chang, Bessie Young
1579: Preventative Care Quality Indicator Adherence
and Factors Affecting Quality Care Measurement in
Patients with Cirrhosis: A Single-centered Study
Steven J. Scaglione, Kirk Shepard, William Adams, Elizabeth
Pappano, Atif M. Ali, Amanda Cheung, Vishnu Vardhan Reddy
Naravadi, Justin Mitchell, Rebecca Tsang, Shaham Mumtaz,
Edward Villa, Susan Zelisko, Stephanie Kliethermes, Nina Clark,
Scott Cotler
1580: Predictors of Attendance at the Gastroenterology
Clinic to Discuss Treatment for Hepatitis C
Susan L. Zickmund, Michael K. Chapko, Barbara H. Hanusa, Ada
O. Youk, Galen E. Switzer, Mary Ann Sevick, David S. Obrosky,
Nichole K. Bayliss, Carolyn L. Zook, Robert A. Arnold
1581: Immigrant Status Influence on Chronic Hepatitis C
Virus Infection Management
Curtis Cooper, Kimberly Corace, Crystal D. Holly, Gary Garber
1582: Community-wide outreach and screening to
reduce hepatitis B and hepatitis C disparities among
Somali immigrants in Minnesota
Nasra H. Giama, Abdirashid Shire, Hassan M. Shaleh, Essa A.
Mohamed, Lewis R. Roberts
1583: Burden of chronic viral hepatitis and liver
cirrhosis in Brazil – The Brazilian Global Burden of
Disease Study
NOVEMBER 10
Juliana R. de Carvalho, Flávia B. Portugal, Luísa S. Flor, Mônica
MONDAY
R. Campos, Renata M. Perez, Cristiane Villela-Nogueira, Joyce
Mendes A. Schramm
1584: Use of non-invasive markers of fibrosis for
prioritizing HCV antiviral drug treatment
Samuel B. Ho, Paul Thuras, Erik J. Groessl, Eric Dieperink
1585: A Universal Testing Programme for Blood Borne
Viruses in an Urban Emergency Department – a call for
widespread ED testing in Ireland
Sarah O’Connell, Darren Lillis, Siobhan O’Dea, Helen Tuite,
Catherine Fleming, Helen Barry, Linda Dalby, Darragh Shields,
Suzanne Norris, Brendan Crowley, Patrick K. Plunkett, Colm J. Bergin
Presenters in Attendance 12:30 – 2:00 PM
 168A POSTER SESSIONS
Poster Sessions
1586: Barriers to Initiating Treatment for Hepatitis C:
Results of a Veteran Population
Susan L. Zickmund, Michael K. Chapko, Barbara H. Hanusa, Ada
O. Youk, Galen E. Switzer, Mary Ann Sevick, Nichole K. Bayliss,
Carolyn L. Zook, David S. Obrosky, Robert A. Arnold
1587: Results of a Strategy to Identify Kidney
Transplant Recipients with Chronic Hepatitis C for
Interferon-Free Therapies
Genevieve Huard, Anna Patel, Brian Kim, Badr Aljarallah, Ponni
Perumalswami, Joseph A. Odin, Sara Geatrakas, Jawad Ahmad,
Douglas Dieterich, Vinay Nair, Thomas D. Schiano, Gene Y. Im
1588: Outcomes of a HCV treatment programme in
PWID over 10 years support a disease eradication
strategy for all patients in the DAA era
Omar El-Sherif, Ciaran L. Bannan, Shay Keating, Susan McKiernan,
Colm J. Bergin, Suzanne Norris
1589: The Influence of Race on Patient Preferences and
Access to Orthotopic Liver Transplantation and Organ
Donation
Omobonike O. Oloruntoba, Julius M. Wilder, Alastair D. Smith,
Andrew J. Muir, Cynthia A. Moylan
1590: The burden of illness associated with cirrhosis
and impact of universal coverage public health care
system in Thailand: Nationwide study
Kittiyod Poovorawan, Sombat Treeprasertsuk, Kaewjai
Thepsuthammarat, Bubpha -. Kitsahawong, Kamthorn Phaosawasdi
1591: Predictors of Sub-Optimal Hepatitis C Treatment
Adherence: Improving Patient Outcomes
Kimberly Corace, Crystal D. Holly, Gary Garber, Mark Kaluzienski,
Craig Lee, Thomas Shaw-Stiffel, Louise Balfour, Curtis Cooper
1592: High morbidity and mortality in end-stage liver
disease and heart failure
Cristal L. Brown, Bradley G. Hammill, Laura G. Qualls, Lesley H.
Curtis, Andrew J. Muir
1593: Symptomatic Hypogonadism in Patients listed for
Liver Transplantation and Hepatocellular Carcinoma
Anish V. Patel, Vinay Sundaram, Tram T. Tran
1594: Variceal Screening in Cirrhotic Patients
Abhijeet Waghray, Nisheet Waghray, Annette Kyprianou, KV
Narayanan Menon
NOVEMBER 10
MONDAY
Pediatric Liver Disease - Basic Science
1595: Bile salt export pump and basolateral bile
salt uptake transporters are down-regulated in
hepatoblastoma and not in hepatocellular carcinoma
Corina G. Cotoi, Peter T. Clayton, Alberto Quaglia, A. S. Knisely
1596: Hepatic Encephalopathy in Children with Acute
Liver Failure – Utility of Serum Neuromarkers
Nicole A. Toney, Robert H. Squires, Steven H. Belle, Regina M.
Hardison, Michael J. Bell
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1597: Association of NADSYN1, DHCR7, GC and VDR
Genotypes With Steatosis And Liver Inflammation in UK
Paediatric Non-Alcoholic Fatty Liver Disease Patients
Philippa S. Gibson, Emer Fitzpatrick, Alberto Quaglia, Anil
Dhawan, Huihai Wu, Kathryn Hart, Susan Lanham-New, J
Bernadette Moore
1598: Microarray analysis of laser-captured portal
tracts of Jag1+/-Rfng+/- liver reveals possible sub-
population of hepatic progenitors
Lara A. Underkoffler, Emily K. McComb, John Dutton, Anthony
Nelson, Kathleen M. Loomes, Matthew J. Ryan
1599: Jag1+/- Rfng+/- murine livers show aberrant
differentiation of Sox9 progenitors by one week of age
Lara A. Underkoffler, Emily K. McComb, John Dutton, Anthony
Nelson, Kathleen M. Loomes, Matthew J. Ryan
Pediatric Liver Transplantation
1600: Data-Driven Modeling for Precision Medicine
in Pediatric Acute Liver Failure
Ruben Zamora, Yoram Vodovotz, Othman Abdul-Malak, Qi Mi,
Khalid Almahmoud, Rami A. Namas, Derek Barclay, Robert H.
Squires
1601: Analysis of Trends in Incidence, Management,
Etiology and Death [TIMED] due to Pediatric Acute Liver
Failure [ALF] in the United States: Results of Analysis of
the National Pediatric Health Information Systems [PHIS]
Database, 2008-2013
Sakil Kulkarni, Carla Perez, Caren Pichardo, Lina I. Castillo,
Michael A. Gagnon, Conseulo Beck-Sague, Erick Hernandez, Rani
S. Gereige
1602: Low Rate of Recurrent Primary Sclerosing
Cholangitis in Pediatric Orthotopic Liver Transplant
Recipients
Sarah Taylor, Steven J. Lobritto, Mercedes Martinez, Jennifer
Vittorio, Adam Griesemer, Tomoaki Kato, Jean C. Emond, Nadia
Ovchinsky
1603: Intravenous pentamidine is efficacious for
pneumocystis carinii/jiroveci pneumonia (PCP)
prophylaxis in pediatric liver and small bowel
transplant patients
Abigail Clark, Trina S. Hemmelgarn, Rohit Kohli, Lara Danziger-
Isakov, Ashley Teusink
1604: Nutritional Status and Perioperative Nutritional
Support in Children after Liver Transplantation
Jaime C. Silva, Stacey S. Beer, Ursula G. Kyle, Mariana Treviño
Ramos, Jennifer L. Lusk, Ryan Himes, Moreshwar Desai, John A.
Goss, Jorge Coss-Bu
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
Poster Session 4
Tuesday, November 11
POSTER VIEWING: 8:00 AM - Noon
Hall C
Presenters in attendance:
10:30 AM - NOON
Those posters identified as AASLD Presidential Poster of Distinction
by a ribbon icon have received review scores that place them
within the top 10 percent of all posters. We encourage you to
make them a priority as you visit the poster sessions.
HBV: Diagnostics, Epidemiology,
Prevention, Natural History
1605: Prevalence of Precore and Dual Basal Core
Promoter HBV Variants in a Racially Diverse Cohort of
Patients with Chronic HBV Infection in North America
Daryl Lau, Lilia Ganova-Raeva, Raymond T. Chung, Geoffrey
Johnson, Kyong-Mi Chang, Mauricio Lisker-Melman, Obaid S.
Shaikh, Harry L. Janssen, Abdus S. Wahed, Anna S. Lok
1606: Evolution rules of hepatic fibrosis at different
natural history phases of chronic HBV infection in 637
Chinese patients
Qing He, Xuejiao Liao, Shuling Ai, Qingrong Tang, Qi Yuan Tang,
Feijian Ao, Zhiyu Li, Bing Bai
1607: Influence of Delta Virus Infection on the
Clinical Spectrum, Serologic and Virologic Status in
Chronic Hepatitis B Virus Genotype D
Rabab F. Omar, Rasha Ahmed, Dina Sabry, Mahmoud Abdel
Alim, Mira Atef, Naglaa Zayed
1608: Incidence of Hepatocellular Carcinoma after
HBsAg seroclearance in Chronic Hepatitis B patients: a
need for Surveillance
Gi-Ae Kim, Han Chu Lee, Yeonjung Ha, Eui Ju Park, Jihyun An
1609: Effect of Race on the Risk of Hepatocellular
Cancer in U.S. Veterans with Chronic Hepatitis B Virus
Infection
Sahil Mittal, Jennifer R. Kramer, Peter Richardson, Hashem
El-Serag, Fasiha Kanwal
1610: Epidemiology of Hepatitis B Virus Infection
according to Genotype in Alaska Native People
Michael Bruce, Lance Ching, Prabhu P. Gounder, Lisa Bulkow,
Philip R. Spradling, Mary Snowball, Susan Negus, Brian J.
McMahon
1611: Hepatitis B Screening and Prevalence among
High-Risk Populations within the Department of
Veterans Affairs
Lisa I. Backus, Pamela S. Belperio, Timothy P. Loomis, Larry A.
Mole
Poster Viewing: 8:00 AM – Noon
169A
1612: Delta Hepatitis Within the Veterans Affairs
Medical System
Tatyana Kushner, David E. Kaplan
1613: Early on-treatment HDV RNA kinetics are not
predicitve for long-term response to a PEG-IFNa therapy
of hepatitis delta
Michael Wöbse, Cihan Yurdaydin, Stefanie Ernst, Svenja Hardtke,
Benjamin Heidrich, Birgit Bremer, Onur Keskin, Ramazan Idilman,
Armin Koch, Michael P. Manns, Heiner Wedemeyer
1614: Hepatocellular Carcinoma Risk By Genotype
Among Hepatitis B Virus Infected Alaska Native
Persons Who Are Below the Age For Which Guidelines
Recommend HCC Surveillance. A Population-Based
Retrospective Cohort Study
Prabhu P. Gounder, Lisa Bulkow, Mary Snowball, Susan Negus,
Philip R. Spradling, Michael Bruce, Brian J. McMahon
1615: Serological and Molecular Epidemiological
Outcomes after Two Decades of Universal Infant
Hepatitis B Virus (HBV) Vaccination in Nunavut, Canada
Chris Huynh, Gerald Y. Minuk, Julia Uhanova, Maureen Baikie,
Lianne Vardy, Thomas Wong, Carla Osiowy
1616: Prospective study of hepatitis B virus reactivation
in rheumatoid arthritis patients on immunosuppressive
therapy: Evaluation of both HBsAg-positive and
-negative cohorts
Akihiro Tamori, Hitoshi Goto, Masahiro Tada, Kentaro Inui, Etsushi
Kawamura, Atsushi Hagihara, Sawako Kobayashi, Hiroyasu
Morikawa, Masaru Enomoto, Yoshiki Murakami, Norifumi Kawada
1617: Loss of immune tolerance is associated with HBV
genotype specific patterns of accumulation of basal core
promotor and precore variants, leading to decline in
HBeAg and HBsAg levels
Gillian Rosenberg, Julianne Bayliss, Anuj Gaggar, Kathryn M.
Kitrinos, Mani Subramanian, Patrick Marcellin, Edward J. Gane,
Henry Lik-Yuen Chan, Rachel Hammond, Xin Li, Danni Colledge,
Margaret Littlejohn, Lilly Yuen, Rosalind Edwards, Kathy Jackson,
Sara Bonanzinga, Scott Bowden, Peter A. Revill, Stephen Locarnini,
Alexander J. Thompson
1618: Analysis of dynamic parameters predicting
HBsAg seroclearance in a cohort of European untreated
hepatitis B (HBV) infected patients: a prospective
longitudinal study (ALBATROS Study)
Viola Knop, Johannes Vermehren, Eva Herrmann, Joerg Petersen,
Peter Buggisch, Heiner Wedemeyer, Markus Cornberg, Stefan
Mauss, Martin F. Sprinzl, Dietrich Hueppe, Thomas Berg,
Florian van Boemmel, Michael Rausch, Tania M. Welzel, Judith
Wuerzburg, Simone Susser, Stefan Zeuzem, Christoph Sarrazin
1619: Anti-HBs loss and HBV Reactivation Between
NOVEMBER 11
Reduced Intensity versus Myeloablative Hematopoietic
TUESDAY
Stem Cell Transplant Regimens
Hawwa Alao, Jeddeo Paul, Robert N. Reger, Elizabeth C. Wright,
Kit Lu, Richard Childs, Marc G. Ghany
Presenters in Attendance 10:30 AM – Noon
 170A POSTER SESSIONS
Poster Sessions
1620: Increases in APRI are Associated with Liver-
Related Death in HIV-Viral Hepatitis Coinfection
Jennifer C. Price, Eric C. Seaberg, Claudia Hawkins, Susan L.
Koletar, Mallory Witt, Chloe L. Thio
1621: Increased risk of developing hepatocellular
carcinoma in chronic hepatitis B patients with transient
elastography-defined subclinical cirrhosis
Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim,
Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
1622: Cirrhosis and its decompensation in chronic
hepatitis B patients with new onset hypertension: A
nationwide cohort study
Yi-Wen Huang, Szu-Chieh Fu, Ting Chuan Wang, Jui-Ting Hu,
Ding-Shinn Chen, Jia-Horng Kao, Sien-Sing Yang
1623: Mapping the HBsAg immune phenotype to
predict HBsAg loss or decline in chronic hepatitis B in
patients receiving nucleot(s)ide analogue therapy
Lucy Y. Lim, Lilly Yuen, Rachel Hammond, Peter W. Angus,
Alexander J. Thompson, Scott Patterson, Thomas Leary, Peng Yin,
Howard Thomas, Stephen Locarnini, Renae Walsh
1624: A newly developed prognosis index Improves
Mortality Prediction in Patients with HBV-related Acute-
on-chronic Liver Failure
Zhihong Wan, Yichen Wu, Shaoli You, HongLing Liu, Bing Zhu,
ShaoJie Xin
1625: The APOBEC3B gene deletion and hepatitis B
virus-associated hepatocellular carcinoma
Ping An, Zheng Zeng, Victor David, Cheryl A. Winkler
1626: HBV nucleic acid quantification from liver tissue
supports antiviral treatment decisions based on serum
markers, but not in all phases of infection
Andrzej Taranta, Magdalena Rogalska-Taranta, Benjamin
Maasoumy, Jerzy Jaroszewicz, Michael P. Manns, Robert Flisiak,
Karsten Wursthorn
1627: Evaluation of liver fibrosis and prediction of
hepatic carcinogenesis for patients with chronic hepatitis
B by a unique glycoprotein: Wisteria floribunda
agglutinin-positive Mac-2 binding protein (WFA+-M2BP)
Shuhei Hige, Itaru Ozeki, Mutuumi Kimura, Tomohiro Arakawa,
Tomoaki Nakajima, Yasuaki Kuwata, Takahiro Sato, Takumi
Ohmura, Yoshiyasu Karino, Joji Toyota, Masashi Mizokami,
Atsushi Kuno, Hisashi Narimatsu
1628: Changing Epidemiology of Hepatitis Delta
Virus Infection in an HBV Hyper-endemic Area with
Nationwide HBV Vaccination Program: the Need of
Booster for High Risk Groups
Hsi-Hsun Lin, Jaw-Ching Wu, Chien-Wei Su
NOVEMBER 11
1629: Prevalence and Molecular Virology of Hepatitis
TUESDAY
Delta Virus in the Western Pacific Region
Kathy Jackson, Meifang Han, Lilly Yuen, Rosalind Edwards, Uma
Devi, Scott Bowden, Qin Ning, Stephen Locarnini, Margaret
Littlejohn
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1630: Investigation of the efficacy of HBV DNA and
HBsAg quantifications and liver stiffness measurements
in identifying inactive HBV infection at a single time
point evaluation
Sergio Maimone, Gaia Caccamo, Giovanni Squadrito, Angela
Alibrandi, Francesca Saffioti, Rosaria Spinella, Giuseppina Raffa,
Teresa Pollicino, Giovanni Raimondo
1631: Serum Caspase-Cleaved Cytokeratin 18
Fragments As A Potential Marker For Predicting Poor
Outcome Of HBV Related Acute-On-Chronic Liver
Failure
ZhuJun Cao, FengDI Li, Kehui Liu, Weiliang Tang, Yuhan Liu, Lanyi
Lin, Hong Yu, Qing Xie, Hui Wang
1632: Efficacy of Third Trimester Maternal Tenofovir
Disoproxil Fumarate Treatment in Interrupting Mother-
to-Infant Transmission of Hepatitis B Virus
Huey-Ling Chen, Chien-Nan Lee, Chin-Hao Chang, Yen-Hsuan Ni,
Shih-Ming Chen, Jen-Jan Hu, Hans Hsienhong Lin, Shu-Chi Mu,
Ming-Wei Lai, Ming-Song Tsai, Ding-Shinn Chen, K. Arnold Chan,
Mei-Hwei Chang
1633: Risk of development of hepatocellular carcinoma
in chronic hepatitis B patients with normal or mildly
elevated alanine aminotransferase levels
Ji Hyeon Lee, Dong Hyun Sinn, Geum-Youn Gwak, Ju-Yeon Cho,
Won Sohn, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee,
Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
1634: Tendency to Develop Acute Hepatitis B and its
Outcome in HIV Coinfection: Comparison with HBV
Infection Alone
Yuichi Nozaki, Akahito Sako, Shintaro Mikami, Yasushi Kojima,
Masatoshi Imamura, Nao Nishida, Masaya Sugiyama, Masaaki
Korenaga, Kazumoto Murata, Tatsuya Kanto, Hiroyuki Gatanaga,
Yoshimi Kikuchi, Shinichi Oka, Mikio Yanase, Naohiko Masaki,
Masashi Mizokami
1635: WITHDRAWN
1636: High levels of Hepatitis B surface antigen (HBsAg)
can exclude significant fibrosis and distinguishes true
‘immune-tolerance’ in children and young adults with
Chronic Hepatitis B
Navjyot K. Hansi, Upkar S. Gill, Amrita Banerjee, Neelan
Surendraraj, Chandni Patel, Sandhia Naik, Graham R. Foster,
Patrick T. Kennedy
1637: Lack of usefulness of serum makers for
assessment of significant liver fibrosis in inactive
carriers of hepatitis B infection
Mar Riveiro-Barciela, Francisco Rodríguez-Frías, Maria Homs,
David Tabernero, Maria Buti, Rafael Esteban
1638: Patients lost to follow up: the experience of an
Australian Hepatitis B Clinic
Phil Ha, Vanessa Bull, Natassia Tan, Stephanie Spring, Lukas J.
Sahhar, Suong T. Le, Anouk T. Dev
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1639: Diagnostic performance of transient elastography
(Fibroscan ®) for the assessment of liver fibrosis in
patients with chronic hepatitis B: Impact of ALT and HBV
DNA serum levels
NANA Koudbi Jean, Tarik Asselah, Michael Adler, Marie Noelle
Hilleret, Jean-Pierre H. Zarski, Alice Marlu, Vincent Leroy
1640: Hepatitis flares are common among patients
receiving chemotherapy for cancers
Jessica P. Hwang, Andrea G. Barbo, Anna S. Lok
1641: Antiviral Therapy and the Development of
Hepatocellular Carcinoma (HCC) in Chronic Hepatitis
B (CHB) Patients with and without Cirrhosis in a US
Population
Derek Lin, Nghia H. Nguyen, Joseph Hoang, Vinh D. Vu, Huy N.
Trinh, Jiayi Li, Jian Q. Zhang, Huy A. Nguyen, Khanh Nguyen,
Mindie H. Nguyen
1642: A Prospective and Large Sample Study for the
Long-term Safety and Clinic Outcome after Postpartum
Withdrawl of Telbivudine Therapy for The Prevention of
Perinatal Transmission of Hepatitis B Virus Infection
Jing Wang, Jinfeng Liu, Yingli He, Yuan Yang, Li Jin, Shulin Zhang,
Yingren Zhao, Tianyan Chen
1643: Clinical Relevance of Viral Blipping During Potent
Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B
Infection
Mayur Brahmania, Willem Pieter Brouwer, Tawnya Hansen, Matt
Kowgier, Jordan J. Feld, David K. Wong, Harry L. Janssen
1644: Preventing HBV reactivation: An automated
prompt to remind oncologists to screen was only
partially successful
Joshua Juan, Lisa K. Hicks, Lauren Lapointe-Shaw, Judy Truong,
Urszula Zurawska, Kelvin Chan, Jordan J. Feld
1645: Validation of Noninvasive Models to Predict Liver
Fibrosis in Patients with Chronic Hepatitis B
Jieyao Cheng, Hong Ma
1646: Factors Predisposing to Development of
Hepatocellular Carcinoma in Chronic Hepatitis B
Patients with Spontaneous Seroclearance of Hepatitis B
Surface Antigen
Eui Ju Park, Danbi Lee, Young-Hwa Chung, Ju Hyun Shim, Kang
Mo Kim, Young-Suk Lim, Han Chu Lee, Yung Sang Lee, Pyo Nyun
Kim, Neung Hwa Park
1647: A ten-year follow-up of patients with dual
chronic hepatitis B and C virus infections: Outcomes and
determinants
Chun-Jen Liu, Tai-Chung Tseng, Tung-Hung Su, Hung-Chih Yang,
Chen-Hua Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao
1648: Hepatocellular Carcinoma Surveillance Rates in
Non-Cirrhotic Patients with Chronic Hepatitis B in the
United States
David S. Goldberg, Adriana Valderama, Rajesh Kamalakar, Sujit
S. Sansgiry, Svetlana Babajanyan, James D. Lewis
Poster Viewing: 8:00 AM – Noon
171A
1649: Hepatitis D: Testing Rates and Seroprevalence at
Two Liver Centers in Northern California
Kidist K. Yimam, Margaret D. Clark, Cara Torruellas, Jennifer L.
Dodge, Jody L. Baron, Christopher L. Bowlus, Stewart Cooper
1650: Assessment of combined serum biomarkers
and fibroscan and dynamic computed tomography in
the detection of hepatic fibrosis in chronic hepatitis b
patients
Gurdal Yilmaz, Iftihar Koksal, Arif M. Cosar, Ugur Kostakoglu
1651: The transplacental hepatitis B core antibody
correlated to the responsiveness of the hepatitis B
vaccine in infants born to HBsAg-positive mothers
Taotao Yan, Jing Wang, Tianyan Chen, Jinfeng Liu, Dan Du, Li Jin,
Yingli He, Yuan Yang, Yuanyuan Li, Yingren Zhao
1652: Stepwise noninvasive assessment to predict
significant fibrosis in chronic hepatitis B patients who do
not meet definite treatment guideline
Jin Dong Kim, Jin Yong Jung, Sun Young Yim, Yeon Seok Seo,
Soon Ho Um, Ho Sang Ryu
1653: HBV Genotype, Drug Resistant Mutation &
Precore/Basal Core Promoter Mutation in Acute
Hepatitis B in Korea
Jong Ho Lee, Sun Pyo Hong, Eun Sun Jang, Sang Jong Park, Seong
Gyu Hwang, Sook-Kyoung Kang, Jin-Wook Kim, Sook-Hyang
Jeong
1654: Kinetics of Hepatitis B Surface Antigen Level
During Telbivudine and Entecavir Treatment Chronic
Hepatitis B Patients
Sun Young Yim, Soon Ho Um, Chang Ho Jung, Tae Hyung Kim,
Eun Sun Kim, Bora Keum, Yeon Seok Seo, Hyung Joon Yim, Hong
Sik Lee, Yoon Tae Jeen, Hoon Jai Chun, Chang Duck Kim, Ho
Sang Ryu
1655: LAW Index as a Novel Non-invasive Indicator for
the Initiation of Antiviral Agent in Patients with Chronic
Hepatitis B
Jae Min Lee, Yeon Seok Seo, Chang Ho Jung, Tae Hyung Kim, Sun
Young Yim, Hyonggin An, Soon Ho Um, Ho Sang Ryu
1656: A new dynamic prognostic model for acute-on-
chronic hepatitis B liver failure based on the clinical and
short-term changes of bio-markers
Zhonghui Duan, Li Chen, Yanmei Feng, Hong-Wei Yu, Zhen Li,
Meixin Ren, Yue-Ke Zhu, Chenggang Jin, Qinghua Meng
1657: Chronic Hepatitis B in Western Europe: A
Retrospective Cohort
Luis Maia, Ana Margarida S. Ribeiro, José Manuel Ferreira, Teresa
Moreira, Isabel Pedroto
NOVEMBER 11
1658: Hepatocellular Carcinoma Replicating Hepatitis B
Virus: a Clinical, Virological and Transcriptional Entity
TUESDAY
Boris Halgand, Guillaume Fallot, Lise Riviere, Christophe Desterke,
Mylene Sebagh, Julien Calderaro, Paulette Bioulac-Sage, Remy
Houlgatte, Marie-Annick Buendia, Didier Samuel, Christine
Neuveut, Cyrille Feray
Presenters in Attendance 10:30 AM – Noon
 172A POSTER SESSIONS
Poster Sessions
1659: The Urgent Unmet Need to Screen for Hepatitis
B virus in African born Patients within the US, and Link
them to Care
Aaron M. Vanderhoff, Hari Shankar, Demetri A. Blanas, Kian
Bichoupan, Daouda Ndiaye, Mulusew Bekele, Ellie Carmody,
Valerie Martel-Laferriere, Saba Bekele, Andrea D. Branch, Douglas
Dieterich, Kim E. Nichols, Ponni Perumalswami
1660: A risk for hepatocellular carcinoma persists long-
term after hepatitis B virus DNA clearance in patients
with associated advanced fibrosis
Blaise K. Kutala, Corinne Castelnau, Nathalie Boyer, Tarik
Asselah, Feryel Mouri, Emilie Estrabaud, Michelle Martinot-
Peignoux, Dominique Valla, Patrick Marcellin
1661: Tenofovir DF prevents HBV reactivation in anti-
HBc positive patients with hematologic malignancies
treated with Rituximab: 12-months results of a
randomized study (PREBLIN study)
Maria Buti, Maria L. Manzano, Rosa María Morillas, Montserrat
Garcia-Retortillo, Leticia Martin, Martin Prieto, Maria Luisa
Gutierrez, Emilio Suarez, Mariano Gomez-Rubio, Javier Lopez,
Francisco Gea, Manuel Rodríguez, Jose M. Zozaya, Miguel
A. Simon, Albert Pardo, Luis Morano, Jose Luis Calleja, Rafael
Esteban
1662: Electronic notifying system improved the
coverage of HBV-related serum markers in the
prevention of HBV reactivation hepatitis
Toshiki Komeda, Shinji Katsushima
1663: Is HBeAg Seroconversion a Valid Surrogate
Marker for Hepatocellular Carcinoma in Chronic
Hepatitis B Patients Treated with Lamivudine or
Entecavir?
Jihyun An, Hwa Jung Kim, Young-Suk Lim, Dong Jin Suh
1664: Pregnancy and chronic hepatitis B – what
markers change post-delivery?
Mary Horner, Matthew J. Bruce, Marie-Ange McLeod, Kath Oakes,
Teresa Bowyer, Thawab Al-Chalabi, Kate E. Childs, Suman Verma,
Phillip M. Harrison, Kosh Agarwal, Ivana Carey
1665: HBeAg levels predict HBeAg seroconversion
during the immune clearance phase of chronic hepatitis
B in patients receiving nucleot(s)ide analogue therapy
Julianne Bayliss, Alexander J. Thompson, Gillian Rosenberg,
Anuj Gaggar, Kathryn M. Kitrinos, Mani Subramanian, Patrick
Marcellin, Edward J. Gane, Henry Lik-Yuen Chan, Xin Li, Danni
Colledge, Margaret Littlejohn, Lilly Yuen, Rosalind Edwards, Kathy
Jackson, Sara Bonanzinga, Rachel Hammond, Scott Bowden,
Stephen Locarnini, Peter A. Revill
1666: The Incidence Of Hepatitis B Virus (HBV) Related
Hepatocellular Carcinoma (HCC) Is Reduced In North
NOVEMBER 11
American Chronic Hepatitis B (CHB) Patients Treated
TUESDAY
With Long-Term Nucleos(t)ide Analog Therapy
Carla S. Coffin, Maryam Rezaeeaval, Jack X. Pang, Lilibeth
Alcantara, Patricia Klein, Kelly W. Burak, Robert P. Myers
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1667: Analysis of hepatitis B surface antigen (HBsAg)
levels using the Lumipulse HBsAg-HQ assay in hepatitis
B virus carriers with HBsAg seroclearance according to
the Abbott ARCHITECT assay
Itaru Ozeki, Tomoaki Nakajima, Shuhei Hige, Yoshiyasu Karino,
Joji Toyota
1668: Associations of Adipokines with Liver Fibrosis
Stages in Patients with Chronic Hepatitis B Virus
Infection
Ching-Sheng Hsu, Wei-Liang Liu, Ding-Shinn Chen, Jia-Horng Kao
1669: Hepatitis B Virus Screening Rates Vary Across
Specialties in Patients Receiving Immunosuppressive
Therapy
Sonali Paul, Asim Shuja, Idy Tam, Sandra Kang, Leonid Kapulsky,
Kathleen Viveiros, Hannah Lee
1670: Understanding the Phases of Chronic Hepatitis
B; the problem and a novel solution using renamed
phases, the Hepatitis B Bear and a video (see “
Understanding Hepatitis B “ on YouTube)
Heidi L. Lord, Jamee Newland, Elena Cama, Carla Treloar, Miriam
T. Levy
1671: Prediction of liver disease in e antigen negative
chronic hepatitis B (CHB)
Gayatri Chakrabarty, Philip Rice, Nick Tatman, Sarah J. Clark,
Ken Laing, Daniel M. Forton
1672: The Neutralizing Activity of Monoclonal HBs
Antibodies Separated from Hepatitis B Vaccinated
Recipients and the Influence of the titers by Different
Measurement Methods
Takako Inoue, Noboru Shinkai, Kumiko Ohne, Shuko Murakami,
Susumu Tsutsumi, Kazuto Tajiri, Hiroyuki Kishi, Shintaro Ogawa,
Masanori Isogawa, Tsunamasa Watanabe, Yasuhito Tanaka
1673: A Newly Developed High-Sensitive HBsAg
Chemiluminescent Enzyme Immunoassay is a Precise
Application as a pre-Transfusion Screening Test to
Detect Occult HBV
Takako Inoue, Kumiko Ohne, Noriyo Ochi, Noboru Shinkai,
Shuko Murakami, Sayuki Iijima, Shintaro Ogawa, Tsunamasa
Watanabe, Yasuhito Tanaka
1674: Biomarkers to predict the clinical outcome of
hepatitis delta
Anika Wranke, Beatriz Calle Serrano, Stefanie Ernst, Benjamin
Heidrich, Janina Kirschner, Birgit Bremer, Svenja Hardtke, Markus
Cornberg, Armin Koch, Michael P. Manns, Christine S. Falk,
Heiner Wedemeyer
1675: Switch to the second generation of nucelos(t)
ide analogues from de-novo lamivudine+adefovir
in sequentially treated chronic hepatitis B patients
improves viral response and leads to sharper HBsAg
decline
Matthew J. Bruce, Mary Horner, Thawab Al-Chalabi, Kath Oakes,
Ashley Barnabas, Suman Verma, Phillip M. Harrison, Kosh
Agarwal, Ivana Carey
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1676: The efficacy of Telbivudine used in entire
pregnancy course in blocking mother-to-child HBV
transmission
Wei Yi, Yao Xie, Yu-Hong Hu, Ming-hui Li
1677: Hepatitis B Core Related Antigen Levels Differ
During The Natural History of Chronic Hepatitis B
Infection
Willem Pieter Brouwer, Gertine van Oord, Milan J. Sonneveld,
Thomas Vanwolleghem, Robert J. de Knegt, Bettina E. Hansen,
Andre Boonstra, Harry L. Janssen
1678: Immunogenicity of Recombinant Hepatitis B
Vaccine in Patients on Maintenance Hemodialysis and
Normal Population of Pakistani Origin
Syed M. Hassan, Arzoo Saeed, Muhammad Osama Butt, Nasir
Hassan Luck, Zaigham Abbas
1679: Higher rates of hepatitis B surface antigen
(HBsAg) seroclearance among males and non-Asian
patients with chronic hepatitis B (CHB) in a large, multi-
center U.S. cohort study
Long H. Nguyen, Christina Wang, Vinh D. Vu, Huy N. Trinh, Jiayi
Li, Jian Q. Zhang, Mindie H. Nguyen
1680: Are Patients with Hepatitis B Virus Infection
Receiving Evaluation and Treatment?: An Analysis of A
Large Insured U.S. Cohort
Loren G. Miller, Rajeshwari S. Punekar, Debra F. Eisenberg,
Samantha Eells, Rakesh Luthra, Thomas Wasser, Honghu Liu
1681: Epidemiological evolution of Chronic Hepatitis
Delta in Italy. An analysis of the Master-B cohort
Giuseppina Brancaccio, Tiziana Giuberti, Gabriella Verucchi,
Fabio Levantesi, Daria Sacchini, Giovanna Fattovich, Salvatore
Madonia, Massimo Fasano, Caius Gavrila, Alessandra Nardi,
Giovanni B. Gaeta
1682: Cross-sectional study to evaluate hepatitis B virus
(HBV) infection screening practices and outcomes in
patients with rheumatic diseases (REBIB-I Study)
Montserrat Garcia-Retortillo, Joana Villaverde, Blanca Sampedro,
Joaquin Cabezas-González, Albert Pardo, Ramon Fontova, Tarek
C. Salman, Maria Pilar Lisbona, Joan Maymo, Blai Dalmau,
Eduard Graell, Jose Inciarte, Raimon Sanmarti, Javier Crespo,
Ricard Sola
1683: Efficacy and safety of long term tenofovir in high
risk patients with hematological malignancies (HM)
to prevent Hepatitis B Virus (HBV) reactivation after
immunosuppressive therapies in real life
Giuseppe Gentile, Eleonora Russo, Federico De Angelis, Alice Di
Rocco, Angelo Fama, Alessandra Micozzi, Alessandro Pulsoni,
Maurizio Martelli, Francesca R. Mauro, Anna P. Iori, Teresa
Petrucci, Antonella Vitale, Guido Antonelli, Robin Foà
1684: Insulin resistance is associated with higher liver
stiffness and increased immune response in inactive
carriers of hepatitis B
Mar Riveiro-Barciela, Francisco Rodriguez-Frias, Maria Homs,
David Tabernero, Rafael Esteban, Maria Buti
Poster Viewing: 8:00 AM – Noon
173A
1685: Pre- and Post-Exposure Prophylaxis against
Hepatitis B Virus Infection by HBV-active Antiretroviral
Therapy
Tsunamasa Watanabe, Susumu Hamada-Tsutsumi, Noboru
Shinkai, Etsuko Iio, Kayoko Matsunami, Sayuki Iijima, Shuko
Murakami, Katsumi Omagari, Masanori Isogawa, Wataru
Sugiura, Yasuhito Tanaka
1686: Effectiveness of an Online, Tailored CME
Curriculum on Chronic Hepatitis B virus (CHB)
Management
Nancy Reau, Catherine C. Capparelli, Jennifer Garick, Wendy
Cerenzia, Simi Hurst
1687: HBV/HIV coinfection is associated with greater
mortality in hospitalized patients with HBV
Ruma Rajbhandari, Raymond T. Chung, Hamed Khalili, Ashwin N.
Ananthakrishnan
1688: The landscape of pregant women with hepatitis B
in a single centre
Enoka Gonsalkorala, Vi Nguyen, Carina Burns, Anne L. Glass,
Miriam T. Levy
1689: HBV infection is associated with greater mortality
in hospitalized patients compared to HCV infection or
alcoholic liver disease
Ruma Rajbhandari, Raymond T. Chung, Ashwin N.
Ananthakrishnan
1690: Hepatitis B core-related antigen (HBcrAg) levels
in patients with chronic hepatitis B undergoing NUC
therapy
Benjamin Maasoumy, Katja Deterding, Jerzy Jaroszewicz, Birgit
Bremer, Patrick Lehmann, Michael P. Manns, Heiner Wedemeyer,
Markus Cornberg
1691: Dynamic of liver stiffness values by Transient
Elastography in inactive HBV carriers
Milana Szilaski, Roxana Sirli, Cristian Ivascu, Oana Gradinaru
Tascau, Alexandra Deleanu, Isabel Dan, Ioan Sporea
1692: Genotype A HBV-persistent infection is associated
with high serum HBsAg concentration in treatment-
naïve patients
Jerzy Jaroszewicz, Malgorzata Pawlowska, Krzysztof
Tomasiewicz, Wlodzimierz W. Mazur, Krzysztof Simon, Anna
Piekarska, Marta Wawrzynowicz-Syczewska, Pawel Rajewski,
Magdalena widerska, Elzbieta Murias-Brylowska, Ewelina Zasik,
Pazgan Simon Monika, Waldemar Halota, Robert Flisiak
1693: Positive Response to Hepatitis B Virus Standard
Vaccination Scheme Among Patients in an HIV Program
Francisco Fuster, Jose Ignacio Vargas, Daniela Jensen, Valeska
Sarmiento, Felipe Peirano, Pedro Acuña, Sabrina Soto, Werner
NOVEMBER 11
Jensen, Rodrigo Ahumada, Marcos Huilcaman, Mario Bruna
TUESDAY
Presenters in Attendance 10:30 AM – Noon
 174A POSTER SESSIONS
Poster Sessions
1694: Identification of a four-gene model to
discriminate mild from moderate fibrosis in patients
with chronic hepatitis B
Emilie Estrabaud, Roberto J. Carvalho-Filho, Olivier Lada, Cédric
Laouénan, Simon Gosset, Ana Carolina F. Cardoso, Ivan Bieche,
Martine Lapalus, Michel Vidaud, Tarik Asselah, Patrick Marcellin
1695: The prevalence of 25(OH)D3 in the patients
of South China with chronic HBV infection and high
25(OH)D3 related with low HBV DNA viral load
Guoli Lin, Yunlong Ao, Xin-Hua Li, Yuankai Wu, Yusheng Jie, Hong
Shi, Xiangyong Li, Fangji Yang, Shu-ru Chen, Yutian Chong
HBV: Virology and Pathogenesis
1696: Associations of HLA-DPB1 with CHB infection
and HBV related HCC in Asia
Nao Nishida, Hiromi Sawai, Kouichi Kashiwase, Mutsuhiko
Minami, Ken Yamamoto, Takehiko Sasazuki, Masaya Sugiyama,
Wai-Kay Seto, Man-Fung Yuen, Yong Poovorawan, Sang Hoon
Ahn, Kwang-Hyub Han, Kentaro Matsuura, Yasuhito Tanaka,
Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi, Jong-Hon
Kang, Shuhei Hige, Tatsuya Ide, Kazuhide Yamamoto, Isao
Sakaida, Yoshikazu Murawaki, Yoshito Itoh, Akihiro Tamori, Etsuro
Orito, Yoichi Hiasa, Masao Honda, Shuichi Kaneko, Eiji Mita,
Kazuyuki Suzuki, Keisuke Hino, Eiji Tanaka, Satoshi Mochida,
Masaaki Watanabe, Yuichiro Eguchi, Masaaki Korenaga, Minae
Kawashima, Katsushi Tokunaga, Masashi Mizokami
1697: Association between the expression of aldo-
keto reductase family 1 member B10 and the risk of
hepatitis B virus-related hepatocellular carcinoma
Masashi Mori, Takuya Genda, Takafumi Ichida, Ayato Murata,
Hironori Tsuzura, Shunsuke Sato, Yutaka Narita, Yoshio
Kanemitsu, Sachiko Ishikawa, Tetsu Kikuchi, Katsuharu Hirano,
Katsuyori Iijima, Ryo Wada, Sumio Watanabe
1698: Induction of hepatitis B virus-specific immune
responses in immunologically humanized mice
Satoshi Aono, Tomohide Tatsumi, Seiichi Tawara, Yoshiki Onishi,
Akira Nishio, Tadashi Kegasawa, Atsuo Takigawa, Hayato Hikita,
Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu, Hiroshi
Suemizu, Takeshi Takahashi, Tetsuo Takehara
1699: Epigenetic regulation of host immunity in HBV
infection
Jinglan Jin, Hongqin Xu, Xiumei Chi, Wanyu Li, Junqi Niu, Shibo Li
1700: A novel humanized cDNA-uPA/SCID mouse for
the study of HBV and HCV infections
Takuro Uchida, Nobuhiko Hiraga, Michio Imamura, Masataka
Tsuge, Hiromi Abe, C. Nelson Hayes, Hiroshi Aikata, Yuji Ishida,
Chise Tateno, Katsutoshi Yoshizato, Kazunari Murakami, Kazuaki
Chayama
NOVEMBER 11
TUESDAY
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1701: A novel TK-NOG based humanized mouse model
for the study of HBV and HCV infection
Nobuhiko Hiraga, Michio Imamura, Takuro Uchida, Tomokazu
Kawaoka, Masataka Tsuge, Hiromi Abe, C. Nelson Hayes,
Hiroshi Aikata, Yuji Ishida, Chise Tateno, Katsutoshi Yoshizato,
Kazuaki Chayama
1702: A detailed systems biology study identifies
unappreciated roles for B-cells in the differentiation
between HBV clinical phases
Thomas Vanwolleghem, Jun Hou, Gertine van Oord, Zwier M.
Groothuismink, Kim Kreefft, Suzan D. Pas, Harry L. Janssen, Andre
Boonstra
1703: Increased IL-17 producing TFh (CD4+CXCR5+
CCR6+) cells help in HBV seroconversion through TNF-α
secretion
Ashish Vyas, Shreya Sharma, Arshi Khanam, Ankit Bhardwaj,
Nirupma Trehanpati, Shiv K. Sarin
1704: Mutational profile of HLA-A2-restricted cytotoxic
T lymphocyte (CTL) epitope env183-191 in chronic HBV-
infected patients and the epitopic mutation’s influence
on CTL activities
Zhihui Xu, Yihui Rong, Yan Liu, Xiaodong Li, Shaoli You, Dongping
Xu, ShaoJie Xin
1705: HBx interact with and modulates the expression
of the DLEU2 lncRNA locus in HBV replicating cells
Francesca Guerrieri, Safaa Jeddari, Daniel D’Andrea, Anna
Tramontano, Massimo Levrero
1706: Differential expression of Fc gamma receptors
contributing to the diverse host immunity during HBV
infection
Jinglan Jin, Ruihong Wu, Xiumei Chi, Wanyu Li, Na Wu, Junqi Niu
1707: No Detectable Resistance to Tenofovir Disoproxil
Fumarate (TDF) in HBeAg+ and HBeAg- Patients with
Chronic Hepatitis B (CHB) After Eight Years of Treatment
Amoreena C. Corsa, Yang Liu, John F. Flaherty, Patrick Marcellin,
Michael D. Miller, Kathryn M. Kitrinos
1708: Functional innate immune responses are
restored with sequential NUC therapy following
Pegylated Interferon–Alpha exposure and not with NUC
monotherapy in Chronic Hepatitis B
Upkar S. Gill, Dimitra Peppa, Harsimran D. Singh, Lorenzo Micco,
Graham R. Foster, Mala K. Maini, Patrick T. Kennedy
1709: Mice with syngeneic human liver and immune
system to study cellular immunity to hepatitis B virus
Eva Billerbeck, Michiel C. Mommersteeg, Amir Shlomai, Jing
W. Xiao, Linda Andrus, Ankit Bhatta, Marcus Dorner, Anuradha
Krishnan, Michael Charlton, Luis Chiriboga, Charles M. Rice, Ype
P. De Jong
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1710: Effect of Immunosuppression and Antiviral
Therapy in Persistent Intracellular Replication among
Hepatitis B Virus and HIV Co-Infected Patients
Anders Boyd, Karine Lacombe, Fabien Lavocat, Sarah Maylin,
Patrick Miailhes, Caroline Lascoux-combe, Constance Delaugerre,
Pierre-Marie Girard, Fabien Zoulim
1711: Bile acids receptor FXR agonists repress HBV
replication in HepaRG cell
Pauline Radreau, Christophe Ramière, Marine Porcherot, Vincent
Lotteau, Patrice André
1712: Toll-like receptor 3-acivated non-parenchymal
liver cells control hepadnaviral replication in HBV-
transgenic mice lacking the surface antigen (HBsAg)
Catherine I. Real, Mengji Lu, Markus Hossbach, Kerstin Jahn-
Hofmann, Ludger M. Ickenstein, Matthias J. John, Hans-Peter
Vornlocher, Reinhold Schirmbeck, Melanie Lutterbeck, Kathrin
Gibbert, Ulf Dittmer, Guido Gerken, Joerg F. Schlaak, Ruth
Broering
1713: Frequency and role of NKp46 and NKG2A
expressing NK cells in patients with chronic hepatitis B
Teppei Yoshioka, Takuya Miyagi, Yoshinobu Yokoyama, Akira
Nishio, Kaori Mukai, Satoshi Aono, Kumiko Nishio, Takatoshi
Nawa, Hayato Hikita, Ryotaro Sakamori, Naoki Hiramatsu,
Tomohide Tatsumi, Tetsuo Takehara
1714: Hepatitis B virus enhances the endo-lysosomal
pathway through the activation of the small GTPase
Rab7 via an interaction between HBe and the Rab7
GAP, TBC1D15
Jun Inoue, Eugene W. Krueger, Jing Chen, Hong Cao, Tooru
Shimosegawa, Mark A. McNiven
1715: HBV infection in humanized chimeric mice has
multiphasic viral kinetics from inoculation to steady
state and an HBV half-life of 1 hr
Yuji Ishida, Tje Lin Chung, Michio Imamura, Nobuhiko Hiraga,
Laetitia Canini, Susan L. Uprichard, Alan S. Perelson, Chise
Tateno, Harel Dahari, Kazuaki Chayama
1716: Effect of bile acid on the entry of hepatitis B virus
via sodium taurocholate cotransporting polypeptide
Jung Wha Chung, Eun Sun Jang, In Young Moon, Gi Hyun Kim,
Kyeong Sam Ok, Jong Ho Lee, Sook-Hyang Jeong, Jin Wook Kim
1717: Distinct helper roles of dendritic cell subsets in NK
cell-dependent HBV suppression in bystander infected
cells
Sachiyo Yoshio, Tatsuya Kanto, Masaya Sugiyama, Hirotaka
Shoji, Yohei Mano, Yoshihiko Aoki, Nao Nishida, Masaaki
Korenaga, Kazumoto Murata, Masashi Mizokami
1718: Establishment of a mouse model of acute
hepatitis B by activation of human cytotoxic T
lymphocytes
Takuro Uchida, Nobuhiko Hiraga, Michio Imamura, Masataka
Tsuge, Hiromi Abe, C. Nelson Hayes, Hiroshi Aikata, Yuji Ishida,
Chise Tateno, Katsutoshi Yoshizato, Kazuaki Chayama
Poster Viewing: 8:00 AM – Noon
175A
1719: Increased fucosyltransferase 2 gene expression
in HBV infection enhances HBV replication
Takayuki Shiomoto, Masao Honda, Takayoshi Shirasaki, Kazuhisa
Murai, Tetsuro Shimakami, Seishi Murakami, Shuichi Kaneko
1720: Extensive Hepatitis B virus (HBV) Core Antigen
Mutation Associated with Massive Intrahepatic
Production of Germline Anti-core IgM and IgG Suggest
a Major Role of Humoral Immunity in the Pathogenesis
of HBV-Associated Acute Liver Failure (ALF)
Zhaochun Chen, Ronald E. Engle, Ashley B. Tice, Zhifeng Long,
Fausto Zamboni, Giacomo Diaz, Patrizia Farci
1721: Plasma Fibroblast Growth Factor 23
Concentration is Increased and Related with Liver Injury
in Patients with HBV Related Acute-on-chronic Liver
Failure
Fangfang Liu, ZhiHong Wan, Hong Zang, Shaoli You, HongLing
Liu, ShaoJie Xin
1722: Virologic and clinical characters of hepatitis B
virus mutations in basal core promoter and precore
region in children with chronic hepatitis B and hepatitis
B related liver cirrosis
Yanwei Zhong, Hongfei Zhang, Shishu Zhu, Yi Dong, Zhiqiang
Xu, Dawei Chen, Hui Dong, Fenglin Di, Limin Wang, Yu Gan,
Fuchuan Wang
1723: HBV genotype study by ultradeep
pyrosequencing reveals complex mixtures and inter-
genotype recombination
Andrea Caballero, Josep Gregori, Maria Homs, David Tabernero,
Maria Blasi, Rosario Casillas, Josep Quer, Leonardo Nieto, Henar
Valbuena, Rafael Esteban, Maria Buti, Francisco Rodriguez-Frias
1724: Analysis of the effect on HBV life cycle by HBV
genome editing using TALEN and CRISPR/Cas9 systems
Hiromi Abe, Tetsushi Sakuma, Masataka Tsuge, Nobuhiko Hiraga,
Michio Imamura, C. Nelson Hayes, Hiroshi Aikata, Takashi
Yamamoto, Kazuaki Chayama
1725: Serum Arginase-1 Levels Are Lower Than
Expected in Hepatitis B-related Acute Liver Failure
Perry H. Dubin, Jody A. Balko, Michelle Gottfried, William M. Lee
1726: Hepatitis B virus recurrence after liver
transplantation and evolution of viral quasispecies
Maria Buti, David Tabernero, Rosario Casillas, Antoni Mas, Maria
Homs, Martin Prieto, Fernando Casafont, Antonio Gonzalez,
Manuel Miras, Jose Ignacio Herrero, Lluis Castells, Rafael Esteban,
Francisco Rodriguez-Frias
1727: Hepatitis B Virus Core Protein Amino Acids 77-78
Play Vital Roles in Capsid Foramation and Function
Kai Deng, Dong Jiang, Lai Wei
NOVEMBER 11
1728: Cytokeratins 8 and 18 are responsible for
TUESDAY
intracellular distribution of the large hepatitis B virus
surface protein
Martin Roderfeld, Dirk Schröder, Yury Churin, Dieter Glebe, Elke
Roeb
Presenters in Attendance 10:30 AM – Noon
 176A POSTER SESSIONS
Poster Sessions
1729: Hepatitis B virus infection efficiency and immune
response decreases with cell density in primary cultured
hepatocytes
C. Nelson Hayes, Hiromi Abe, Sakura Akamatsu, Nobuhiko
Hiraga, Michio Imamura, Masataka Tsuge, Daiki Miki, Hiroshi
Aikata, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki
Chayama
1730: The dual immunoregulatory roles of circulating
iNKT cells during chronic HBV infection
Man Li, Zhen-Hua Zhou, Xue-Hua Sun, Yue-Qiu Gao
1731: Pretreatment Cirrhosis and Higher Body Mass
Index Predicted Alanine Aminotransferase Abnormality
in Patients Achieved Undetectable Serum HBV DNA with
Nucleos(t)ide Analogs Therapy
Yuankai Wu, Yusheng Jie, Xiangyong Li, Guoli Lin, Shu-ru Chen,
Xin-Hua Li, Hong Shi, Fangji Yang, Min Zhang, Mingxing Huang,
Yunlong Ao, Yihua Pang, Yutian Chong
1732: Hepatitis B virus relapse after discontinuation of
long-term treatment with tenofovir in chronic HBeAg-
negative patients
Maria Buti, Maria Homs, Rosario Casillas, David Tabernero, Josep
Gregori, Carolina Gonzalez, Mar Riveiro-Barciela, Maria Teresa
Salcedo, Maria Blasi, Leonardo Nieto, Francisco Rodriguez-Frias,
Rafael Esteban
1733: Clonal Hepatocyte expansion in the young adult
HBV infected liver is at odds with the concept of a
generic immune tolerant disease phase: can additional
clinical parameters distinguish disease phase?
Patrick T. Kennedy, Upkar S. Gill, Antony Chen, Samuel Litwin,
Antonio Bertoletti, William Mason
1734: Toll like Receptor Polymorphisms in Spontaneous
HBsAg Seroconversion
Kamil Özdil, Levent Doganay, Adil Nigdelioglu, Seyma Katrinli,
Oguzhan Ozturk, Zuhal Caliskan, Mehmet Sokmen, Gizem Dinler
1735: Phenotypic Characteristics of PD-1, CTLA-4 and
FoxP3 Expression during Tenofovir therapy in Chronic
Hepatitis B
Hyosun Cho, Chang Wook Kim, Yu seung Kim, Hee Yeon Kim,
Jong Young Choi, Seung Kew Yoon, Chang Don Lee
1736: Hepatitis B virus (HBV) specifically induces
CD4+CD25+CD127-veFoxP3+ with increased anti-tumor
immunity in HBV related HCC compared to Non- HBV-
HCC
Shreya Sharma, Paul David, Rakhi Maiwall, Amrish Sahney, Ritu
Khosla, Ashish Vyas, Shiv K. Sarin, Nirupma Trehanpati
1737: Evaluation of Serum Cytokines and Chemokines
in HBeAg Negative Chronic Hepatitis B Patients
NOVEMBER 11
Yan Cheng, Veonice Bijin Au, John E. Connolly, Seng Gee Lim
TUESDAY
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1738: Associations of single nucleotide polymorphism
rs1053004 in signal transducer and activator of
transcription 3 (STAT3) for risk of hepatocellular
carcinoma in Thai patients with chronic hepatitis B
Nawin Chanthra, Sunchai Payungporn, Natthaya Chuaypen, Pisit
Tangkijvanich
1739: Immune system is required for HBV clearance,
but not enough for explaining the difference in HBV
genotype A and C clearance
Yoshinobu Yokoyama, Hayato Hikita, Teppei Yoshioka, Kaori
Mukai, Satoshi Aono, Takatoshi Nawa, Ryotaro Sakamori, Takuya
Miyagi, Kazuyoshi Ohkawa, Naoki Hiramatsu, Tomohide Tatsumi,
Tetsuo Takehara
1740: Nucleotide analogue improves interferon
responsiveness in HBV-infected human hepatocytes
Masataka Tsuge, Nobuhiko Hiraga, Eisuke Murakami, Michio
Imamura, Hiromi Abe, Daiki Miki, Hidenori Ochi, C. Nelson
Hayes, Kazuaki Chayama
1741: High alpha-fetoprotein is risk factor of
hepatocellular carcinoma in hepatitis B patients with
good efficacy of nucleoside analogues therapy
Noboru Shinkai, Etsuko Iio, Tsunamasa Watanabe, Kentaro
Matsuura, Kei Fujiwara, Shunsuke Nojiri, Yasuhito Tanaka
1742: NKP46 Is Potentially Involved in Control of
Hepatitis B Virus Replication and Modulation of Liver
inflammatory
Wanyu Li, Yanfang Jiang, Yanjun Cai, Yue Qi, Jinglan Jin, Xiaomei
Wang, Junqi Niu
1743: Serum soluble CD40 is associated with liver
injury in patients with chronic hepatitis B
Hong-hui Shen, Bing-ke Bai, Panyong Mao
1744: Association study of next-generation sequencing
determined HBV heterogeneity and antiviral efficacy of
Lamivudine treatment
Yue Han, Ling Gong, Xin-xin Zhang
1745: High-throughput hepatitis B and D virus model
systems for discovery of targets for viral cure
Eloi R. VERRIER, Charlotte Bach, Laura Heydmann, Amelie Weiss,
Rajeevkumar G. Tawar, Daniel Felmlee, Sarah Durand, David
Durantel, Fabien Zoulim, François Habersetzer, Michel Doffoel,
Catherine Schuster, Laurent Brino, Camille C. Sureau, Mirjam B.
Zeisel, Thomas F. Baumert
1746: Model of HBV/HDV super-infection to study
mechanisms of viral interplay and antivirals
Dulce Alfaiate, Natali A. Abeywickrama-Samarakoon, Barbara
Testoni, Julie Lucifora, Fabien Zoulim, Jean-Claude Cortay, Paul
Deny, David Durantel
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1747: Serial Changes of Cellular, Humoral, and Innate
Immune Responses following Immunosuppressive
Chemotherapies Responsible for Hepatitis B Virus
Reactivation
Hidetaka Matsuda, Tatsushi Naito, Takuto Nosaka, Tomoyuki
Nemoto, Masahiro Ohtani, Katsushi Hiramatsu, Hiroyuki Suto,
Yasunari Nakamoto
1748: The rtA181S mutation of hepatitis B virus
primarily confers resistance to adefovir dipivoxil
Yan Liu, Xiaodong Li, ShaoJie Xin, Zhihui Xu, Rongjuan Chen, Jing
Yang, Li Chen, Vincent W. Wong, Dongliang Yang, Henry Lik-
Yuen Chan, Dongping Xu
HCV: Health Economics and Cost
Effectiveness
1749: Projecting the budget impact of interferon
(IFN)-free direct-acting antiviral (DAA)-based regimens
for hepatitis C treatment in France: a model-based
analysis (ANRS 95141)
Sylvie Deuffic-Burban, Dorothee Obach, Valerie Canva-Delcambre,
Stanislas Pol, Francoise Roudot-Thoraval, Daniel Dhumeaux,
Yazdan Yazdanpanah
1750: Evaluation of the Long-Term Health Outcomes
of Ledipasivir/Sofosbuvir (LDV/SOF) and Sofosbuvir-
based Regimens for Patients With Chronic Hepatitis C
(CHC) And Liver Cirrhosis Across Genotypes 1 to 4 (GT
1-4): Results from a Decision-Analytic Markov Model
Stuart C. Gordon, Aijaz Ahmed, Sammy Saab, Zobair Younossi
1751: Evaluation of the Health Outcomes for
Ledipasvir/Sofosbuvir in Early vs. Delayed Treatment
According to Fibrosis Stage of Patients with Chronic
Hepatitis C Virus (HCV) Genotype 1 Infection: Results
from a Decision-Analytic Markov Model
Aijaz Ahmed, Stuart C. Gordon, Sammy Saab, Zobair Younossi
1752: Who should be prioritized for HCV antiviral
treatment? A cost-effectiveness analysis including
individual and population prevention benefits
Natasha K. Martin, Peter Vickerman, Gregory J. Dore, Jason
Grebely, Graham R. Foster, Alec Miners, Sharon Hutchinson,
David J. Goldberg, Thomas C. Martin
1753: Per-Protocol Subgroup Analysis of Ledipasvir
and Sofosbuvir for Chronic HCV in the ION-3 Trial
Thomas R. O’Brien, Krystle A. Kuhs, Ruth M. Pfeiffer
1754: A Decision- Analytic Markov Model To Evaluate
The Health Outcomes of Ledipasvir/Sofosbuvir (LDV/
SOF) for Patients with Chronic Hepatitis C (HCV)
Genotype 1 (GT1) Infection
Zobair Younossi, Sammy Saab, Aijaz Ahmed, Stuart C. Gordon
Poster Viewing: 8:00 AM – Noon
177A
1755: Sofosbuvir-Containing Regimens for Chronic
Hepatitis C (CHC) Infection: Insights from a Work
Productivity Economic Model
Zobair Younossi, Yushan Jiang, Nathaniel Smith, Maria Stepanova,
Rachel Beckerman
1756: Cost-effectiveness of the Hepatitis C Self-
Management Program
Erik J. Groessl, Samuel B. Ho, Marisa Sklar, Ted Ganiats
1757: Estimating the Number of Patients with Chronic
Hepatitis C Infection According to Liver Fibrosis Stage in
the United States
Fujie Xu, Andrew J. Leidner, Xin Tong, Scott D. Holmberg
1758: Pre-transplant sofosbuvir and ribavirin
for patients with advanced liver disease and
chronic hepatitis C awaiting deceased donor liver
transplantation: A cost-effectiveness analysis
Alissa J. Wright, Arthur Y. Kim, Jay A. Fishman, Benjamin P. Linas,
Raymond T. Chung
1759: Demographics and Clinical Characteristics
Associated with High Healthcare Resource Utilization
(HRU) and Costs among Chronic Hepatitis C (CHC)
Patients
Joyce LaMori, Neeta Tandon, François Laliberté, Guillaume
Germain, D. Pilon, Patrick Lefebvre, Avinash Prabhakar
1760: Disease Burden of Chronic Hepatitis C Virus
(HCV) Infection in Poland
Robert Flisiak, Waldemar Halota, Krzysztof Tomasiewicz, Kaja
Kostrzewska, Homie Razavi, Erin Gower
1761: Estimating projected costs and quality-adjusted
life expectancy associated with daclatasvir plus
asunaprevir in difficult to treat Japanese patients
chronically infected with hepatitis C genotype 1b
Philip McEwan, Thomas Ward, Yong Yuan, Anupama Kalsekar,
Isao Kamae, Mariko Kobayashi, Sachie Inoue, Ann C. Tang,
Hiromitsu Kumada
1762: Assessing the Health Economic Value of Each Unit
of SVR Improvement in HCV Infection
Thomas Ward, Hayley Bennett Wilton, Philip McEwan, Anupama
Kalsekar, Yong Yuan
1763: The impact of different strategies to reduce the
burden of chronic hepatitis C infection, using new direct
acting antivirals in Sweden
Ann-Sofi Duberg, Sarah Blach, Karolin Falconer, Martin Kåberg,
Homie Razavi, Soo Aleman
1764: Virologic outcomes, adverse events, and
healthcare costs associated with therapy of chronic HCV
NOVEMBER 11
infection in clinical practice: results from the CMPASS
study
TUESDAY
Stefan Mauss, Maria Buti, Stephen D. Ryder, Vasily A. Isakov,
Raymundo Paraná, Trong Le, Anupama Kalsekar, Gilbert J. L’Italien
Presenters in Attendance 10:30 AM – Noon
 178A POSTER SESSIONS
Poster Sessions
HCV: Virology, Pathogenesis, and
Immunology
1765: EFTUD2 alters hepatitis C virus replication by
modulating the RIG-I/MDA5 pathway
Chuanlong Zhu, Jian Hong, Dahlene Fusco, Cynthia Brisac,
Esperance A. Schaefer, Soung Wong Jeong, Lee F. Peng, Wenyu
Lin, Raymond T. Chung
1766: Impaired inhibition of HCV IRES translation by
Type I and Type III interferon in human hepatoma cell
line with an unfavorable SNP rs12979860 of IL-28B
gene
Pauline Ferraris, Partha K. Chandra, Rajesh Panigrahi, Fatma
Aboulnasr, Ramazan Kurt, Jean-Michel Pawlotsky, Ludwig Wilkens,
Tong Wu, Luis A. Balart, Srikanta Dash
1767: Identification of HCV-specific and non-specific
follicular T helper cell signatures during acute and
chronic HCV-infection in blood and liver
Bijan Raziorrouh, Kathrin Sacher, Rajeevkumar G. Tawar, Florian
Emmerich, Thomas F. Baumert, Robert Thimme, Tobias Boettler
1768: Induction of Obesity-related Gene PLA2G16
in Acute Homologous and Heterologous HCV Infection
Associated with Development of Viral Persistence
Lucy Golden-Mason, Hugo R. Rosen
1769: Mipomersen, an FDA-approved anti-sense
inhibitor of apoB100, has anti-HCV effect in-vitro
Esperance A. Schaefer, James Meixiong, Daniel L. Motola,
Dahlene Fusco, Cynthia Brisac, Shadi Salloum, Jay Luther, Wenyu
Lin, Mary P. McGowan, Lee F. Peng, Raymond T. Chung
1770: Novel in vitro models for assembly of VLDL and
low-density hepatitis C virus particles
Ursula Andreo, Margaret A. Scull, Ype P. De Jong, Vyas Ramanan,
Brenna Flatley, Robert E. Schwartz, Shengyong Ng, Alice A. Chen,
Edward A. Fisher, Sangeeta Bhatia, Charles M. Rice
1771: HIV and HCV co-operatively increase
transcriptional activation in hepatocytes and hepatic
stellate cells in a novel live reporter cell co-culture model
of infection
Shadi Salloum, Eoin R. Feeney, Rohit Jindal, Shyam Sundhar Bale,
Cynthia Brisac, Martin L. Yarmush, Raymond T. Chung
1772: Aminoterminal Amphipathic α-Helix AH1 of HCV
NS4B Possesses a Dual Role in RNA Replication and
Virus Production
Jerome Gouttenoire, Roland Montserret, David Paul, Simon Meister,
Rosa Castillo, Audrey Kennel, Ralf Bartenschlager, Francois Penin,
Darius Moradpour
1773: Specific variation of CpG methylation in non-
NOVEMBER 11
cancerous areas of hepatocellular carcinoma after
TUESDAY
successful hepatitis C virus treatment
Masashi Nishikawa, Masao Honda, Kazunori Kawaguchi, Rika
Horii, Tetsuro Shimakami, Kuniaki Arai, Taro Yamashita, Yoshio
Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Shuichi Kaneko
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1774: TACSTD2 is a Novel HCV Host Cofactor that
Regulates Claudin and Occludin Localization and is
Downregulated in HCV-Associated Hepatocellular
Carcinoma (HCC)
Vandana Sekhar, Marta Melis, Giacomo Diaz, Ronald E. Engle,
Juraj Kabat, Ashley B. Tice, Nihal Altan-Bonnet, David E. Kleiner,
Paolo Lusso, Suzanne U. Emerson, Fausto Zamboni, Patrizia Farci
1775: Human liver sinusoidal endothelial cell-derived
exosomes augment intrinsic anti-viral pathways in HCV-
infected hepatocytes: Differential Effects of Type I vs
Type III Interferons
Michael Kriss, Silvia Giugliano, Michael Edwards, Evgenia
Dobrinskikh, Lucy Golden-Mason, Hugo R. Rosen
1776: Regulation of Hepatitis C Virus Infection by Long
Non-Coding RNAs
Tetsuro Shimakami, Masao Honda, Takayoshi Shirasaki, Fanwei
Liu, Masaya Funaki, Kazuhisa Murai, Takayuki Shiomoto, Seishi
Murakami, Shuichi Kaneko
1777: LECT2 specifically induced by IL28B regulates
interferon response and HCV replication
Takayoshi Shirasaki, Masao Honda, Tetsuro Shimakami, Kazuhisa
Murai, Takayuki Shiomoto, Hirofumi Misu, Toshinari Takamura,
Stanley M. Lemon, Seishi Murakami, Shuichi Kaneko
1778: The Hepatic Group 2 Innate Lymphocyte Cell
(ILC2)/IL-33 Axis is Dysregulated in Chronic HCV
Infection
Lucy Golden-Mason, Christina Christianson, Linling Cheng, Rafeul
Alam, Hugo R. Rosen
1779: Interleukin-22 mediates liver fibrosis via
activating hepatic stellate cells in patients with hepatitis
C
Jingmin Zhao, Liyuan Wu, Jin Li, Chaonan Guo, Hanwei Li,
Wenshu Li, Shuhong Liu, Keming Zhang, Ping Zhao
1780: Hepatitis C Promotes Diabetes by Increasing
Hepatic Insulin Resistance and Pancreatic Beta Cell
Failure Via Suppression of Betatrophin a Novel Islet Cell
Growth Factor
Robert K. Vincent, Sophie C. Cazanave, Hae-Ki Min, Faridoddin
Mirshahi, Divya P. Kumar, Amon Asgharpour, Kalyani Daita,
Karnam S. Murthy, T. Jake Liang, Arun J. Sanyal
1781: NS3, NS5A and NS5B Coevolution in Patients
Experiencing Virological-Failure with First-Generation
Protease Inhibitors
Velia Chiara Di Maio, Valeria Cento, Daniele Di Paolo, Francesco
De Leonardis, Alessandra F. Manunta, Valeria Micheli, Monica
Tontodonati, Ada Bertoli, FrancescoPaolo Antonucci, Lorenzo
Nosotti, Carlo F. Magni, Jacopo Vecchiet, Maria Stella Mura,
Massimo Andreoni, Filomena Morisco, Martina Spaziante, Nicola
Caporaso, Giustino Parruti, Giuliano Rizzardini, Sergio Babudieri,
Gloria Taliani, Mario Angelico, Carlo Federico Perno, Francesca
Ceccherini-Silberstein
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1782: HCV Minicores Are Heavily Secreted by Cells in
Apolipoprotein Complexes
Ahmed M. Elshamy, Francis J. Eng, Erin H. Doyle, Ursula Andreo,
Naga S. Veerapu, Arielle L. Klepper, Anthony S. Muerhoff, Suresh
M. Desai, Ronald E. Gordon, Charles M. Rice, Andrea D. Branch
1783: Treatment Response, IFNL3 (IL28B) and IFNL4
Genotype and Hepatic Expression of Interferons and
Interferon-Stimulated Genes in Patients with Chronic
Hepatitis C
Mazen Noureddin, Yaron Rotman, Emmanuel Thomas, Fang
Zhang, Heiyoung Park, Barbara Rehermann, T. Jake Liang
1784: Neutralising anti-envelope antibodies in
uninfected individuals that are repeatedly exposed to
HCV
Paraskevi Mandalou, Rachael Swann, Arvind H. Patel, Matthew
E. Cramp
1785: HCV specificity of the activating NK cell receptor
KIR2DS2
Sorcha A. Cassidy, Mengya Liu, Mohammed M. Naiyer, Arvind
H. Patel, Marco Purbhoo, Salim I. Khakoo
1786: The anti-HCV gene SART1 regulates EIF4G3 and
GORASP2 expression through exon splicing
Wenyu Lin, Jian Hong, Chuanlong Zhu, Dahlene Fusco, Esperance
A. Schaefer, Cynthia Brisac, Lee F. Peng, Raymond T. Chung
1787: Rapid normalization of proinflammatory cytokine
levels during potent antiviral therapy with sofosbuvir
plus ribavirin in patients with genotype 2 and 3 HCV
infection
David L. Wyles, Luisa M. Stamm, Matthew Paulson, Qinghua
Song, Diana M. Brainard, Robert T. Schooley
1788: Transmitted/Founder Hepatitis C Viruses Induce
Cell Type- and Genotype-Specific Differences within the
Liver
Angela Mitchell, Amy Stone, Linling Cheng, Kimberly Ballinger,
Michael Edwards, Mark B. Stoddard, Hui Li, Lucy Golden-Mason,
George M. Shaw, Salman Khetani, Hugo R. Rosen
1789: Virology analyses of HCV isolates from genotype
4 patients treated with simeprevir in combination with
peginterferon/ribavirin in the Phase III RESTORE study
Bart Fevery, Thierry Verbinnen, Monika Peeters, Mauro Zucchetto,
James Witek, Wolfgang Jessner, Sandra De Meyer, Oliver Lenz
1790: Serum Lipid and Sterol Analysis in Hepatitis
C (HCV) Genotype 2 and 3 Infections Treated with
Sofosbuvir (SOF) and Ribavirin (RBV) Regimens
Zobair Younossi, Maria Stepanova, Francesco Negro, James M.
Estep, Paul J. Clark, Sharon L. Hunt, Lisa E. Kratz, Qinghua Song,
Matthew Paulson, Luisa M. Stamm, Diana M. Brainard, Mani
Subramanian, John G. McHutchison, Keyur Patel
Poster Viewing: 8:00 AM – Noon
179A
1791: Different mechanisms mediate insulin and
interferon resistance in chronic hepatitis C patients with
early and late stage liver fibrosis
Kazuhisa Murai, Masao Honda, Tetsuro Shimakami, Takayoshi
Shirasaki, Takayuki Shiomoto, Hirofumi Misu, Toshinari Takamura,
Seishi Murakami, Shuichi Kaneko
1792: Behavioral risk changes in young people who
inject drugs following rapid HCV testing
Alice K. Asher, Jennifer Evans, Judith A. Hahn, Alya Briceno,
Kimberly Page
1793: The HCV NS3/4A protease-helicase binds to high
molecular weight telomerase holoenzyme complexes
Zhaowen Zhu, M. Meleah Mathahs, Warren N. Schmidt
1794: HCV Protein Expression Induces Activation of the
Akt1 Pathway In Hepatocytes, A Possible Trigger for
Hepatocarcinogenesis
Mohamed R. Imache, Jacqueline Polyte, Jean-Michel Pawlotsky,
Herve Lerat
1795: Cross-reactive and neutralizing E2 antibodies
from a spontaneous clearer without Hepatitis C virus
reinfection despite prolonged high-risk behavior
Sabrina Merat, Richard Molenkamp, Koen Wagner, Sylvie M.
Koekkoek, Dorien van den Berg, Etsuko Yasuda, Bart P. Grady,
Maria Prins, Arjen Q. Bakker, Menno D. de Jong, Hergen Spits,
Janke Schinkel, Tim Beaumont
1796: Introduction Of a Neutralization Resistant HCV-
1a Variant among HIV Positive Men Who Have Sex
With Men in Amsterdam
Sabrina Merat, Sylvie M. Koekkoek, Xiomara V. Thomas, Jan T.
van der Meer, Marc van der Valk, Menno D. de Jong, Hergen
Spits, Tim Beaumont, Richard Molenkamp, Janke Schinkel
1797: Expression of tumor suppressor PTPRD is
downregulated in HCV-infected primary human
hepatocytes and liver tissue of patients with chronic
HCV infection
Amina Ababsa, Francois H. Duong, Claire Gondeau, Markus H.
Heim, Thomas F. Baumert, Joachim Lupberger
1798: High-Level Resistance to Hepatitis C – A Possible
Role for Innate Immunity
Maggie M. Ow, Doha Hegazy, Usama Warshow, Matthew E.
Cramp
1799: Apolipoprotein E Functionally Obscures Hepatitis
C Virus from Neutralizing Antibodies
Daniel J. Felmlee*, Catherine Fauvelle*, Mathieu Lefèvre,
Laura Heydmann, Marie-Sophie Hiet, Isabel Fofana, François
Habersetzer, Ross Milne, Arvind H. Patel, Koen Vercauteren,
Philip Meuleman, Mirjam B. Zeisel, Ralf Bartenschlager, Catherine
NOVEMBER 11
Schuster, Thomas F. Baumert
TUESDAY
Presenters in Attendance 10:30 AM – Noon
 180A POSTER SESSIONS
Poster Sessions
1800: Expression of IFNλ4 in liver and PBMC is closely
associated with higher basal expression of ISGs and
impaired induction of IL28B by interferon treatment in
chronic hepatitis C non-responder patients
Miyako Murakawa, Yasuhiro Asahina, Mina Nakagawa, Naoya
Sakamoto, Sayuri Nitta, Fukiko Kawai-Kitahata, Miki Taniguchi,
Takako Watanabe, Yasuhiro Itsui, Sei Kakinuma, Mamoru
Watanabe
1801: Serum biomarker profile can predict the outcome
of acute HCV infection
Verena Schlaphoff, Katja Deterding, Svenja Hardtke, Julia Hengst,
Christine S. Falk, Birgit Bremer, Michael P. Manns, Markus
Cornberg, Heiner Wedemeyer
1802: Free apolipoprotein E inhibits HCV replication by
inducing an ABCG1-dependent cholesterol efflux
Emilie Crouchet, Mathieu Lefèvre, Eloi R. VERRIER, Thomas F.
Baumert, Catherine Schuster
1803: Impaired Insulin-Driven Gluconeogenesis Shut-
Down By HCV Proteins Through Uncoupling Of Foxo1/
AKT Signaling Leads To a Pre-Diabetic State In HCV
Transgenic Mice
Herve Lerat, Jacqueline Polyte, Aurore Gaudin, Mohamed R.
Imache, Christophe Magnan, Fabienne Foufelle, Jean-Michel
Pawlotsky
1804: Identification of OCIAD1 as Cellular Substrate of
the HCV NS3-4A Protease
Huong T.L. Tran, Kenichi Morikawa, Rose Zibi, Viet Loan Dao Thi,
Francois Penin, Markus H. Heim, Manfredo Quadroni, Jerome
Gouttenoire, Darius Moradpour
1805: Spontaneous HCV clearance in HIV-infected
individuals with chronic hepatitis C bearing IL28B-CC
alleles on antiretroviral therapy
Laura Benítez-Gutiérrez, Teodoro Martín, Alfonso Ángel-Moreno,
María J. Cítores, Francisca Portero Azorin, Valentin Cuervas-Mons,
Carmen de Mendoza
1806: A single amino acid substitution in HLA-DQB1 as
well as an IFNL4 variant strongly affect susceptibility to
chronic hepatitis C
Daiki Miki, Hidenori Ochi, Atsushi Takahashi, C. Nelson Hayes,
Yuji Urabe, Hiromi Abe, Atsushi Ono, Sakura Akamatsu, Takashi
Nakahara, Noriaki Seki, Eisuke Murakami, Yizhou Zhang, Takuro
Uchida, Yohji Honda, Satoshi Yoshimi, Tomoki Kobayashi, Keiichi
Masaki, Hiromi Kan, Tomokazu Kawaoka, Masataka Tsuge,
Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami, Hiroshi
Aikata, Shoichi Takahashi, Norio Akuta, Fumitaka Suzuki, Kenji
Ikeda, Hiromitsu Kumada, Yoshiyasu Karino, Joji Toyota, Tatsuhiko
Tsunoda, Michiaki Kubo, Naoyuki Kamatani, Yusuke Nakamura,
Kazuaki Chayama
NOVEMBER 11
1807: Replication of HCV RNA Depends on its
TUESDAY
Degradation by the Cellular RNAses and not on the
Translational Efficiency of its Untranslated Regions
Patrice Bruscella, Tony Durand, Michel Ventura, Jean-Michel
Pawlotsky, Cyrille Feray
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1808: Dynamics of the Virus-specific CD8 T cell
Repertoire during HCV Reinfection
Mohamed S. Abdel-Hakeem, Julie Bruneau, Hugo Soudeyns,
Naglaa H. Shoukry
1809: NK Cell Function Normalizes after 4 Weeks of
IFN-free Therapy of Chronic Hepatitis C
Elisavet Serti, Xenia Chepa-Lotrea, Yun Ju Kim, Nancy Fryzek, T.
Jake Liang, Marc G. Ghany, Barbara Rehermann
1810: Persistently infected HCV cell culture impairs RBV
antiviral activity through clathrin mediated trafficking of
ENT1
Rajesh Panigrahi, Partha K. Chandra, Pauline Ferraris, Ramazan
Kurt, Imogen Coe, Tomami Furihata, Robert F. Garry, Tong Wu,
Luis A. Balart, Srikanta Dash
1811: Vδ2 γδ T cell functional dichotomy in chronic
hepatitis C virus infections
Wenwei Yin, Qiongfang Zhang, Hong Ren, Dazhi Zhang
1812: Promoted liver fibrosis in hepatitis C virus
transgenic mouse fed an atherogenic high-fat diet is
accompanied by abnormal expression of the glycolysis-
related gene pyruvate kinase M2
Riuta Takabatake, Masao Honda, Hikari Okada, Tetsuro
Shimakami, Takayoshi Shirasaki, Taro Yamashita, Yoshio Sakai,
Takuji Tanaka, Shuichi Kaneko
1813: Involvement of hepatitis C virus infection in
the regulation of chemo-sensitivity of hepatocellular
carcinoma cells
Takatoshi Nawa, Tomohide Tatsumi, Akira Nishio, Seiichi Tawara,
Yoshiki Onishi, Satoshi Aono, Hayato Hikita, Ryotaro Sakamori,
Takuya Miyagi, Naoki Hiramatsu, Tetsuo Takehara
1814: Chaperone-mediated Autophagy Targets IFNAR1
for Lysosomal Degradation in Free Fatty Acid Treated
HCV Cell Culture
Ramazan Kurt, Partha K. Chandra, Fatma Aboulnasr, Rajesh
Panigrahi, Pauline Ferraris, Krzysztof Reiss, Tong Wu, Luis A.
Balart, Srikanta Dash
1815: Identification of a TSCM phenotype HCV-specific
CD8+ T cell response with superior functionality in
chronic HCV infection
Bertram Bengsch, Kristin Ladell, Bianca Martin, James E. McLaren,
Katja Nitschke, Christoph Neumann-Haefelin, David A. Price,
Robert Thimme
1816: Acute Hepatitis C Virus infection Induces Anti-
host Cell Receptor Antibodies with Virus-neutralizing
Properties
Rajeevkumar G. Tawar, Michael Roggendorf, Helga Meisel,
Nicolas Meyer, Francois-Loic Cosset, Thomas Berg, Mirjam B.
Zeisel, Thomas F. Baumert
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1817: Genetic polymorphism in interferon-λ4 gene and
treatment response to peginterferon and ribavirin in
Japanese chronic hepatitis C
Hisayoshi Watanabe, Ri Sho, Takafumi Saito, Kei Mizuno,
Tomohiro Katsumi, Chikako Sato, Kazuo Okumoto, Yuko Nishise,
Yoshiyuki Ueno
1818: Systematic identification of microRNAs
functionally involved in the HCV life cycle
Sophie Pernot, Simonetta Bandiera, Erika Girardi, Amelie Weiss,
Sarah Durand, Wolfgang Raffelsberger, Laurent Brino, Sebastien
Pfeffer, Thomas F. Baumert, Mirjam B. Zeisel
1819: Elevated hepatic lipid and interferon stimulated
gene (ISG) expression in patients infected with hepatitis
C virus genotype-3 (HCVGT-3) relative to patients with
non-alcoholic steatohepatitis (NASH)
Shikha Shrivastava, Eric G. Meissner, Emily K. Funk, Seerat
Poonia, Virendra Shokeen, Arun Thakur, Shyam Kottilil, Shiv K.
Sarin, Nirupma Trehanpati
1820: Full Length and Subgenomic HCV Infection,
Endosomal TLR Stimulation, and Differentiation Increase
Macrophage Immunoregulatory Galectin-9
Noah M. Harwood, Lucy Golden-Mason, Hugo R. Rosen, John A.
Mengshol
1821: IFNL4- and IFNL3-associated polymorphisms
strongly influence spontaneous expression of IFN-alpha
receptor-1 and response to exogenous IFN-alpha in
vitro in PBMC from HCV-infected patients
Eleonora Lalle, Licia Bordi, Claudia Caglioti, Anna Rosa
Garbuglia, Concetta Castilletti, Gianpiero D’Offizi, Chiara Taibi,
Maria R. Capobianchi
1822: Modulation of HCV infection through KHSRP-
Dependent Regulation of miRNA 122 Maturation and
Intracellular RNA Degradation
Patrice Bruscella, Jean-Michel Pawlotsky, Cyrille Feray
1823: Effect of aging on fibrotic change based on
sequential liver biopsy in chronic hepatitis C patient
who achieved an SVR
Yoshihiko Tachi
1824: NK cell anti-tumor activity was boosted by
SAHA identified to induce the expression of a GWAS-
discovered HCV-HCC susceptibility gene MICA
Kaku Goto, Ryosuke Muroyama, Wenwen Li, Ryo Nakagawa,
Yasuo Matsubara, Naoya Kato
1825: The Scaffold Protein IQGAP2 is Essential for the
Innate Control of HCV Infection in Hepatoma Cells
Cynthia Brisac, Shadi Salloum, Stephane Chevaliez, Eoin R.
Feeney, Esperance A. Schaefer, Chuanlong Zhu, Jian Hong,
Dahlene Fusco, Lee F. Peng, Wenyu Lin, Raymond T. Chung
1826: Allosteric Heat Shock Protein Inhibitors Block
Hepatitis C Virus Assembly
Ronik Khachatoorian, Ekambaram Ganapathy, Vaithilingaraja
Arumugaswami, Asim Dasgupta, Samuel W. French
Poster Viewing: 8:00 AM – Noon
181A
1827: The IL28B SNP has a stronger regulatory effect
on the expression of OAS1 than a nearby SNP located
downstream of OAS1 in chronic HCV patients
Daiki Miki, Hiromi Abe, C. Nelson Hayes, Hidenori Ochi,
Tomokazu Kawaoka, Sakura Akamatsu, Atsushi Ono, Takashi
Nakahara, Noriaki Seki, Eisuke Murakami, Yizhou Zhang, Takuro
Uchida, Yohji Honda, Keiichi Masaki, Hiromi Kan, Masataka
Tsuge, Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami,
Hiroshi Aikata, Michiaki Kubo, Kazuaki Chayama
1828: Pretreatment induction of ISGs in the presence
of IFNL4 in hepatocytes but not in white blood cells is
related with poor induction of ISGs following IFN-α
therapy
Hiromi Abe, C. Nelson Hayes, Nobuhiko Hiraga, Michio Imamura,
Masataka Tsuge, Daiki Miki, Hiroshi Aikata, Hidenori Ochi, Yuji
Ishida, Chise Tateno, Katsutoshi Yoshizato, Kazuaki Chayama
1829: Quercetin inhibits both replication and assembly
of hepatitis C virus by blocking the viral NS3 and the
host diacylglycerol acyltransferase type 1
Angela Rojas, Sophie Clément, Matthieu Lemasson, Jose A. Del
Campo, Marta García-Valdecasas, Antonio Gil-Gómez, Isidora
Ranchal, Juan Bautista, Arielle R. Rosenberg, Francesco Negro,
Manuel Romero-Gomez
1830: Infection and Replication of Hepatitis C Virus in
Vero cells Derived from Green Monkey Kidney
Asako Murayama, Nao Sugiyama, Takaji Wakita, Takanobu Kato
1831: Impact of Donor Host Genetics on HCV Viral
Evolution After Post Liver Transplantation
Sandra C. Silva Arrieta, Sandra Franco, María-Carlota Londoño,
Miguel Angel Martinez, Xavier Forns, Todd M. Allen, Alberto
Sanchez-Fueyo, Christian Brander
1832: Lysophosphatidylcholine acyltransferase 1
is downregulated by hepatitis C virus: impact on
production of lipo-viro-particles
Frauke Beilstein, Matthieu Lemasson, Veronique Pene, Arielle R.
Rosenberg, Sylvie Demignot
1833: Increased Frequency of CD39+ HCV-Specific CD4
T cells Correlates with Progression to Chronic Hepatitis C
Diana Y. Chen, Brandon Robilotti, Lyndon K. Matsubara, Joelle
Brown, Jasneet Aneja, Stephanie Kulaga, Lia Lewis-Ximenez,
Eddie A. James, William W. Kwok, Arthur Y. Kim, Georg M. Lauer
1834: Impaired IFN signaling in chronic hepatitis C
patients with advanced fibrosis via the TGF-β signaling
pathway
Masao Honda, Takayoshi Shirasaki, Tetsuro Shimakami, Kazuhisa
Murai, Takayuki Shiomoto, Hikari Okada, Riuta Takabatake,
Yoshio Sakai, Taro Yamashita, Stanley M. Lemon, Seishi
Murakami, Shuichi Kaneko
NOVEMBER 11
TUESDAY
Presenters in Attendance 10:30 AM – Noon
 182A POSTER SESSIONS
Poster Sessions
1835: Interferon Lambda-4 (IFNL4) TT allele is
associated with lower expression of genes associated
with early inflammation after initiation of treatment
J. Michael Estep, Kellie Perry, Kameron Tavakolian, Zahra
Younoszai, Maria Stepanova, Ali Noorzad, Richard Binder,
Zobair Younossi
1836: Hepatitis C Proteins Interact Directly with Early
Stage Autophagy Proteins
Ciara Harty, Orla M. Crosbie, Elizabeth Kenny-Walsh, Liam J.
Fanning
1837: Cryoglobulins and autoantibodies:Anti-nuclear
antibodies detection in cryoprecipitates of an Hepatitis C
Virus-positive cohort
Gian Ludovico Rapaccini, Umberto Basile, Francesca Gulli,
Eleonora Torti, Luigi Colacicco, Paola Cattani
1838: Anti-viral but not anti-fibrotic activity of natural
killer cells from HCV patients is significantly reduced by
liver normoxic conditions
Franziska Wolter, Andreas Glässner, Benjamin Krämer, Pavlos
Kokordelis, Claudia Zwank, Dominik J. Kaczmarek, Christian P.
Strassburg, Ulrich Spengler, Jacob Nattermann
1839: Down regulation of hsa-miR146b-5p might affect
the immunopathogenesis of chronic hepatitis C patients
Yasuteru Kondo, Masashi Ninomiya, Osamu Kimura, Takayuki
Kogure, Yasuhito Tanaka, Yu Nakagome, Tomoaki Iwata,
Tatsuki Morosawa, Yasuyuki Fujisaka, Tomoo Kobayashi, Tooru
Shimosegawa
1840: Monocytes-derived Galectin-9 induces the
cytotoxixcity of NK cells in chronic hepatitis C
Akira Nishio, Tomohide Tatsumi, Takahiro Suda, Atsuo Takigawa,
Tadashi Kegasawa, Onishi Yoshiki, Seiichi Tawara, Satoshi
Aono, Takatoshi Nawa, Hayato Hikita, Ryotaro Sakamori, Takuya
Miyagi, Naoki Hiramatsu, Tetsuo Takehara
1841: Characterization of a lymphotropic HCV-J6JFH1
replication in human primary B cells
Masato Nakai, Tsukasa Seya, Misako Matsumoto, Hussein H. Aly,
Jun Itoh, Seiji Tsunematsu, Fumiyuki Sato, Yoko Tsukuda, Katsumi
Terashita, Takuya Sho, Goki Suda, Mitsuteru Natsuizaka, Koji
Ogawa, Naoya Sakamoto
1842: Impaired expression of Type I and Type II
interferon-receptors in HCV infected chronic liver
disease and liver cirrhosis
Partha K. Chandra, Feyza Gunduz, Sidhartha Hazari, Ramazan
Kurt, Rajesh Panigrahi, Bret Poat, David S. Bruce, Ari J. Cohen,
Humberto E. Bohorquez, Ian C. Carmody, George E. Loss, Tong
Wu, Luis A. Balart, Srikanta Dash
1843: The CC allele at rs12979860 IL28B is associated
NOVEMBER 11
with higher hepatic fibrosis in HCV patients with
genotype 4
TUESDAY
Gamal E. Shiha, Waleed Samir, Seham Seif, Ayman Eldesoky,
Reham Soliman
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1844: Evidence of CD8+ T cell dysfunction in chronic
HCV infection with pronounced impairment of liver cells
compared to circulating cells
Stephanie C. Burke, Lorna Carrasco-Medina, Curtis Cooper,
Angela M. Crawley
1845: Prevalence of the NS3 protease Q80K naturally
occurring variant in Hepatitis C patients in Denmark
Anja Ernst, Henrik Krarup
1846: NKG2D Expression on Natural Killer T Cells, but
not NK Cells, Predicts Viral Response to DAA/ PEG-IFN/
RBV Therapy in Chronic Hepatitis C
Po-sung Chu, Hirotoshi Ebinuma, Nobuhiro Nakamoto, Shingo
Usui, Hidetsugu Saito, Takanori Kanai
1847: Assessment of Free Light Chains in HCV positive
patients undergoing Rituximab treatment
Umberto Basile, Laura Gragnani, Francesca Gulli, Alessia Piluso,
Cristina Stasi, Maria Teresa Dell’Abate, Eleonora Torti, Monica
Monti, Gian Ludovico Rapaccini, Anna Linda Zignego
1848: Emergence or selection of resistant associated
variant immediately after initiation of the therapy is
predictive for failure of direct acting antiviral therapy:
ultra-deep sequencing analyses for serial time points
Takako Watanabe, Yasuhiro Asahina, Mina Nakagawa, Sei
Kakinuma, Yasuhiro Itsui, Miki Taniguchi, Miyako Murakawa,
Hiroko Nagata, Mika Miura, Shinya Maekawa, Nobuyuki
Enomoto, Mamoru Watanabe
1849: Aldo-keto reductase family 1 member B10
expression predicts the risk of hepatocellular carcinoma
development in chronic hepatitis C patients who
achieved sustained virological response to interferon-
based anti-viral therapy
Ayato Murata, Takuya Genda, Takafumi Ichida, Shunsuke Sato,
Hironori Tsuzura, Yutaka Narita, Yoshio Kanemitsu, Sachiko
Ishikawa, Tetsu Kikuchi, Masashi Mori, Katsuharu Hirano,
Katsuyori Iijima, Ryo Wada, Sumio Watanabe
1850: Markers of Intestinal Enterocyte Injury and
Systemic Inflammation in HIV, HCV & HIV/HCV
co-infection
Alysse G. Wurcel, Paula Grasberger, Jessica K. Paulus, Gina
Masse, Christine Wanke, Tamsin A. Knox
Hepatitis B Therapy
1851: Tenofovir Disoproxil: Effective and Safe in
Prevention of Mother-to-child Transmission of Hepatitis
B Virus
Hongfei Huang, Quanxin Wu, Yuming Wang
1852: Incidence of Hepatocellular Carcinoma (HCC)
in non-cirrhotic chronic hepatitis B (CHB) patients with
low ALT levels in a multicenter US Cohort
Joseph K. Hoang, Nghia H. Nguyen, Derek Lin, Vinh D. Vu, Huy
N. Trinh, Jiayi Li, Jian Q. Zhang, Huy A. Nguyen, Khanh Nguyen,
Mindie H. Nguyen
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1853: Risk and Prediction of Hepatitis B Reactivation
in Inactive Carriers Receiving Pre-emptive Antiviral
Therapy During Cancer Chemotherapy
Jonggi Choi, Jihyun An, Ju Hyun Shim, Hyung-Don Kim, Yeon-Jung
Ha, Mi-Jung Jun, Young Joo Yang, Seung Bum Lee, Gi Ae Kim, Jee
Eun Yang, Eui Ju Park, Danbi Lee, Kang Mo Kim, Young-Suk Lim,
Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh
1854: Efficacy of Entecavir versus Lamivudine for
Antiviral Prophylaxis in Hepatitis B Patients Receiving
Cancer Chemotherapy
Jonggi Choi, Jihyun An, Ju Hyun Shim, Hyung-Don Kim, Yeon-Jung
Ha, Mi-Jung Jun, Young Joo Yang, Seung Bum Lee, Gi Ae Kim, Jee
Eun Yang, Eui Ju Park, Danbi Lee, Kang Mo Kim, Young-Suk Lim,
Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh
1855: Profound Reduction of HBV Covalently Closed
Circular DNA with Long-term Nucleoside/tide Analogue
Therapy
Ching-Lung Lai, Danny Wong, Philip Ip, Malgorzata Kopaniszen,
Wai-Kay Seto, James Fung, Fung-Yu Huang, Brian P. Lee, Giuseppe
Cullaro, Chi Hang Wu, Charles Cheng, Chi Hang J. Yuen, Vincent
Ngai, Man-Fung Yuen
1856: Long-term Nucleos(t)ide Analogue Consolidation
Therapy Reduces Risk of Relapse in Chronic Hepatitis B
Heng Chi, Bettina E. Hansen, Pauline Arends, Mahmoud Abu-
Amara, Colina Yim, Jordan J. Feld, Robert J. de Knegt, David K.
Wong, Harry L. Janssen
1857: ALN-HBV, a GalNAc-siRNA Enhanced
Stabilization Chemistry RNAi Therapeutic for the
Treatment of Chronic Hepatitis B Virus Infection
Laura Sepp-Lorenzino, Marc Abrams, Leon Carayannopoulos,
Martin Koser, Steve Ludmerer, Klaus B. Charisse, Daniel Freedman,
Vasant Jadhav, Kallanthottathil G. Rajeev, Greg Hinkle, Satya
Kuchimanchi, Martin A. Maier, Muthiah Manoharan, Rachel
Meyers, Stuart Milstein, Andrew G. Sprague
1858: On-treatment alpha-fetoprotein levels have
a strong association with hepatocellular carcinoma
development among chronic hepatitis B patients
receiving entecavir
Ryoko Yamada, Naoki Hiramatsu, Yuki Tahata, Naoki Morishita,
Naoki Harada, Tsugiko Oze, Takayuki Yakushijin, Sadaharu Iio,
Yoshinori Doi, Eiji Mita, Masahide Oshita, Toshifumi Ito, Taizo
Hijioka, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara,
Yasuharu Imai, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi,
Norio Hayashi, Tetsuo Takehara
1859: Risk of Hepatocellular Carcinoma Among Treated
Patients With Chronic Hepatitis B vs Chronic Hepatitis C
Gi-Ae Kim, Seungbong Han, Jihyun An, Young-Suk Lim
1860: Prenylation inhibition with lonafarnib decreases
hepatitis D levels in humans
Christopher Koh, Cihan Yurdaydin, Stewart Cooper, David Cory,
Harel Dahari, Vanessa Haynes-Williams, Mark A. Winters,
Matthew Bys, Ingrid C. Choong, Ramazan Idilman, Onur Keskin,
Laetitia Canini, Peter Pinto, Erin F. Wolff, Rachel Bishop, David E.
Kleiner, Jay H. Hoofnagle, Jeffrey Glenn, Theo Heller
Poster Viewing: 8:00 AM – Noon
183A
1861: Evidence for Ongoing Low-level Viremia in
Patients with Chronic Hepatitis B Receiving Long-term
Nucleos(t)ide Analog Therapy
Patrick Marcellin, Edward J. Gane, Robert Flisiak, Michael P.
Manns, Kelly D. Kaita, Anuj Gaggar, Lanjia Lin, Kathryn M. Kitrinos,
John F. Flaherty, Mani Subramanian, John G. McHutchison, Harry
L. Janssen, Maria Buti
1862: Clinical outcomes of tenofovir disoproxil
fumarate (TDF) treatment versus no treatment for
pregnant women with active chronic hepatitis B (CHB)
and elevated alanine aminotransaminase (ALT)
Wei Yi, Calvin Q. Pan, Min Liu, Haodong Cai
1863: HBsAg clearance after addition of 48 weeks of
PEGIFN in HBeAg negative CHB patients on Nucleos(t)
ide therapy with undetectable HBV DNA for at least one
year: a multicenter randomized controlled phase III trial
ANRS-HB06 PEGAN study: preliminary findings
Marc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrié,
Lawrence Serfaty, Patrick Marcellin, Noelle Pouget, Dominique
Guyader, Christophe Hezode, Magali Picon, Xavier Causse,
Vincent Leroy, Jean-Pierre Bronowicki, Ghassan Riachi, Isabelle
Rosa, Pierre Attali, Jean-Michel Molina, Yannick Bacq, Albert
Tran, Jean Didier Grange, Fabien Zoulim, Hélène Fontaine, Inga
Bertucci, Magali Bouvier-Alias, Fabrice Carrat, Yves Benhamou
1864: Efficacy and Safety of Telbivudine in Preventing
Mother-to-infant HBV Transmission in HBV-infected
Pregnant Women in Immune Tolerant Phase
Qiuju Sheng, Yang Ding, Han Bai, Jingyan Wang, Chong Zhang,
Lianrong Zhao, Xiaoguang Dou
1865: Entecavir Plus Tenofovir Combination Therapy in
Patients with Multi-drug Resistant Chronic Hepatitis B:
The 48-Week Results of A Multicenter, Prospective Study
Jun Yong Park, Chang Wook Kim, Si Hyun Bae, Sang Hoon Ahn
1866: Entecavir reduces the incidence of hepatocellular
carcinoma in patients with chronic hepatitis B
Tetsuya Yasunaka, Fusao Ikeda, Akinobu Takaki, Tomonori Seno,
Koichi Takaguchi, Kazuhide Yamamoto
1867: Altered underlying tubular function in HBV
monoinfected patients receiving nucleos(t)ide analogs in
a real-world setting: MENTE Study
Sonia Rodriguez Novoa, Javier García-Samaniego, Martin Prieto,
Jose Luis Calleja, Juan Manuel Pascasio, Manuel B. Delgado,
Javier Crespo, Maria Buti, Lucía Bonet, Juan I. Arenas, Conrado
M. Fernandez Rodriguez, Ricard Sola, Enrique Fraga Rivas, Luisa
González-Diéguez, Óscar Núñez, Manuel Praga, Javier del Pino,
Manuel Romero-Gómez, Rosa María Morillas, Moisés Diago,
Angeles Castro
1868: Hepatitis B Core Related Antigen Levels Are
NOVEMBER 11
Associated With Response To ETV and PEG-IFN
TUESDAY
Treatment In HBeAg-Positive Chronic Hepatitis B Patients
Willem Pieter Brouwer, Milan J. Sonneveld, Qing Xie, Qing
Zhang, Fehmi Tabak, Adrian Streinu-cercel, Jiyao Wang, Gertine
van Oord, Thomas Vanwolleghem, Suzan D. Pas, Robert J. de
Knegt, Andre Boonstra, Bettina E. Hansen, Harry L. Janssen
Presenters in Attendance 10:30 AM – Noon
 184A POSTER SESSIONS
Poster Sessions
1869: IFNL4 polymorphisms predict sustained response
and HBsAg clearance in interferon treated HBeAg
negative chronic hepatitis B patients
Enrico Galmozzi, Pietro Lampertico, Floriana Facchetti, Federica
Invernizzi, Giampaolo Mangia, Mauro Viganò, Roberta Soffredini,
Massimo Colombo
1870: Incidence of Hepatocellular Carcinoma in a
National Cohort of Chronic Hepatitis B Patients on Long
Term Entecavir Treatment- the ENUMERATE study
Joseph Ahn, Joseph K. Lim, Hannah Lee, Calvin Q. Pan, Mindie
H. Nguyen, Huy N. Trinh, Tram T. Tran, Danny Chu, Albert Min,
Son T. Do, Jocelyn Woog, Ajitha Mannalithara, Anna S. Lok, W.
Ray Kim
1871: Entecavir Safety and Effectiveness in a National
Cohort of Chronic Hepatitis B Patients in the United
States - the ENUMERATE study
Joseph Ahn, Hannah Lee, Joseph K. Lim, Calvin Q. Pan, Mindie
H. Nguyen, W. Ray Kim, Huy N. Trinh, Tram T. Tran, Danny Chu,
Albert Min, Son T. Do, Jocelyn Woog, Ajitha Mannalithara, Anna
S. Lok
1872: Early hepatic flares during ETV treatment are
rare and do not require treatment adaptation in chronic
hepatitis B without cirrhosis
Pauline Arends, Heng Chi, Ivana Carey, Ashley S. Brown,
Massimo Fasano, David J. Mutimer, Katja Deterding, Ye H. Oo,
Joerg Petersen, Florian van Bömmel, Robert J. de Knegt, Jurrien G.
Reijnders, Thomas Berg, Tania M. Welzel, Stefan Zeuzem, Teresa
Santantonio, Heiner Wedemeyer, Maria Buti, Pierre Pradat,
Fabien Zoulim, Bettina E. Hansen, Harry L. Janssen
1873: The Antiviral Response to the Toll-Like Receptor
7 Agonist GS-9620 in Preclinical Models of Chronic
Hepatitis B is Associated with an Intrahepatic Cytotoxic
T Cell Transcriptional Signature
Li Li, Peng Yue, Robert E. Lanford, Stephan Menne, Congrong
Niu, Stephane Daffis, Daniel Tumas, Abigail Fosdick, William E.
Delaney, Simon P. Fletcher
1874: Long-Term HDV-RNA Suppression – HBsAg
Clearance in Chronic Hepatitis D Following Interferon
Therapy
Grazia A. Niro, Antonina Smedile, Rosanna Fontana, Antonella
Olivero, Alessia Ciancio, Fabrizia Pittalunga, Nicola Coppola,
Heiner Wedemeyer, Kalliopi Zachou, Aldo Marrone, Massimo
Fasano, Teresa Santantonio, Giuseppe Lotti, Angelo Andriulli,
Mario Rizzetto
1875: Decline in Quantitative Serum HBsAg Level
during Consolidation Therapy Following HBeAg Loss
in HBeAg-positive Chronic Hepatitis B Patients Treated
with Entecavir
Wen-Pang Su, Cheng-Yuan Peng, Hsueh-Chou Lai, Chia-Hsin Lin,
NOVEMBER 11
Po-Heng Chuang, Sheng-Hung Chen
TUESDAY
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1876: The role of hepatitis B surface antigen
quantification predict HBV reactivation after
discontinuation of nucleos(t)ide analogs treatment in
chronic hepatitis B patients with cirrhosis
Chien-Hung Chen, Chuan-Mo Lee, Tsung-Hui Hu, Chao-Hung
Hung, JIng-Houng Wang, Sheng-Nan Lu
1877: Entecavir Improves Liver Function and Fibrosis
in Patients with Hepatitis B Virus-associated Liver
Cirrhosis: A 2 Years-Multicenter Study
Seung Kak Shin, Oh Sang Kwon, Jong Eun Yeon, Jeong Han Kim,
So Young Kwon, Sang Jun Suh, Yun Soo Kim, Ju Hyun Kim
1878: Efficacy and safety of telbivudine versus tenofovir
treatment based on the Roadmap concept: Results
from a randomized, controlled trial in HBeAg-negative
chronic hepatitis B patients
Zahary Krastev, Iskren A. Kotzev, Mustafa K. Celen, David Mc
Neeley, Kamal A. Hamed
1879: Cytokines Induced by a Toll-Like Receptor 7
Agonist Potently Inhibit HBV RNA, DNA and Antigen
Levels in Primary Human Hepatocytes
Congrong Niu, Stephane Daffis, Mei Yu, Guofeng Cheng, William
E. Delaney, Simon P. Fletcher
1880: Tenofovir Mono-rescue therapy vs. Tenofovir
plus Entecavir combination-rescue therapy in chronic
hepatitis B with lamivudine and entecavir resistance: a
Korean multi-center study
Sangheun Lee, Jun Yong Park, Hana Park, Moon Young Kim, Sang
Hoon Ahn, Pumsoo Kim, Kwang-Hyub Han
1881: Increased HBsAg Decline in Sustained
Responders After Discontinuation of Long-term
Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B
Heng Chi, Bettina E. Hansen, Mahmoud Abu-Amara, Colina Yim,
Pauline Arends, Jordan J. Feld, Annemiek A. van der Eijk, Robert J.
de Knegt, David K. Wong, Harry L. Janssen
1882: Addition of Peginterferon Alfa-2b During Long-
term Nucleos(t)ide Analogue Therapy Increases HBeAg
Seroconversion and HBsAg Decline – Week 48 Results
From a Multicenter Randomized Controlled Trial
(PEGON Study)
Heng Chi, Qing Xie, Ning-Ping Zhang, Xun Qi, Chen Liang, Simin
Guo, Qing Guo, Pauline Arends, Ji-yao Wang, Elke Verhey,
Robert J. de Knegt, Bettina E. Hansen, Harry L. Janssen
1883: Response-guided therapy to peginterferon
in chronic hepatitis B using on-treatment HBsAg
quantification: a meta-analysis
Hong Peng, Fang Wei, Junying Liu, Huaidong Hu, Peng Hu, Hong
Ren
1884: Prospective Observational Cohort Study For The
Durability Of Oral Antiviral Treatment In Patients With
Chronic Hepatitis B: Quit Study
Jun Yong Park, Kyu sik Chung, Young Eun Chon, Hyon Suk Kim,
Wonseok Kang, Seung Up Kim, Beom Kyung Kim, Do Young Kim,
Kwang-Hyub Han, Sang Hoon Ahn
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1885: A baseline predictive tool for selecting HBeAg-
negative chronic hepatitis B patients who have a high
probability of achieving sustained immune control with
peginterferon alfa-2a
Pietro Lampertico, Vivien Rothe, Antonietta Caputo, George V.
Papatheodoridis
1886: A predictive tool for selecting HBeAg-positive
chronic hepatitis B patients who have a high probability
of HBV DNA suppression and HBeAg seroconversion
with peginterferon alfa-2a
Henry Lik-Yuen Chan, George V. Papatheodoridis, Diethelm
Messinger, George Bakalos, Pietro Lampertico
1887: Randomized Controlled Trial of Switching
to Tenofovir Disoproxil Fumarate Monotherapy in
Lamivudine-Resistant Chronic Hepatitis B Patients with
Undetectable HBV Viral Load under Lamivudine/-
Adefovir Add-on Therapy: The First Interim Analysis
Yi-Hsiang Huang, Chien-Wei Su, Yuan-Jen Wang, Yi-Shin Huang,
Kuei-Chuan Lee, Ming-Chih Hou, Han-Chieh Lin
1888: 24 Weeks Of Peg-Ifn Is As Good As 48 Weeks
In Hbeag-Positive Genotype B Patients With An Early
Hbsag Response
Milan J. Sonneveld, Henry Lik-Yuen Chan, Teerha Piratvisuth,
Jidong Jia, Vincent W. Wong, Edward J. Gane, Bettina E. Hansen,
Yun -Fan Liaw, Harry L. Janssen
1889: The Pattern and Predictors of Serum HBsAg
Decline in Chronic Hepatitis B Patients Receiving Up to
Five Years of Entecavir Therapy
Hsueh-Chou Lai, Cheng-Yuan Peng, Wen- Pang Su, Chia-Hsin Lin,
Po-Heng Chuang, Sheng-Hung Chen
1890: Interferon-inducible protein 10 (IP10) serum
levels predict the decline of HBsAg serum levels in
HBeAg-negative chronic hepatitis B (CHBe-) patients
treated with tenofovir disoproxil fumarate (TDF)
George V. Papatheodoridis, Christos K. Triantos, Emilia
Hadziyannis, Konstantinos Zisimopoulos, Anastasia Georgiou,
Theodoros Voulgaris, Jiannis Vlachogiannakos, Vasiliki
Nikolopoulou, Spilios Manolakopoulos
1891: Quantitative hepatitis B core antibody level is a
new predictor for treatment response in HBeAg-positive
chronic hepatitis B patients receiving peginterferon
Gui-Qiang Wang, FengQin Hou, NingShao Xia
1892: Anti-HBV effectiveness and mechanisms of
Chinese herbal extract-Suduxing
Weiming Yao, Yan Liu, Zhihui Xu, Lanlan Si, Penggao Li, Lvping
Bo, Jinchu Lan, Dongping Xu
1893: Higher AFP during hepatitis B flare is associated
with greater reduction in HBsAg during Nuc therapy
Rachel Wen-Juei Jeng, Yi-Cheng Chen, Ming-Ling Chang, Yun -Fan
Liaw
Poster Viewing: 8:00 AM – Noon
185A
1894: Effect of antiviral treatment on liver stiffness
and its correlation to hepatocarcinogenesis in chronic
hepatitis B
Naoto Kawabe, Keisuke Osakabe, Senju Hashimoto, Michihito
Murao, Yoshifumi Nitta, Takuji Nakano, Hiroaki Shimazaki,
Toshiki Kan, Kazunori Nakaoka, Masashi Ohki, Takagawa Yuka,
Takamitsu Kurashita, Emi Matsuo, Tomoki Takamura, Aiko Fukui,
Toru Nishikawa, Naohiro Ichino, Kentaro Yoshioka
1895: Durability of HBeAg Seroconversion of
Telbivudine as Monotherapy and as Combination
Therapy with Adefovir Dipivoxil for Chronic Hepatitis B
Patients with High ALT Level: A Prospective, Multicenter,
Cohort Study
Yang Ding, Chong Zhang, Qiuju Sheng, Mingxiang Zhang,
Feng Wu, Baojun Song, Weili Zhu, Jingyan Wang, Lilan Shi,
Xiaoguang Dou
1896: Tenofovir versus Entecarvir in Antiviral-Naïve
Chronic Hepatitis B Patients: Preliminary 48-Week
Results
Young Joo Yang, Ju Hyun Shim, Hyung-Don Kim, Yeonjung Ha,
Mi-Jung Jun, Seung Bum Lee, Jee Eun Yang, Gi-Ae Kim, Eui Ju Park,
Jihyun An, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee,
Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh
1897: Tenofoivr treatment in chronic hepatitis B patients
with suboptimal response to adefovir with prior
lamivudine resistance
Joohan Park, Hyo Jung Cho, Sun Young Park, Seon Joo Ahn, Soon
Sun Kim, Jae Youn Cheong, Sung Won Cho
1898: A prospective, open-label cohort study
comparing the efficacy, safety and drug resistance of
entecavir monotherapy versus de novo combination
of lamivudine and adefovir dipivoxil in naïve HBeAg-
positive chronic hepatitis B patients with high HBV viral
load (The Climber Study): a preliminary analysis
Wei Guo, Di Wu, Peng Wang, Jing-Feng Chen, Yan-hong Xu,
Weiming Yan, Ke Ma, Meifang Han, Jianxin Song, Junying Qi,
Jiaquan Huang, Yuancheng Huang, Xiping Zhao, Dong Xu, Qin
Ning
1899: Tenofovir Montherapy in Chronic Hepatitis B
Patients with Genotypic Resistance to Previous Antiviral
Therapy - a Cohort Study
Jihyun An, Young-Suk Lim, Gi Ae Kim, Hyung-Don Kim, Ju Hyun
Shim, Kang Mo Kim, Han Chu Lee, Young-Hwa Chung, Danbi Lee,
Yung Sang Lee, Dong Jin Suh
1900: Outcome of chronic hepatitis B patients who
discontinued nucleos(t)ide analogue therapy
Suna Yapali, Kelly Oberhelman, Anna S. Lok
1901: Efficacy of Entecavir plus Tenofovir Combination
NOVEMBER 11
Therapy for Chronic Hepatitis B Patients with Multi-Drug
TUESDAY
Resistant Strains
Yun Bin Lee, Jeong-Hoon Lee, Dong Hyeon Lee, Hyeki Cho,
Hongkeun Ahn, Won-Mook Choi, Young Youn Cho, Minjong Lee,
Jeong-Ju Yoo, Yuri Cho, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim,
Jung-Hwan Yoon, Chung Yong Kim, Hyo-Suk Lee
Presenters in Attendance 10:30 AM – Noon
 186A POSTER SESSIONS
Poster Sessions
1902: Nucleoside Drug Resistance and Potential HBV
Vaccine-Escape Mutation Caused by Telbivudine
Treatment in a Chronic Hepatitis B Patient
Senol Comoglu, Ayten Kadanali, Behiye Dede, Gul Karagoz,
Kevser K. Tatar, Murat Sayan, Nur B. Ozdemir, Zeynep S. Çakar
1903: Entecavir plus adefovir or entecavir plus tenofovir
for patients with chronic hepatitis B resistant to
neucleot(s)ide analogues
Jung Gil Park, Young Oh Kweon, Won Young Tak, Se Young Jang,
Su Hyun Lee, Soo Young Park
1904: Estimating The Probability Of Response To
Peginterferon Alfa In Hbeag-Positive Chronic Hepatitis
B: The Epic-B Predictor
Milan J. Sonneveld, Vincent W. Wong, Jun Cheng, Teerha
Piratvisuth, Jidong Jia, Stefan Zeuzem, Edward J. Gane, Yun -Fan
Liaw, Willem Pieter Brouwer, Qing Xie, Jinlin Hou, Henry Lik-Yuen
Chan, Harry L. Janssen, Bettina E. Hansen
1905: Excellent Theraputic Response to Tenofovir
Dipivoxil Fumarate (TDF) in Chronic Hepatitis B Pregnant
Women with Resistance to Prior Anti-viral Therapy
Hua Zhang, Calvin Q. Pan, Xin Liu, Qian Bian, Qiumei Pang, Yun
X. Zhu, Qing Liu, Ruihua Tian
1906: Tenofovir versus entecavir in the treatment of
chronic hepatitis B with severe acute exacerbation
Chao-Hung Hung, Chien-Hung Chen, Sheng-Nan Lu, Tsung-Hui
Hu, JIng-Houng Wang, Chuan-Mo Lee
1907: Combination with Nucleoside Analogues was
not Superior to Tenofovir Monotherapy in Patients with
Drug-resistant Chronic Hepatitis B
Sae Hwan Lee, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim,
Boo Sung Kim, Soung Won Jeong, Jae Young Jang, Young Don
Kim, Gab Jin Cheon
1908: Tenofovir-Induced Fanconi Syndrome In Chronic
Hepatitis B Monoinfected Patients Successfully Rescued
By Entecavir
Mauro Viganò, Alessandra Brocchieri, Angiola Spinetti, Serena
Zaltron, Giampaolo Mangia, Floriana Facchetti, Alessandro
Fugazza, Francesco Castelli, Massimo Colombo, Pietro Lampertico
1909: A Comparison of the Efficacy and Safety of
Entecavir Versus Lamivudine Through 240 Weeks of
Treatment in Korean Patients with HBeAg-negative
Chronic Hepatitis B
Kwan Sik Lee, Young-Oh Kweon, Soon Ho Um, Byung-Ho Kim,
Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon Ju Lee, Dong
Joon Kim, Tae Hun Kim, Young Sok Lee, Kwan Soo Byun, Dae-
Ghon Kim, Myung Seok Lee, Cyril Llamoso, Kyungha Yu, Dong
Jin Suh
NOVEMBER 11
TUESDAY
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1910: Does interferon treatment reduce hepatocellular
carcinoma incidence in HBeAg positive chronic hepatitis
B patients?
Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, Taito
Fukushima, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta,
Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda,
Mariko Kobayashi, Hiromitsu Kumada
1911: Association between Genotype and the
HBsAg Levels at HBeAg Loss in HBeAg-positive
Chronic Hepatitis B Patients Treated with Entecavir or
Peginterferon Alfa-2a
Cheng-Yuan Peng, Hsueh-Chou Lai, Wen- Pang Su, Chia-Hsin Lin,
Po-Heng Chuang, Sheng-Hung Chen
1912: Durability of HBeAg Seroconversion After
Treatment with Entecavir or Tenofovir in Chronic
Hepatitis B Patients
Tse-Ling Fong, Edward A. Mena, Andy S. Yu, Quang-Quoc Phan,
Steven-Huy B. Han, Andy Tien, Andrew J. Velasco, Vinh-Huy
Leduc, Myron J. Tong
1913: Nucleoside Analogues treatment in Patients with
Acute and Subacute liver failure related to hepatitis B
virus
Bing Zhu, Shaoli You, HongLing Liu, Yihui Rong, Hong Zang,
ZhiHong Wan, ShaoJie Xin
1914: Durability of Nucleos(t)ide Analogues Treatment
in Patients with Chronic Hepatitis B: The Role of APASL
Guideline
Yi-Hsiang Huang, I-Cheng Lee, Cheuk-Kay Sun, Chien-Wei Su,
Yuan-Jen Wang, Han-Chieh Lin
1915: Suppression of Hepatitis B Virus Replication by
Dandelion extracts and Traxasterol in Vitro
Ying Yang, Feng Chen, Jihua Xue, Jing Wang, Chaochao Qin, Yu
Shi, Weixia Liu, Zhi Chen
1916: The estimated glomerular filtration rate changes
in chronic hepatitis B patients during nucleos(t)ide
analogues treatment
Yi-Cheng Chen, Rachel Wen-Juei Jeng, Wei Teng, Chao-Wei Hsu,
Chun-Yen Lin, I-Shyan Sheen, Rong-Nan Chien, Yun -Fan Liaw
1917: Efficacy and Safety of Telbivudine in Chinese
Children and Adolescents with Chronic Hepatitis B
Hongfei Zhang, Shishu Zhu, Yi Dong, Limin Wang, Zhiqiang Xu,
Dawei Chen, Yu Gan, Fuchuan Wang
1918: Similar Renal Function Profile in Chronic Hepatitis
B (CHB) Patients Treated with Tenofovir (TDF) vs.
Entecavir (ETV) Monotherapy – A Multicenter Matched
Case Cohort Study
Nghi B. Ha, Kevin Ku, Nghiem B. Ha, Kevin T. Chaung, Huy N.
Trinh, Mindie H. Nguyen
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1919: Effect of achieving drug-free status and HBs
antigen decline in sequential therapy with Peg-IFN alfa-
2a on long-term nucleoside analog treated patients
Ken Nishino, Miwa Kawanaka, Jun Nakamura, Takahito Oka,
Noriyo Urata, Daisuke Goto, Mitsuhiko Suehiro, Hirofumi
Kawamoto, Gotaro Yamada
1920: Entecavir monotherapy vs. lamivudine-adefovir
combination therapy for chronic hepatitis B infection: a
5-year randomized controlled trial
Guan Huei Lee, Wah Wah Phyo, Yock Young Dan, Yin-Mei Lee,
How Cheng Low, Kieron B. Lim, Maung Aye Thwin, Poh Seng Tan,
Seng Gee Lim
1921: Long-term Follow-up and Treatment Rates of
Treatment-Eligible Chronic Hepatitis B (CHB) Patients: A
Multicenter Cohort Study
Vinh D. Vu, Ailinh Do, Nghia H. Nguyen, Lily H. Kim, Huy N.
Trinh, Huy A. Nguyen, Khanh Nguyen, Mindie H. Nguyen
1922: 2-years impact of entecavir (ETV) on liver fibrosis
and activity as assessed by FibroTest – ActiTest and
Liver Stiffness Measurement (LSM) in chronic hepatitis B
(CHB) patients
Fabien Zoulim, Xavier Causse, Vincent Leroy, Denis Ouzan,
Nathalie Ganne-Carrié, Valerie Bourcier, Victor de Ledinghen,
Philippe Mathurin, Marika Rudler, Joseph Moussalli, Dominique
Thabut, Luminita Bonyhay, Vlad Ratziu, Fabienne Drane, Yen Ngo,
Mona Munteanu, Thierry Poynard
1923: Efficacy of tenofovir disoproxil fumarate in
chronic hepatitis B patients with genotypic resistances to
other nucleos(t)ide analogues
Tae Jung Yun, Soon Ho Um, Chang Ho Jung, Tae Hyung Kim, Seok
Bae Yoon, Sun Young Yim, Bora Keum, Yeon Seok Seo, Hyung
Joon Yim, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang
Duck Kim, Ho Sang Ryu
1924: Factors relevant to relapse in chronic hepatitis B
patients after off-therapy of telbivudine and lamivudine:
focused on long-term durability
Hong-Ying Pan, Hong-Yi Pan, Li Chen, DanHong Yang, HaiJun
Huang, YongXi Tong, Cui-Rong Chen, XingJiang Jian
1925: Course of partial virological response to entecavir
under long-term entecavir therapy in ptatients with
chronic hepatitis B
Joohan Park, Hyo Jung Cho, Sun Young Park, Seon Joo Ahn, Soon
Sun Kim, Jae Youn Cheong, Sung Won Cho
Poster Viewing: 8:00 AM – Noon
187A
Hepatitis C: New Agents (Not
Approved)
1926: Baseline and Post-baseline Resistance
Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir
± RBV
Christoph Sarrazin, Hadas Dvory-Sobol, Evguenia S. Svarovskaia,
Brian Doehle, Joseph F. McCarville, Phillip S. Pang, Nezam H.
Afdhal, Kris V. Kowdley, Edward J. Gane, Eric Lawitz, John G.
McHutchison, Michael D. Miller, Hongmei Mo
1927: CPI-431-32, a Novel Cyclophilin A Inhibitor,
Simultaneously Blocks Replication of HCV and HIV-1
Viruses in a Novel in Vitro Co-Infection Model
Philippe Gallay, Michael Bobardt, Dan Trepanier, Daren Ure,
Cosme Ordonez, Robert T. Foster
1928: Interferon-Free Regimens of Ombitasvir and
ABT-450/r With or Without Ribavirin in Patients With
HCV Genotype 4 Infection: PEARL-I Study Results
Stanislas Pol, K. Rajender Reddy, Tolga Baykal, Christophe
Hezode, Tarek Hassanein, Patrick Marcellin, Marina Berenguer,
Katarzyna M. Fleischer-Stepniewska, Coleen Hall, Christine
Collins, Regis A. Vilchez
1929: 100% SVR4 in Japanese Patients with Chronic
Genotype 1 Hepatitis C Virus Infection Receiving
Ledipasvir/Sofosbuvir Fixed Dose Combination for 12
Weeks: Results from a Multicenter Phase 3 Study
Masashi Mizokami, Tetsuo Takehara, Osamu Yokosuka, Naoya
Sakamoto, Masaaki Korenaga, Hitoshi Mochizuki, Kunio Nakane,
Hirayuki Enomoto, Mikio Yanase, Hidenori Toyoda, Fusao Ikeda,
Takuya Genda, Takeji Umemura, Hiroshi Yatsuhashi, Tatsuya Ide,
Nobuo Toda, Kazushige Nirei, Yoshiyuki Ueno, Yoichi Nishigaki,
Juan Betular, Bing Gao, Akinobu Ishizaki, Masa Omote, Phillip S.
Pang, Steven J. Knox, William T. Symonds, John G. McHutchison,
Namiki Izumi, Masao Omata
1930: Alisporivir Selectively Eliminates HCV-Created
Double Membrane Vesicles by Disrupting CypA-NS5A
interactions in Infected Hepatocytes
Udayan Chatterji, Michael Bobardt, Malcolm Wood, Philippe
Gallay
1931: SVR12 Rate of 98.6% in 992 HCV Genotype
1b-Infected Patients Treated with ABT-450/r/
Ombitasvir and Dasabuvir With or Without Ribavirin
Massimo Colombo, Ola Weiland, Daniel E. Cohen, Jean-Francois
J. DuFour, Hendrik Reynaert, Moises Diago, Erica Villa, Adrian
Streinu-Cercel, Wangang Xie, Tolga Baykal, Jeffrey Enejosa, Eoin
Coakley, Roger Trinh, Thomas Podsadecki
1932: On Treatment HCV RNA as a Predictor of
Virologic Response in the Ledipasvir/Sofosbuvir Phase 3
Program for HCV Genotype 1 Infection: Analysis of the
NOVEMBER 11
ION-1, ION-2, and ION-3 Studies
TUESDAY
Tania M. Welzel, Eva Herrmann, Patrick Marcellin, Nezam H.
Afdhal, Kris V. Kowdley, Luisa M. Stamm, Yanni Zhu, Phillip S.
Pang, John G. McHutchison, Stefan Zeuzem
Presenters in Attendance 10:30 AM – Noon
 188A POSTER SESSIONS
Poster Sessions
1933: PEARL-IV Trial: Subgroup Analysis of
Genotype 1a-Infected Patients Treated With ABT-450/r/
Ombitasvir With Dasabuvir With or Without Ribavirin
David Eric Bernstein, Yan Luo, Jacob P. Lalezari, David L. Wyles,
William King, Naoky Tsai, Mitchell N. Davis, Thomas E. Sepe,
Jeffrey Fessel, Martin King, Thomas Podsadecki, Curtis Cooper
1934: SVR12 Rate of 95.7% in 209 HCV Genotype
1-Infected Null Responders Treated With ABT-450/r/
Ombitasvir and Dasabuvir With or Without Ribavirin
Ira M. Jacobson, Jean-Francois J. DuFour, Jeffrey Enejosa, Robert J.
de Knegt, Peter Ferenci, Hendrik Reynaert, Adrian M. Di Bisceglie,
Lois Larsen, Tolga Baykal, Lino Rodrigues-Jr, Thomas Podsadecki,
Donald M. Jensen, Fred Poordad
1935: Early Improvement in the HepQuant® (HQ)-
SHUNT Function Test during Treatment with Ledipasvir/
Sofosbuvir in Liver Transplant Recipients with Allograft
Fibrosis or Cirrhosis and Patients with Decompensated
Cirrhosis who have not undergone Transplantation
Jacqueline G. O’Leary, James R. Burton, Steve M. Helmke, Andrea
Herman, Michael W. Cookson, Shannon Lauriski, James F. Trotter,
Jill M. Denning, Phillip S. Pang, John G. McHutchison, Gregory T.
Everson
1936: Pooled analysis of resistance in patients
treated with ombitasvir/ABT-450/r and dasabuvir with
or without ribavirin in Phase 2 and Phase 3 clinical
trials
Preethi Krishnan, Rakesh Tripathi, Gretja Schnell, Thomas Reisch,
Jill Beyer, Michelle Irvin, Wangang Xie, Lois Larsen, Thomas
Podsadecki, Tami Pilot-Matias, Christine Collins
1937: All-oral Dual Combination of Daclatasvir
plus Asunaprevir Compared with Telaprevir plus
Peginterferon Alfa/Ribavirin in Treatment-naive
Japanese Patients Chronically Infected with HCV
Genotype 1b: Results from a Phase 3 Study
Kazuaki Chayama, Fumitaka Suzuki, Yoshiyuki Suzuki, Joji Toyota,
Yoshiyasu Karino, Yoshiiku Kawakami, Shigetoshi Fujiyama,
Takayoshi Ito, Yoshito Itoh, Etsuko Tamura, Tomoko Ueki, Hiroki
Ishikawa, Misti Linaberry, Eric A. Hughes, Hiromitsu Kumada
1938: ABT-450/r/Ombitasvir + Dasabuvir With or
Without Ribavirin in HCV Genotype 1-infected Patients
Receiving Stable Opioid Substitution Treatment: Pooled
Analysis of Efficacy and Safety in Phase 2 and Phase 3
Trials
Massimo Puoti, Curtis Cooper, Mark S. Sulkowski, Graham R.
Foster, Thomas Berg, Erica Villa, Federico Rodriguez-Perez, Vinod
Rustgi, David L. Wyles, Martin King, Barbara H. McGovern,
Heiner Wedemeyer
NOVEMBER 11
TUESDAY
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1939: TURQUOISE-I: 94% SVR12 in HCV/HIV-1
Coinfected Patients Treated with ABT-450/r/Ombitasvir,
Dasabuvir and Ribavirin
David L. Wyles, Mark S. Sulkowski, Joseph J. Eron, Roger Trinh,
Jay Lalezari, Jihad Slim, Joseph C. Gathe, Chia C. Wang, Richard
Elion, Fritz Bredeek, Robert O. Brennan, Gary Blick, Amit Khatri,
Krystal Gibbons, Yiran Hu, Linda Fredrick, Tami Pilot-Matias,
Barbara Da Silva-Tillmann, Barbara H. McGovern, Andrew L.
Campbell, Thomas Podsadecki
1940: Pharmacokinetics of Co-Administered HCV
Protease Inhibitor MK-5172 and NS5A Inhibitor
MK-8742 in Volunteers with End-Stage Renal Disease
on Hemodialysis or Severe Renal Impairment Not on
Hemodialysis
Wendy W. Yeh, Luzelena Caro, Zifang Guo, Hwa Ping Feng,
Henry U. Davis, Megan Kozisek, Daria Stypinski, Chun Feng,
Carrie Mitchell, Anne Gillespie, Nita Ichhpurani, William L.
Marshall, Kenneth C. Lasseter, Thomas C. Marbury, Joan R.
Butterton
1941: HELIX-2, A Phase II Study of Samatasvir in
Combination with Simeprevir, Low Dose Ritonavir-
boosted TMC647055 + Ribavirin in Treatment-naïve or
Interferon/ribavirin Treated, Relapsed Genotype 1 HCV-
infected Subjects
Eric Lawitz, Maribel Rodriguez-Torres, Tuan T. Nguyen, Aasim
M. Sheikh, Hillel Tobias, Joseph S. Galati, John M. Hill, Anna
S. Lok, David R. Nelson, Gloria Dubuc Patrick, Jie Chen, Dodie
Frank, Xiao-Jian Zhou, John Sullivan-Bolyai, Leen Vijgen, Pieter
Van Remoortere, René Verloes, Gaston Picchio, Douglas L. Mayers
1942: Resistance Analysis of Treatment-Naïve HCV
Genotype 1-6 Infected Patients Treated with Sofosbuvir
in Combination with GS-5816 for 12 Weeks
Brian Doehle, Viktoria Gontcharova, Ramakrishna K.
Chodavarapu, John McNally, Raymond T. Chung, Gregory T.
Everson, John G. McHutchison, Michael D. Miller, Hongmei Mo
1943: Daclatasvir in combination with asunaprevir and
BMS-791325 for prior null responders with chronic HCV
genotype 1 infection
Gregory T. Everson, Karen D. Sims, Paul J. Thuluvath, Howard
Schwartz, Tarek Hassanein, Eric Lawitz, Lynn R. Webster, Norbert
Brau, Taddese Desta, Joseph S. Galati, Reem H. Ghalib, Norman
Gitlin, Steven-Huy Han, Federico Hinestrosa, Maribel Rodriguez-
Torres, Ronald Nahass, Peter J. Ruane, Wen-Lin Luo, Fiona
McPhee, David F. Gardiner
1944: Safety of Ledipasvir/Sofosbuvir with and without
Ribavirin for the Treatment of Patients with Chronic HCV
Genotype 1 Infection: An Analysis of the Phase 3 ION
trials
Saleh Alqahtani, Nezam H. Afdhal, Stefan Zeuzem, Stuart C.
Gordon, Alessandra Mangia, Paul Y. Kwo, Jenny C. Yang, Xiao
Ding, Phillip S. Pang, John G. McHutchison, Patrick Marcellin, Kris
V. Kowdley, Mark S. Sulkowski
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1945: Virologic Response Rates to All Oral Fixed-
Dose Combination Ledipasvir/Sofosbuvir Regimens
Are Similar in Patients With and Without Traditional
Negative Predictive Factors in Phase 3 Clinical Trials
Ira M. Jacobson, Paul Y. Kwo, Kris V. Kowdley, Jenny C. Yang,
Yanni Zhu, Robert H. Hyland, Phillip S. Pang, John G. McHutchison,
Mark S. Sulkowski, Nezam H. Afdhal
1946: A Next Generation HCV DAA Combination:
Potent, Pangenotypic Inhibitors ABT-493 and ABT-530
with High Barriers to Resistance
Teresa Ng, Tami Pilot-Matias, Liangjun Lu, Thomas Reisch, Tanya
Dekhtyar, Preethi Krishnan, Jill Beyer, Rakesh Tripathi, Ron B.
Pithawalla, Armen Asatryan, Andrew L. Campbell, Jens Kort,
Christine Collins
1947: Concordance between SVR4, SVR12 and SVR24
in Genotype 1 HCV-Infected Patients who Received All
Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir
With Or Without Ribavirin in Phase 3 Clinical Trials
David Eric Bernstein, Alessandra Mangia, Norbert Brau, Jenny
C. Yang, Julie Ma, Robert H. Hyland, Phillip S. Pang, John G.
McHutchison, K. Rajender Reddy, Michael W. Fried
1948: High Rates of SVR in Patients with Genotype
1 HCV Infection and Cirrhosis After Treatment with
Ledipasvir/Sofosbuvir+Ribavirin or Ledipasvir/
Sofosbuvir+GS-9669 for 8 weeks
Eric Lawitz, Fred Poordad, Robert H. Hyland, Jing Wang, Phillip
S. Pang, William T. Symonds, John G. McHutchison, Fernando E.
Membreno
1949: Evaluation of the Resistance Profile of Ledipasvir
(LDV), a Nonstructural Protein 5A (NS5A) Inhibitor,
in Genotype (GT) 1 Chronically Infected HCV Subjects
Treated with LDV-Containing Regimens without
Sofosbuvir (SOF)
Kathryn M. Kitrinos, David L. Wyles, Hadas Dvory-Sobol, Angela
Worth, Bin Han, Diana M. Brainard, Bittoo Kanwar, Michael D.
Miller, Hongmei Mo
1950: Time to Viral Suppression is Not Related to
Achievement of SVR12 in HCV GT1-infected Patients
Treated with ABT-450/r/Ombitasvir and Dasabuvir
With or Without Ribavirin
Mark S. Sulkowski, Michael W. Fried, Resat Ozaras, Vasily Isakov,
David L. Wyles, Peter Ferenci, Jordan J. Feld, Filipe Calinas,
Michael Gschwantler, Martin King, Tolga Baykal, Edward J. Gane
1951: Safety of ABT-450/r/Ombitasvir + Dasabuvir
With or Without Ribavirin in HCV Genotype 1-infected
Patients: Results From Phase 2 and Phase 3 Trials
Michael W. Fried, Adrian M. Di Bisceglie, John M. Vierling,
Edward J. Gane, Frederik Nevens, Simone I. Strasser, Ola
Weiland, Sorin Rugina, Sandra S. Lovell, Barbara Da Silva-
Tillmann, Nancy Shulman, Naoky Tsai, David R. Nelson
Poster Viewing: 8:00 AM – Noon
189A
1952: The Pharmacokinetics of Ledipasvir, an HCV
Specific NS5A Inhibitor, in HCV-Uninfected Subjects
with Severe Renal Impairment
Erik Mogalian, Anita Mathias, Jenny C. Yang, Phillip S. Pang, Lisa
Moorehead, Maria G. Hernandez, Kenneth C. Lasseter, Daniel
Ries, Richard A. Robson, Gernot Klein
1953: Adherence to Prescribed Doses of ABT-450/r/
Ombitasvir, Dasabuvir, and Ribavirin in the Phase 3
PEARL-II, PEARL-III, and PEARL-IV Trials
David Eric Bernstein, Rui T. Marinho, Daniel E. Cohen, Fritz
Bredeek, Ferenc Schneider, Gunnar P. Norkrans, Manuela G.
Curescu, Michael Bennett, Marina Maevskaya, Jeffrey Fessel,
Wangang Xie, Yan Luo, Jeffrey Enejosa
1954: Identification and treatment of multiple subtypes
of HCV genotype 4 in the PEARL-I study with ombitasvir
and ABT-450/r ± ribavirin
Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Preethi
Krishnan, Tolga Baykal, Coleen Hall, Regis A. Vilchez, Tami Pilot-
Matias, Christine Collins
1955: Safety and efficacy outcomes of all-oral
daclatasvir-containing regimens in patients with or
without cirrhosis in phase 2 and 3 studies
Donald M. Jensen, Ira M. Jacobson, Hiromitsu Kumada, Joji
Toyota, Mark S. Sulkowski, Michael P. Manns, Jia-Horng Kao,
Jeong Heo, Philip Yin, Patricia Mendez, Eric A. Hughes, Stephanie
Noviello
1956: Potent Antiviral Activity of ABT-493 and ABT-530
With 3-Day Monotherapy in Patients With and Without
Compensated Cirrhosis With Hepatitis C Virus (HCV)
Genotype 1 Infection
Eric Lawitz, William D. O’Riordan, Bradley L. Freilich, Terry D.
Box, J. Scott Overcash, Wei Liu, Andrew L. Campbell, Chih-Wei
Lin, Armen Asatryan, Jens Kort
1957: Pharmacokinetics of Cyclosporine and
Tacrolimus, Following Coadministration with the Direct
Acting Antiviral Combination, ABT-450/r, Ombitasvir
and Dasabuvir, in Liver Transplant Patients with
Genotype-1 HCV Infection
Prajakta Badri, Apurvasena Parikh, Eoin Coakley, Bifeng Ding,
Walid Awni, Sandeep Dutta, Rajeev Menon
1958: No Differences in the Efficacy of Fixed-Dose
Combination Ledipasvir/Sofosbuvir in Patients
According to Fibrosis Stage Determined by Liver Biopsy
or Laboratory Biomarker in Phase 3 Clinical Trials
Stuart C. Gordon, Michael W. Fried, Paul Y. Kwo, Jenny C.
Yang, Yanni Zhu, Robert H. Hyland, Phillip S. Pang, John G.
McHutchison, K. Rajender Reddy, Patrick Marcellin
NOVEMBER 11
TUESDAY
Presenters in Attendance 10:30 AM – Noon
 190A POSTER SESSIONS
Poster Sessions
1959: HCVerso1: A phase III study of faldaprevir (FDV)
plus deleobuvir (DBV) and ribavirin (RBV) for chronic
HCV genotype (GT)-1b infection in treatment-naïve
patients
Christoph Sarrazin, Francesco Castelli, Massimo Puoti, Mitchell
L. Shiffman, Liliana Preotescu, Xavier Forns, Maria Buti, Eric M.
Yoshida, Marc Bourlière, Célia Oliveira, Jerry O. Stern, Wulf O.
Boecher, George Kukolj, Carla Haefner, Richard Vinisko, Miguel
Garcia, Federico J. Mensa
1960: Deep Sequencing Analysis Of Variants Resistant
To Ns5a Inhibitors In Patients With Genotype 1b
Hepatitis C Virus Infection
Shinya Maekawa, Mika Miura, Mitsuaki Sato, Nobutoshi Komatsu,
Yasuhiro Nakayama, Taisuke Inoue, Minoru Sakamoto, Nobuyuki
Enomoto
1961: Safety of ABT-450/r/Ombitasvir + Dasabuvir
With or Without Ribavirin in HCV Genotype 1-infected
Patients: Results From PEARL II, PEARL III, and PEARL IV
Jacob P. Lalezari, Ronald Pruitt, Yan Luo, Richard J. Aspinall,
Giovanni B. Gaeta, Iwona Olszok, William King, Selim Gurel,
Yiran Hu, Jeffrey Enejosa, Daniel E. Cohen, Nancy Shulman,
Velimir A. Luketic
1962: TURQUOISE-II: Trends in Liver Fibrosis Testing,
Hepatic Synthetic Function, and Platelet Counts at
Baseline and 12 Weeks After Treatment With ABT-
450/r/Ombitasvir and Dasabuvir With Ribavirin in
HCV Genotype 1-Infected Patients with Cirrhosis
Mitchell L. Shiffman, Kris V. Kowdley, Stefan Zeuzem, David J.
Mutimer, Marc Bourlière, Thomas Berg, Samuel S. Lee, Sandra S.
Lovell, Leticia Canizaro, Roger Trinh, Guy Neff, Paul Y. Kwo
1963: Impaired Early Viral Kinetics in Patients with
Cirrhosis treated with Interferon-free Regimens - The
Impact of Portal Pressure
Mattias Mandorfer, Karin Kozbial, Albert Stättermayer, Sandra
Beinhardt, Philipp Schwabl, Remy Schwarzer, Michael Trauner,
Arnulf Ferlitsch, Harald Hofer, Markus Peck-Radosavljevic, Peter
Ferenci
1964: Resistance Analysis of Hepatitis C Virus (HCV)
from Genotype 1 and 4 Treatment-naïve Subjects
Receiving Samatasvir in Combination with Simeprevir
and Ribavirin in a 12-week Phase II Clinical Trial
Bianca Heinrich, John P. Bilello, Eric Lawitz, Maribel Rodriguez-
Torres, Tuan T. Nguyen, Aasim M. Sheikh, Hillel Tobias, Joseph S.
Galati, John M. Hill, Anna S. Lok, David R. Nelson, Leen Vijgen,
Pieter Van Remoortere, René Verloes, Gaston Picchio, Gloria
Dubuc Patrick, Maria Seifer, Douglas L. Mayers
1965: Long-term follow-up of patients treated with
daclatasvir-based regimens in phase 2 and 3 studies
K. Rajender Reddy, Stanislas Pol, Paul J. Thuluvath, Hiromitsu
NOVEMBER 11
Kumada, Joji Toyota, Kazuaki Chayama, James M. Levin, Eric
TUESDAY
Lawitz, Adrian Gadano, Wayne Ghesquiere, Guido Gerken,
Maurizia R. Brunetto, Cheng-Yuan Peng, Ruben Terg, Marcelo O.
Silva, Simone I. Strasser, Jeong Heo, Fiona McPhee, Zhaohui Liu,
Misti Linaberry, Eric A. Hughes, Stephanie Noviello
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1966: HCVerso2: A phase III study of faldaprevir
(FDV) plus deleobuvir (DBV) and ribavirin (RBV) for
chronic HCV genotype (GT)-1b infection in treatment-
naïve patients including those ineligible for pegylated
interferon (PegIFN)
David R. Nelson, Pietro Andreone, Massimo Colombo, Filipe
Calinas, Antonio Olveira, Jean Delwaide, Dieter Häussinger,
Denis Ouzan, Simone I. Strasser, Tarik Asselah, Curtis Cooper,
Jerry O. Stern, Wulf O. Boecher, George Kukolj, Stella Aslanyan,
Qiqi Deng, Edward Wang, Federico J. Mensa
1967: Pharmacokinetics of asunaprevir, daclatasvir
and raltegravir in HCV/HIV co infected patients, with
or without cirrhosis, and previously null responders
to pegylated interferon + ribavirin (ANRS HC30 -
QUADRIH study)
Anne-Marie Taburet, Lionel Piroth, Hubert Paniez, Mélanie Simony,
Valerie Furlan, Aurélie Barrail-Tran, Corine Vincent, Eric Rosenthal,
Eric Billaud, Hugues Aumaître, François Bailly, Martine Resch,
Laurence Meyer, Jean-Michel Molina
1968: Efficacy by Race or Geographic Region in HCV
Genotype 1-infected Patients Treated with ABT-450/
ritonavir/Ombitasvir and Dasabuvir With or Without
Ribavirin
John M. Vierling, Massimo Puoti, David Eric Bernstein, Naoky Tsai,
Ola Weiland, Manuel Romero Gómez, Florin A. Caruntu, Jean-
Francois J. DuFour, Filipe Calinas, Lois Larsen, Fernando Tatsch,
Pietro Andreone
1969: Safety of ABT-450/r/Ombitasvir + Dasabuvir
With or Without Ribavirin in HCV Genotype 1-infected
Patients ≥65 Years of Age: Results From Phase 2 and 3
Trials
Steven L. Flamm, Edward J. Gane, Jean-Francois J. DuFour, Vinod
Rustgi, Vincent G. Bain, Darrell H. Crawford, Pietro Andreone,
Tarek Hassanein, Wlodzimierz W. Mazur, Sandra S. Lovell,
Barbara Da Silva-Tillmann, Nancy Shulman, Massimo Puoti, Terry
D. Box, Ira M. Jacobson
1970: Ledipasvir/Sofosbuvir is Safe and Effective in
Nosocomially Infected Patients with Advanced Age and
Significant Cardiac Co-Morbidities
Raymond T. Chung, Georg M. Lauer, Luisa M. Stamm, Lin Liu,
Hongmei Mo, Phillip S. Pang, Diana M. Brainard, John G.
McHutchison, Arthur Y. Kim
1971: Durability of Sustained Virologic Response in
Hepatitis C Infected Patients Treated with IFN-Free DAA
Regimens
Sara Jones, Miriam Marti, Zayani Sims, Anita Kohli, Sarah
Kattakuzhy, Tess L. Petersen, Rachel Silk, Michael A. Polis, Henry
Masur, Shyam Kottilil, Anu Osinusi
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
1972: ABT-450/r/Ombitasvir + Dasabuvir With or
Without Ribavirin in HCV Genotype 1-infected Patients
with History of Depression or Bipolar Disorder: Pooled
Analysis of Efficacy and Safety in Phase 3 Trials
David R. Nelson, K. Rajender Reddy, Adrian M. Di Bisceglie,
Peter Ferenci, Darrell H. Crawford, Rudolf E. Stauber, Alexey A.
Yakovlev, Victor de Ledinghen, Holger Hinrichsen, David Eric
Bernstein, Robert J. de Knegt, Tarek Hassanein, Suzanne Norris,
Junyuan J. Xiong, Barbara H. McGovern, Kosh Agarwal
1973: Characteristics of HCV-Infected Patients with
Cirrhosis Requiring Ribavirin Dose Reduction During
Treatment with Direct-Acting Antivirals
Ira M. Jacobson, Xavier Forns, Stefan Zeuzem, Christophe Hezode,
Mitchell L. Shiffman, Stanislas Pol, Marina Berenguer, Michael W.
Fried, Kosh Agarwal, Kris V. Kowdley, Sandra S. Lovell, Manal
Abunimeh, Roger Trinh, Barbara H. McGovern, Antonio Craxi
Hepatitis C: Preclinical Development
1974: A Phase I/IIa Study Assessing 7-day Dosing
of IDX21437 in Subjects Infected with Hepatitis C Virus
(HCV)
Edward J. Gane, Eric Sicard, Serghei Popa, Xiao-Jian Zhou, Marie-
Francoise Temam, Jie Chen, Dodie Frank, Eileen F. Donovan, Keith
Pietropaolo, Douglas L. Mayers
1975: A 4-N-Hydroxycytidine Ribonucleoside
Phosphoramidate Delivers Intracellularly Three Distinct
Active 5’-Triphosphate Nucleosides that are Potent
Inhibitors of HCV Polymerase
Raymond F. Schinazi, Franck Amblard, Sijia Tao, Maryam
Ehteshami, Sheida Amiralaei, Hao Li, Jadd Shelton, Tony Whitaker,
Tami R. McBrayer, Steven J. Coats
1976: Drug-Drug Interaction Profile Of The Fixed-
Dose Combination Tablet Ledipasvir/Sofosbuvir
Polina German, Phillip S. Pang, Liang Fang, Diana Chung, Anita
Mathias
1977: Hepatocellular carcinoma development of
hepatitis C virus patients with eradication to interferon
therapy: a large scale, long-term study of 2266 patients
Yuko Nagaoki, Hiroshi Aikata, Tomoki Kobayashi, Takayuki
Fukuhara, Noriaki Naeshiro, Daisuke Miyaki, Tomokazu
Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura,
Hideyuki Hyogo, Yoshiiku Kawakami, Hidenori Ochi, Kazuaki
Chayama
1978: ACH-3422, A Novel HCV NS5B RNA
Polymerase Nucleotide Inhibitor, Demonstrates
Improved Potency Over Sofosbuvir Against HCV
Genotype-3 Replicons In Vitro
Yongsen Zhao, Steven Podos, Joanne L. Fabrycki, Dharaben Patel,
Wengang Yang, Guangwei Yang, Jason Wiles, Avinash Phadke,
Mingjun Huang
Poster Viewing: 8:00 AM – Noon
191A
1979: MK-8408, A Potent and Selective NS5A Inhibitor
with a High Genetic Barrier to Resistance and Activity
Against HCV Genotypes 1-6
Ernest Asante-Appiah, Rong Liu, Stephanie Curry, Patricia
McMonagle, Sony Agrawal, Donna Carr, Laura Rokosz, Frederick
Lahser, Karin Bystol, Robert Chase, Stuart Black, Eric B. Ferrari,
Paul Ingravallo, Shiying Chen, Ling Tong, Wensheng Yu, Joseph
Kozlowski
1980: First Time in Human (FTIH) and Proof of Concept
(POC) Studies of GSK2878175 (GSK175), a Potent Pan-
Genotypic Non-Nucleoside NS5B Polymerase Inhibitor
of HCV Replication
Stephen D. Gardner, Joseph Kim, Benjamin Van Hecke, Maribel
Rodriguez-Torres, Lucinda Elko-Simms, Sharon Baptiste-Brown,
Vincent Lopez, Etienne F. Dumont, Robert Hamatake, Kevin Gan,
Z. Joe Zhu, Martin Leivers, Melanie T. Paff, Zhi Hong
1981: Modeling HCVcc infection reveals new insights
into the dynamics that maintain the in vitro HCV steady
state and the mechanisms of action of the NS5A
inhibitor daclatasvir
Natasha Sansone, Harel Dahari, Gitanjali Subramanya, Alan S.
Perelson, Susan L. Uprichard
1982: A Novel Approach to HCV Resistance Selection
Featuring Short Treatment Duration and Reduced
Interference from Host Cell Adaptation
Joanne L. Fabrycki, Yongsen Zhao, Dharaben Patel, Lingling Jia,
Guangwei Yang, Steven Podos, Avinash Phadke, Mingjun Huang,
Wengang Yang
1983: Preclinical Characterization of AL-516, a Potent
Guanosine Based Nucleotide Polymerase Inhibitor for
the Treatment of Chronic Hepatitis C
Hua Tan, Kenneth Shaw, Andreas Jekle, Jerome Deval, Zhinan Jin,
Amy Fung, Yuen Tam, Lawrence M. Blatt, Sushmita M. Chanda,
Qingling Zhang, Guangyi Wang, Natalia Dyatkina, Julian A.
Symons, Leo Beigelman, David B. Smith
1984: Prevention of HCV virologic breakthrough during
protease inhibitor monotherapy by addition of an SR-BI
targeting monoclonal antibody
Koen Vercauteren, Ahmed A. Mesalam, Richard Brown, Fulvia
Troise, Juliane Doerrbecker, Naomi Van Den Eede, Ali Farhoudi,
Riccardo Cortese, Geert Leroux-Roels, Thomas Pietschmann,
Alfredo Nicosia, Philip Meuleman
1985: Antiviral Activity and Resistance Emergence:
Combinations of the NS5B Nucleotide Inhibitor ACH-
3422 with Other Antiviral Agents in Vitro
Dharaben Patel, Yongsen Zhao, Joanne L. Fabrycki, Guangwei
Yang, Steven Podos, Jason Wiles, Avinash Phadke, Mingjun
Huang, Wengang Yang
NOVEMBER 11
TUESDAY
Presenters in Attendance 10:30 AM – Noon
 192A POSTER SESSIONS
Poster Sessions
1986: Pharmacokinetics and Safety of Pan-Genotypic,
Direct Acting Protease Inhibitor, ABT-493, and NS5A
Inhibitor, ABT-530, Following 3 day Monotherapy
in HCV Genotype-1 Infected Subjects with or without
Compensated Cirrhosis
Chih-Wei Lin, Wei Liu, Armen Asatryan, Andrew L. Campbell,
Sandeep Dutta
1987: Pharmacokinetics and Drug-Drug Interaction
between Samatasvir, an NS5A Inhibitor, and
Co-administered Simeprevir, an NS3/4A Protease
Inhibitor, and Low Dose Ritonavir-Boosted TMC647055,
a Non-Nucleoside NS5B Inhibitor, in Healthy Volunteers
and HCV-Infected Subjects
Xiao-Jian Zhou, Keith Pietropaolo, Dodie Frank, Jie Chen, Rolf
van Heeswijk, John Sullivan-Bolyai, Pieter Van Remoortere, René
Verloes, Douglas L. Mayers
1988: The Combination of MK-5172, an NS3 inhibitor,
and MK-8408, an NS5A Inhibitor, Presents a High
Genetic Barrier to Resistance in HCV Genotypes
Frederick Lahser, Karin Bystol, Stephanie Curry, Patricia
McMonagle, Rong Liu, Ellen Xia, Robert Chase, Stuart Black, Eric
B. Ferrari, Ling Tong, Wensheng Yu, Joseph Kozlowski, Ernest
Asante-Appiah
1989: AL-335, a Novel Potent anti-HCV Nucleotide
Analog, Demonstrates Synergistic Activity when
Given in Combination with other anti-HCV DAAs in a
Subgenomic Replicon System
Hua Tan, Kenneth Shaw, Natalia Dyatkina, Guangyi Wang, Leo
Beigelman, David B. Smith, Lawrence M. Blatt, Julian A. Symons
1990: Plasma microRNA-122 levels decrease
significantly in chronic hepatitis C patients treated with
miravirsen
Meike van der Ree, Adriaan J. van der Meer, Adrianus C. van
Nuenen, Soren Ottosen, Amy Patick, Harry L. Janssen, Neeltje A.
Kootstra, Hendrik W. Reesink
1991: HCV Nucleoside Inhibitors can Exhibit Genotype
Specific Differences in Activity
Elizabeth D. Anton, Kristi Strommen, Wei Huang, Amber A. Rivera,
Christos J. Petropoulos, Franck Amblard, Raymond F. Schinazi,
Jacqueline D. Reeves
1992: Prevention of hepatitis C virus infection by
adoptive allogeneic immunotherapy using suicide gene-
modified lymphocytes: an in vitro proof-of-concept
Céline Leboeuf, Joelle Roser-Schilder, Mélanie Lambotin, Sarah
Durand, Tao Wu, Marina Deschamps, Christophe Ferrand, Pierre
Tiberghien, Patrick Pessaux, Thomas F. Baumert, Eric Robinet
1993: Comparison of Three 2’-C-Methyl Guanosine
Prodrugs for Hepatitis C including a Novel β-D-2’-C-Me-
NOVEMBER 11
2,6-Diaminopurine Ribonucleoside Phosphoramidate
TUESDAY
(RS-1389): Interspecies Hepatocyte and Human
Cardiomyocyte Metabolism Profiles
Sijia Tao, Zhou Longhu, Hongwang Zhang, Shaoman Zhou,
Sheida Amiralaei, Jadd Shelton, Steven J. Coats, Raymond F.
Schinazi
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
1994: Evaluation of TG-2349, a novel HCV Protease
Inhibitor with Pan-Genotypic Activity, in Replicon-Mouse
Models with Luciferase Reporter
Ying-Huey Huang, Chih-Ming Chen, Hung-Ming Hsu, Chu-Chung
Lin, Chi-Hsin R. King, Ming-Chu Hsu
1995: HCV kinetics in uPA-SCID chimeric mice
with humanized livers during intravenous silibinin
monotherapy
Swati DebRoy, Nobuhiko Hiraga, Michio Imamura, Laetitia
Canini, Ralf T. Pohl, Stefano Persiani, Susan L. Uprichard, Alan S.
Perelson, Chise Tateno, Kazuaki Chayama, Harel Dahari
1996: The Antiviral Profile of TG-2349, a novel HCV
Protease Inhibitor with Pan-Genotypic Activity
Chih-Ming Chen, Yi-Fen Chen, Chu-Chung Lin, Chi-Hsin R. King,
Ming-Chu Hsu
1997: IDX21459, a Uridine Nucleotide Prodrug,
Shows a Favorable Preclinical Profile as a Direct-acting
Antiviral Agent (DAA) against HCV
Christopher D. Chapron, Kusum S. Gupta, Massimiliano La Colla,
Brenda Hernandez-Santiago, Maria Seifer, Hassan Rashidzadeh,
Ilaria Serra, Shouqi Luo, Xin-Ru Pan-Zhou, Christopher Brynczka,
Bianca Heinrich, Jinsoo Lim, Francois-Rene Alexandre, Roger Rush
1998: Lack of Clinically Relevant Pharmacokinetic
Drug-Drug Interaction between Norgestimate/Ethinyl
Estradiol and Pangenotypic HCV NS5A Inhibitor
GS-5816 in HCV-Uninfected Female Subjects
Erik Mogalian, Diana M. Brainard, John McNally, Gong Shen,
Jennifer Cuvin, Anita Mathias
Portal Hypertension - Experimental
1999: Partial Vasopressin 1α (V1α) Receptor Agonism
Reduces Portal Hypertension And Hyperaldosteronism
Thereby Inducing A Powerful Diuretic And Natriuretic
Effect In Cirrhotic Rats With Ascites
Guillermo Fernández-Varo, Denise Oró, Edward Cable, Kazimierz
Wisniewski, Pere Gines, Wladimiro Jiménez
2000: Changes in cardiac output, pulmonary dynamics
and incidence of volume overload in Cirrhotics receiving
20% Albumin infusion
Saggere M. Shasthry, Manoj Kumar, Jelen K. Singh, Shiv K. Sarin
2001: Sarcopenia of cirrhosis is mediated by
hyperammonemia-mediated transcriptional
upregulation of myostatin due to impaired β-catenin
signaling
Michela Giusto, Gangarao Davuluri, Samjhana Thapaliya, Uyen
Tran, Oliver Wessely, Sathyamangla V. Naga Prasad, Srinivasan
Dasarathy
2002: Hemodynamic effects of the oral non peptide
compound AVE0991
Sabine Klein, Chandana B. Herath, Frank E. Uschner, Josephine
A. Grace, Robert Schierwagen, Christian P. Strassburg, Tilman
Sauerbruch, Peter W. Angus, Jonel Trebicka
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
2003: Cerium Oxide Nanoparticles Reduce Portal
Hypertension and Show Antiinflammatory Properties in
CCl4-Treated Rats
Denise Oró, Guillermo Fernández-Varo, Vedrana Reichenbach,
Tetyana Yudina, Eudald Casals, Gregori Casals, Bernadino
Gonzalez de la Presa, Víctor Puntes, Wladimiro Jiménez
2004: A Large Animal Model of Portal Hypertension
and Cirrhosis in the FAH-Deficient Pig
Shennen A. Mao, Jaime Glorioso, Raymond D. Hickey, Meng
Yin, Joseph Lillegard, James E. Fisher, Ronald J. Marler, Markus
Grompe, Scott L. Nyberg
2005: NCX-6560, a nitric oxide-donating atorvastatin,
lowers portal pressure and has a better hepatic toxicity
profile than atorvastatin in cirrhotic rats
Sarai Rodríguez, Imma Raurell, Rafael Esteban, Joan Genescà,
María Martell
2006: The Beneficial Effects of P2X7 Antagonism on
Hepatic Fibrogenesis and Portal-Systemic Collaterals in
Rats with Bile Duct Ligation
Hung-Chun Tung, Teh-Ia Huo, Fa-Yauh Lee, Hui-Chun Huang
2007: In Cirrhosis, Calcium Desensitization Underlies
Reduced Myogenic Tone in Small Resistance Mesenteric
Arteries
Ravirajsinh Jadeja, Sandeep Khurana
2008: Obliterative Portal Venopathy in subjects without
portal hypertension: an unknown planet
Maria Guido, Samantha Sarcognato, Aurelio Sonzogni, Marco
Senzolo, Marco Pizzi, Stefano Fagiuoli, Maria Grazia Lucà,
Luciano Giacomelli, Guido Colloredo
2009: Hedgehog-signaling and angiogenesis in cirrhotic
and non-cirrhotic portal hypertension
Frank E. Uschner, Ganesh Ranabhat, Michaela Granzow, Steve S.
Choi, Sabine Klein, Robert Schierwagen, Esther Raskopf, Christian
P. Strassburg, Kanishka Hiththetiya, Tilman Sauerbruch, Anna Mae
Diehl, Jonel Trebicka
2010: Sarcopenia in alcoholic liver disease
accompanied by increased malondialdehyde-aldehyde
adducts and oxidative stress
Samjhana Thapaliya, Gangarao Davuluri, Megan R. McMullen,
Laura E. Nagy, Geoffrey M. Thiele, Sathyamangla V. Naga
Prasad, Srinivasan Dasarathy
2011: Rifaximin and propranolol combination therapy
is more effective than propranolol monotherapy in
the hepatic venous pressure gradient response and
propranolol dose reduction–A Pilot study
Youn zoo Cho, Moon Young Kim, Soon Koo Baik, Sang Ok Kwon,
Dong Joon Kim, Ki Tae Suk, Gab Jin Cheon, Young Don Kim, Dae
Hee Choi
Poster Viewing: 8:00 AM – Noon
193A
2012: Hemodynamic changes in hepatic circulation
and hepatic arterial buffer response after modulation
of splenic circulation in an in-vivo human experimental
model
Nobuhisa Akamatsu, Yasuhiko Sugawara, Taku Aoki, Tomohiro
Tanaka, Sumihito Tamura, Yoshihiro Sakamoto, Kiyoshi
Hasegawa, Junichi Kaneko, Norihiro Kokudo
2013: MicroRNA-128 is a Key Regulator of Hepatic
Dimethylarginine Dimethylaminohydrolase-1 (DDAH-1)
in a Rodent Model of Cirrhosis and Portal Hypertension
Gautam Mehta, Helen Jones, Vikram Sharma, Nathan Davies,
Rajiv Jalan, Rajeshwar Mookerjee
2014: Fibroblastic reticular cells are the major
contributors to splenomegaly and spleen stiffness in
portal hypertension
Chao Dong, Teruo Utsumi, Li Gong, Yasuko Iwakiri
2015: Systems Biology Analysis of Omeprazole Therapy
in Cirrhosis Demonstrates Significant Shifts in Gut
Microbiota Composition and Function
Jasmohan S. Bajaj, I. J. Cox, Naga Betrapally, Douglas M.
Heuman, Mitchell L. Schubert, Roger Williams, Melanie White,
Nicole Noble, Masoumeh Sikaroodi, Simon D. Taylor-Robinson,
Patrick M. Gillevet
2016: Oxidative stress plays an important role in
pathogenesis of hyperdynamic circulation in portal
hypertensive rats
Hongqun Liu, Noura Alhassan, Samuel S. Lee
2017: Blood brain barrier permeability is increased in
hepatic encephalopathy related to cirrhosis, through a
hyperammonemia-dependent mechanism
Sarah Mouri, Haquima El Mourabit, Colette Rey, Romain Morichon,
Dominique Wendum, Elisabeth Lasnier, Chantal Housset, Nicolas
Weiss, Dominique Thabut
2018: Prognostic Significance of the Hemodynamic and
Clinical Staging in the Prediction of Mortality in Patients
with Chronic Liver Disease
Sang Hyun Park, Ki Tae Suk, Eun Jin Kim, Hyo Sun Kim, Chang
Seok Bang, Hyoung Su Kim, Ji Won Park, Sung Eun Kim, Myoung
Kuk Jang, Choong Kee Park, Myung Seok Lee, Sang Hoon Park,
Dong Joon Kim
2019: Acute effect of Udenafil on portal pressure in
cirrhotic rats
Frank E. Uschner, Sabine Klein, Robert Schierwagen, Bernhard
Tewes, Christian P. Strassburg, Wolfgang Kreisel, Tilman
Sauerbruch, Jonel Trebicka
2020: Probiotic prevents the development of Portal
hypertension in a rabbit endotoxin induced portal
NOVEMBER 11
hypertension model
TUESDAY
Nidhi Chaudhary, Rashmi Babbar, Shiv K. Sarin
Presenters in Attendance 10:30 AM – Noon
 194A POSTER SESSIONS
Poster Sessions
2021: Bone Marrow Predicts Liver Regenerative
Response To Growth Factors In Decompensated
Cirrhosis
Lovkesh Anand, Avinash Kumar, Chhagan Bihari, Chandan K.
Kedarisetty, Anupam Kumar, Sheetalnath Rooge, Rakhi Maiwall,
Shiv K. Sarin
2022: Outcomes in Orthotopic Liver Transplantation;
Rotational Thromboelastrography (ROTEM) versus
Standard of Care: a Retrospective Study
Christopher M. Esber, Loren Brook, Nicole O’Bleness, A. James
Hanje
Stem Cell Biology
2023: DNMT1 is essential for postnatal liver
development
Kosuke Kaji, Valentina M. Factor, Jesper B. Andersen, Nikolay
Korokhov, Marian E. Durkin, Elizabeth A. Conner, Snorri S.
Thorgeirsson
2024: Matrix Metalloproteinase-14 regulates the
maturation of fetal hepatic stem/progenitor cells in mice
Satoshi Otani, Sei Kakinuma, Akihide Kamiya, Fumio Goto, Shun
Kaneko, Seishin Azuma, Yasuhiro Asahina, Mamoru Watanabe
2025: Targeting CD133(+) cancer stem cells by
inhibiting glycolytic metabolism through miR-122
Kyoungsub Song, Hyunjoo Kwon, Chang Han, Srikanta Dash,
Tong Wu
2026: Identification of a novel Wnt-responsive
hepatocyte stem cell population in the normal liver
Bruce M. Wang, Roel Nusse
2027: Long-term engineered cultures of iPSC-derived
human hepatocytes for disease modeling and drug
screening
Salman Khetani, Dustin Berger, Brenton R. Ware, Matthew
Davidson
2028: Recapitulation of Human Hepato-Biliary
Organogenesis in Self-assembled Liver Organoid
Culture
Dipen Vyas, Pedro M. Baptista, Emma Moran, Shay Soker
2029: Generation of human hepatocyte-like cells from
urine
Vanessa Sauer, Xia Wang, Krisztina Tar, Tatyana Tchaikowskaya,
Yanfeng Li, Chandan Guha, Namita Roy-Chowdhury, Jayanta Roy-
Chowdhury
2030: Human pluripotent stem cell derived hepatocyte-
like cells integrated in microfluidic platform for drug
NOVEMBER 11
screening applications
TUESDAY
Giovanni G. Giobbe, Federica Michielin, Alessandro Zambon,
Stefano Giulitti, Camilla Luni, Nicola Elvassore, Annarosa Floreani
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
2031: TSG-6 is involved in repair response in carbon
tetrachloride-induced acute liver injury in mice
Sihyung Wang, Jieun Kim, Jeongeun Hyun, Youngmi Jung
2032: Characterization and expansion mechanisms of
human iPS cell-derived hepatic progenitor-like cells
Kota Tsuruya, Akihide Kamiya, Hiromi Chikada, Kazuya Anzai,
Yoshitaka Arase, Shunji Hirose, Tatehiro Kagawa, Tetsuya Mine
2033: A Comprehensive Analysis of Gene Mutations in
Liver Cancer Stem Cells
Takehiro Hayashi, Taro Yamashita, Tsuyoshi Suda, Tomomi
Hashiba, Yoshirou Asahina, Mariko Yoshida, Tomoyuki Hayashi,
Yoshimoto Nomura, Yasumasa Hara, Kouki Nio, Naoki Oishi,
Hajime Sunagozaka, Hajime Takatori, Masao Honda, Shuichi
Kaneko
2034: Human biliary tree stem cells are efficiently
reprogrammed to functional β-pancreatic islet cells by a
synthetic human PDX1 peptide
Vincenzo Cardinale, Gaia Scafetta, Rosa Puca, Michele De Canio,
Francesca Sicilia, Guido Carpino, Domenico Casa, Rocco C.
Panetta, Pasquale Bartolomeo Berloco, Giorgio Federici, Eugenio
Gaudio, Marella Maroder, Domenico Alvaro
2035: Hyaluronic acid-based efficient cryopreservation
of human biliary tree stem/progenitor cells (hBTSCs)
demonstrated by biologic, genetic and molecular studies
Vincenzo Cardinale, Lorenzo Nevi, Raffaele Gentile, Guido
Carpino, Alice Fraveto, Alessia Torrice, Alfredo Cantafora,
Vincenzo Pasqualino, Giovanni Casella, Daniela Bosco,
Alessandro Pintore, Giuseppe Spagnolo, Michela Nardacci,
Pasquale Bartolomeo Berloco, Eugenio Gaudio, Domenico Alvaro
Varices and Bleeding
2036: Progression of hyperdynamic circulation in
compensated cirrhosis with portal hypertension and
response to β-blockers
Càndid Villanueva, Agustin Albillos, Joan Genescà, Juan G.
Abraldes, Jose Luis Calleja, Carles Aracil, Rafael Bañares, Rosa
María Morillas, Maria Poca, Beatriz Peñas, Salvador Aguustin,
Juan Carlos Garcia-Pagan, Oana Pavel, Jaime Bosch
2037: Effect of Simvastatin in Portal Hypertension
Priscila P. Flores, Guilherme F. Rezende, Ubiratan Cassano,
Monica Soldan
2038: Effect of Simvastatin in Portal Hypertension
Priscila P. Flores, Monica Soldan, Guilherme F. Rezende
2039: Variceal bleeding at diagnosis of portal vein
thrombosis does not increase mortality in patients with
cirrhosis
Carlos Noronha Ferreira, Teresa Rodrigues, Patrícia Sousa,
Fernando Ramalho, Paula Alexandrino, José F. Velosa
HEPATOLOGY, VOLUME 60, NUMBER 4 (SUPPL) POSTER SESSIONS
Poster Sessions
2040: Osteopontin is a new non-invasive parameter of
portal hypertension in patients with liver cirrhosis
Radan Bruha, Marie Jachymova, Jaromir Petrtyl, Libor Vitek, Petr
Urbanek, Karel Dvorak
2041: Embolization of splenic artery contributes
to controlling elevated portal venous pressure and
promoting improved hepatic function induced by
occlusion of portosystemic shunts in patients with
cirrhosis
Tsuyoshi Ishikawa, Shogo Shiratsuki, Takashi Matsuda, Takuya
Iwamoto, Taro Takami, Shuji Terai, Isao Sakaida
2042: A simple scoring system using MELD-Na and the
stage of hepatocellular carcinoma for prediction of early
mortality after acute variceal bleeding in patients with
liver cirrhosis
Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Kazuhiko Hayashi,
Masatoshi Ishigami, Hidemi Goto
2043: Prognostic factors affecting treatment
outcomes of acute variceal bleeding in patients with
hepatocellular carcinoma: a single center prospective
study
Soo Young Park, Su Hyun Lee, Se Young Jang, Jung Gil Park, Won
Young Tak, Young Oh Kweon, Hyun Young Woo, Jeong Heo, Eun
Jeong Kang, Yu Rim Lee
2044: VITRO-score predicting clinically significant portal
hypertension
Stephanie Hametner, Alexandra Etschmaier, Arnulf Ferlitsch,
Alexander Ziachehabi, Rainer Schöfl, Monika Ferlitsch, Andreas
Maieron
2045: Indocyanine Green 15-min Retention test (ICG-
r15) as a predictor of clinical decompensation in
patients with compensated liver cirrhosis
Andrea Lisotti, Francesco Azzaroli, Buonfiglioli Federica, Marco
Montagnani, Paolo Cecinato, Claudio Calvanese, Simoni Patrizia,
Alberto Porro, Domenico Fiorillo, Alessandro Cucchetti, Antonio
Colecchia, Rita Golfieri, Davide Festi, Giuseppe Mazzella
2046: Prospective validation of Baveno V definitions
and criteria for failure to control bleeding in portal
hypertension
Won Young Tak, Soo Young Park, Young Oh Kweon, Se Young
Jang, Su Hyun Lee, Jung Gil Park, Jeong Heo, Hyun Young Woo
2047: Long-Term Outcome of 139 Patients with Liver
Cirrhosis Receiving Balloon-Occluded Retrograde
Transvenous Obliteration for Gastric Fundal Varices
Yukinori Imai, Manabu Nakazawa, Satsuki Ando, Kayoko
Sugawara, Satoshi Mochida
2048: WITHDRAWN
Poster Viewing: 8:00 AM – Noon
195A
2049: Survival of acute peptic ulcer bleeding in cirrhosis
as compared with variceal bleeding using current first-
line therapies
Alba Ardèvol, Jose Castellote, Joaquim Profitos, Carles Aracil,
Josep Castellvi, Oana Pavel, Gemma Ibañez Sanz, Diana Horta,
Josep M M. Calafat, Barbara Gomez-Pastrana, Càndid Villanueva
2050: Hemodynamic response to non-selective beta-
blockers is not influenced by the presence of metabolic
syndrome
Simona Bota, Philipp Schwabl, Mattias Mandorfer, Petra Salzl,
Arnulf Ferlitsch, Michael Trauner, Markus Peck-Radosavljevic,
Thomas Reiberger
2051: Impact of anticoagulant and antiaggregant
therapy on portal hypertension-related upper
gastrointestinal bleeding in patients with liver cirrhosis.
Results from a prospective multicentric observational
study
Dominique Thabut, Yann Le Bricquir, Nicolas Carbonell, Xavier
Causse, Jessica Coelho, Jean françois D. Cadranel, Jean Paul
Cervoni, Andre Jean Remy, Isabelle Archambeaud, Khaldoun
Elriz, Florent Ehrhard, Joanna Pofelski, Christophe Bureau, Bruno
Bour, Florian Rostain, Francois Dewaele, Julien Vergniol, Jacques
Arnaud Seyrig, Anne-Laure Pelletier, Farah Zerouala, Anne
Guillygomarc’h, Arnaud Pauwels
2052: Applicability of Early TIPS in a US Based Tertiary
Care Center
Swaytha Ganesh, Jyothsna Talluri, Siva Talluri, Ali Al-khafaji,
Shahid M. Malik
2053: The improvement of hepatic hemodynamics
and liver function before and after balloon - occluded
retorograde transvenous obliteration
Ryuta Shigefuku, Hideaki Takahashi, Yoshihito Yoshida, Tomohiro
Tamura, Yohei Noguchi, Hiroki Ikeda, Kotaro Matsunaga,
Nobuyuki Matsumoto, Chiaki Okuse, Fumio Itoh, Shigeru Sase,
Michihiro Suzuki
2054: HVPG predicting prognosis in patients with
cirrhosis. Does it matters to use free hepatic vein
pressure or inferior vena cava pressure?
Gilberto Silva-Junior, Anna Baiges, Fanny Turon, Karina G.
Ramírez Ibarra, Vera Costa Santos, Annalisa Berzigotti, Virginia
Hernandez-Gea, Jaime Bosch, Juan Carlos Garcia-Pagan
2055: Risk of esophageal varices predicted by share
wave velocity
Hiroko Iijima, Tomoko Aoki, Chikage Nakano, Kenji Hashimoto,
Akio Ishii, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda,
Yoshiyuki Sakai, Hironori Tanaka, Yoshinori Iwata, Hirayuki
Enomoto, Masaki Saito, Shuhei Nishiguchi
NOVEMBER 11
TUESDAY
Presenters in Attendance 10:30 AM – Noon
 196A POSTER SESSIONS
Poster Sessions
2056: Prospective observational study of portal-
hypertensive bleeding in 914 cirrhotic patients in France
(CHOC study) : high proportion of high-risk patients but
limited access to TIPS
Dominique Thabut, Andre Jean Remy, Nicolas Carbonell, Xavier
Causse, Jessica Coelho, Jean françois D. Cadranel, Jean Paul
Cervoni, Slim Bramli, Isabelle Archambeaud, Philippe Ah-soune,
Florent Ehrhard, Alexandre Pariente, Christophe Bureau, Jean-
Pierre Dupuychaffray, Florian Rostain, Florence Skinazi, Julien
Vergniol, Rl Vitte, Anne-Laure Pelletier, Jean Henrion, Anne
Guillygomarc’h, Stéphanie Combet, Arnaud Pauwels
2057: Should bleeding from gastric varices be
prevented? A portuguese center experience
Tiago Cúrdia Gonçalves, Joana Magalhães, Carla M. Marinho,
José Cotter
2058: Correction of coagulopathy in non-bleeding
cirrhotic patient undergoing Minor Invasive Procedures:
A Systematic Review
Matthew J. McConnell, Ruben Hernaez, Sarah Sewaralthahab,
Saleh Alqahtani
2059: The efficacy of balloon-occluded retrograde
transvenous obliteration (BRTO) and coil assisted
retrograde transvenous obliteration (CARTO) for the
treatment of bleeding gastric varices and hepatic
encepholopathy
Lisa N. Waller, Scott Schwartz, Dilip Moonka, Amir Prushani,
Syed-Mohammed R. Jafri
2060: Long-term result and safety of endoscopic
N-Butyl-2-cyanoacrylate injection of gastric varices :
Focused on the variceal location
Wonhyeong Park, Seo Young Yang, Do Young Kim, Woong Sun
Yoo, Tae Gyoon Kim, Tae Kyu Lim
NOVEMBER 11
TUESDAY
Denotes AASLD Presidential Poster of Distinction
HEPATOLOGY, October, 2014
2061: The Child-Turcotte-Pugh (CTP) score is best at
predicting 6-week mortality in patients with acute
variceal hemorrhage (AVH): Analysis of a U.S. Multi-
Center Prospective Study
Brett E. Fortune, Guadalupe Garcia-Tsao, Maria Ciarleglio,
Yanhong Deng, Michael B. Fallon, Samuel Sigal, Naga P.
Chalasani, Joseph K. Lim, Adrian Reuben, Hugo E. Vargas, Gary
Abrams, Michele Bishop Lewis, Tarek Hassanein, James F. Trotter,
Arun J. Sanyal, Kimberly L. Beavers, Daniel Ganger, Paul J.
Thuluvath, Norman D. Grace, Roberto J. Groszmann
2062: Clinically significant hyponatremia is a rare side
effect of terlipressin treatment for vericeal bleeding and
hepatorenal syndrome when used as first line agent
Ruth Bolier, Bart van Hoek, Hein W. Verspaget, Minneke Coenraad
2063: Cyanoacrylate Therapy for the Treatment of
Gastric Varices: A New Method
Virendra Singh, Rajiv R. Singh, Navneet Sharma
2064: The long-term clinical outcome of balloon-
occluded retrograde transvenous obliteration for gastric
varices
Noriaki Naeshiro, Hiroshi Aikata, Hiromi Kan, Tomoki Kobayashi,
Takayuki Fukuhara, Yohji Honda, Daisuke Miyaki, Tomokazu
Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura,
Yoshiiku Kawakami, Hideyuki Hyogo, C. Nelson Hayes, Kazuaki
Chayama
2065: Safety of Endoscopy in Patients with End-stage
Liver Disease
Prasun K. Jalal